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There is strong evidence that higher bone mineral density (BMD) is a risk factor 
for osteoarthritis (OA), although the association with OA progression is unclear. 
It is uncertain if observational associations reflect a causal effect of bone on joint 
deterioration, or shared underlying biology. 
 
I examined the role of BMD in OA progression by determining change in 
radiographic sub-phenotypes (osteophytes, joint space narrowing) at the hip and 
knee in individuals with high bone mass (HBM, L1 and/or total hip Z-
score>+3.2), comparing progression to their relatives without HBM (Chapters 
6,7). HBM individuals had increased progression of radiographic OA sub-
phenotypes at both joints, compared to their relatives. Metabolomics analysis did 
not identify any metabolic traits, and thus metabolic pathways, which could 
mediate the association between HBM and OA (Chapter 8). 
 
I next performed multivariable Mendelian randomization (MVMR) in UK 
Biobank to determine if BMD exerts a causal effect on OA, independent of 
confounding by body mass index (BMI) (Chapter 9). MVMR identified a BMI-
independent causal effect of BMD on hip and knee OA (26% and 36% increased 
odds per SD increase, respectively).  
 
Subsequently, I analysed the underlying biological pathways contributing to 
both BMD and OA, by calculating the proportion of variance in hospital-
diagnosed hip and knee OA explained by genetic variation in the Wnt signalling, 
TGFβ superfamily and osteoclast differentiation pathways (Chapter 10). This 
analysis provided evidence for a BMD-independent contribution of these 
pathways to OA. Further MVMR analyses identified a BMI-independent causal 
effect of circulating IGF-1 on risk of hospital-diagnosed hip and knee OA (49% 
and 22% increased odds per SD increase, respectively, Chapter 11).  
  
This work suggests a role of BMD in structural OA progression at the hip and 
knee, reflecting a direct role of bone in joint deterioration, as well as shared 
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GAG  Glycosaminoglycan 
GC   Genomic Control 
GCP   Genetic Causality Proportion 
 
 30 
GDF5  Growth Differentiation Factor-5 
GEE   Generalized Estimating Equations 
GEFOS  Genetic Factors for Osteoporosis 
GIANT  Genetic Investigation of Anthropometric Traits 
GO   Genetics of Osteoarthritis 
GP   Growth Plate 
GWAS  Genome Wide Association Study 
HA   Hyaluronic Acid 
HBM  High Bone Mass 
HCS   Hertfordshire Cohort Study 
HDL   High Density Lipoprotein 
HES   Hospital Episode Statistics 
HRC   Haplotype Reference Consortium 
HRT   Hormone Replacement Therapy 
HR-QoL  Health Related Quality of Life 
HWE  Hardy-Weinberg Equilibrium 
IBS   Identical By State 
ICC   Intraclass Correlation Coefficient 
ICD International Statistical Classification of Diseases and Related 
Health Problems 
IGF-1  Insulin-like Growth Factor-1 
IGFBP-3  IGF Binding Protein-3 
IHH   Indian Hedgehog 
IL   Interleukin 
IMD   Index of Multiple Deprivation 
IPAQ  International Physical Activity Questionnaire 
IQR   Interquartile Range 
IVW   Inverse Variance Weighted 
JoCo   Johnston County Osteoarthritis Project 
JSN   Joint Space Narrowing 
KL   Kellgren-Lawrence 
KNHANES Korean National Health and Nutrition Survey 
LCV   Latent Causal Variable 
LD   Linkage Disequilibrium 
LDL   Low Density Lipoprotein 
LM   Lean Mass 
LMM  Linear Mixed Model 
LMWM  Low Molecular Weight Metabolites 
LRP   Low-density lipoprotein Receptor-related Protein 
LS   Lumbar Spine 
MAF  Minor Allele Frequency 
MCP   Metacarpophalangeal 
M-CSF  Macrophage Stimulating Factor 
MET   Metabolic Equivalent Task 
MetS  Metabolic Syndrome 
MGP  Matrix Gla Protein 
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mJSW  minimal Joint Space Width 
MMP  Matrix Metalloproteinase 
MPC   Mesenchymal Progenitor Cell 
MR   Mendelian Randomization 
MRI   Magnetic Resonance Imaging 
MrOS  Study of Osteoporotic fractures in Men 
MRU  Musculoskeletal Research Unit 
MSC   Mesenchymal Stem Cell 
MVMR  Multivariable Mendelian Randomization 
NBT   North Bristol NHS Trust 
NCP   Non-Collagenous Protein 
NEA   Non-Effect Allele 
NHS   National Health Service 
NMR  Nuclear Magnetic Resonance 
NTX-1  N-terminal Telopeptide of Type 1 Collagen 
OA   Osteoarthritis 
OAI   Osteoarthritis Initiative 
OARSI  Osteoarthritis Research Society International 
OPC   Osteochondral Progenitor Cell 
OPG   Osteoprotegerin 
OR   Odds Ratio 
OSQ   Osteoporosis Screening Questionnaire 
OSX   Osterix 
P1NP  N-terminal Propeptide of Type 1 Collagen 
PA   Physical Activity 
PBMC  Peripheral Blood Mononuclear Cell 
PC   Principal Component 
PIP    Proximal Interphalangeal 
POC   Primary Ossification Centre 
pQCT  peripheral Quantitative Computed Tomography 
PRS   Polygenic Risk Score 
PTH   Parathyroid Hormone 
PTHrP  Parathyroid Hormone-related Protein 
QC   Quality Control 
RANK  Receptor Activator of Nuclear factor Kappa-B 
RANKL  Receptor Activator of Nuclear factor Kappa-B Ligand 
RCI   Reliable Change Index 
RCT   Randomised Controlled Trial 
REC   Research Ethics Committee  
RS   Rotterdam Study 
RUNX2  Runt-related transcription factor-2 
SD   Standard Deviation 
SE   Standard Error 
SEKOIA  Strontium Ranelate in Knee Osteoarthritis 
SES/SEP  Socio-Economic Status/Position 
SF   Synovial Fluid 
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SNP   Single Nucleotide Polymorphism 
SOC   Secondary Ossification Centre 
SOF   Study of Osteoporotic Fractures 
SOS   Speed Of Sound 
SOX9  SRY-Box Transcription Factor-9 
StR   Strontium Ranelate 
TASOAC  Tasmanian Older Adult Cohort 
TB   Total Body 
TBFM  Total Body Fat Mass 
TBLM  Total Body Lean Mass 
TGFβ  Transforming Growth Factor-β 
TH   Total Hip 
THR   Total Hip Replacement 
TJR   Total Joint Replacement 
TKR   Total Knee Replacement 
TNF   Tumour Necrosis Factor 
TRAcP  Tartrate Resistant Acid Phosphatase 
TREAT-OA Translation Research in Europe Applied Technologies for OA 
VEGF  Vascular Endothelial Growth Factor 
VIBE  Vertical Impacts on Bone in the Elderly 
VLDL  Very Low Density Lipoprotein 









Joints occur at the margin between two bones. Joints are an organ consisting of 
multiple interdependent tissues. There are two main types of joints: synovial and 
solid joints (1). Synovial are the most common type of joint and are found at the 
ends of human long bones and are distinguished by the presence of a cavity 
surrounding the joint components (1,2) (section 1.1.1). Solid joints have no 
capsule and instead the components of the joint are bound by connective tissue 
(1). 
Joints can be further classified by shape and movement (1). The different shapes 
of joints are plane, hinge, pivot, bicondylar, condylar, saddle and ball and socket 
(1). Bicondylar joints are named as such as there are two contact points in the 
joint; an example is the knee joint (1). In terms of movement, joints can be 
uniaxial, biaxial, or multiaxial (1). Multiaxial joints are named due to their ability 
to move along multiple axis; an example is the ‘ball and socket’ hip joint (1).  
1.1.1. Features of a synovial joint 
Figure 1 presents the structure of a knee joint, an example of a synovial joint. The 
knee consists of the common features of a synovial joint: the synovium which 
encapsulates the joint, a synovial cavity consisting of synovial fluid (SF), articular 
cartilage (AC), subchondral bone and tendons and ligaments (all discussed in 
detail below) (3). The knee joint is highly specialised to provide frictionless 
movement despite being a weight-bearing joint and has additional features (the 






Figure 1: Structure of a synovial joint (the knee). 
 
Reproduced from (3). 
 
Features common to all synovial joints 
Articular cartilage 
AC is an avascular and aneural tissue of up to 3mm thickness (3). This tissue 
allows movement of the joint with limited friction and dissipates load to protect 
the underlying subchondral bone (3). There is one cell type present in the AC: the 
chondrocyte. Chondrocytes secrete an extracellular matrix (ECM) consisting 
mainly of type II collagen and proteoglycans, along with water to maintain the 
pressure within the cartilage, to withstand mechanical load (3). The main 
proteoglycan, aggrecan, has glycosaminoglycan (GAG) chains which bind to 
water, generating the stiffness of cartilage, whilst collagen provides the strength 
(3). The majority of AC is uncalcified, with the exception of a thin layer adjacent 
to the subchondral bone; where this layer meets the uncalcified cartilage is called 
the tidemark. The calcified region of cartilage is involved in the transition of 
mechanical properties between cartilage and bone (3).  
Capsule and synovium 
The capsule is a fibrous structure which encapsulates the joint, providing blood 
vessels which bring nutrients to the joint, as well as lymphatic vessels and nerve 
fibres (3). The capsule supports the synovium, which is a thin layer of cells 
(maximum two cells deep), which maintains an aseptic environment in the joint, 
through type A synovial cells (3). The synovium is involved in joint lubrication 
by the synthesis and secretion of hyaluronic acid (HA) and lubricin by the type B 
synovial cells (3). The capsule and synovium are a source of mesenchymal 
progenitor cells (MPCs, also referred to as MSCs), which can differentiate into 
chondrocytes (3). 




SF coats the joint surface and provides nutrition to the joint (3). There are two 
main constituents of SF: HA and lubricin. Lubricin is synthesized in response to 
mechanical forces in the joint and provides lubrication (3). HA is involved in 
lubrication and nutrient transfer to cartilage (4). 
Subchondral bone 
The subchondral bone plate is the layer of cortical bone underlying the joint, at 
the end of the long bones. It is thinner and less stiff than other cortical bone, with 
its thickness related to cartilage thickness and the thickness of the trabecular 
bone underneath, rather than body size (3). Underlying the bone plate is the 
subchondral trabecular bone, which provides support and absorbs forces (5). 
Cortical and trabecular bone are described in section 2.1.2. 
Tendons and ligaments 
The ligaments of a joint connect the two bones, providing stability, whilst the 
tendons connect the bone to muscle, converting muscle contractions into 
movement of the joint (6). Both tendons and ligaments are composed of collagen 
fibres (mainly type I). 
Knee-specific features 
Infrapatellar fat pad 
The fat pad between the patella and femur, also known as Hoffa’s fat pad, 
provides a source of MPCs, which differentiate into chondrocytes (3). 
Menisci 
Medial and lateral menisci in the knee joint, formed mainly of type I collagen 
fibrils, are responsible for dissipating mechanical load (particularly during knee 
flexion), absorbing impact and maintaining stability, to prevent joint injury (6). 





Arthritis is a disease of the joints and osteoarthritis (OA) is the most common 
form of arthritis. OA is colloquially known as ‘wear and tear’ arthritis, although 
as discussed in section 1.2.2, this is an outdated term. OA used to be thought of 
as cartilage degradation, but evidence has since lead to the current thinking that 
OA is a disease of the whole joint (7). Osteoarthritis Research Society 
International (OARSI), proposed the following definition in 2015 (8): 
 
OA can be defined as primary or secondary depending upon its aetiology. 
Secondary OA is caused by joint injury or comorbid disease. Primary OA 
develops without injury or comorbid disease, most likely due to a combination of 
risk factors (discussed in section 1.2.5). OA can further be defined as either 
atrophic or hypertrophic based on radiographic features. Atrophic OA describes 
severe cartilage loss without features of extra bone formation, whereas 
hypertrophic OA is characterized by excess bone formation without cartilage loss 
(9). These radiographic features will be discussed in more detail in section 0. 
1.2.2. Pathogenesis 
OA used to be known as ‘wear-and-tear arthritis’ due to the prior belief that the 
pathogenesis of OA was solely based on the degeneration of AC. It is now widely 
accepted that OA is a condition affecting all tissues of a synovial joint, caused by 
an imbalance between anabolic and catabolic processes within the joint (10). This 
“Osteoarthritis is a disorder involving movable joints characterized by cell stress and 
extracellular matrix degradation initiated by micro- and macro-injury that activates 
maladaptive repair responses including pro-inflammatory pathways of innate immunity. The 
disease manifests first as a molecular derangement (abnormal joint tissue metabolism) 
followed by anatomic, and/or physiologic derangements (characterized by cartilage 
degradation, bone remodelling, osteophyte formation, joint inflammation and loss of normal 
joint function), that can culminate in illness”. 
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has led to the hypothesis that OA is a syndrome, whereby a range of pathogenic 
pathways lead to an end-stage phenotype of joint destruction (10). The 
pathogenic processes of OA are presented in Figure 2 and detailed below.  
 
Figure 2: Pathogenic processes occurring in an OA joint. 
 
Reproduced from (11). 
 
Cartilage degeneration 
Chondrocytes normally maintain matrix integrity by producing matrix 
degrading enzymes such as the metalloproteinases (MMPs) or aggrecanases 
(such as A Disintegrin And Metalloproteinase with Thrombospondin motifs 
[ADAMTS]4/5) to degrade the damaged tissue and producing new matrix to 
replace the damaged tissue (11-14). However, in OA, the production of matrix-
degrading enzymes exceeds the anabolic processes leading to progressive 
cartilage loss (15). The disequilibrium between the anabolic and catabolic 
processes in OA is thought to be caused by mechanical injury, inflammation or 
age-related declines in the anabolic properties or number of chondrocytes (13-
15). Additionally, receptors on chondrocytes can bind to advanced glycation end 
products, which accumulate with age, causing a shift to catabolism (11).  
When catabolism exceeds anabolism, loss of aggrecan due to the action of 
aggrecanases reduces the concentration of GAGs in the matrix, altering the water 
content of the cartilage and making it less able to withstand mechanical loading 
and increasingly vulnerable to further damage (16). During the pathogenic 
process of OA, chondrocytes start to produce inflammatory mediators, such as 
cytokines and chemokines (15,16). These inflammatory mediators, along with the 
accumulation of products of cartilage degradation, stimulate MMP and 
ADAMTS synthesis by the chondrocytes (Figure 2) (14-16). Accumulation of 
these inflammatory mediators, in addition to abnormal loading due to reduced 
cartilage integrity, leads to chondrocyte hypertrophy. Hypertrophic 
chondrocytes, which are terminally differentiated, produce less type II collagen 
Image removed for copyright purposes  
 
 39 
but produce catabolic factors such as MMP13 (17). As cartilage is aneural, initial 
cartilage degeneration does not cause pain. However, as OA progresses, vascular 
invasion of the cartilage from the subchondral bone (see below), mediated by 
vascular endothelial growth factor (VEGF), and innervation occurs, contributing 
to pain severity (10,16,18,19).  
Osteophyte formation 
Formation of additional bony ‘spurs’ at the joint margin, known as osteophytes, 
is a characteristic feature of OA, visible on a radiograph (section 0). These form 
due to the reactivation of endochondral ossification (the process of forming bone 
from cartilage, described in section 2.1.3) (10). It is thought that formation of 
osteophytes is stimulated by growth factors such as insulin-like growth factor-1 
(IGF-1) and transforming growth factor-β (TGFβ); both can be produced by 
chondrocytes or subchondral osteoblasts, and expression levels of both have 
been correlated with OA severity (15,16,18). It has been hypothesized that 
osteophyte formation represents an attempt to repair the joint by increasing the 
surface area, to dissipate load and prevent irreparable damage to the cartilage 
(19). Alternatively, animal studies suggest that osteophytes form due to blood 
vessel penetration into degrading cartilage (15). 
Subchondral bone remodelling and sclerosis 
Subchondral bone plays a key role in OA pathogenesis, although it is currently 
unknown if changes in subchondral bone remodelling precede, or are a 
consequence of, cartilage degeneration (14,18). Increased bone remodelling early 
in OA, where bone resorption exceeds formation, leads to thinning of the 
subchondral bone plate (18). This could reflect a response by osteocytes to repair 
microcracks in the bone, or a response to cytokines produced by deteriorating 
cartilage (18). Endochondral ossification is re-established at the tidemark, 
creating multiple tidemarks, and thickening of the calcified cartilage, reducing 
the area of the non-calcified cartilage (11,18). Bone marrow lesions (BMLs) can be 
seen on a magnetic resonance imaging (MRI) scan early in the disease process, 
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these are a feature of microdamage to the subchondral bone and associated 
increased vascularity (19).   
As OA progresses, subchondral bone formation increases, but the bone is poorly 
mineralized. This is due to the production of TGFβ by the subchondral 
osteoblasts, increasing production of the Wnt inhibitor Dickkopf-related protein-
2 (DKK-2), which inhibits mineralization (the Wnt signalling pathway is 
described in section 2.1.3) (18). The composition of α chains in type I collagen 
(section 2.1.1) is altered, which further contributes to hypomineralization (14). An 
increase in thickness of the subchondral bone plate with poor mineralization 
generates a sclerotic bone plate which is stiff and creates greater pressure on the 
underlying cartilage (16). This is known as subchondral sclerosis and can be 
visualized on a radiograph (section 0) as a marker of severe and irreparable 
damage (19). The trabecular number and volume of the underlying trabecular 
bone is increased (14). Subchondral bone cysts can occur at the later stage of 
disease, where complete cartilage loss has occurred; cysts reflect the entry of SF 
into bone marrow (14).  
Synovitis 
Synovitis, which refers to synovial inflammation, is believed to be occur 
secondary to initial joint damage, due to the degradation products of both 
cartilage and bone, such as type II collagen fragments. Synovitis is therefore often 
localized to regions of damaged cartilage or bone (11,15,16). These degradation 
products cause an immune response in the synoviocytes, which produce 
cytokines, MMPs and aggrecanases leading to further cartilage degeneration 
(11,20). Synovitis leads to excess SF secretion which causes swelling and joint 
effusion (15). Synovitis is also characterized by hyperplasia of the synovial 
membrane due to proliferation of the synoviocytes, which increases synovial 
vascularity (10,15). 
Inflammation  
Although OA used to be thought of as a non-inflammatory condition, recent 
evidence suggests a role of chronic low-grade inflammation in OA pathogenesis 
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(15). Damage-associated molecular patterns in the joint, produced due to the 
breakdown of the cartilage ECM, trigger an innate immune response and 
subsequent production of inflammatory mediators (21). This leads to increased 
synthesis of MMPs and ADAMTSs and reduced synthesis of type II collagen 
(15,16). IL1β, a proinflammatory cytokine, stimulates IL6 production by 
chondrocytes (16). IL6 stimulates osteoblasts in subchondral bone to produce 
matrix-degrading enzymes, which can diffuse into AC, leading to further 
cartilage degradation (16). Synoviocytes additionally produce these 
proinflammatory cytokines in response to collagen degradation products (11,14). 
However, it is currently unknown if inflammation is a cause or response to 
cartilage damage, as joint inflammation (e.g. due to injury) could be the initial 
factor causing the initial imbalance between anabolic and catabolic processes 
(15). Despite clear in vitro evidence and biological plausibility for a role of the 
proinflammatory mediators IL1β and TNFα in OA pathogenesis, trials of drugs 
targeting these cytokines have not demonstrated efficacy, suggesting that one 
cytokine alone is not key to OA pathogenesis (21). Alternatively, as inflammation 
is often present prior to development of radiographic features, it may be that 
these pro-inflammatory cytokines have a more important role in initial disease 
development rather than progression (21). 
Hypothesized model of pathogenesis 
Although it is now widely accepted that OA is a disease of the whole joint, it is 
currently unclear whether pathogenic changes in the subchondral bone or 
changes in AC occur first. Burr and Gallant (18) generated a hypothesized model 
of OA pathogenesis, whereby repetitive joint loading leads to initial subchondral 
bone remodelling. This in turn leads to vascular invasion of the deeper layers of 
cartilage, allowing cartilage access to chondrolytic enzymes. Products of cartilage 
degeneration potentially stimulate synovitis and loss of cartilage integrity, 
leading to increased subchondral bone formation as an adaptive response to the 
greater loads. This would generate a pathological cycle as the increased 
subchondral bone formation would lead to subchondral sclerosis (densification 
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of the subchondral bone plate) and further cartilage loss. Burr and Gallant’s 
hypothesized model is presented in Figure 3. 
 
Figure 3: Hypothesized timeline of processes in OA pathogenesis. 
 
 
Reproduced from (18). 
 
1.2.3. Diagnosis 
There is no laboratory test to specifically diagnose OA. In a clinical setting, 
diagnosis generally occurs upon presentation of a patient to a healthcare setting 
due to symptoms (11). Diagnosis of OA is normally based on either radiographic 
features and/or clinical symptoms (22). Common symptoms of OA include pain, 
especially after use of the joint, which often improves on rest, and stiffness of the 
joint upon wakening in the morning. Clinical signs often examined to aid clinical 
diagnosis of OA include crepitus, bony enlargement, a reduced range of 
movement, tenderness upon palpation of the joint and malalignment and/or 
instability (22). Criteria for diagnosing OA of the hand, hip and knee have been 
developed by the American College of Rheumatology and these are summarised 
in Table 1. 
 
Table 1: American College of Rheumatology criteria for diagnosis of OA of the hand, hip, 
and knee.  





Hand pain, aching or stiffness plus at least two of: 
• Hard tissue enlargement of at least two joints 
• Hard tissue enlargement of two or more distal interphalangeal joints 
• Less than three swollen metacarpophalangeal joints 
• Deformity of at least one joint 
Joints assessed: 2nd/ 3rd distal interphalangeal, 2nd/3rd proximal interphalangeal, 
first carpometacarpal of both hands 
Hip 
Hip pain plus at least two of: 
• Erythrocyte sedimentation rate <20mm/hour 
• Femoral or acetabular osteophytes 
Image removed for copyright purposes  
 
 43 
• Superior, axial, or medial joint space narrowing  
Knee Pain plus at least five of: 
• Aged 50+ years 
• Stiffness <30 minutes 
• Crepitus 
• Bony tenderness 
• Bony enlargement 




• Rheumatoid factor <1:40 
• Synovial fluid signs of 
OA 
Pain, osteophytes plus 
at least one of: 
• Aged 50+years 




Pain plus at least three 
of: 
• Aged 50+ years 







• No palpable 
warmth 
Adapted from (23-25). 
 
Radiographic OA in a research setting 
Radiographic definition using plain X-ray is currently the most common method 
for assessing OA in research settings, although MRI methods are more sensitive 
to change over time. MRI can detect early features in the pathogenic process and 
features unobservable on a radiograph, such as early cartilage changes and 
BMLs, and MRI is likely to become the standard way for diagnosing OA in 
research studies in the future (9,11,16). 
Several key features of OA can be viewed on a standard radiograph: loss of joint 
space (used as a marker of cartilage degeneration), osteophytes, subchondral 
sclerosis, and subchondral cysts (26). Malalignment at the knee and deformity of 
the femoral head are additional features of OA which can be visualized on a 
radiograph. Not all features may be present. The tibiofemoral joint of the knee is 
imaged using an anteroposterior (AP) knee X-ray and the patellofemoral joint is 
imaged with a lateral view. Radiographic knee OA in most epidemiological 
studies refers to tibiofemoral OA. Knee X-rays are normally performed in a 
weight-bearing position (i.e. standing), to observe narrowing of the joint space. 
This can be with the knee in a semi-flexed or extended position, with the semi-
flexed position generating more accurate measures of medial minimal joint space 
width (mJSW) (27). Hip OA is normally viewed on an AP pelvis radiograph, 
performed with the patient in a supine position. Examples of hip and knee 
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radiographs, with and without features of OA, are presented in Figure 4 and 
Figure 5. X-rays of the hand can be performed to diagnose hand, finger, or thumb 
OA, normally with a posteroanterior view (Figure 6). OA most commonly affects 
the distal interphalangeal (DIP), carpometacarpal (CMC, the thumb case) and the 
proximal interphalangeal (PIP) joints of the hand (Figure 6) (28). 
 
Figure 4: AP knee radiographs showing the tibio-femoral joint. 
 
The radiograph on the left is normal (i.e. no features of OA evident). The radiograph on 
the right displays large osteophytes of the tibia and femur margins, both medially and 
laterally, and severe medial joint space narrowing. Reproduced from (29). 
 
Figure 5: AP pelvic radiographs showing the hip. 
  
The radiograph on the left is normal (i.e. no features of OA evident). The radiograph on 
the right displays large osteophytes of the femur and acetabulum, both superior and 
inferior, and severe medial joint space narrowing. Reproduced from (29). 
 
Figure 6: Joints of the hand commonly affected by OA (left) and a radiograph of a DIP 
joint severely affected by OA (osteophytes and JSN). 
 
Reproduced from (28,29). 
 
In research settings, Kellgren-Lawrence (KL) grading is commonly used to define 
OA severity (30). KL grading evaluates OA severity on a scale of 0-4, with zero 
representing a joint with no radiographic features of OA, and four representing 
severe OA, with a cut-off of two and above used to define the presence of OA 
(30). The radiographic criteria for each of the grades for knee OA, originally 
proposed by Kellgren and Lawrence in 1957, are presented in Table 2. However, 
various interpretations of the gradings now exist (31). A 2008 review identified 
five different interpretations of the KL grades for knee OA across 18 cohort 
studies, mainly differing in the level of joint space narrowing (JSN) required for 
grades two and three (32). Radiographic atlases have been generated to 
Image removed for copyright purposes  
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standardize the grading of the individual radiographic sub-phenotypes (i.e. 
osteophytes, JSN, subchondral sclerosis) (29,33). Quantitative measures of JSW, 
performed on the medial aspect of the knee or the superior aspect of the hip, can 
be used as more sensitive measures of change in cartilage thickness over time. 
 
Table 2: Grading criteria for radiographic knee OA originally proposed by Kellgren and 
Lawrence (29). 
Grade Radiographic features 
0 No radiographic features of OA observed 
1 Doubtful JSN, possible osteophytes 
2 Definite osteophytes, possible JSN 
3 Moderate osteophytes, JSN, some sclerosis, possible deformity of bone ends 




Data from the Global Burden of Disease study 2010 generated worldwide 
prevalence estimates of 3.8% for knee and 0.9% for hip OA (34). Prevalence is 
increasing; data from the US highlighted that the number of people with clinical 
hand, hip or knee OA increased from approximately 21 million in 1995 to 27 
million in 2005 (35). This reflects an ageing population and the increasing 
prevalence of risk factors such as obesity (section 1.2.5) (36).  
Prevalence estimates vary by joint studied, with much higher estimates for hand, 
compared to hip or knee OA, and a higher prevalence of knee compared to hip 
OA. Analyses of individuals aged 50 years or older from the Framingham 
population determined a prevalence of 20% for radiographic hip OA in the 
cohort from 2002-2005, with a much lower prevalence of symptomatic hip OA, at 
4.2% (37). Prevalence estimates for radiographic knee OA of 31% for men and 
34% women have been measured in an earlier Framingham cohort (1983-1985) 
(38). In the Rotterdam study, the prevalence of radiographic OA in at least one 
hand joint was 67% for women and 55% for men (39). However, prevalence of 
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symptomatic OA of the hand is much lower, with 14% women and 7% of men 
diagnosed with symptomatic hand OA in the 1992-1995 Framingham cohort (40).  
Estimates for the prevalence of OA vary depending upon the definition used, for 
example the prevalence of radiographic OA is higher than the prevalence of 
symptomatic OA, as radiographic OA is commonly required alongside 
symptoms to define symptomatic OA (41,42). There is discordance between 
radiographic and symptomatic evidence for OA and it is estimated that up to 
50% of individuals with radiographic OA do not have symptoms (43). Prevalence 
estimates even vary within definitions; although a KL grade of two or more is 
normally used to determine OA, other thresholds can be used (44,45). As 
discussed earlier, a KL grade of two can be interpreted in different ways and 
Kerkhof et al identified four different interpretations for knee OA and two for hip 
OA in the Translation Research in Europe Applied Technologies for OA (TREAT-
OA) consortium (45). When the definitions were standardized across studies, the 
maximum prevalence estimates decreased from 55% to 25% for knee OA and 
from 33% to 10% for hip OA (45).  
The prevalence of radiographic OA varies by population, with African 
Americans displaying a greater prevalence of both radiographic and 
symptomatic hip and knee OA compared to Caucasians in the Johnston county 
OA project (JoCo) (46,47). Analyses of a Chinese population in Beijing identified 
a lower prevalence of hip and hand OA compared to US Caucasian populations, 
but Chinese women had a higher prevalence of knee OA (48-50). 
Incidence 
Generally, studies of the incidence of OA have been based either on incidence of 
radiographic OA in cohorts drawn from the general population (Framingham 
and Chingford) (40,51,52) or data extracted from routine healthcare records (53-
57). Data derived from both sources have revealed a higher incidence for women 
compared to men (51,53-57) and studies investigating site-specific incidence 
consistently show a greater incidence of knee, compared to hip and hand OA 
(Figure 7) (53,56,57).  
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Figure 7: Incidence of OA at the hand, hip and knee across age groups and stratified by 
sex. 
 
Reproduced from (10). 
 
The largest study of the incidence of hand, hip and knee OA in the general 
population was performed by Prieto-Alhambra et al, who utilised primary care 
record data covering approximately 3.3 million individuals, representing 
approximately 80% of the population of Catalonia, Spain (56). They observed an 
overall incidence of 2.4 per 1000 person-years for hand, 2.1 per 1000 person-years 
for hip and 6.5 per 1000 person-years for knee OA (56). The incidence of both hip 
and knee OA increased with age up until age 80, with a steep increase in 
incidence seen between ages 50 and 70 years for knee OA (Figure 7) (56). The 
incidence of hand OA in women rose steeply between ages 45 and 55 years, 
reflecting the menopausal period (56). A decrease in incidence of knee OA after 
age 80 years may reflect survivor bias, whereby individuals who are less likely to 
develop knee OA (e.g. because they are not obese) are more likely to survive to 
this age (56). Analysing primary care records from Staffordshire, UK, Yu et al also 
identified an increasing incidence rate for individuals aged 35-44 years, from 0.3 
per 1000 person-years in 2003 to 2.0 per 1000 person-years in 2010 (57). This 
increasing risk in younger individuals likely reflects an increasing prevalence of 
risk factors such as obesity (section 1.2.5).  
Estimates of the incidence of radiographic OA in cohort studies are slightly 
higher at 2-3% per year (51,52). This probably reflects the use of radiographic 
definitions in cohort studies, where everyone is X-rayed even if they do not 
display symptoms. The inclusion of those with possible radiographic features at 
baseline (i.e. KL=1) in the population at risk in cohort studies may also increase 
incidence rates. Leyland et al identified a five-times greater odds of incident knee 
OA in those with a KL grade of one at baseline compared to those with a KL 
grade of zero (52). 




OA conveys a significant socioeconomic burden worldwide. The economic costs 
can be separated into direct and indirect costs (36). Direct costs include the costs 
to healthcare services, of which the majority is attributable to total joint 
replacement (TJR) surgery (58). The estimated direct cost of OA in the UK in 2010 
was £1billion (58). Indirect costs can be experienced at both a societal and an 
individual level and represent the cost related to lost productivity due to the 
disease. This includes being absent from work and having reduced capability 
when present at work, for both the individual with OA and their caregiver(s) 
(59). The total economic cost of OA in the UK has previously been estimated at 
1.1% of the gross national product (60). These costs do not include the costs of 
associated comorbidities.  
The social burden attributable to OA can be measured using the number of years 
lived with disability. OA is estimated to cause 2.8% of worldwide disability (61) 
and is estimated to account for 2.4% of all years lived with disability (36). This 
made OA the 12th greatest cause of global years lived with disability worldwide 
in 2016 and it is expected to rise to the fourth greatest this year (2020) (62,63). The 
social burden includes costs such as reduced quality of life (QoL), depression and 
pain (36). 
1.2.5. Risk factors  
Risk factors for OA can be categorised as systemic or joint-level risk factors. 









Age is arguably the strongest risk factor for developing OA. As discussed in 
section 1.2.4, incidence rates for hip, knee and hand OA increase with age up 
until the eighth decade (42). This pattern reflects the accumulation of other risk 
factors with time (42), such as cumulative exposure to mechanical damage from 
joint loading (physical activity [PA], obesity). It further reflects the reduced 
ability of the joint to react to mechanical injury, for example the loss of muscle 
mass and strength with ageing will reduce mechanoprotective gait responses 
(64). Reduced cartilage matrix synthesis and increased activation of degradation 




It is well-established that women have a much greater risk of developing OA of 
the hand and knee compared to men, with less of a sex contribution to hip OA 
risk (10,56,65). Risk differences between men and women for hand OA peak 
around the age of the menopause (Figure 7) (56). This suggests a key role of 
postmenopausal declines in oestrogen in OA pathogenesis in women, 
particularly for hand OA (56). Consistent with a protective role of oestrogen, a 
randomised controlled trial (RCT) of oestrogen use, in women who had 
undergone a hysterectomy from the Women’s Health Initiative, identified a 
lower risk of TJR in those taking oestrogen compared to placebo (66).  
Sex differences in cartilage volume could explain the greater risk of OA in 
women. Lower cartilage volume in women compared to men has been observed 
at the hip and knee (67-70). Differences in knee cartilage volume have been 
observed in both children and adults, with these differences independent of bone 
and body size and levels of PA. The sex difference increased after age 55 years, 
suggesting a role of sex hormones in cartilage maintenance in later life (69,70). 
Sex differences in OA risk could alternatively be explained by postmenopausal 
bone loss (the role of bone in OA pathogenesis is detailed in Chapter 3) or 
reduced muscle strength in women (71). 
Genetics 
OA is highly heritable, but heritability varies by joint. A study of discordance 
between monozygotic and dizygotic female sibling pairs from the UK generated 
a heritability estimate of 58% for radiographic hip OA, with a higher heritability 
estimate of 64% for hip JSN specifically (72). Heritability estimates for the knee 
were lower in female twin pairs recruited from the same population (44%) (73) 
and higher in mixed-sex twin pairs recruited from an Australian population 
(61%) (74). In another study of patients receiving a total knee replacement (TKR) 
from Nottinghamshire, UK, and their siblings, the overall heritability estimate for 
knee OA was 62%, with evidence for a stronger genetic component in men than 
women (78% vs 49%) (75). Spector et al estimated the heritability for radiographic 
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hand OA at 65% in a population of British women and identified larger 
heritability estimates for osteophytes at the hand and knee (72%) compared to 
JSN in the same joints (46%) (73). OA-related loci identified from genetics studies 
are detailed in section 1.2.6. 
Race/ethnicity 
As highlighted in section 1.2.4, the prevalence and incidence of OA varies by 
race/ethnicity. Racial/ethnic differences could reflect differences in the 
frequency of genetic variants conferring a greater risk for OA (section 1.2.6) or 
differences in other risk factors, for example a greater prevalence of valgus 
malalignment in Chinese men (see below) (76). Racial/ethnic differences in OA 
risk could also reflect behavioural differences such as differences in levels of PA 
or differences in diet (see below).  
Obesity 
There is strong evidence to suggest that a high body mass index (BMI) is a risk 
factor for knee OA, with a dose-response relationship whereby obese individuals 
appear to be at a greater risk than overweight individuals (77,78). A higher BMI 
has also been related to an increased risk of hip OA, although the magnitude was 
weaker than seen for the knee (79). Further evidence for a key role of obesity in 
OA pathogenesis is the improvement of OA symptoms observed in weight loss 
intervention studies (80). 
Sex appears to modify the effect of BMI on risk of knee OA, with a stronger 
relationship observed in women than men (77,79). However, modification of the 
effect of BMI on risk for hip OA by sex is less clear, with one large Norwegian 
registry-based study observing an increased risk of total hip replacement (THR) 
with increasing BMI for women (81), whereas another observed a stronger 
magnitude for men (82). A dose-response relationship with duration of time 
being overweight has been observed, suggesting that high BMI throughout the 
lifecourse confers a greater risk for OA (79). This is consistent with the 
Norwegian registry-based analysis of over 1 million individuals, identifying that 
obesity prior to age 25 years was a strong risk factor for THR in later life (82).  
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A strong relationship between BMI and knee and hip OA can be explained by 
increased loading on the joint, increasing stress on AC. However, there is some 
evidence for a relationship between BMI and hand OA (83), suggesting that joint 
loading is not the sole mediator of the relationship between BMI and OA. BMI is 
a measure of adiposity (i.e. amount of adipose tissue). Adipose tissue synthesizes 
and releases adipokines, which are signalling molecules that can be pro-
inflammatory (84,85). These adipokines include adiponectin, leptin, and the 
cytokines IL6 and TNFα, discussed in section 1.2.2. Leptin receptors have been 
observed on chondrocytes and increased leptin has been measured in the 
cartilage and SF in OA (84). It has been suggested that leptin is required for 
chondrocyte hypertrophy, a key process in OA pathogenesis (84). Adiponectin 
production is lower in obese individuals; adiponectin has been shown to 
downregulate chondrocyte MMP13 production in vitro, suggesting that obesity 
may contribute to cartilage destruction through reduced adiponectin production 
(84).  
Nutritional factors  
Diet may be involved in OA pathogenesis, not just through its influence on BMI, 
but through the effect of diet on the production of pro-inflammatory mediators 
(86,87). For example, the classic Western diet is rich in red meat, dairy and 
refined grains, which leads to higher levels of cytokines such as IL6 (86). In terms 
of individual nutrients, higher omega-6 fatty acid intake has been associated with 
BMLs and higher total fat intake has been associated with increased knee JSN in 
a study of individuals with OA (87). Lipids can accumulate in AC and therefore 
may contribute to cartilage degeneration (87). Positive relationships between 
hypercholesterolaemia and knee/hand OA have been observed in cross-sectional 
analyses and statins, which lower cholesterol, may be beneficial in reducing risk 
of incident clinical OA and progressive knee OA (87). There is some evidence to 
suggest that vitamin C supplements may prevent incident knee OA (86,87). 
Vitamin K, which is involved in bone and cartilage mineralization, deficiency 
may be a risk factor for hand and knee OA, with an intervention study 
suggesting that there is a beneficial effect of vitamin K supplementation on hand 
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JSN in those with vitamin K deficiency (86). Magnesium deficiency has been 
related to OA risk; it is hypothesized that magnesium deficiency may lead to 
crystal formation in, and hence damage to, AC (86). Finally, small benefits of 
vitamin D supplementation have been reported in some clinical trials, although 
several others have observed no beneficial effect of vitamin D supplementation 
on cartilage volume or pain severity (86,88).  
Physical activity 
There is evidence to suggest that both high levels of PA, as well as physical 
inactivity, could be risk factors for OA (13). High levels of PA can subject the 
joint to repeated abnormal loading and increase the risk of joint injury (13) 
(discussed below). This could explain the greater risk of knee OA in elite 
footballers (89). Conversely, physical inactivity is related to obesity, which is a 
strong risk factor for OA (see above). Furthermore, PA may be beneficial in 
reducing pain and increasing function in those with lower limb OA (90,91). This 
may be through improved muscle strength, reducing further joint stress. The 
effect of PA may differ across different pathogenic features of OA; higher levels 
of PA are positively related to osteophyte formation but inversely related to 
cartilage defects (89).  
Bone mineral density 
The evidence suggesting that higher bone mineral density (BMD) is a risk factor 
for OA is discussed in Chapter 3.  
Occupation 
Individuals working in certain occupations are at a higher risk of OA, 
particularly at the knee and hip (77,92-95). Kellgren and Lawrence first observed, 
in 1952, that miners were at a greater risk of knee OA, compared to office or 
manual workers (96). Since then, evidence has consistently suggested that 
individuals in occupations such as manual labour, agriculture, fishing, 
construction, and machine operation are at a greater risk of lower-limb OA 
(77,92,94,97). The relationship between occupation and OA is not limited to 
lower limb OA; occupations with repetitive hand movements, such as dentistry, 
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are associated with a higher risk of hand OA and occupations involving heavy 
loading are associated with a higher risk of spine, neck and hand OA (92). 
The mechanism by which certain occupations increase risk of OA is based on the 
movements required to perform the role and the abnormal mechanical loads 
these movements transmit through the joint (see below). For example, it has been 
estimated that kneeling leads to a transmission of 70% of the body weight 
through a small surface area of the tibia/patella (95). A recent review concluded 
that roles involving repeated kneeling, squatting, lifting, and climbing are 
associated with the development of knee OA or the aggravation of pre-existing 
knee OA (95). Heavy lifting appeared to be the main factor contributing to hip 
OA (95).  
Smoking 
Whether smoking is a risk or protective factor for OA is currently unclear. There 
is limited evidence to suggest that smoking increases risk of knee cartilage 
degradation and pain (98). However, there are several studies suggesting that 
current smoking may be related to a reduced odds of OA, particularly at the knee 
(99-101). The most recent meta-analysis of 38 studies addressing the role of 
smoking on knee OA identified a 20% reduced risk of knee OA in ever smokers 
compared to non-smokers, as well as a dose-response relationship with number 
of cigarettes per day (101). The authors hypothesized that this relationship could 
reflect the anti-inflammatory properties of nicotine (101). However, the authors 
did note that the inverse relationship between smoking and knee OA could be 
explained by BMI, as smokers tend to be thinner than non-smokers (101). Some 
studies adjusted for BMI, however, this is complicated by potential collider bias, 
as BMI may be a common outcome of both smoking and other risk factors for 
OA, leading to spurious inverse relationships between smoking and these other 
risk factors (102). Another explanation for the inverse relationship between BMI 
and smoking is that these meta-analyses included studies from a hospital setting, 
where controls are often selected from non-musculoskeletal patients, who are 




Joint biomechanics  
Repeated abnormal mechanical loading of the joint can lead to damage of AC, as 
well as the ligaments and the meniscus (93). Anatomical factors, such as altered 
joint morphology or limb alignment (see hip shape and knee malalignment, 
below), as well as poor muscle function in the muscle groups near to the joint 
(e.g. poor quadriceps function and knee OA) are chronic contributors to 
abnormal mechanical loading of the joint (11,103). Age-related degeneration of 
the meniscus can also contribute to altered biomechanics at the knee by 
increasing load (103).  
Joint injury 
Although previous joint injury is traditionally thought of as a cause of secondary 
OA, joint injury is an acute cause of altered biomechanics and can lead to an 
extreme alteration in load distribution across the joint, for example through 
reduced stability due to loss of the cruciate ligament, traumatic damage to the 
cartilage or meniscal damage (103,104). Knee injuries such as anterior cruciate 
ligament (ACL) tears could lead to OA development through knee instability, 
altering the mechanical forces through the joint (105). ACL tears due to injury are 
often associated with damage to other tissues, including cartilage and the 
meniscus, further contributing to altered joint biomechanics (103). Alternatively, 
injuries including ACL tears and meniscal tears could lead to OA via an 
inflammatory response (93). Evidence for a role of abnormal loading includes a 
case-control study by Englund et al, which identified a greater prevalence of knee 
OA in the contralateral knee in patients who had undergone meniscectomy, 
compared to the controls from the general population (106).  
Two meta-analyses have concluded that knee injury is associated with 
subsequent development of knee OA (93,100,107), although there is currently no 
evidence to suggest that knee injury leads to an increased risk of knee OA 
progression (108). Silverwood et al identified 13 cohort studies determining the 
relationship of knee injury to onset of knee OA, 12 of which identified an 
 
 56 
increased risk. Upon meta-analysis of these studies, the odds of developing knee 
OA were 2.8 times higher in those with a previous knee injury (100). Similarly, in 
a meta-analysis of 24 studies of knee OA, knee pain and/or knee OA 
progression, Muthuri et al generated a similar magnitude of effect for cohort 
studies (107).  
Hip shape 
Developmental abnormalities of the hip increase the risk of hip OA development; 
individuals with mild developmental dysplasia of the hip are 10 times more 
likely to develop hip OA (109). Femeroacetabular impingement (FAI), which 
causes abnormal contact between the femur and acetabulum, is highly prevalent 
in European populations (109). FAI can be categorized as either a cam deformity, 
where the femoral neck (FN)-femoral head junction is extended, leading to 
reduced sphericity of the femoral head, or a pincer deformity, characterised by 
acetabular over-coverage (Figure 9) (109,110). There is strong evidence for a role 
of cam deformity in hip OA development, but less evidence for a role of pincer 
deformity (110-112). A recent analysis of approximately 4,500 individuals from 
the Rotterdam study, with follow-up over approximately nine years, observed an 
association between cam deformity and incident hip OA only in those aged 55-65 
years in stratified analyses (112), suggesting that cam leads to earlier 





Figure 9: Illustration of a cam-type deformity (left) and a pincer-type deformity (right) 
compared to a normal hip (middle). 
 
Reproduced from (113). 
 
More recently, research addressing the role of hip shape in hip OA development 
has focused on the contribution of subtle variations in hip shape within the 
general population. Several studies have employed statistical shape modelling to 
quantify these subtle changes in hip shape, for example an analysis of the 
Chingford and Cohort Hip-Cohort Knee (CHECK) populations consistently 
identified a relationship between a flatter FN to head junction, along with a 
flatter greater trochanter and more prominent acetabular wall, with hip OA 
(110,111). However, the limitation of most analyses aimed at determining the role 
of hip shape in OA development is that hip shape measurements are generally 
performed in populations of older adults and there is a possibility that the 
presence of osteophytes can alter measurements (i.e. reverse causality), 
particularly the alpha angle used to assess cam deformities (112).  
Knee malalignment 
Varus (bowleg) and valgus (knock-knee) malalignment are risk factors for knee 
OA progression, with more severe cartilage defects and greater changes in tibial 
cartilage volume observed by MRI in those with more severe varus 
malalignment (114). The effect of malalignment on OA progression is likely to be 
mediated by abnormal joint loading, providing extra stress on the cartilage and 
meniscus (115). There have been fewer studies of malalignment and incident 
knee OA, but those few have found stronger evidence for a role of varus, 
compared to valgus, malalignment (116-118). Weight may modify the effect of 
malalignment on the knee joint: Brouwer et al observed a stronger relationship 
between malalignment and incident knee OA in overweight individuals 
compared to normal/underweight individuals (116).  





The first locus associated with OA risk was a single nucleotide polymorphism 
(SNP) located in the 5’ untranslated region of the Growth Differentiation Factor-5 
(GDF5) gene (119). This SNP was associated with hip OA at genome-wide 
significance in two independent Japanese populations and knee OA in Japanese 
and Han Chinese populations (119). As it was known that GDF5 is involved in 
joint formation (120), the authors identified the SNP by sequencing variants 
within this specific gene, rather than a genome-wide approach. The association 
between the GDF5 locus and knee and hip OA was later replicated in European 
populations (121-123). GDF5 is a ligand in the TGFβ signalling pathway (section 
2.1.3,3.3.2).  
Since the discovery of GDF5, 18 genome-wide association studies (GWAS) of OA 
phenotypes have been published according to the GWAS catalog (124-142). These 
GWAS have identified 96 novel OA-associated loci (Figure 10). These identified 
loci are mainly common variants which have small effects on OA risk, with the 
exception of three rare variants (minor allele frequency [MAF]<5%), annotated to 
COMP, CHADL and EP300, which had an odds ratio (OR)>5 for hip OA 
(135,140). The COMP and CHADL variants were identified by whole genome 
sequencing of THR cases and controls in an Icelandic population and represent 
missense and frameshift mutations, respectively (135).  
Other loci identified include SMAD3, encoding a transcription factor in the TGFβ 
signalling pathway (137), TGFB1 and BMP5 which encode ligands for the TGFβ 
signalling pathway (141), and PTHLH (also known as PTHRP) (131). PTHLH is 
an important regulator of cartilage mineralization during endochondral 
ossification and stimulates proliferation of immature osteoblasts (143). An 
analogue of PTHLH is used as an osteoporosis treatment (abaloparatide, section 
2.2). Estimates from the latest (and largest) GWAS meta-analysis of up to 77,052 
cases and 378,169 controls suggest that the current identified loci explain 14.7% 
of the narrow-sense heritability (i.e. the heritability due to additive, but not 
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dominant variants, and excluding gene-gene interactions (144)) for knee OA and 
51.9% for hip OA (141). 
To maximise sample size, most of these GWAS have been based on OA defined 
by one of several methods (TJR, clinical definition/hospital diagnosis, self-report 
or radiographic) (124,127,128,130,132,139,141,145). This heterogeneity may 
explain the low proportion in narrow-sense heritability currently explained. Only 
three of the published GWAS have been based purely on a radiographic 
definition of OA, but these studies did not identify any loci associated with 
radiographic OA at genome-wide significance (125,126,134). However, it should 
be noted that these studies were small (N<10,000). To-date, only one GWAS has 
been published aiming to identify loci associated with individual radiographic 
sub-phenotypes. A meta-analysis of hip mJSW identified four loci: TGFA, 
PIK3R1, SUPT3H-RUNX2 and DOT1L, of which the TGFA, SUPT3H-RUNX2 and 





Figure 10: Summary of the novel genome-wide significant loci identified over the last 12 
years. 
 
Point sizes are proportional to the effect size (OR). Named genes represent the annotated 
genes provided from the GWAS catalog (https://www.ebi.ac.uk/gwas/, downloaded 20th 
February 2020). The ASTN2 locus was initially identified in a female-only analysis of 
THR (131), but was later associated with OA of the hip in a mixed-gender population 
(141). The DOT1L locus was identified in relation to hip OA in a male-only analysis 
(132), but has been identified in a GWAS of hip mJSW including males and females 
(147). SMAD3 was identified in an analysis of cross-phenotype associations with OA 
and BMD (137). Figure updated from (148). 
 
In addition to loci identified by GWAS in large populations, whole exome 
sequencing in three Finnish families has recently identified novel rare variants 
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segregating with OA within two families (149). One variant was a mis-sense 
variant in the OLIG3 gene, of which expression has been linked to Wnt signalling 
during neuronal development (149). The other variant was a 5’ UTR variant of 
FIP1L1. 
1.2.7. Management 
Treatment of OA mainly focuses on managing symptoms, as treatments to slow 
joint degeneration, or to repair damaged joints, are currently lacking. 
Management of symptoms can be achieved using non-steroidal anti-
inflammatory drugs to reduce the pain (or opioids in severe cases), via weight 
loss in obese patients to limit joint loading and reduce structural progression, 
and by physiotherapy to strengthen the muscles around the joint to reduce 
abnormal load (22,26). Other aids such as braces and insoles can be used for 
lower limb OA to stabilise the joint (22). In severe cases, surgical intervention 
may be required. This normally involves performing a TJR. TJR are performed 
for most joints affected by OA, but most commonly for the hip, knee, or base of 
the thumb joint (26). However, joint replacements can be associated with 
complications such as infections, leg-length discrepancy, and spontaneous 
dislocations (6) and approximately 9% of patients with THR and 20% with TKR 
still have chronic pain after surgery (150).  
It was previously thought that degenerative changes in cartilage were 
irreversible (151), hence the focus on management of symptoms. However, 
evidence from clinical trials of interventions to reduce mechanical loading, such 
as knee joint distraction which can cause increases in cartilage thickness (152-
154), provide hope that cartilage can be repaired, and further treatments can be 








CHAPTER 2.  BONE   
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2.1. Bone biology 
The human skeleton is vital to provide shape, protect organs, for locomotion and 
is an important store of minerals (particularly calcium) to maintain mineral 
homeostasis (155). The human skeleton consists of over 200 bones, which can be 
grouped as long (e.g. the femur), short (e.g. tarsals), flat (e.g. cranial bones), 
sesamoid (e.g. the patella) or irregular (e.g. vertebrae) (130,156). Bone is a 
dynamic tissue, which is constantly remodelled throughout the lifespan, for 
example to adapt to mechanical strain placed upon it by movement.  
2.1.1. Composition of bone tissue 
Bone is a composite tissue composed of bone cells and ECM (157). There are 
three types of bone cells: osteoblasts, osteocytes, and osteoclasts. The ECM is 
composed of inorganic mineral salts, water, and an organic phase of collagen, 
non-collagenous proteins, and lipids (157).  
Bone cells 
Osteoblasts 
Osteoblasts derive from mesenchymal stem cells (MSCs) and are the cells 
responsible for bone formation. Osteoblasts produce type I collagen, which forms 
over 90% of the organic bone matrix, and regulate mineralization of this matrix 
(158). Osteoblasts produce receptor activator of nuclear factor kappa-B ligand 
(RANKL), which binds to RANK on osteoclast precursors, thus triggering 
osteoclast maturation and bone resorption (section 2.1.4) (158). However, 
osteoblasts can produce osteoprotegerin (OPG), which binds to RANKL so that it 
cannot bind to RANK, thus inhibiting bone resorption (158). A number of key 
transcription factors and pathways regulate osteoblast proliferation, 
differentiation, and survival; these will be discussed in section 2.1.3. Mature 
osteoblasts undergo apoptosis, line the surface of bone, or are embedded in the 




Osteocytes are the most common cell type in bone (approximately 90-95%) (159). 
Osteocytes form large dendritic processes called canaliculi, which connect in a 
network with other osteocytes, functioning as a system of intercellular 
communication (159). Osteocytes are mechanosensory cells which produce 
signalling molecules to signal to osteoblasts and osteoclasts as a response to 
mechanical loading (160). It has been suggested that RANKL can be expressed 
along the dendritic processes, stimulating differentiation of osteoclast precursors 
and thus resorption (159). Osteocytes produce sclerostin, an inhibitor of the 
canonical Wnt signalling pathway (section 2.1.3), which leads to inhibition of 
new bone formation by osteoblasts (159). In response to loading, osteocytes 
reduce sclerostin expression and inhibit osteoclasts, whereas during unloading 
sclerostin and RANKL are expressed (159). Osteocyte apoptosis is important for 
bone repair as it stimulates resorption by osteoclasts (159). However pathogenic 
apoptosis of osteocytes can lead to excessive bone resorption and skeletal 
fragility (159). Disorientation of canaliculi and decreased connectivity, associated 
with a loss of osteocyte ability to sense damage and initiate repair, can lead to 
bone resorption (159).  
Osteoclasts 
Osteoclasts are multinucleated cells derived from monocytes originating from 
the bone marrow (161). They are responsible for bone degradation. Two key 
cytokines regulate the differentiation of osteoclasts: RANKL and Macrophage 
Stimulating Factor (M-CSF). M-CSF contributes to the proliferation, 
differentiation, and survival of several cells from the monocyte lineage (161). 
Attachment of the osteoclast to the bone surface is mediated by integrins, which 
are cell surface attachment molecules recognizing specific motifs on bone 
proteins (161). Upon attachment, acidified vesicles containing molecules, such as 
the lysosomal enzyme Cathepsin-K, are transported to the plasma membrane in 
contact with the bone (161). Fusion of these vesicles to the membrane results in 
formation of the ruffled membrane, which is a unique feature of osteoclasts (161). 
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The contents of the vesicles are then exocytosed into the acidic environment, 
created by a proton pump and a chloride channel in the membrane (161). This 
acidic environment mobilizes bone mineral, exposing the type I collagen to 
degradation by enzymes such as Cathepsin-K (161-163). 
Bone matrix 
Bone mineral 
The inorganic bone mineral is the largest component of the bone matrix and 
constitutes approximately 65% of the total bone weight (164). The mineral 
component of the bone matrix is a modified version of the naturally occurring 
mineral hydroxyapatite, containing calcium and phosphate ions (157). As bone 
matures, mineral crystals grow in size and become plate-like in structure, 
aligning in parallel with the collagen fibrils, strengthening the collagen (157,164). 
Hydroxyapatite forms a source of calcium, phosphate, and magnesium ions, 
maintaining homeostasis of these ions (157).  
Type I collagen 
Type I collagen is the most abundant protein in the bone matrix and the major 
component of the organic component of the bone matrix (~90%) (164). It 
generates a scaffolding, providing structure to the bone, binding other proteins. 
Type I collagen is a triple helix structure, formed of two α1 chains and an α2 
chain, which aggregate to form fibrils (157,164,165). Each collagen chain is 
composed of approximately 1000 amino acids, with a Glycine-X-Y repeat, with X 
and Y commonly representing proline and hydroxyproline respectively, which 
are essential for helix formation and other properties such as water binding (155). 
Fibrils are connected by crosslinks (155). The pattern of aggregation of fibrils 
depends on the type of bone: woven bone contains fibrils arranged in a random 
formation whereas lamellar bone contains fibrils arranged in sheets (166). 
Non-collagenous proteins and other components 
Non-collagenous proteins (NCPs) form approximately 10-15% of the protein 
content of bone (157). NCPs have various roles, including organization of the 
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ECM, regulating mineralization and co-ordinating interactions of the cells or 
mineral with the matrix (157). Approximately 25% of these NCPs are derived 
from non-skeletal sources, particularly from the serum (157). An example of an 
NCP derived from the serum is albumin, which binds to the hydroxyapatite 
crystals, inhibiting their growth (157). Proteoglycans, discussed in section 1.1.1, 
are an NCP present in the bone matrix and function in matrix organization, 
water and ion retention and regulation of TGFβ signalling (section 2.1.3) (157). 
Other NCPs include proteins with gla residues, which enhance calcium binding 
(157). These include matrix gla protein (MGP), which is a negative regulator of 
mineralization, and osteocalcin, which is a bone specific gla protein which 
possibly regulates osteoclast activity (157). As osteocalcin is bone-specific, it can 
function as a marker of osteoblast activity and thus bone formation (section 
2.1.4).  
Other non-protein components of the bone matrix include water and lipids. 
Water constitutes approximately 10% of the weight of bone and functions in 
maintaining the collagen structure of the bone matrix (157). Water can be bound 
to collagen/mineral or flowing through the osteocyte canaliculi, where it has a 
suggested role in intercellular signalling in response to mechanical loading (155). 
2.1.2. Structure of bone 
There are two types of bone present in the adult human skeleton: cortical 
(compact) and trabecular (cancellous or spongy). Both are types of lamellar bone. 
These two types of bone differ in their structure. Cortical bone, forming a greater 
proportion of bone mass, has low porosity, approximately 3-5% (155,164). 
Cortical bone is composed of Haversian systems which are also known as 
secondary osteons (155). Secondary osteons are a central canal, containing a 
blood vessel, nerve fibres and lymphatics, surrounded by concentric sheets of 
lamellar bone containing osteocytes (Figure 11). The blood vessels in the 
secondary osteons are connected by Volkmann’s canals, which additionally 
connect the secondary osteons to the marrow vasculature (155). In the long 
bones, cortical bone is found in the diaphysis surrounding the trabecular bone 
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(Figure 11), providing strength, support, and protection in response to load 
bearing (155,164). 
Trabecular bone is formed of plates and rods of lamellar bone, running roughly 
parallel to the bone surface, with approximately 75-85% porosity, which is filled 
with bone marrow (155,164). The vertebrae and ribs are composed of 
predominantly trabecular bone (155). The periosteum is a thin membrane 
covering the outer surface of the diaphysis of a long bone and contributes to 
bone formation along the outer surface (Figure 11). The endosteal surface lines 
the marrow cavity within the diaphysis (155). 
 
Figure 11: Structure of a long bone (left) and the cortical and trabecular bone components 
(right). 
 
Reproduced from https://training.seer.cancer.gov/anatomy/skeletal/. 
 
2.1.3. Bone formation 
There are two main types of bone formation during skeletogenesis: endochondral 
and intramembranous ossification. Intramembranous ossification does not 
involve a cartilage structure; it occurs when MSCs, migrated to ossification 
centres, condense to form osteoblasts, which lay down osteoid for mineralization 
(160,167). This process occurs in the formation of the flat bones of the cranial 
vault and the clavicle (160). Endochondral ossification requires a cartilage 
structure for ossification (160). This process occurs during skeletogenesis, 
postnatal growth, modelling and fracture repair and is involved in the formation 
and growth of long bones. 
Endochondral ossification 
The process of endochondral bone formation begins with the condensation of 
MPCs at the site of bone development to form a cartilage model (167). The MPCs 
proliferate and express cell adhesion molecules, leading to condensation (Figure 
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12A) (160). Within the condensations, MPCs differentiate into chondrocytes, 
which produce ECM leading to the formation of a cartilage structure (160). A 
sheath called the perichondrium forms around the cartilage from peripheral 
spindle-shaped cells (168). The perichondrium becomes the primary source of 
chondroblasts for the cartilage structure (Figure 12B). Chondrocytes near the 
centre of the developing limb flatten and align into columns and further 
differentiate into hypertrophic chondrocytes (Figure 12C) (160). Hypertrophic 
chondrocytes produce signalling molecules such as VEGF, leading to 
vascularization and calcification, as well as growth factors responsible for 
osteoblast differentiation, marrow cavity formation and formation of the primary 
ossification centre (POC, Figure 12D) (160). Chondrocytes secrete MMPs to 
degrade the cartilage matrix and hypertrophic chondrocytes transdifferentiate 
into osteoblasts (160). The degrading cartilage forms a scaffold for further bone 
formation (160). Vascular invasion allows osteoblast precursor cells to migrate to 
the POC and deposit type I collagen, which later mineralizes to form bone 
(Figure 12E). Growth plates (GP) form at the end of the growing long bone, 
which are a site of continuous bone formation in the growing skeleton. The GP is 
separated from the AC at the joint margin by a secondary ossification centre 
(SOC) during early postnatal growth (160). At the end of puberty, these 
cartilaginous GPs are converted to bone and the only cartilage that remains is the 
AC at the joint margin.   
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Figure 12: The key stages of endochondral ossification. 
 
Orange cells in stage (A) represent mesenchymal progenitor cells and in stage (B) 
represent perichondral progenitors. In stages (C-E) orange cells represent late-stage 
hypertrophic chondrocytes. Blue cells represent chondrocytes, purple cells are 
prehypertrophic chondrocytes and green cells represent hypertrophic chondrocytes. Light 
blue cells in stage (E) represent articular chondrocytes. Red lines represent blood vessels 
and black lines represent osteoblasts/ bone matrix. Reproduced from (160). 
 
Regulation of endochondral ossification 
SRY-Box Transcription Factor-9 (SOX9) and RUNX Family Transcription Factor-2 
(RUNX2) are key transcription factors regulating whether osteochondral 
progenitor cells (OPCs) differentiate into osteoblasts or chondrocytes (Figure 13) 
(160). OPCs are differentiated from MPCs due to β-catenin mediated gene 
expression (169). SOX9 is the “master regulator of cartilage formation”, 
regulating OPC differentiation into chondrocytes (160). RUNX2 is essential for 
the differentiation of OPCs into preosteoblasts (160). RUNX2 controls expression 
of osteoblast specific genes, including type I collagen and osteocalcin (169). The 
key role of RUNX2 in osteoblast differentiation is demonstrated by knockout 
mice models, who have an unmineralized cartilage skeleton due to no osteoblasts 
(169). The transcription factor Osterix (OSX) is a key regulator of later 
differentiation of preosteoblasts into mature osteoblasts (160). Osx expression is 
regulated by RUNX2, but knockout mice lack osteoblasts, suggesting that OSX is 
essential for osteoblast differentiation (169). 
 
Figure 13: Key signalling pathways and transcription factors regulating endochondral 
ossification and differentiation of MPCs to osteoblasts or chondrocytes. 
 
Reproduced from (160). 
 
The five key signalling pathways regulating endochondral ossification are Wnt 
signalling, Bone Morphogenetic Protein (BMP) and TGFβ signalling (which form 
Image removed for copyright purposes  
Image removed for copyright purposes  
 
 70 
the TGFβ superfamily), Notch signalling and Indian Hedgehog (IHH) signalling. 
The role of each of these pathways is discussed below. 
Other modulators of osteoblast activity include parathyroid hormone (PTH) and 
PTH-related protein (PTHrP), which can activate several intracellular pathways, 
leading to bone formation or bone loss depending on their intermittent or 
continuous presence, respectively (169). Growth factors, such as IGF-1, also play 
a role in bone development (169). 
The Wnt signalling pathway 
Ligands for the Wnt signalling pathway are Wnt glycoproteins (169). These act 
through frizzled-related transmembrane receptors and low-density lipoprotein 
receptor-related protein (LRP) co-receptors (169). There are two sub-pathways to 
the Wnt signalling pathway: canonical and non-canonical (Figure 14). The 
canonical pathway, involving β-catenin and the receptors LRP5/6, has a key role 
in osteoblast differentiation (170). β-catenin forms a complex with APC, GSK3 
and CK1 in the cytoplasm in the absence of Wnt ligands, where GSK3 
phosphorylates β-catenin, leading to its degradation (169,170). In the presence of 
Wnt ligands, this complex dissociates and β-catenin translocates to the nucleus, 
where it interacts with transcription factors, leading to transcription of genes 
involved in osteoblast differentiation (169). Canonical Wnt signalling is regulated 
by secreted frizzled-related proteins (FRPs), which interact extracellularly with 
Wnts, blocking their interaction with Frizzled receptors, as well as sclerostin and 
dikkopf-1 (DKK-1), which bind to LRP5/6 and block Wnt interaction (170).  
 
Figure 14: The canonical (a) and non-canonical (b) Wnt signalling pathways. 
 
Reproduced from (171). 
 
The TGFβ superfamily 
The TGFβ superfamily can be separated into two key signalling mechanisms: 
canonical, SMAD-dependent signalling, and non-canonical signalling via p38-
MAPK (172,173). TGFβ signalling regulates expression of RUNX2 and SOX9 
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(160,172,173). The TGFβ pathway can be further divided into the TGFβ receptor-
dependent and the BMP receptor-dependent pathways. These two pathways 
differ in their receptors, ligands and the SMADs that they activate (the TGFβ-
specific pathway activates SMAD2/3 whereas the BMP-specific pathway 
activates SMAD1/5/8 [SMAD8 is also known as SMAD9]) (169). However, the 
receptors and ligands are similar, and they share a common signalling 
mechanism (Figure 15). The ligands form dimers to interact with a type 1 and 
type 2 serine/threonine kinase receptor (169,174). The type 2 receptor then 
phosphorylates and activates the type 1 receptor, which then phosphorylates the 
pathway-specific SMAD, allowing interaction with SMAD4 (common to both 
pathways), leading to translocation of the SMAD complex to the nucleus, 
association with target transcription factors and expression of target genes 
(169,174). These target genes vary between ligands, for example BMP2 ligand is 




Figure 15: Diagram summarizing the TGFβ and BMP signalling pathways. 
 
Reproduced from (175).  
 
Notch signalling 
The role of the Notch signalling pathway in promoting or inhibiting osteoblast 
differentiation appears to vary, possibly depending on the stage of 
differentiation (169). There are three Notch ligands (delta, serrate and Lag2), 
which bind to transmembrane notch receptors (169). This leads to cleavage of the 
intracellular domain by presenilin which then translocates into the nucleus, 
forming a complex with CSL family DNA binding proteins and the recruitment 
of co-activators, ultimately leading to the transcription of target genes (169).  
Ihh signalling 
Indian hedgehog signalling leads to expression of RUNX2 via the transcription 
factor GLI2 (169). In the presence of the IHH ligand, inhibition of the 
Smoothened receptor by the Patched-1 receptor is depleted, allowing signalling 
via the GLI2 transcription factor (169). Ihh signalling also leads to expression of 
PTHRP, which in turn downregulates chondrocyte hypertrophy at the growth 
plate (176). Mice deficient in Ihh lack osteoblasts in new bone formed by 
endochondral ossification (169). 
2.1.4. Bone metabolism 
There are two processes of bone metabolism: bone modelling and bone 
remodelling. Bone modelling occurs when either bone formation occurs without 
prior resorption, or bone resorption occurs without subsequent formation (177). 
Bone modelling alters the size and/or shape of bone and is important for 
periosteal expansion during growth (177). Bone remodelling is a coupled process 
of bone resorption and formation and is important to repair microdamage and 
maintain mineral homeostasis in adulthood (177,178).  




Bone remodelling occurs at a structure called a basic multicellular unit (BMU) 
and consists of five stages (178): 
1. Activation: osteoclast precursor cells are recruited to the site of resorption, 
fuse to form multinucleated osteoclasts and are activated. The activated 
osteoclasts then bind to the bone matrix (section 2.1.1), creating a sealing 
zone for resorption (Figure 16A). 
2. Resorption: the process of bone resorption by osteoclasts (section 2.1.1) 
lasts approximately two weeks and ends with the programmed cell death 
of the osteoclasts (Figure 16B). A resorption cavity is created. 
3. Reversal: unmineralized matrix on the resorbed bone surface is removed 
and a non-collagen mineralized matrix is deposited, called the cement 
line, to enhance the adherence of osteoblasts (Figure 16C). This stage lasts 
for approximately one month. 
4. Formation: new osteoid is deposited by osteoblasts and subsequently 
mineralized (Figure 16D). This is the longest stage of the bone remodelling 
process (177). 
5. Termination: bone formation is stopped by apoptosis of osteoblasts or 
their differentiation into osteocytes or bone lining cells (Figure 16E). 
 
Figure 16: The bone remodelling cycle. 
 
Reproduced from (179). 
 
Regulation of bone remodelling 
The OPG-RANK-RANKL system (described in section 2.1.1) is a key regulator of 
the activation and resorption stages. Osteoclasts are initially recruited due to 
microdamage in the bone matrix disrupting osteocyte canaliculi, leading to the 
release of cytokines, such as RANKL, responsible for osteoclast recruitment (178). 
RANKL expression by bone lining cells is increased during the activation phase 
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(180). Glucocorticoid use and continuous use of PTH also upregulate 
RANK/RANKL expression (178). Oestrogen is an important regulator of bone 
remodelling. Oestrogen receptors are expressed on all bone cells (177). Reduced 
oestrogen levels can lead to osteocyte apoptosis, releasing pro-inflammatory 
cytokines which promote osteoclast recruitment (177). The TGFβ superfamily 
(section 2.1.3) is involved in the coupling of bone resorption and bone formation. 
Active forms of TGFβ ligands are released during resorption, leading to the 
recruitment and differentiation of OPCs during reversal and formation (174).  
Measuring bone metabolism 
Based on the knowledge of the structure of the bone matrix and the processes 
involved in bone remodelling, assays have been developed to measure specific 
products of both bone formation and resorption, to give an estimate of the 
current rate of bone turnover. These bone turnover markers (BTMs) can be used 
to predict major osteoporotic fractures or to determine response to, and the ideal 
dosage for, medications for osteoporosis (section 2.2) (181). Telopeptides at the 
N-terminal (NTX-1) and C-terminal (CTX-1) of type I collagen are cleaved during 
bone resorption and released into the circulation (164). NTX-1 or CTX-1 levels 
can therefore be measured in serum or urine to provide an estimate of the level 
of bone resorption (181). CTX-1 can be measured in the non-isomerized (α) form, 
which is mainly derived from new bone, but more commonly the β isomer (β-
CTX) is measured, which reflects breakdown of older bone (182). N-terminal 
propeptide of type I collagen (P1NP) is released into the circulation by 
posttranslational cleavage of type I procollagen and can therefore be used as a 
measure of osteoblast function and thus bone formation (181). However, 
measurement of BTMs is affected by circadian variations, diet, and seasonality 
and therefore measurements should be taken from fasting samples following a 
standardized protocol (181). 
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2.2. BMD and osteoporosis 
BMD is a measurement of the bone mineral content (BMC) per unit of bone area 
and low BMD is used clinically to identify individuals with osteoporosis, at high 
risk of fracture. BMD is commonly assessed through Dual X-ray Absorptiometry 
(DXA) scanning. DXA scanning is the preferred method for assessing BMD 
clinically as it is relatively quick, with low radiation and DXA-assessed BMD 
correlates with fracture risk, the clinical endpoint that interventions for 
osteoporosis are trying to prevent (183,184). Every DXA scanner, regardless of 
manufacturer, has a radiation source which emits two energy levels. The 
difference in attenuation of these two energy levels, as they pass through 
different tissues with varying composition, is detected by a radiation detector 
and transferred to computer software linked to the scanner, which allows an 
image to be generated and quantitative measurements of BMD and soft tissue 
mass to be calculated (184).   
In the UK, DXA scanning is performed on the National Health Service (NHS) if 
an individual is determined to be at risk of low density (e.g. due to long-term 
steroid treatment, use of aromatase inhibitors for breast cancer, previous 
fracture). A T-score for the number of standard deviations (SDs) below a sex-
matched young adult population mean is generated (185). A BMD T-score <-2.5 
is used by the World Health Organization to determine osteoporosis. 
Osteoporosis is a metabolic bone disorder characterized by low bone mass and 
reduced bone strength, leading to an increase in bone fragility and risk of 
fracture (186,187). Most cases are caused by age-related bone loss due to a decline 
in bone formation, relative to resorption, at BMUs, as a consequence of a reduced 
number of MSCs to differentiate into osteoblasts (177). This is usually caused by 
an overall increase in bone turnover, with the increase in bone resorption greater 
than the increase in formation. There is overall loss of bone strength, as newly 
formed bone is hypomineralized, increasing fracture risk (177). 
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2.2.1. Treatments for osteoporosis 
Several drug therapies have been developed and routinely used for treatment of 
osteoporosis. These can be split into two categories: antiresorptives and anabolic 
drugs. Antiresorptive drugs increase BMD by reducing osteoclast activity. 
Bisphosphonates are the first therapy normally given to postmenopausal women 
with osteoporosis (188). Bisphosphonates bind to hydroxyapatite, where they are 
released during bone resorption, taken up by osteoclasts, leading to reduced 
bone resorption due to inactivation or apoptosis of the osteoclasts (188). As 
discussed in section 2.1.4, bone resorption is coupled, so the decrease in bone 
resorption due to use of bisphosphonates is followed by a decrease in bone 
formation, but the decrease in the rate of bone formation is slower than the 
decrease in the rate of formation (188). Denosumab is a monoclonal antibody 
specific for RANKL, inhibiting RANKL binding to the RANK receptor on 
osteoclasts (189). Denosumab therefore reduces bone resorption, leading to an 
overall decrease in bone turnover (189).  
Anabolic drugs increase bone formation by increasing osteoblast activity. 
Evidence suggests that anabolic drugs may cause greater increases in BMD, 
particularly at the spine, compared to antiresorptive drugs (190). Teriparatide is 
an anabolic drug routinely used to treat osteoporosis. Teriparatide is an amino 
terminal fragment of PTH (190). Despite continuous administration of PTH 
increasing bone resorption, intermittent administration can stimulate bone 
formation by downregulation of Wnt signalling antagonists (178,191). 
Romosozumab is the latest osteoporosis drug to be licenced in the UK. 
Romosozumab is an anti-sclerostin antibody, reducing Wnt antagonism and 
increasing bone formation and suppressing bone resorption (192). 
2.3. High bone mass 
As discussed in section 2.2, a T-score threshold <-2.5 is used to define 
osteoporosis. However, an equivalent threshold has not been set to define high 
BMD (high bone mass [HBM]). There are cases where a high BMD value on a 
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DXA scan does not necessarily mean a lower fracture risk (193). For example, 
artefactual elevations in lumbar spine (LS)-BMD measured by DXA scan can 
occur due to the presence of osteophytes and subchondral sclerosis (section 
1.2.2). Artefactual elevations in BMD due to osteophytes can be determined by 
progressive increases in BMD with decreasing LS vertebrae (193). Other 
conditions artefactually elevating LS-BMD include diffuse idiopathic skeletal 
hyperostosis and ankylosing spondylitis, which are associated with an increased 
fracture risk, and vascular calcification of the abdominal aorta (193). The 
presence of surgical metalwork can lead to artefactual BMD measurements (193). 
2.3.1. Rare monogenic HBM disorders 
In addition to artefactual elevations in BMD, there are several known monogenic 
disorders causing extremely high BMD measurements on DXA scans. These can 
be separated into two types: disorders characterised by reduced osteoclastic bone 
resorption (the osteopetroses) and disorders characterized by increased bone 
formation (193). Although osteopetroses are associated with dense bones, bones 
are brittle and liable to fracture (193). An example of osteopetrosis is 
pycnodysostosis, caused by non-synonymous mutations leading to inactivation 
of Cathepsin-K (194).  
An example of a monogenic condition leading to excess bone formation is 
sclerosteosis, caused by a loss-of-function mutation in the SOST gene (193). 
Features of sclerosteosis include a reduced fracture risk, gigantism, mandible 
enlargement and compressed cranial nerves leading to hearing loss and 
headaches (193). Van Buchem’s disease is a milder version of sclerosteosis caused 
by an intronic deletion in SOST (193). Mutations in the LRP4 gene also cause 
sclerosteosis, by inhibiting the interaction between LRP4 and sclerostin (195). A 
similar phenotype is observed for activating LRP5 mutations (193), of which 13 
have been identified as associated with HBM (196).  
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2.3.2. The HBM study 
Approximately one-third of HBM observed on routine DXA scans is not 
explained by artefactual elevations or the monogenic disorders described in 
section 2.3.1 (193). The HBM study was therefore set up to identify the 
underlying genetic aetiology causing unexplained HBM, to further understand 
how bone mass is regulated, with the hope of identifying novel therapeutic 
targets for osteoporosis. 
The HBM study is a multi-centre study of individuals with unexplained 
generalized high BMD, and their family and relatives without HBM, recruited 
from 15 NHS centres across England and Wales (1). Recruitment of this cohort 
began with a screen of 335,115 DXA scans on NHS databases at 13 centres (2 
centres recruited patients prospectively) for a T-score or Z-score >+4. Identified 
scans were visually inspected; 49.4% had elevated BMD due to degeneration and 
9.7% had artefacts or were unverifiable. The overall prevalence of unexplained 
HBM was 0.18% (197).  
To determine the effect of osteoarthritic changes on BMD at the LS, 562 LS scans 
with a Z-score >+4 at the largest centre, Hull, were graded for OA severity using 
KL grading (198). BMD of each vertebra was associated with OA grade, except 
for the L1 vertebra, for which BMD was not associated with OA (198). Therefore, 
the definition of HBM was based on L1-BMD. It was assumed that both the L1 
vertebra and total hip (TH) would be affected, but not necessarily to the same 
extent. A definition based on that previously published by Little et al (199) was 
therefore used, with HBM being defined as either [1] L1 BMD Z-score >+3.2 plus 
TH Z-score >1.2 or [2] TH Z-score >3.2 plus L1 Z-score >1.2. Overall, 41% (258) of 
identified HBM individuals were recruited (Figure 17). 
 
Figure 17: Screening and recruitment of the HBM study population. 
 
Reproduced from (197). 
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Index cases were asked to invite their first-degree relatives and spouses to 
participate in the study. Recruitment ran from July 2005 to April 2010. The aim of 
including relatives was to determine the pattern of inheritance of HBM 
(monogenic or polygenic). 236 relatives and 61 spouses were recruited to the 
study (Figure 17). All participants were aged 18-90 years and all but three were 
Caucasian. To characterize the HBM phenotype, index cases and 
relatives/spouses were invited to their local HBM centre for a detailed clinical 
assessment and interview. In first-degree relatives, HBM case status was defined 
as summed TH plus L1 Z-score >+3.2, to overlap the index case distribution. 
HBM in spouses was defined as for index cases. Ninety-four first-degree relatives 
and three spouses had HBM.  
2.3.3. The HBM phenotype 
Compared to relatives/spouses without HBM, individuals with HBM (including 
index cases and relatives with HBM) had an enlarged mandible, broad frame, 
were more likely to have misshapen or extra bone at tendon or ligament 
insertions and a reduced odds of reporting a family history of fracture. These 
features were suggestive of a mild skeletal dysplasia (197).  
Bone phenotype of HBM 
Peripheral quantitative computed tomography (pQCT) analyses of 98 HBM 
individuals and 65 controls at the largest centre, Hull, identified higher 
trabecular and cortical bone area, periosteal circumference, trabecular and 
cortical BMD, and strength-strain index at the distal tibial site in HBM 
individuals (200). The same pattern was not seen at the radius, suggesting that 
there is an interaction between HBM status and weight-bearing activity on 
cortical/trabecular BMD, which suggests that individuals with HBM have an 
increased responsiveness to mechanical strain (200). The inverse relationship 
between TB-BMC and age in female HBM individuals was much weaker than 
relatives without HBM, suggesting that HBM individuals are less likely to lose 
bone as they age (201). 
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Metabolic phenotype of HBM 
Initial phenotyping of HBM individuals identified a higher BMI than relatives 
and spouses without HBM (197). Further assessment of body composition on 
DXA scans found that HBM individuals had a higher percentage of total body fat 
mass (TBFM) compared to relatives/spouses without HBM (201). Adjustment for 
TH-BMD attenuated the relationship between HBM and TBFM, whereas 
adjustment for TBFM only minimally attenuated differences in BMD between 
HBM individuals and relatives/spouses without HBM, suggesting that BMD 
mediates the relationship between HBM and increased TBFM, rather than 
increased TBFM responsible for the higher BMD. There was also a trend towards 
lower bone turnover in HBM individuals, with lower levels of osteocalcin. 
Osteocalcin knockout mice have been observed to be insulin resistant with 
greater fat mass (FM) (202). Therefore, it has been hypothesized that HBM 
individuals may have a genetic tendency for lower bone turnover, leading to 
reduced serum osteocalcin and increased TBFM (201). However, adjustment for 
bone turnover did not attenuate the relationship between HBM and TBFM, 
although it should be noted that BTMs measured at one timepoint will not be 
reflective of bone turnover during growth and development. It has been 
hypothesized that bone formation is increased in early life in HBM which leads 
to suppression of bone turnover in later life (201). 
2.3.4. Genetics of HBM 
Sequencing of LRP5, LRP4 and SOST in HBM individuals identified three known 
missense LRP5 mutations and two novel missense LRP5 mutations in 11 adults 
from 7 families, all of which were heterozygous and the highest BMD of all HBM 
individuals (196). All mutations identified were predicted to have functional 
consequences resulting in decreased Wnt antagonism. Two mutations in the 
SOST binding site had the most extreme phenotypic consequences. A novel 
nonsense mutation in exon two of SOST was identified, as well as a previously 
reported SNP in exon one in eight cases and two intergenic SNPs in nine cases 
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(196). A novel intronic mutation near exon 25 of LRP4 was identified, as well as a 
common LRP4 SNP in 56 individuals (196).  
A lack of mutation in genes known to cause monogenic HBM disorders in the 
majority of HBM individuals led to the hypothesis that HBM could be caused by 
the polygenic inheritance of multiple loci known to influence BMD in the general 
population (203). A GWAS in the HBM population (combined with individuals 
from the Anglo-Australasian Genetics Consortium (AOGC) with a TH-BMD Z-
score >1.5 and low bone mass controls (Z-score<-1.5) identified that the observed 
p-values for 49 known BMD loci (204) were smaller than expected by chance (i.e. 
there was an over-representation of common BMD variants in the HBM 
population) (203).  
Whole exome sequencing and pedigree analysis of HBM individuals (without 
LRP5 or SOST mutations) identified a novel autosomal dominant mutation in 
SMAD9 (205). This variant was additionally found in two unrelated individuals, 
one from HBM and one from the AOGC high TH-BMD population. The variant 
was not present in the AOGC low BMD population and is rare in the general 






CHAPTER 3.  THE 
RELATIONSHIP BETWEEN 





3.1. Epidemiological evidence for a relationship 
between BMD and OA 
Foss and Byers first observed, in 1972, that OA of the hip was rarely present in 
cases of hip fracture and that those with OA of the hip had above average 
metacarpal BMD, suggestive of an inverse relationship between osteoporosis and 
OA (206). Since then, the relationship between BMD and radiographic OA has 
been extensively studied. Evidence for an association between BMD and 
prevalent OA has been generally consistent, despite the variation in site of BMD 
(LS, hip, total body [TB], radius, calcaneus) and OA (hip, knee, hand) assessment 
(Figure 18). However, evidence for associations with incident/progressive OA 
has been less consistent (207). This section summarizes the epidemiological 
evidence for relationships between BMD and prevalent, incident, and 
progressive OA at various skeletal sites.  
3.1.1. Cross-sectional evidence 
Prevalent OA 
Evidence from cohort studies 
The relationship between BMD and prevalent radiographic OA has been 
investigated in a wealth of cohorts sampled from the general population (Figure 
18). Analyses in women from the study of osteoporotic fractures (SOF), the first 
Rotterdam study (RS) population (RS1), men from the study of osteoporotic 
fractures in men (MrOS) and female twins from the St Thomas UK adult twin 
register, all identified positive relationships between hip or FN-BMD and hip OA 
(208-211). There is consistent evidence for a relationship between hip OA and 
BMD of the LS, radius, and calcaneus (208). 
Positive relationships between BMD and knee OA have also been identified. The 
first analysis was performed on a population of 932 individuals from the 
Framingham study (212). This study assessed OA of the knee four years prior to 
BMD measurement at the femur and radius. This study found a higher FN-BMD 
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in women with a KL grade of 1 or 2, compared to those with no features of OA. 
This study also identified higher BMD in women, but not men, with knee 
osteophytes (212). Subsequent analyses identified positive relationships between 
hip/FN BMD and knee OA in Chingford women, the RS population, women 
from the Michigan Bone Health study, and the Korean National Health and 
Nutrition Examination Survey (KNHANES) (209,213-215). Associations between 
knee OA and LS-BMD have been identified in Chingford women, women from 
the Michigan Bone Health Study and both men and women from KNHANES 
(213-215). However, analysis of the Dong-gu Korean cohort identified an inverse 
relationship between FN-BMD and knee OA, reflecting an inverse relationship 
with JSN (216). 
The relationship between BMD and prevalent hand OA is less well characterised. 
A study of 979 Chingford women identified a higher mean LS-BMD in those 
with OA at the DIP or CMC and greater FN-BMD in those with CMC OA (213). 
A further study of women from the Michigan Bone Health Study identified a 
positive relationship between TB-BMD and overall hand OA severity score (217). 
As observed at the knee joint in the Dong-gu cohort, FN-BMD was inversely 
related to hand JSN in this population, but hand osteophytes and sclerosis were 





Figure 18: Summary of evidence for associations between BMD and radiographic OA from cross-sectional and longitudinal analyses. 
 





Evidence from case-control studies 
In addition to cohort studies of the relationship between BMD and prevalent OA, 
some studies have collected opportunistic BMD data in OA patient populations, 
for example pre-operative THR or TKR patients with confirmed OA, and have 
compared BMD in these patients to age-matched control populations. Arokoski 
et al measured FN and calcaneus BMD in 27 men with unilateral or bilateral hip 
OA and 30 age-matched controls but did not find evidence for a difference in 
BMD between cases and controls, although they did find that FN-BMC and 
volume were 18% higher in hip OA cases compared to controls (218). Iwamoto et 
al observed a higher BMD at the radius in 305 postmenopausal women with knee 
OA compared to 369 controls without knee OA, and a positive correlation 
between BMD and KL grade up to grade 3, after which BMD decreased (219). 
Glowacki et al compared hip BMD between hips of 34 individuals undergoing 
unilateral THR and observed a higher FN and trochanteric BMD in the hip due to 
be replaced, compared to the contralateral hip, but did not observe a difference 
in TH-BMD between the two hips, suggesting artefactual elevations in FN-BMD 
due to features of OA (220). Similarly, Goerres et al compared TH-BMD in 161 
unilateral knee OA cases and found a lower hip BMD in the same leg as the 
affected knee, compared to the contralateral hip (221). Several papers by Karlsson 
and colleagues have determined differences in TB-BMD Z-scores between 62 hip 
OA cases and 187 controls (222), 112 knee OA cases and 243 controls (223,224) 
and 39 hand OA cases (defined as OA of the DIP and/or CMC joints) and 164 
controls (225). Cases were referred to a hospital in Sweden and controls were 
randomly selected from Statistics Sweden population records. In all papers, TB-
BMD was higher in cases compared to controls for both men and women (222-
224), with the exception of male hand OA cases, who did not have higher BMD 
than male controls (225). 
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HBM and prevalent OA 
An increased prevalence of overall radiographic hip and knee OA in individuals 
with HBM (section 2.3.2) compared to relatives and general population controls 
has been observed, with age-, sex- and BMI-adjusted ORs of 1.52 (95% CI 1.09, 
2.11) and 1.62 (1.22, 2.16) for hip and knee OA, respectively (226,227). 
Adjustment for BMI made little difference to the results for hip OA but 
attenuated the OR for knee OA from 2.38, suggesting that the increased FM of 
HBM individuals partially mediates the relationship between HBM and knee 
OA, with mediation analysis suggesting that 45% of the effect of HBM on knee 
OA is mediated by BMI (227).  
When analysing the individual radiographic sub-phenotypes of OA 
(osteophytes, JSN, subchondral sclerosis), an increased odds of osteophytes in 
HBM individuals was observed at both joints and an increased odds of 
subchondral sclerosis was observed at the hip. However, there was no difference 
in odds of JSN, between individuals with and without HBM, at either joint 
(226,227). These associations are suggestive of a ‘bone-forming’ phenotype in 
HBM individuals. The same pattern of increased odds of osteophytes but not JSN 
in individuals with HBM compared to unaffected relatives was also observed in 
the (non-weight-bearing) DIP and CMC joints (228). 
3.1.2. Longitudinal evidence 
Incident OA  
In epidemiological studies, incident radiographic OA is normally defined as a 
joint with a KL grade >2 at follow-up, which had been free of OA at baseline 
(KL<2). The relationship between BMD and incident OA of the hip and/or knee 
has been studied in the following cohorts: the Michigan bone health study, the 
Framingham study, the Chingford study, RS, the Baltimore longitudinal study of 
aging, the MOST study and JoCo. Overall, there is relatively consistent evidence 
to suggest higher BMD is associated with incident knee OA, but less clear 
evidence to suggest a relationship with incident hip OA. 
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The first longitudinal analysis of the relationship between BMD and incident OA 
was published by Sowers et al in 1999, who studied the incidence of hand and 
knee OA in 482 women, with a mean age of 37 years, from the Michigan bone 
health study (214). The authors observed a 0.8SD higher mean FN-BMD Z-score 
in those with incident knee OA within three years of follow-up, compared to 
those who did not develop knee OA during follow-up; however, the authors did 
not find evidence for a relationship between BMD and incident hand OA (214). 
An association between FN-BMD and incident knee OA was also observed in a 
population of 473 women with a mean age of 71 from the Framingham study, 
followed-up over approximately nine years (229). In a population of 119 men and 
76 women, with mean age 61 years, from the Baltimore longitudinal study of 
aging, higher LS, but not FN, BMD predicted an increased odds of incident knee 
OA over an average of 10 years of follow-up (230). In a population of 975 
individuals aged over 45 years from the JoCo study, a higher risk of developing 
incident knee OA over a median of 6.5 years was observed in those with 
intermediate, but not high, TH-BMD, suggesting a non-linear relationship 
between TH-BMD and incident knee OA (231). Bergink et al studied the 
relationship between BMD and incident knee OA in a population of 619 women 
and 496 men from RS, over on average 6.5 years. They observed that the 
difference in baseline FN and LS-BMD between those with and without incident 
knee OA at follow-up was greater for men than women (232). 
Studying the individual radiographic phenotypes of OA, Hart et al identified a 
6.3% higher mean LS-BMD and 3.9% higher mean FN-BMD in women with 
incident knee osteophytes, but evidence for higher BMD at either site was much 
weaker in those with incident JSN amongst Chingford women (233). However, in 
the MOST study cohort, BMD was associated with an increased odds of JSN 
(defined by change in JSN grade of at least half a grade) and an increased odds of 
osteophyte worsening (increase of one grade for any osteophyte) in those 
without OA at baseline, suggesting that BMD is related to the incidence of both 
osteophytes and JSN (234). 
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Fewer studies have examined the relationship between BMD and incident hip 
OA. In the JoCo analysis by Barbour et al, amongst 928 adults free of hip OA at 
baseline (KL<2), TH-BMD was unrelated to incident hip OA, as defined by 
radiographic criteria. However, an inverse relationship between TH-BMD and 
incident symptomatic radiographic OA (i.e. symptoms and radiographic 
evidence of OA in a hip without both at baseline) was observed (231). In RS, no 
evidence was found to support a linear relationship between FN-BMD and 
incident hip OA, although when the population was divided by quartile of FN-
BMD, there was a higher odds of incident OA in the highest quartile compared to 
the lowest quartile only, suggesting a threshold effect (235).  
Progressive OA 
Evidence supporting an association between BMD and progressive OA is limited 
and inconsistent (207). Zhang et al studied the relationship between FN-BMD and 
knee OA progression in a female population from the Framingham study. They 
defined OA progression as an increase of KL grade in those with a KL grade of at 
least two at baseline. They found a lower odds of OA progression with 
increasing BMD quartile (229). When analysing the individual sub-phenotypes, 
they found evidence that higher BMD was associated with a reduced odds of JSN 
progression but there was no dose-response relationship between BMD quartile 
and osteophyte progression (229). Hart et al similarly found a lower hip, but not 
LS, BMD in those with progressive OA and JSN in women from the Chingford 
study (233). An analysis of the RS population failed to identify an association 
between FN-BMD and progressive knee OA but did observe a relationship 
between LS-BMD and knee OA progression (232). Further analyses of RS 
identified an increased odds of hip OA progression per SD increase in FN-BMD 
(235). 
Summary of evidence 
Overall, the evidence from both cross-sectional and longitudinal observational 
analyses provides consistent evidence for a relationship between high BMD and 
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risk of OA. However, the role of BMD in OA progression is less clear. One 
possible explanation is that studies of OA progression have been performed in 
case-only populations. This could result in a selection bias whereby risk factors 
for disease incidence can be spuriously inversely associated due to ‘conditioning’ 
on case status, leading to spurious inverse associations of risk factors with 
progression if there are unmeasured confounders related to both incidence and 
progression (236). Alternatively, there may truly be an inverse relationship 
between BMD and OA progression due to a positive relationship between BMD 
and cartilage thickness, meaning higher BMD is related to reduced progression 
of JSN. To progress from KL grade two to three or four at the knee, JSN needs to 
occur. The results of Zhang et al suggest that higher BMD is specifically 
associated with reduced JSN, but not osteophyte, progression. Therefore, further 
analyses of progression of the individual radiographic sub-phenotypes of OA are 
required. 
HBM, BMD and joint replacement 
Joint replacement surgery can be used as an indicator of severe OA, as OA is the 
most common reason for performing TKR/THR (237). TJR reflects a combination 
of pain and reduced function, along with radiographic features of OA (238). In an 
analysis of the HBM population, Hardcastle et al identified a higher odds of TJR 
at any site in HBM individuals compared to their relatives without HBM, 
reflecting a greater than 4.5 times higher odds of hip replacement (partial or 
total) (239). Evidence for an increased odds of knee replacement was much 
weaker. When comparing the prevalence of TJR at any site in the HBM 
population, aged over 65 years, with general population data from the Health 
Survey for England, a higher prevalence of TJR in HBM individuals was 
observed, whereas there was no difference in prevalence between the relatives 
without HBM and the general population (239). These findings are consistent 
with a more recent analysis in TASOAC, which identified a positive relationship 
between LS and TB-BMD and risk of THR, but no relationships between LS, TH 
or TB-BMD measures and TKR were observed (240). The authors did, however, 
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observe a relationship between medial tibia subchondral BMD and risk of TKR. 
Overall, the findings of these two studies suggest that higher BMD is related to a 
greater risk of severe, end-stage OA at the hip, suggestive of a positive 
relationship between BMD and hip OA progression. 
3.2. Bone turnover and OA 
Evidence from observational studies 
Several cross-sectional and longitudinal analyses have examined the relationship 
between BTMs (section 2.1.4) and OA, with inconsistent findings. As bone 
turnover is inversely related to BMD, one may expect to see lower levels of BTMs 
in those with OA. Peel et al found evidence for inverse relationships between 
BTMs and severity of spinal OA (241) and Sowers et al found lower osteocalcin 
levels in both knee and hand OA cases (214). Garnero et al similarly reported 
lower osteocalcin, as well as lower CTX-1, in outpatients with knee OA 
compared to controls, and identified an inverse relationship between osteocalcin 
levels and severity of OA symptoms assessed by total Western Ontario and 
McMaster Universities OA (WOMAC) index (242). 
Inconsistent with these studies suggesting increased bone turnover is related to a 
reduced risk of OA, Stewart et al identified higher osteocalcin levels in cases with 
clinically diagnosed hip OA, compared to controls (243). Bettica et al identified 
higher levels of urinary CTX-1 and NTX-1 in Chingford women with progressive 
knee OA, compared to controls without OA or osteoporosis (244). However, 
CTX-1 and osteocalcin were unrelated to knee OA in a population of men from 
the Hertfordshire Cohort Study (HCS) (245). Hunter et al studied twin pairs from 
the St Thomas twins registry and identified a higher concentration of 
deoxypyridinoline, a marker of bone resorption, in individuals with knee OA, 
compared to those without knee OA, but no difference in osteocalcin (246). Min 
et al identified higher OPG levels in those with KL grade 4 knee OA compared to 
those with a KL grade 2 or 3, suggestive of higher bone turnover in those with 
more severe OA (247).  
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Inconsistencies in these studies could reflect the fact that they are measuring 
systemic bone turnover, rather than bone turnover localized to the subchondral 
bone. Dieppe et al found evidence for a relationship between subchondral bone 
turnover, as assessed by bone scintigraphy, and progression of JSN (248). A 
similar relationship with radiographic changes was observed at the hand (249). 
Nwosu et al compared levels of serum tartrate resistant acid phosphatase 5b 
(TRAcP5b), produced by osteoclasts, to the density of TRAcP-positive osteoclasts 
in the subchondral bone and found a positive relationship, suggesting that serum 
BTMs correlate with subchondral bone turnover. The authors further identified a 
positive relationship between TRAcP5b and WOMAC pain scores and 
subchondral sclerosis (250). 
Evidence from clinical trials 
Further evidence for a role of bone turnover in OA progression is provided by 
clinical trials of drugs affecting bone turnover. Strontium ranelate (StR) is an 
osteoporosis treatment suggested to reduce bone resorption whilst increasing 
bone formation. A post hoc analysis of 1,105 women from a clinical trial for 
spinal osteoporosis, who also had spinal OA, found that StR improved back pain 
compared to those taking placebo and resulted in a 42% reduction in progression 
of radiographic OA compared to placebo (251). Another post-hoc analysis of 
2,617 women from a StR osteoporosis trial identified a reduction in CTX-II, a 
marker of cartilage degradation, over three years in women taking StR (252). This 
evidence led to the design of the StR in knee OA (SEKOIA) trial, which was a 
three-year double-blinded trial to determine if StR protects from knee OA 
progression (253). The trial recruited 1,371 patients with knee OA and found 
evidence for reduced cartilage degeneration in the treatment group compared to 
the placebo group, and those taking a higher dose also had improvements in 
WOMAC pain and physical function scores compared to those taking the 
placebo (254,255). A further MRI analysis also identified that those taking the 
higher dose had reduced cartilage volume loss and attenuated BML progression 
compared to those taking the placebo (256). Hypothesized mechanisms by which 
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StR protects from OA progression include reduced subchondral bone 
remodelling or a direct effect on reduced chondrocyte apoptosis (257). 
Evidence from clinical trials of the bisphosphonate risedronate have similarly 
suggested a possible role of bone turnover in OA progression. The first one-year 
trial of 231 patients with knee OA from the UK determined the effect of two 
doses of risedronate, compared to placebo, on radiological changes and changes 
in symptoms. Improvements in total WOMAC scores, reflecting improvement in 
symptoms, were observed for both doses compared to placebo (258). There was 
also an improvement in the patient global assessment of disease for the higher 
dose of risedronate, compared to placebo (258). A larger, two-year, trial, 
including North American and European individuals with medial compartment 
knee OA did not observe differences in the change in WOMAC scores between 
those taking risedronate and those taking the placebo, nor did they observe 
differences in change in mJSW (259), suggesting potential population-specific 
effects of risedronate on OA symptoms. It should be noted that decreases in 
average pain scores were observed in all groups, of similar magnitude to 
previously observed (258). However, a decrease in CTX-II was observed (259), 
which was subsequently related to reduced radiological progression at two years 
(as defined by change in mJSW) (260).  
3.3. Insights from genetic studies 
3.3.1. Determining the causal effect of BMD on OA risk 
Although there is a wealth of evidence to suggest an observational relationship 
between BMD and OA, it is currently unclear whether this represents a true 
causal effect of BMD on OA, or shared underlying biological pathways 
contributing to bone and joint development and homeostasis.  
Consistent with a direct causal effect of BMD on OA, Funck-Brentano et al 
identified a causal effect of FN-BMD on both hip and knee OA using Mendelian 
randomization (MR) analyses for causal inference (MR is described in section 
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5.3.3) (261). However, the authors did not determine the causal effect of hip and 
knee OA on FN-BMD; lack of evidence for this direction of effect would 
strengthen the evidence for a direct causal effect of BMD on OA. MR analyses 
have also provided some evidence for a causal effect of LS-BMD on knee OA 
(139,261). In a study of knee OA cases and controls from OA Initiative (OAI) and 
JoCo, Yerges-Armstrong et al identified an association between four BMD-
associated SNPs and knee OA (262). The four SNPs associated with knee OA 
were among the most strongly associated BMD, which is as expected of a causal 
relationship (one would expect, in the case of a true causal effect, for the SNP-
outcome association to increase as the SNP-exposure association increases).  
3.3.2. Evidence for shared aetiology 
Converse to a direct causal effect of BMD on OA, when exploring the genome-
wide genetic correlation between BMD and OA, Hackinger et al identified a 
genetic correlation between LS-BMD, but not FN-BMD, and combined OA (hip 
and/or knee OA), with weaker evidence for a genetic correlation with hip and 
knee OA individually (137). One could hypothesize that a genetic correlation 
specific to LS-BMD reflects artefactual elevation of BMD, in the presence of OA, 
by spinal osteophytes. However, the authors also found some evidence for a 
genetic correlation between TB-BMD measured in childhood and combined OA 
(137). TB-BMD measurement during childhood will not be affected by features of 
OA, which suggests that there may be a true genetic correlation between BMD 
and OA, reflecting shared genetic aetiology. In this section I will discuss the 
evidence for shared biological pathways contributing to BMD and OA. 
The Wnt signalling pathway in OA pathogenesis 
There is overwhelming evidence to suggest that the Wnt signalling pathway, 
outlined in section 2.1.3, plays a role in OA pathogenesis (171,263-265), which is 
consistent with shared underlying biology between BMD and OA. Evidence 
suggests that both overactivation of, as well as a reduction in, Wnt signalling can 
be deleterious for the joint structure, particularly cartilage.  
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Wnt antagonists and OA 
An early OA genetic analysis by Loughlin et al identified a SNP (rs7775) in exon 6 
of FRZB (encoding a Wnt antagonist), which was more frequent in females with 
hip OA undergoing THR, compared to controls without hip OA (266). Lane et al 
later determined the relationship between rs7775 and radiographic hip OA 
phenotypes in SOF; the minor allele was associated with a slight increased risk of 
JSN in this population (267). Individuals with the minor allele, in combination 
with the minor allele for another variant in exon 4 (rs288326), had an increased 
risk of severe JSN (267). The MAF for rs7775 was increased in individuals from 
RS with generalized OA, compared to controls without OA (268). Rs7775 was 
related to diminished Wnt signalling antagonism in vitro (266), providing 
evidence for a role of Wnt inhibitors in reducing OA risk. In a large meta-
analysis of the TREAT- OA consortium, rs288326 was related to hip OA (122) ; 
rs288326 was also associated with reduced Wnt antagonism in vitro (266), 
providing further evidence for a role of reduced Wnt antagonism in hip OA. 
Consistent with a role of FRZB in reducing OA risk, lower FRZB mRNA in 
osteoarthritic cartilage samples, compared to healthy cartilage, has been 
demonstrated (269), as well as an inverse correlation between FRZB expression 
and expression of markers of cartilage degeneration (270).  
DOT1L, a histone methyltransferase, is involved in the downregulation of Wnt 
signalling and cartilage preservation (271). Further suggestive of a role of Wnt 
inhibition in reducing OA risk, a SNP in the DOT1L gene was associated with hip 
mJSW with genome-wide significance (147), and the same SNP has been 
associated with a reduced risk of hip OA (147,272).  
Additionally, several studies of human cartilage samples suggest that DKK1 
expression is lower in OA cartilage compared to healthy cartilage (247,269), 
although others have suggested than DKK1 expression is higher in damaged 
cartilage (273,274). Using a mouse model, Funck-Brentano et al observed lower 
DKK1 expression in the non-calcified zone of damaged cartilage compared to 
healthy cartilage (275); however, expression was higher in the subchondral bone 
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of knees with OA, with the authors concluding that increased expression in bone 
maintains cartilage homeostasis via the regulation of bone factors such as VEGF 
(275). Consistent with this theory, Zarei et al observed higher expression in 
subchondral bone underlying partially damaged cartilage, compared to normal 
or fully defected cartilage in femoral heads extracted during THR (276).  
Studies of SOST knockout mice showed that the knockouts had more severe 
cartilage lesions compared to wildtype mice (277). Chan et al (2011) provided 
evidence that SOST may protect against cartilage proteolysis (278). However, 
others have found no difference in cartilage lesions in SOST knockout mice (279), 
whilst Zhou et al identified more rapid OA development following surgical 
induction of OA in mice overexpressing SOST (280). Sclerostin expression has 
been found to be decreased in osteocytes of the subchondral bone in OA 
(278,279,281) and this decreased expression was associated with subchondral 
bone thickening (278). However, other studies have shown increased sclerostin 
staining in bone tissue and cartilage from tibial plateaus of TKR patients, 
compared to healthy control samples (282).  
Wnt receptors, ligands and downstream targets and OA 
In addition to studies of the role of Wnt antagonists in OA pathogenesis, the role 
of Wnt receptors and downstream signalling molecules have been investigated. 
Blom et al identified higher expression of WISP1, a Wnt responsive gene, in 
human OA cartilage and synovium (283). Nalesso et al observed more severe OA 
in Wnt16 knockout mice compared to wildtype, suggesting that the Wnt16 ligand 
has a role in preserving cartilage after joint injury (284). However, Van den Bosch 
et al provided evidence to suggest that Wnt16 overexpression in the synovium of 
a mouse model leads to increased expression of markers of cartilage 
degeneration (270), whereas Tornqvist et al found no change in OA severity in 
transgenic mice specifically overexpressing Wnt16 in osteoblasts (285). Lrp5 
knockout mice displayed more cartilage degeneration compared to wildtype 




The TGFβ super-family 
As discussed in section 1.2.6, the first genetic locus associated with OA risk was 
linked to the GDF5 gene. GDF5 encodes a ligand for the TGFβ superfamily 
signalling pathway (section 2.1.3). In addition to GDF5, genetic analyses have 
identified other TGFβ and BMP ligands, mediators, and inhibitors with a 
potential role in OA pathogenesis. Two SNPs in the BMP2 gene were linked to an 
increased odds of knee JSN in Chingford women (288). Yamada et al identified a 
relationship between a polymorphism in the TGFβ1 gene and risk of spinal 
osteophytosis; the same allele related to increased osteophytosis was also related 
to a reduced risk of osteoporosis (289). More recently, a cross-phenotype meta-
analysis identified a novel locus in the SMAD3 gene, which is related to both LS-
BMD and hip/knee OA (137). Another study found higher expression of TGFβ1 
and SMAD3 in human OA cartilage samples compared to healthy cartilage 
samples, but reduced expression of BMP2 (290). GREM1, encoding an inhibitor of 
the BMP signalling pathway, mRNA levels were lower in cartilage from 
osteoarthritic joints compared to cartilage extracted from healthy individuals 
(269). Further evidence for a role of expression of GREM1 in OA pathogenesis is 
the identification of a SNP, located 80kb downstream of the gene in a gene 
regulatory region, as related to hip OA in RS (291). A genetic variant in the ASPN 
gene, encoding a TGFβ pathway inhibitor, has been linked to OA risk in several 
populations (175).  
With regards to experimental evidence for a role of the TGFβ signalling in OA 
pathogenesis, mice with mutations resulting in loss-of-function of Smad3 had a 
joint phenotype characterized by osteophyte formation and loss of cartilage (292). 
The same phenotype was observed in mice with cartilage-specific knockout of 
Alk5, encoding a TGFβ receptor (293), as well as mice with cartilage-specific 
deletion of Tgfbr2 (294). Furthermore, mice with cartilage-specific overexpression 
of Smurf2, a TGFβ inhibitor, generated osteophytes and subchondral sclerosis 
and had a reduced cartilage area (295). Conversely, in another study, mice with 
cartilage-specific loss of Tgfbr2 expression, resulting in loss of TGFβ signalling, 
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displayed reduced cartilage loss after destabilization of the medial meniscus, 
compared to wildtype mice (296). In a human RCT, injection of human 
chondrocytes expressing TGFβ1 from a viral vector into AC of knee OA patients 
reduced progression of cartilage loss, but not osteophyte progression, compared 
to injection of a placebo (297). In a mouse study, treatment with an inhibitor of 
the ligands TGFβ1 and TGFβ3 resulted in reduced osteophyte formation but also 
reduced cartilage proteoglycan content and cartilage volume (298), suggesting 
that TGFβ signalling may have opposing effects on osteophyte formation and 
cartilage maintenance.  
Experimental evidence suggests that the TGFβ-specific vs the BMP-specific 
pathway may be involved at different stages of OA pathogenesis; in a guinea pig 
model, the number of Smad2/3-expressing chondrocytes decreased with OA 
progression, whereas the number of chondrocytes expressing Smad1/5/8 
increased (299). As well as the action of TGFβ signalling on expression of 
chondrogenic transcription factors, BMP signalling pathway may be involved in 
OA pathogenesis via cross-talk with the canonical Wnt signalling path; 
chondrocytes treated with BMP2 displayed increased expression of the Wnt 
inhibitors FRZB and DKK1 (269) and increased LRP5 expression and activated 
nuclear β-catenin (300). 
Overall, there is clear evidence for a key role of both the BMP and TGFβ 
signalling pathways in OA pathogenesis. However, it is unclear the exact 
contribution of each pathway to individual features of OA pathogenesis.  
Cathepsin-K 
Evidence suggests a role of Cathepsin-K in OA pathogenesis. A locus annotated 
to CTSK was associated with hip OA in a recent GWAS (141). In addition to 
degradation of type I collagen of bone, Cathepsin-K is able to cleave type II 
collagen of cartilage (301). Cathepsin-K is expressed by human chondrocytes 
(301) and mRNA levels have been observed to be higher in OA cartilage (302), 
with levels correlated to OA severity (303). A CTSK knockout mouse showed 
delayed development of OA after surgery, compared to wildtype mice (304). An 
 
 99 
RCT of a Cathepsin-K inhibitor, MIV-711, in individuals with knee OA from 
across Europe found evidence for reduced MRI-assessed features of structural 
progression in those taking either of the two doses of the intervention, compared 
to placebo (305). Improvements in pain score, which was the primary outcome, 
were not observed in those taking either dose of the inhibitor, although the 
duration of the trial was only six months (305). 
3.4. PhD aims  
The overall aim of this PhD thesis is to develop understanding of the role of bone 
in OA pathogenesis. In order to do this, I firstly aim to clarify the role of BMD in 
knee and hip OA progression by determining the relationship between HBM and 
OA progression. I aim to determine if there are differential associations of HBM 
with osteophyte progression, compared to JSN progression, as seen for prevalent 
OA sub-phenotypes. Secondly, I aim to perform metabolomics analysis to 
identify metabolic traits associated with both HBM and OA sub-phenotypes and 
determine if these metabolic traits mediate the relationship between high BMD 
and OA. Any metabolic mediators of the BMD-OA relationship could represent 
metabolic pathways involved in the pathogenesis of bone-forming OA. Thirdly, I 
aim to use bidirectional MR to clarify the direction of causality between BMD, 
OA, and BMI. If bidirectional causal associations are observed, this could 
indicate that biological pleiotropy explains the BMD-OA observational 
relationships. However, if I observe a causal effect of BMD on OA, without a 
bidirectional causal pathway, this will strengthen the evidence for a direct causal 
role of BMD on OA. Fourthly, I aim to perform pathway-specific genetic analyses 
to determine the role of pathways in bone development and homeostasis in OA 
pathogenesis. Pathways of interest include the Wnt signalling pathway, the 
TGFβ superfamily (both involved in osteoblast development and hence bone 
formation, as discussed in section 2.1.3), the pathway regulating osteoclast 
differentiation (and thus bone resorption) and the IGF-1 axis which regulates 
endochondral ossification and hence skeletal development. The aims of this PhD 











The aims of this PhD thesis can be split into six key research questions, each 
representing a separate results chapter: 
Question 1: Is HBM related to radiographic and clinical features of knee 
OA progression? (Chapter 6) 
In this chapter, I use baseline and follow-up knee radiographs from the 
HBM study population to determine the relationship between HBM and 
progression of the individual radiographic sub-phenotypes (i.e. osteophytes 
and JSN). I use data collected from the postal questionnaires, completed at 
follow-up, to determine the relationship between HBM and knee pain, 
stiffness, and functional limitations. 
Question 2: Is HBM related to radiographic and clinical features of hip 
OA progression? (Chapter 7) 
As described for knees, I will use baseline and follow-up pelvic radiographs 
from the HBM study population to determine the relationship with hip OA 
sub-phenotype progression and will use questionnaire data to determine 
the relationship between HBM and symptoms of hip OA. 
Question 3: What are the metabolic predictors of radiographic OA sub-
phenotypes of the hand, hip and knee and do these metabolic traits 
mediate the HBM-OA relationship? (Chapter 8) 
In Chapter 8, I will use metabolomics to determine relationships between 
multiple metabolic traits and radiographic OA sub-phenotypes. I will 
determine if the metabolic traits are related to HBM, BMD and bone 
turnover. I aim to replicate any observed associations in cohorts sampled 
from the general population to determine generalizability, and to determine 
if any HBM/BMD and OA-related metabolic trait mediates the HBM-OA 
relationship. 
Question 4: Is BMD a causal risk factor for OA, independent of BMI? 
(Chapter 9) 
In this chapter, I firstly aim to use bidirectional MR analyses to determine 
the causal effects of BMD and BMI on hospital-diagnosed hip and knee OA 
in UK Biobank (and vice versa). If any causal effects are identified, I aim to 
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use multivariable MR (MVMR) to determine independent causal effects. I 
will then use BMD polygenic risk scores (PRS) to determine if BMD has 
specific causal effects on individual radiographic sub-phenotypes. 
Question 5: What is the contribution of key bone pathways to OA risk? 
(Chapter 10) 
In this chapter, I will calculate the proportion of variance explained in OA 
risk and OA sub-phenotypes by key bone pathways. I will compare the 
proportion of variance explained to the proportion of variance explained in 
BMD estimated from heel ultrasound (eBMD). I will also determine the 
relationship between circulating sclerostin levels and OA sub-phenotypes. 
Question 6: Is IGF-1 a risk factor for hand, hip, or knee OA? (Chapter 11) 
My final research question will be answered in Chapter 11, by determining 
the observational associations between serum IGF-1 and hospital-diagnosed 
hand, hip, and knee OA in the UK Biobank population. MR will be 




CHAPTER 4.  METHODS: HBM 








As outlined in section 3.4, a key aim of this PhD is to determine the relationship 
between HBM and radiographic and clinical features of OA progression. 
Addressing this involved novel data collection in the HBM study population 
(section 2.3.2). I collected follow-up data from all alive and contactable 
individuals from the HBM study population. I designed a questionnaire to 
characterize clinical features of OA progression, such as pain and TJR, arranged 
follow-up X-rays to determine changes in radiographic features of OA, and 
follow-up DXA scans to assess body composition in this population. In this 
chapter, I will outline how these data were collected and cleaned ready for 
analysis, which will be discussed in the next chapter. 
4.1. Ethical considerations 
4.1.1. Application for research ethics committee (REC) 
approval 
The follow-up questionnaire (section 4.2), along with the plan for follow-up 
radiographic data collection (section 4.3,4.4) were submitted for approval to the 
South West-Central Bristol REC. The flowchart detailing the process for 
participant contact for the follow-up studies is displayed in Figure 20. Due to the 
time lapse between the initial and follow-up data collection (up to 12 years), the 
REC requested an additional step be added to the follow-up data collection 
process, whereby all individuals who were alive and had not withdrawn consent 
were contacted in writing, asking them to sign a consent form if they were happy 
to still be contacted about the study. Only when an individual had provided 
written consent for future contact could they be contacted about the study 
questionnaire and invited for imaging. Ethical approval for the follow-up study 
was provided on 18th August 2016 (REC reference 05/Q2001/78-amendment 21) 








Figure 20: Flowchart detailing the follow-up data collection process. 
 
aArrangements were made for those originally recruited at the seven centres able to 
perform follow-up DXA/X-rays (plus those from Yeovil were invited to attend Bath); 








4.2. Questionnaire design 
To assess clinical progression of OA (in terms of pain and TJR surgery), I 
designed a postal questionnaire. The overall aim for the questionnaire was to 
collect data on measures of OA severity, such as pain, and collect data on 
relevant covariates. However, it was important to ensure that the questionnaire 
was not too long, as this would reduce participant compliance.  
4.2.1. Rationale for question selection 
To ensure reliability and validity of the data collected, the questionnaire collated 
questions from questionnaires previously used by other cohort studies or 
validated specific-use questionnaires. I will discuss the selection and previous 
use of these questions. The questionnaire is provided in Appendix 7.  
Bones and Joints 
Arthritis questions from the British Women’s Heart and Health Survey 
(BWHHS) 
BWHHS is a prospective cohort study investigating risk factors for heart disease 
in 4,286 women randomly selected from 23 towns in England, Scotland, and 
Wales (306). Four postal questionnaires have been sent to consenting 
participants. The questions taken from BWHHS questionnaires were deemed to 
be valid due to the prior publication of analyses using these data, and the 
observed relationships of arthritis with BMI and prevalent and incident 
locomotor activity limitation (307-309). The questions reproduced included ‘Have 
you ever been told by a doctor that you have arthritis?’, ‘If yes, please give the type of 
arthritis’ and ‘Which joints are affected?’ These questions were included to allow 
participants to self-report OA, as self-reported OA could potentially identify 







The WOMAC index is a widely used and validated questionnaire employed in 
OA research as a measure of pain, stiffness, and limitation of physical function 
(310). The questionnaire consists of three subscales: five questions for pain; two 
questions for stiffness and 17 for physical function. Each question is answered on 
a five-point scale, from 0 representing no pain/stiffness/difficulty performing an 
activity, to 4 representing extreme pain/stiffness/limitation of activity. The 
WOMAC index can be used to produce a pain score, a stiffness score and a 
physical function score for the hip and knee separately. A short-form version of 
the WOMAC function index was proposed by Whitehouse et al to reduce 
participant burden by limiting the physical function section to the seven most 
important questions (based on data analysis and the opinion of Rheumatologists) 
(311). This questionnaire has been validated in patients with varying severities of 
OA (311,312). Due to the relevance of including all three WOMAC sections for 
both the hip and knee, I decided to use the short version of the WOMAC in this 
questionnaire, significantly reducing the number of questions and page count of 
the questionnaire.  
Arthritis procedure questions from the HCS (EPOSA) questionnaires 
HCS includes a population of 2,997 people living in Hertfordshire, who were 
born between 1931 and 1939 (313). The EPOSA sub-study is a collaboration of six 
European cohorts with the aim of determining the impact of OA (314). Four 
hundred and 44 HCS participants have been recruited into this sub-study (314). 
A question about surgical procedures for knee OA was taken from the follow-up 
study of knee OA questionnaire. These procedures included steroid injection, 
cartilage operation and knee washout/lavage/arthroscopy. This question was 
included firstly because it indicates clinical OA, in that pain was severe enough 
to require surgical intervention, but secondly knee OA procedures could reduce 
the symptoms recorded in the questionnaire. The question was adapted to read 






arthritis?’ instead of ‘for osteoarthritis’ so that participants who did not know what 
type of arthritis they had would not skip this question. 
Mobility questions from the Osteoporosis Screening Questionnaire (OSQ) 
The OSQ is currently used by the North Bristol Trust (NBT) DXA service to aid 
calculation of a fracture risk (FRAX) score for patients (315). The questionnaire 
has been developed based on the advice of Rheumatologists and Geriatricians 
and asks about a variety of factors which may affect fracture risk. Due to the 
regular use and refinement of this questionnaire, to aid interpretation of DXA 
scan results and inform treatment, the questions selected from the questionnaire 
were deemed to be sufficiently reliable. Questions taken from the OSQ include a 
mobility aid and a walking distance question, which can be used as two further 
clinical measures of OA severity, as the further the participant can walk unaided, 
the less severe their lower-limb OA is likely to be. Regular use of a mobility aid 
indicates that mobility is severely affected, potentially by painful OA. The 
walking unaided question was adapted from the OSQ to quantify distance rather 
than time. The large age range of the cohort added the problem of deciding 
whether to use metric or imperial measures of distance. ‘Unaided’ was adapted to 
‘before you need to stop and rest’ as the question follows the mobility aid question, 
and it may have caused confused the participant to ask how far they can walk 
unaided immediately after them selecting the mobility aid they use. This 
wording of the question made it possible for those who cannot walk without a 
mobility aid, such as a walking stick, to still answer the question. 
Health and demographics 
Vertical Impacts on Bone in the Elderly (VIBE) questionnaire 
The VIBE study is a multi-centre epidemiological study investigating the effect of 
vertical impacts, achieved during habitual PA, on bone parameters such as BMD 
(316). The education question ‘What is the highest level of education or training that 
you have successfully completed?’, and the relevant categories (e.g. CSE/ School 






questionnaire. The VIBE questionnaire specifically asks which education level 
achieved by the age of 26, but due to the large age range of the HBM participants 
and the youngest participant being below the age of 26, the question was 
adapted to be highest education level ever achieved. This was based on the 
advice of Dr Rachel Cooper from the National Survey for Health and 
Development. Educational attainment, a measure of individual-level 
socioeconomic status (SES), is a potential confounder when measuring the 
relationship between HBM and pain. As some participants resided in Wales, and 
the Index of Multiple Deprivation (IMD) only includes English postcodes, IMD 
was not a suitable measure. Education was selected over other measures of SES, 
such as income or occupation, due to the large age range of the HBM population, 
meaning some participants may not have reached their peak occupation level 
and others will be retired meaning their current income may not reflect the 
income they received in the past. Another question adapted from the VIBE 
questionnaire addressed prior joint replacement. The ‘reason for joint replacement’ 
question was added to ascertain whether the joint replacement was due to 
arthritis, which is an indicator of OA progression, or another reason such as a 
fracture.  
EQ5D-5L 
The EuroQol EQ5D questionnaire is a short and simple standardized 
questionnaire designed to measure health-related QoL (HR-QoL) for a range of 
diseases. It is one of the most commonly used generic measures of HR-QoL 
worldwide (317). This generic measure of HR-QoL was included, along with the 
disease-specific measure (see WOMAC above), to capture overall health status, 
including the effect of any comorbid conditions. The questionnaire measures HR-
QoL in five domains: pain/discomfort, depression/anxiety, mobility, self-care, 
and usual activities. Within each domain there are five levels from which to 
select; no pain/problems/depression to extreme pain/extremely depressed or 
unable to walk/look after oneself/take part in usual activities. The validity of the 






chronic health conditions in six different countries, including patients with 
arthritis (318).  
International Physical Activity Questionnaire (IPAQ) 
PA is a potential confounder of any relationship between BMD and OA 
progression. Lifetime and past week PA have previously been measured in the 
HBM cohort using a postal questionnaire. To update current PA status of 
participants, the short form version of the IPAQ questionnaire was included in 
the questionnaire. The short-form IPAQ measures three types of PA over the past 
week, vigorous activities (such as aerobics), moderate activities (such as carrying 
light loads) and walking. Participants were asked how many days over the past 
week they had performed such activities, and if they had, how many hours and 
minutes spent participating in these activities on an average day, if known. The 
IPAQ short form has been psychometrically tested in 12 developing and 
developed countries, by comparison of the score with an objective measure of PA 
and has acceptable reliability and validity (319).  
4.2.2. Questionnaire piloting  
Advice on clinical content was sought from Dr Celia Gregson, Professor Jon 
Tobias, and Dr Emma Clark, who are clinicians with experience in 
musculoskeletal research. Their advice included adding more clinical OA 
questions, such as use of mobility aids and adapting questions to make them 
more patient-friendly (e.g. adapting ‘osteoporosis’ to ‘osteoporosis (brittle bones)’). 
Other advice on clinical content was to remove ‘due to arthritis’ from the 
WOMAC questions, so that pain, stiffness, and difficulty performing activities 
were all captured even if the participant had not had a diagnosis of arthritis. 
Other questions to assess OA severity, such as effect on walking distance, were 
recommended and subsequently added to the questionnaire.  
Questionnaires were next trialled by two qualitative researchers in the 
Musculoskeletal Research Unit (MRU). Their advice included adding a contact 






participants who they could contact for help. They advised that it may not be 
necessary to ask the participant their name, postcode, and date of birth as the 
questionnaire had been labelled with their unique ID. However, these were still 
included to check the details were correct and to allow data checking if there 
were discrepancies with the IDs (i.e. human error when labelling the 
questionnaires with the ID, discrepancies when sending multiple questionnaires 
from the same household). The cover sheet was removed by the administrator 
after the questionnaire was returned and stored separately to retain anonymity. 
They recommended adapting the wording of the WOMAC questions as the 
questions originally read ‘…the amount of pain you are currently 
experiencing…please enter the pain experienced in the last 48 hours’. Due to the 
contradiction of currently and past 48 hours, which could confuse the 
participant, the question was adapted to ‘the amount of pain you have experienced… 
please enter the amount you have experienced in the last 48 hours’.  
Once the questionnaires had been adjusted based on this advice, the 
questionnaire was piloted by two members of the Patient Experience Partnership 
in Research group, a group of Musculoskeletal service users who regularly meet 
with researchers to aid development of research project literature. Their feedback 
was positive, with only a few comments, such as to emphasize on the front of the 
questionnaire that some questions may seem similar but were still important. 
4.2.3. Questionnaire formatting 
I formatted the questionnaire for scanning using ABBYY FormDesigner and 
Flexicapture software (Version 10, http://www.abbyy.com/flexicapture/). 
ABBYY FormDesigner allowed me to format the questionnaire with page 
anchors and barcodes for page recognition, aiding the design of a project in 
Flexicapture which automatically recognised text and checkmarks. Completed 
questionnaires could then be scanned by the study administrator. After scanning, 
the Flexicapture software checks each individual answer has been recognised 






Microsoft Excel dataset. This methodology limits data entry errors, compared to 
entering all answers individually into a database, and is much quicker than 
manual data entry.  
4.2.4. Questionnaire data cleaning 
Data were exported to a Microsoft Excel file and imported into Stata (Version 13). 
Variables were renamed with the prefix ‘hm2_’ to represent follow-up data when 
linked with baseline data. Basic data checks were carried out. These included 
checking for duplicate IDs and discrepancies between gender and gender-
specific responses, for which four were found. These four discrepancies were 
matched to two couples who had accidentally completed each other’s 
questionnaires.  
Joints 
Free-text answers for ‘Other’ types of arthritis were checked and re-coded as 
necessary: responses including “wear * tear” were recoded as ‘Osteoarthritis’ and 
“zero negative” was recoded as ‘Rheumatoid arthritis’, assuming the participant 
meant ‘sero-negative’. Individuals stating that their arthritis type was 
“osteoporosis” were recoded as not having arthritis. ‘Other’ free text responses 
were checked for joints affected by arthritis. In one case, “fingers” had been stated 
but the participant had not selected ‘Yes’ for arthritis in hands/wrists and 
therefore this individual was recoded as having hand arthritis. Responses for 
joint replacements were checked for consistency. In some cases, individuals did 
not respond to the ‘Have you ever had a joint replacement?’ question, or responded 
as ‘No’, but had later stated that they had a knee replacement, so these 
individuals were recoded as ‘Yes’ for joint replacement. Categorical variables 
were created concerning the reason for joint replacement for each of the left knee, 
right knee, left hip, and right hip, based on the free text responses. Free text 
responses of “arthritis”, “pain”, “worn” and “wear and tear” were coded as 






“limping”, “bi-lateral knee replacement” and “estimate” were coded as 
‘uncategorised’.  
Self-reported arthritis was checked against radiographic OA at baseline. Thirty-
one individuals reporting arthritis at follow-up had a knee KL score <2 at 
baseline and 32 reporting hip arthritis had a Croft score <3 at baseline (i.e. no 
radiographic OA). Of the 31 with self-reported knee arthritis, all had an incident 
diagnosis (i.e. after the date of their first X-ray), a score >25 on at least one 
WOMAC knee domain or a TKR due to arthritis. All individuals self-reporting 
hip arthritis had a diagnosis after their first X-ray, a score >25 on at least one of 
the WOMAC hip domains or a THR due to arthritis. Self-reported joint 
replacement was validated using baseline TB DXA images, where available. No 
discrepancies were identified.  
WOMAC pain, stiffness and function scores were calculated for both the hip and 
knee based on the average value for each subscale, multiplied by 25 (320). Total 
scores for each subscale were subtracted from 100 to give a score from 0 to 100, 
with 100 representing no pain, stiffness, or limitation of function. If one pain 
question out of the five was unanswered, the value was imputed as the mean of 
the other four questions (320). If fewer than four of the function responses were 
missing, these values were mean imputed based on the answered function 
questions (320). Although this protocol was developed for the full version of the 
WOMAC, it has been used for the reduced version (311).  
Demographic variables 
Education was further sub-categorised to match the categories used by the Avon 
Longitudinal Study of Parents and Children (ALSPAC) maternal cohort (321) 
and categories are summarised in Table 3. Additional free text answers when 









Table 3: Categorisation of education responses. 
1. CSE/ None 
• None of these 
• CSE/ School Certificate 
• Leaving certificate 
2. Vocational 
• Apprenticeship 
• Qualifications in shorthand typing or 
other skills (e.g. hairdressing) 
• Nursery nurse 
• Private secretary 
• Agriculture 
3. O Level or equivalent  • GCSE/ O Level 
4. A Level or equivalent 
• GCE/ A Level/ Scottish Highers 
• Other teaching qualification 
• State enrolled nurse 
• State registered nurse 
• Other para-medical qualification 
• Top class 6th form (Ireland) 
• National diploma 
• Ordinary National Certificate (ONC) 
• City & Guilds 
• NNEB 
5. Degree Level  
• Diploma of Higher Education 
• Bachelor’s degree (e.g. BA, BSc) 
• Other degree level qualification (e.g. 
graduate membership of a 
professional institute) 
• Higher degree (e.g. Master’s/ PhD) 
• PGCE- Postgraduate Cert. of 
Education 
• Higher National Certificate (HNC) 
• Higher National Diploma (HND) 
• Chartered insurance institute 
Responses in italics represent additional free text answers when ‘Other’ was selected, 
which were manually coded. 
 
Health 
Responses to the five EQ5D questions were converted to index values using the 
crosswalk index value calculator and the UK value set (322). For example, an 
individual responding that they have no problems with mobility, self-care, 
performing their usual activities and no pain or depression would score ‘11111’ 
which is given a value of 1.0 and those reporting that they are unable to walk, 
wash/dress themselves, unable to do their usual activities, with extreme pain 






an individual were missing a response for any domain, an index value could not 
be calculated. 
Physical activity 
The responses to the IPAQ questions were scored following the protocol on the 
IPAQ website (https://sites.google.com/site/theipaq/scoring-protocol). Values 
were calculated for total amount of time per day spent doing each activity type in 
minutes (vigorous, moderate, and walking). As recommended in the guidelines, 
values of less than 10 minutes were recoded as 0. Capped variables were then 
generated based on a maximum time of 180 minutes per day. MET-minutes for 
each activity type were then calculated: 
 
The three values were then summed to generate total weekly MET-minutes.  
4.3. DXA data 
As discussed in section 2.2, DXA scanning is the most common way to assess 
BMD and is used routinely in the NHS. In the HBM study, follow-up TB, 
bilateral TH (or unilateral, scanning the same hip as baseline) and LS DXA scans 
were performed on consenting participants using standard NHS operating 
procedures at each hospital. DXA scans additionally assess body composition 
(TBFM and total body lean mass [TBLM]). Data were transferred in electronic 
form, anonymised with the study ID, from each site. Paper copies of the DXA 
scan images were sent to Bristol so that I could inspect the images for positioning 
errors or metal artefacts (section 4.3.1, 4.3.2), apart from Hull, where the chief 
DXA technician performing all scans, Maxine Osgerby, had generated a 
spreadsheet noting positioning errors and metal artefacts.  
“Walking MET-minutes= 3.3 x capped walking minutes x number of days of walking 
Moderate MET-minutes= 4 x capped moderate activity minutes x number of days of 
moderate activity 







4.3.1. Coding metal artefacts  
Despite being asked to remove metal before scanning, metal artefacts were still 
common on DXA scan images, namely wedding rings, jewellery/watches, and 
TJRs. All images were visually inspected for metalwork. Metalwork was coded 
using the same methodology as baseline (323): 
 
Table 4: Coding of metal artefacts on DXA scans. 
Code Artefact 
0 No visible metal artefact on images 
1 Rings 
2 Other larger jewellery e.g. bracelets 
3 Joint replacement (any joint) 
 
This generated a variable for adjustment in regression models using the DXA 
data. However, only one individual had a metal artefact categorised as ‘other 
large jewellery’ and therefore categories two and three were combined when 
using this variable. 
4.3.2. Positioning errors 
Sometimes, when a patient is obese or particularly tall, their full body does not fit 
within the DXA field and some tissue is not captured in the TB image. Most 
commonly, parts of the arm can be missing from the image. DXA technicians can 
correct the patient’s positioning so that at least one half of the body is within the 
image and then TB values for FM, lean mass (LM) and BMC can be generated by 
doubling the FM, LM and BMC for the side fully within the image. However, not 
all DXA technicians will correct for this and in some cases parts of both arms can 
be missing. All TB scans were visually inspected for this and a code of ‘1’ was 







4.3.3. Standardizing BMD  
There are two main manufacturers of DXA scanners: Hologic Inc. (Bedford, MA, 
USA) and GE-Lunar Inc. (Madison, WI, USA). Scanner type varied by site, with 
Bath, Bristol, Oxford, Sheffield, and St Georges using Hologic, and Cambridge 
and Hull using Lunar, scanners. To limit within-person error due to differences 
in scanner manufacturer and localised protocol at baseline and follow-up, I, with 
the help of Karen Ireland, tried to ensure that all participants attended their 
original centre. 10 individuals were unable to attend their original centre due to 
logistical restrictions or because their original centre (Yeovil) could not perform 
follow-up scans. However, these 10 individuals attended a site with the same 
type of scanner used as at their original centre. 
Each manufacturer has its own calibration methods, regions of interest and 
algorithms for calculating BMD, TBFM and TBLM (324). This leads to variation 
in DXA measurements between scanners; an analysis by Genant et al found that 
total LS-BMD was 11.7% lower when assessed by a Hologic scanner compared to 
a GE-Lunar scanner (325). Equations have therefore been developed to generate 
standardized BMD (sBMD, mg/cm2) for the LS (325) and TH (326). Hui et al later 
optimized these equations (327). The Hui equation for converting LS-BMD to 
sBMD for Hologic and GE-Lunar scanners is presented in Equation 1 (327). The 
Hanson equations for converting BMD of the femur are presented in Equation 2 
(326). 
 
Equation 1: Conversion of Hologic and GE-Lunar LS-BMD values to sBMD. 
 
Equation 2: Conversion of Hologic and GE-Lunar TH-BMD values to sBMD. 
 
𝑠𝐵𝑀𝐷 = 1000 ∗  1.055 ∗  𝐵𝑀𝐷𝐻𝑜𝑙𝑜𝑔𝑖𝑐  –  0.972 +  1.0436  
𝑠𝐵𝑀𝐷 = 1000 ∗ (0.9683 ∗  𝐵𝑀𝐷𝐿𝑢𝑛𝑎𝑟 − 1.1 + 1.0436) 
 𝑠𝐵𝑀𝐷 = 1000 ∗  1.008 ∗  𝐵𝑀𝐷𝐻𝑜𝑙𝑜𝑔𝑖𝑐  + 0.006 






These calibration equations were developed for the old-style pencil-beam DXA 
scanners, with a single detector. Later DXA scanners use fan-beam technology to 
assess BMD, which have multiple radiation detectors (184), and this has led to 
greater variation in technology between the two major manufacturers. Fan et al 
validated the use of the equation for TH sBMD using fan-beam scanners but 
found that differences still existed between scanners for LS-sBMD (4.1% for L1-
L4 BMD) (328). However, I used these equations to generate sBMD for all 
participants, in line with the sBMD values generated at baseline by Dr Celia 
Gregson (323). 
4.4. Radiographic data collection 
X-rays were performed at Hull, Sheffield, Cambridge, Bath, Bristol, Oxford, and 
St Georges following standard clinical operating procedures. Bilateral AP knee 
and dominant hand X-rays were performed on all consenting individuals and AP 
pelvis X-rays performed on all consenting individuals aged over 40 years. 
4.4.1. Anonymising radiographs 
Systems for data transfer varied by site. Sites were asked to remove all 
identifiable information from the DICOM images before transfer. Most sites 
transferred the anonymised DICOM images on discs labelled with a unique 
identifier and provided an excel spreadsheet to link the disc to the participant ID. 
Image files were relabelled with an anonymous ID using the same relabelling 
system as at baseline (329) to ensure that baseline radiographs could not be 
distinguished from follow-up when grading. An excel spreadsheet linking the 
filename to the participant ID and timepoint (baseline or follow-up) was 
generated for data linkage.  
To ensure that all files had the same date stamp, so that baseline and follow-up 
radiographs could not be distinguished, all files were converted to TIFFs using 
an ImageJ macro designed by Dr Jenny Gregory at the University of Aberdeen. 






information, which was important for accurate quantitative measures of mJSW 
and tibial plateau width (section 4.4.5).  
4.4.2. Choice of radiographic atlas 
The HBM radiographs were graded at baseline using the Burnett atlas 
(33,226,227). As I was going to regrade all baseline radiographs for individuals 
with follow-up data, I did not need to use the same atlas as previously used. I 
therefore chose to use the updated OARSI (Altman and Gold) atlas as this atlas 
includes additional osteophyte variables (e.g. grading medial and lateral for both 
the tibia and femur) (29), providing additional information and increasing 
phenotypic variability. This atlas was also chosen as it is a widely used atlas for 
grading radiographic features of OA. Radiographs were compared to the OARSI 
atlas to determine the semi-quantitative grade for each feature.  
4.4.3. Ensuring consistency in radiographic measures 
To ensure gradings were not affected by environmental factors such as lighting 
and computer screen specification, all readings were performed on the same 
computer, in the same location. To ensure readings were as consistent as 
possible, all readings at the knee were performed within a fortnight and all 
readings at the hip were performed within another fortnight. Each grade was 
determined by comparing the radiographic image to the atlas images, and a 
grade was only given for osteophytes if the osteophyte was at least as large as 
that shown in the atlas. 
4.4.4. Assessing reliability of measures 
Intra-rater reliability determines how reliable measurements by one reader are, 
by determining the similarity of two measurements of the same construct (e.g. 
measurement of mJSW) by one reader. Higher intra-rater reliability suggests less 
measurement error. Inter-rater reliability represents the reliability of a 
measurement of a construct by two different readers. High inter-rater reliability 






Intra- and inter-rater reliability for categorical variables were determined by 
kappa statistics. Kappa statistics compare the proportion of agreement between 
observers with the proportion expected by chance using the following formula: 
If there is perfect agreement between observers, κ will be 1. If the agreement 
between observers is the same as expected by chance, κ will be 0 (330). Landis 
and Koch suggested a classification system to determine strength of agreement 
(Table 5). 
 
Table 5: Threshold values to determine strength of agreement proposed by Landis and 
Koch (1977). 






0.81-1 Almost perfect 
 
Reliability for continuous variables was determined using the intraclass 
correlation coefficient (ICC). The ICC is a measure of the ratio of variance 
between individuals to the variance between different observations of the same 
individual (i.e. measurement error). The ICC is calculated using one-way 
ANOVA as follows: 
 
Where σ2i is the variance in measurements between individuals and σ2o is the 
variance between the repeated observations. If there is no variation between 
observations, the ICC will be 1. An ICC close to one therefore represents highly 
reproducible results. 
𝜿 =
 𝑨𝒐𝒃𝒔 −  𝑨𝒆𝒙𝒑












Bland Altman plots were generated for continuous measures. These are plots of 
the mean of the two measurements (x) against the difference between the two 
measurements (y) (331). A line is plotted at the mean difference and two 
additional lines at the mean plus or minus the SD of the difference between the 
two methods/assessors. If agreement between two methods, or between two 
assessors, is good, all measurements should lie within the two lines either side of 
the mean. These plots can be inspected for systematic bias, such as the difference 
increasing with increasing measurements.  
4.4.5. Training to grade radiographic knee OA using the 
OARSI atlas 
As a non-clinician, I did not have prior experience of reading radiographs and 
grading features of OA. I therefore attended one-on-one training sessions with 
Dr Sarah Hardcastle, a Consultant Rheumatologist, who has extensive experience 
grading radiographic OA. During these sessions, we discussed a range of 
radiographs of differing severities, comparing the images to the atlas, and 
determining if we agreed on the grading for each feature of OA. After three 90-
minute sessions, I graded the training set of 30 radiographs which had been 
specifically picked by Dr Martin Williams, Consultant Radiologist, NBT, as they 
reflected a range of severities of KL grade. Dr Hardcastle also graded the 
radiographs and then after a two-week break, I regraded the 30 radiographs. 
Inter- and intra-rater reliability were determined, as described in section 4.4.4. 
ICC statistics were calculated using the Stata ‘loneway’ command and kappa 
statistics using the ‘kapci’ command. For variables with more than two levels, 
weighted kappas were calculated, using the parametric weight (‘wgt(w2)’) 
option, to account for the fact that an osteophyte graded as two versus three 
would have less of an impact on analyses than grading the same radiograph as a 
grade zero versus grade two (and the same for JSN). Full inter- and intra-rater 






and inter-rater weighted kappas were >0.6. Dr Hardcastle and I agreed these 
were sufficient to start grading the full set of images. 
Additional quantitative measures 
In addition to the semi-quantitative radiographic sub-phenotypes, additional 
measurements were generated for mJSW (a continuous, indirect measure of 
cartilage thickness) and maximum tibial plateau width (to enable adjustment for 
bone size). As the X-rays were performed at NHS hospitals, they were stored as 
DICOM files, which retained the image scaling information (except a small 
proportion, 2%, which were compressed), allowing these measures to be 
performed. The measurements were performed in ImageJ (332) using a macro 
custom-designed by Dr Gregory. I adapted the macro to include the image 
filename in the exported Excel file, for data linkage. Measurements were 
performed using the ImageJ line tool, with the macro providing prompts to 
ensure measurements were performed on the right side first and that mJSW was 
measured first. The macro stores the results in a table and prompts the user to 
save the file (in Excel format) after each measurement. 
mJSW was measured at the narrowest gap between the tibial plateau and the 
medial femoral condyle (Figure 21). When the line was placed in the most 
appropriate position, ‘OK’ was selected on the prompt and then the macro 
prompts the user to draw a line to measure maximal tibial plateau width. The 
line was placed at the widest point beneath the tibial plateau, ensuring that any 
tibial osteophytes were not included in the measurement (Figure 22). After the 
line was placed, ‘OK’ was selected and the macro prompts the user to pan to the 








Figure 21: Measurement of mJSW using the custom-designed ImageJ macro. 
 
 




4.4.6. Reliability of full radiographic knee OA readings 
Readings of the full HBM set of knees (pooled and anonymised baseline and 
follow-up radiographs) were performed in December 2018. After grading all 
available radiographs, a random sample of 18 individuals (10%) were selected 
using the Stata ‘runiform()’ command. To limit possible bias from unblinding, this 
was carried out by Dr Celia Gregson. Dr Gregson then copied the baseline and 






folder, where I could regrade the images, blind to whether they were baseline or 
follow-up images. Intra-rater statistics for prevalent OA variables for all 36 pairs, 
regardless of baseline or follow-up status, are presented in Appendix 9. 
The intra-rater reliability was relatively weak for JSN, particularly before 
weighting (0.42 for medial, 0.24 for lateral). This meant that overall KL grades 
were also less reliable (0.54), as a knee received a KL grade of 3 only if JSN was 
present. I identified that the reason for the lower reliability of the JSN grades was 
that a lot of the knee radiographs were marginally rotated, but not enough to be 
categorised as grossly rotated and excluded from analyses. However, rotation of 
the knee can make the joint space appear narrowed. It became clear as I graded 
the radiographs that I had to be more cautious grading JSN on the rotated 
radiographs. This meant the later gradings, including the second gradings, were 
more reliable in terms of JSN compared to the first readings, particularly over the 
first few days of grading. I therefore repeated the grading of the 10% sample to 
determine if the lack of reliability for the JSN scores was due to an improvement 
of detection of rotation throughout the grading process. Intra-rater reliability 
statistics for the second and third readings are presented in Appendix 10. Kappa 
scores had increased for all semi-quantitative variables, including osteophytes, 
and all weighted kappas were >0.8. Hence, I decided to regrade all radiographs 
for the semi-quantitative features (reliability was already >0.9 for the continuous 
measures, so to save time these were not repeated). After the full regrading, the 
72 radiographs were regraded to check for drift and the final intra-rater 
reliability statistics are presented in Table 6. Inter-rater reliability was then 
checked using the readings from the full set of regradings and Dr Hardcastle’s 




Table 6: Final intra- and inter-rater reliability statistics for knee radiographic gradings. 
  Intra-rater Inter-rater 
 N Unweighted Weighted Unweighted Weighted 
  Kappa 95% CI Kappa 95% CI Kappa 95% CI Kappa 95% CI 
KL 69 0.731 0.597, 0.860 0.900 0.813, 0.950 0.549 0.399, 0.692 0.847 0.758, 0.914 
Medial femoral osteophyte 69 0.755 0.504, 0.943 0.929 0.826, 0.978 0.416 0.205, 0.649 0.830 0.674, 0.922 
Medial tibial osteophyte 69 0.765 0.587, 0.907 0.875 0.745, 0.956 0.609 0.448, 0.780 0.860 0.777, 0.919 
Lateral femoral osteophyte 69 0.681 0.404, 0.898 0.880 0.693, 0.983 0.697 0.471, 0.911 0.914 0.793, 0.971 
Lateral tibial osteophyte 69 0.802 0.571, 1 0.853 0.714, 1 0.677 0.421, 0.875 0.836 0.662, 0.935 
Medial JSN 69 0.935 0.710, 1 0.975 0.848, 1 0.440 0.224, 0.655 0.668 0.427, 0.836 
Lateral JSN 69 1 1, 1 1 1, 1 0.486 0,1 0.691 0,1 
Medial sclerosis 69 0.378 -0.176, 0.932   0.378 -0.176, 0.932   
Lateral sclerosis 69 1 1, 1   0.660 0.038, 1   
Chondrocalcinosis 69 0.881 0.652, 1   0.704 0.387, 1   
Any OA (>=2) 69 0.795 0.641, 0.950   0.774 0.616, 0.932   
Severe OA (>=3) 69 0.872 0.7,1   0.799 0.613, 0.986   
Any osteophyte (>=1) 69 0.795 0.641, 0.950   0.842 0.710, 0.975   
Moderate osteophyte (>=2) 69 1 1, 1   0.722 0.497, 0.947   
Any JSN (>=1) 69 0.939 0.821, 1   0.532 0.319, 0.744   
Moderate JSN (>=2) 69 1 1, 1   0.706 0.394, 1   
Any sclerosis 69 0.549 0.096, 1   0.469 0.027, 0.911   
  ICC 95% CI   ICC 95% CI   
mJSW 139 0.995 0.993, 0.998   0.990 0.985, 0.995   





Weighted kappas for intra-rater reliability for the semi-quantitative measures 
were all >0.8, representing almost perfect agreement (333). Unweighted kappas 
for the binary variables were all >0.795, except for subchondral sclerosis, possibly 
explained by the fact that this was such a rare finding, with only one case of 
lateral sclerosis and four cases of medial sclerosis observed. Apart from lateral 
JSN, weighted inter-rater kappas were >0.8. Most of the binary variables had 
kappas >0.6, representing substantial agreement (333). Again, kappas were low 
for subchondral sclerosis (particularly medial), representing only moderate (any 
subchondral sclerosis) or fair (medial sclerosis) agreement. Inter-rater reliability 
for any JSN was much lower than that for intra-rater reliability, reflecting an 
undercalling by myself. However, after discussion with Dr Hardcastle, this was 
deemed acceptable as I was consistent in my gradings of JSN and therefore 
undercalling JSN at both baseline and follow-up would not systematically bias 
results.  
As the quantitative measurements had been performed using the same 
methodology by Dr Hardcastle during her analysis of the full set of baseline knee 
radiographs, I determined the correlation between my full set of measurements 
on the baseline radiographs and Dr Hardcastle’s readings from 2014. There was a 
strong correlation between my measurements and those performed by Dr 
Hardcastle (r>0.8, Appendix 11), particularly for maximal tibial plateau width. 
Bland Altman plots confirmed good agreement between these measurements 
(Appendix 11). Reassuringly, mJSW measurements decreased with increasing 
semi-quantitative JSN grade, as assessed by the OARSI atlas at both baseline and 
follow-up (Figure 23, Figure 24) and there was a greater decrease in mJSW 
between baseline and follow-up with those with a greater change in semi-








Figure 23: Boxplot of semi-quantitative medial JSN grade at baseline against measured 
medial mJSW at baseline. 
 
 
Figure 24: Boxplot of semi-quantitative medial JSN grade at follow-up against measured 










Figure 25: Boxplot of change in summed semi-quantitative JSN score (medial and lateral) 
against change in measured medial mJSW. 
 
 
As maximum tibial plateau width is less likely to change over 8 years, I checked 
agreement between maximum tibial plateau width measured at baseline and 
follow-up, as a further test of the reliability of the continuous measurements 
(Appendix 11). Overall, there was a strong correlation between these two 
variables (r=0.92).  
As a final check of the validity of the radiographic sub-phenotype measures, 
associations between change in summed osteophyte and JSN scores and 
outcomes expected to be associated with OA progression were determined. This 
included use of a walking aid and WOMAC pain, stiffness, and functional 
limitation scores (section 4.2.1). Table 7 displays these associations. Both change 
in osteophytes and change in JSN were associated with a higher pain score at 
follow-up. Change in osteophyte score was also associated with more stiffness 
and functional limitation and there was some evidence for an association 
between change in JSN score and these outcomes (greater magnitude of effect but 







Table 7: Associations between change in osteophytes or JSN over 8 years and clinical OA 
outcomes at follow-up. 
 Change in osteophyte score Change in JSN grade 
 OR (95% CI) P OR (95% CI) P 
Use of walking aid  1.00 (1.00, 1.00) 0.604 1.00 (1.00, 1.00) 0.307 
 β (95% CI) P β (95% CI) P 
WOMAC knee pain score 0.39 (0.17, 0.62) 7.31x10-4 1.08 (0.05, 2.10) 0.039 
WOMAC knee stiffness score 0.48 (0.18, 0.77) 0.002 0.57 (-0.35, 1.49) 0.227 
WOMAC knee function score 0.39 (0.16, 0.61) 7.28x10-4 0.65 (-0.30, 1.60) 0.178 
OR per 1 grade increase in osteophyte or JSN score between baseline and follow-up. β 
represents the increase in WOMAC score (out of 100) per 1 grade increase in osteophyte 
or JSN score between baseline and follow-up. 
 
4.4.7. Training to grade radiographic hip OA using the 
OARSI atlas 
Training to grade radiographic features of hip OA followed the same structure as 
grading knee OA. However, hip radiographs were more difficult to read, 
particularly when determining JSN, and therefore five 90-minute training 
sessions were required before grading the training set. Croft scores, rather than 
KL grades, were used as an overall measurement of OA severity. The advantage 
of determining Croft score over KL grade at the hip is the additional level to 
reflect JSN without osteophytes (334).  
Measurement of hip mJSW 
Hip mJSW was assessed at baseline using HipMorf software (Oxford, UK) (226). 
However, as access to this software was no longer available, I investigated other 
options for measuring mJSW. The AUGMENT study uses the software 
BoneFinder, developed by Claudia Lindner and Tim Cootes at the University of 
Manchester (http://bone-finder.com/, patent number EP 2893491) to place 
points around the outline of the hip on a radiograph or DXA image. Points can 
also be placed along the acetabular eyebrow. Dr Jon Parkinson, University of 






the femoral head and along the acetabular eyebrow and then calculate the 
shortest distance between these two curves. Due to time constraints and 
expertise, points were placed on all baseline and follow-up images by Dr Monika 
Frysz, University of Bristol. I then placed points on a subset of 36 pairs of hips, 
which were remarked by Dr Frysz, to calculate inter-rater and intra-rater 
reliability, respectively. Points were placed starting at the superior lateral 
curvature of the femoral head (Figure 26). 15 additional points were then placed, 
evenly spaced, around the femoral head, ending at the superior medial curvature 
of the femoral head (Figure 27). 
 









Figure 27: 15 Additional points placed evenly spaced around the femoral head ending at 
the superior medial curvature. 
 
 
A point was then placed at the lateral edge of the acetabular eyebrow, ignoring 
any osteophytes, if present. The point was placed at the lowest edge at the most 
lateral point of the sclerotic line, as displayed in Figure 28. An additional seven 
points were then placed along the acetabular eyebrow, ending where there was a 
break in the line or a change in thickness or angle (Figure 29). The protocol for 







Figure 28: Placement of the first acetabular point in BoneFinder. 
 
 





Once all points had been placed on all images, I ran a python script for all points 
files to generate the measurement of mJSW. The python script extracted pixel 
spacing from the DICOM image file, so that a measurement in mm was 
generated, rather than in pixels (for all non-compressed images). The script 
generated an image of the outline of the femoral head and the acetabulum, 







Figure 30: Figure generated by the python script showing the point on the curves where 
mJSW was measured (the narrowest point between the two curves). 
 
 
The intra-rater ICC of the mJSW measurements was 0.73 (0.58,0.83) and the inter-
rater ICC was 0.68 (0.53,0.82). Baseline measures of mJSW using BoneFinder were 
compared to Dr Hardcastle’s previous baseline measurements from HipMorf 
(Appendix 13). There was a strong correlation between the BoneFinder and 
HipMorf measurements (r=0.8) but the ICC was lower (0.35 [0.23,0.46]). It 
appeared that the BoneFinder method was generally overestimating the value of 
mJSW compared to HipMorf. However, I was interested in the change between 
baseline and follow-up rather than the absolute values, I decided to use the 
measurements of mJSW provided by the Bone Finder method. The BoneFinder 
measurements, reassuringly, seemed to correlate with the semi-quantitative 
measurements of hip JSN ( 
Figure 31-Figure 33) and the Bland-Altman did not identify systematic bias (no 









Figure 31: Relationship between superior JSN grade determined by the OARSI atlas (x) 




Figure 32: Relationship between superior JSN grade determined by the OARSI atlas (x) 








Figure 33: Relationship between change in overall hip JSN grade determined by the 
OARSI atlas (x) and change in mJSW measurement determined by BoneFinder (y). 
 
 
4.4.8. Reliability of hip radiographic gradings 
Hip radiograph readings of the full HBM set (pooled and anonymised baseline 
and follow-up radiographs) were performed in October 2019. After grading all 
available radiographs, each study ID was imported into Stata with their baseline 
and follow-up anonymous filename. A random sample of 18 individuals (10%) 
were selected. Intra- and inter-rater statistics for prevalent OA variables for all 
hips, regardless of baseline or follow-up status, are presented in Table 8. Both 
intra- and inter-rater reliability statistics were lower for hips than seen for knees 
and were particularly low for JSN. JSN was rare in the set of radiographs 
regraded and where it was present, it was mild, with no hips scoring above 
grade one. Osteophyte severity were generally less severe than seen at the knees. 
All intra-rater kappas and all inter-rater kappas, except inferior acetabular 
osteophytes and superior JSN, represented moderate to substantial agreement 






for the training set (Appendix 15), which represented a range of OA severities, it 




Table 8: Intra- and inter-rater reliability statistics from grading the full set of HBM hips. 
*Observed by SH but not AH. 
  
  Intra-rater Inter-rater 
 N Unweighted Weighted Unweighted Weighted 
Croft score 69 0.611 0.404, 0.772 0.744 0.421, 0.940 0.498 0.305, 0.705 0.627 0.344, 0.836 
Superior acetabular osteophytes 69 0.588 0.347, 0.791 0.704 0.338, 0.891 0.528 0.325, 0.802 0.607 0.175, 0.800 
Superior femoral osteophytes 69 0.738 -0.018, 1 0.849 0, 1 0.575 0, 0.847 0.733 -0.015, 1 
Inferior femoral osteophytes 69 0.883 0.646, 1 0.961 0.793, 1 0.518 0.211, 0.825 0.766 0.422, 0.950 
Inferior acetabular osteophytes 69 0.489 -0.111, 1   0.378 -0.176, 0.932   
Medial JSN 69 0.660 0, 1   0.477 0, 0.849   
Superior JSN 69 0.489 0, 1   0.386 0, 1   
Acetabular sclerosis 69 none seen   none seen   
Femoral sclerosis 69 1 1, 1   0*   
Subchondral cysts 69 none seen   0*    
          
Croft >3 69 0.793 0.398, 1   0.850 0.561, 1   
Any osteophyte 69 0.688 0.488, 0.888  0.612 0.410, 0.814    




As seen at the knee, change in summed osteophyte score was strongly associated 
with subsequent increased pain, stiffness, and functional limitations (Table 9). 
Change in JSN score was associated with subsequent WOMAC scores, with a 
larger magnitude of effect, although CIs were much wider and overlapped the 
null for hip pain, reflecting the lower variability in change in JSN score (scored 
out of six vs 10 for osteophytes).  
 
Table 9: Associations between change in hip osteophytes or JSN and clinical OA 
outcomes at follow-up. 
 Change in osteophyte score Change in JSN grade 
 OR (95% CI) p OR (95% CI) p 
Use of walking aid at follow-up  1.07 (0.74, 1.56) 0.711 1.73 (0.71, 4.22) 0.225 
 β (95% CI) p β (95% CI) p 
WOMAC hip pain score 2.90 (0.31, 5.48) 0.028 10.0 (-1.97, 22.0) 0.101 
WOMAC hip stiffness score 3.13 (0.35, 5.90) 0.027 12.5 (3.45, 21.6) 0.007 
WOMAC hip function score 3.23 (0.62, 5.84) 0.015 14.6 (5.64, 23.6) 0.001 
OR per 1 grade increase in summed osteophyte or JSN score. β represents the increase in 
WOMAC score per grade increase. From person-level analyses of 125 individuals, 












5.1. Statistical methods 
Prior to commencing all analyses presented in this thesis, I generate an analysis 
plan detailing the variables and methods for analysis and any planned sensitivity 
analyses. I generated a list of potential confounders from literature searches. The 
analysis plan was then circulated to my supervisors and collaborators and the 
plan was refined based on their comments, including suggestions of additional 
covariates to analyse.  
5.1.1. Descriptive statistics 
I tabulated all categorical variables prior to analysis to determine variables were 
coded correctly (e.g. to check coding of missing values). Descriptive statistics 
comparing categorical variables, between those with and without data or 
between HBM cases and relatives without HBM, were generated as the number 
and percentage for each category and using χ2 tests to test between category 
differences in proportions. I visually inspected all continuous variables using 
histograms, to determine normality and to detect outliers. I calculated descriptive 
statistics for normally distributed variables as the mean and SD. Differences in 
means between HBM cases and relatives were determined using T-tests, or 
ANOVA for more than two categories. For non-normal variables, I calculated the 
median and interquartile range (IQR), and differences between groups using 
non-parametric Mann-Witney U-tests. 
5.1.2. Regression analyses 
I generated estimates of the effect of binary or continuous exposures on 
continuous outcomes by linear regression, using multivariable analyses to adjust 
for potential confounding variables. When analysing binary exposures, the effect 
sizes generated were differences in the mean outcome between the reference and 
the alternative category. For continuous exposures, effect sizes were the unit 
increase in outcome per unit increase in the exposure. Generally, exposure 






intervals (CIs) were calculated for effect estimates, as 1.96 standard errors (SEs) 
above and below the effect estimate. I analysed binary outcomes using logistic 
regression, adjusting for potential confounders. Estimates of ORs for binary 
exposures represent the OR in the alternative compared to the reference category 
and, for continuous exposures, the OR per unit change in the exposure. Analyses 
were restricted to those with complete data for all confounders. 
Dealing with skewed outcomes 
The main continuous outcomes analysed, namely the WOMAC scores and 
changes in semi-quantitative sub-phenotype grades, were highly positively 
skewed with many participants having a score of zero (see Chapter 6,Chapter 7). 
I checked for the most appropriate transformation for each variable using the 
Stata ‘gladder’ command, however many of the continuous variables were heavily 
zero-skewed and therefore none of the transformations normalized the data. I 
therefore included the Stata ‘robust’ option to generate heteroskedasticity-robust 
(Huber-White) SEs (335,336). 
There was also the possibility of a ceiling effect for some of the outcomes 
analysed, as WOMAC scores had a limit of 100 (representing the maximum 
pain/stiffness or limitation of function) and the progression variables had a 
maximum value of 12 for osteophytes and six for JSN. Tobit regression modelling 
is an alternative to least-squares regression, which models the outcome as a 
latent variable and estimates the line beyond the limit of the measurement 
(337,338). However, tobit models assume that there would be a normal 
distribution should values have been observed beyond the limit of measurement 
(339). Tobit modelling is more sensitive to violations of assumptions of 
homoskedasticity and normally distributed residuals (339). In ordinary least-
squares, if assumptions are not met, the SE will be underestimated, leading to 
CIs that are too narrow. However, in tobit regression, both the beta and SE will 
be biased by violations of the assumptions (339). I therefore decided to use least-






Accounting for clustering  
To increase sample size and statistical power, all available knees/hips were 
analysed. That meant that an individual could contribute up to two knees or hips 
to an analysis. As two knees/hips from the same individual are likely to be more 
correlated in terms of OA severity and covariates than two knees/hips from 
different individuals, they are not independent observations, and I needed to 
account for this ‘clustering’ in my analyses. Additionally, as non-index cases and 
controls from the HBM study population were recruited through, and were 
relatives or spouses of, HBM index cases, there was a need to account for family-
level clustering in analyses. OA severity is likely to be more strongly correlated 
within a family compared to between different families. Individuals from the 
same family are more likely to share genetic variants that may be associated with 
HBM or OA, and OA risk factors such as a high BMI (section 1.2.5), than 
individuals from different families. I selected generalized estimating equation 
(GEE) models as the most appropriate analyses for clustered data as these are 
more suitable for binary and skewed outcomes, compared to other methods such 
as random effects models (330). GEE does not explicitly model clustering in the 
data to generate an effect estimate for a particular individual, but instead 
generates an estimate of the average effect for a population (330). SEs are 
adjusted for clustering. The correlation between observations in a cluster is 
specified; I used an exchangeable correlation structure as this structure assumes 
the correlation is the same between all pairs in a cluster (330). In the case of joint-
level analysis, this assumption is correct as there are only two observations in a 
cluster.  
I performed all GEE analyses twice: once using all knees/hips and accounting for 
within-individual correlation and once using the most severely affected 
knee/hip per individual or the sum of radiographic sub-phenotype severity 
across both joints (person-level) and accounting for correlation within families. 
More complex statistical models are available to model the within- and between-






(i.e. three-level multilevel mixed effects models) (340). However, these models 
are more computationally intensive and complicated to interpret. As I was 
interested in the overall effect of HBM on OA outcomes, rather than how effects 
differ between individuals or between families, I used the more straightforward 
GEE models. 
All statistical analyses were performed in Stata version 13/15 (StataCorp, USA) 
or R version 3.5.1. 
5.2. Cohorts 
Although analysing the HBM study population represents a novel way to 
determine observational associations between high BMD and OA progression, 
the HBM population is relatively small and therefore unsuitable for genetic 
analyses. Larger populations were therefore studied for genetic analyses. A 
summary of the contribution of data from each cohort is presented in Table 10. 
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5.2.1. UK Biobank 
UK Biobank recruited over 500,000 individuals across the UK, aged 38-73, 
between 2006 and 2010 (341), to generate a health resource with the aim of 
“improving the prevention, diagnosis and treatment of a wide range of serious and life-
threatening illnesses” (342). Participants were selected from a range of locations 
across the UK to cover the socioeconomic, ethnic and landscape heterogeneity 
(341). Access to data can be applied for by any researcher registered with UK 
Biobank; application is submitted via the UK Biobank website 
(https://www.ukbiobank.ac.uk/). UK Biobank received REC ethical approval 
(REC reference: 11/NW/0382) and electronic signed consent was provided by all 
participants. Participants attended one of 22 research centres across the UK for 
baseline data collection. At the assessment centre, participants filled in touch-
screen questionnaires and completed computer-assisted interviews to collect data 
including lifestyle factors, health status and sociodemographic factors (341,343). 
Physical and functional measurements were performed, including measurement 
of height and weight and BMD at the heel using ultrasound (341). Blood samples 
were collected at the baseline assessment, which have been used for genotyping 
(section 5.3.1) and biomarker assays (section 11.2.2).  
The UK Biobank population contributed to analyses to determine the BMI-
independent causal effect of BMD on OA (Chapter 9), analyses to determine the 
contribution of bone pathways in OA pathogenesis (Chapter 10) and analyses of 
the causal effect of serum IGF-1 on OA risk (Chapter 11). Analyses were 
performed under application number 17295, using data released in April 2019. 
5.2.2. The Rotterdam study 
RS is a prospective cohort of 14,926 individuals aged 45 and above residing in the 
city of Rotterdam, the Netherlands (344). The aim of the study was to determine 






cohorts, recruited at different times and with varying levels of follow-up (Figure 
34). The first cohort (RS1) included 7,983 adults, aged 55-106, from the Ommoord 
district, recruited 1989-1993 (344,345). This cohort has been followed up up to 
five times. In 2000-2001, 3,011 additional individuals from the region who had 
reached the age of 55 years, or who were aged over 55 and had moved to the 
district, were recruited as the RS2 cohort. A total of four assessment cycles have 
been performed for RS2. The RS3 cohort included 3,932 individuals aged 45-54 
years from Ommoord, recruited from 2006-2008. This cohort has been followed 
up once. Recruitment of RS4 began in 2016, recruiting individuals aged 40+ years 
from Ommoord (344). Ethical approval has been provided by the Erasmus 
Medical Centre Medical Ethics Committee and the Netherlands Ministry of 
Health, Welfare and Sports (344). At baseline, a home-based interview and a 
clinic-based assessment were performed, which included imaging (including 
DXA and X-rays) and collection of blood samples for biomarker assessment and 
genotyping.  
The Rotterdam data was used to replicate the metabolomics analysis of BMD and 
OA sub-phenotypes (Chapter 8), to determine the association between BMD PRS  
and OA sub-phenotypes (Chapter 9) and to determine the contribution of bone 




Figure 34: Diagram of the design and data collection of the Rotterdam study population. 
 
Reproduced from (344). 





ALSPAC is a cohort of 14,541 pregnancies with an estimated delivery date 
between April 1991 and December 1992, recruited 1990-1992, from the former 
Avon area, southwest England (346,347). The women and resulting offspring 
(N=13,988 alive at one year) have been followed up for almost 30 years with 
questionnaires and clinical assessment. An additional 456 offspring were 
recruited at age 7 during recruitment phase two, 262 were recruited between 
ages 8-18 during recruitment phase three and 195 at ages 19-26 during 
recruitment phase four (348). Ethical approval has been provided by the 
ALSPAC ethics and law committee and the local REC. The mothers have been 
invited to attend four research clinics for a variety of outcome assessment 
measures (including DXA scans): Focus on Mothers (FOM)1 between December 
2008 and July 2011, FOM2 between July 2011 and June 2013, FOM3 between 
March 2013 and March 2014 and FOM4 between April 2014 and March 2015. All 
children were invited to assessment clinics at age 7, 8, 9, 10, 11, 12.5, 13.5, 15.5, 
17.5 and 24 years.  
The ALSPAC data was used to replicate the metabolomics analysis of bone 
turnover presented in Chapter 8, as BTMs have not been measured in either UK 
Biobank or RS. Analyses were performed under ALSPAC executive committee-
approved proposal B3083. 
5.3. Genetic analyses 
5.3.1. Genotype data and quality control (QC) 
UK Biobank 
The genotyping and pre-imputation QC methods for the UK Biobank population 
are described in full elsewhere (349). A summary of the pre-imputation QC and 
imputation procedure has been published by Mitchell et al (350): 
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“The UK Biobank full data release contains data on all successfully genotyped samples 
(n=488,377). 49,979 individuals were genotyped using the UK BiLEVE array and 
438,398 the UK Biobank axiom array. Pre-imputation QC, phasing and imputation are 
described elsewhere (349). In brief, prior to phasing, multiallelic and rare SNPs 
(MAF≤1%) were removed. Phasing of genotype data was performed using a modified 
version of the SHAPEIT2 algorithm (349). Genotype imputation to a reference set, 
combining the UK10K haplotype and HRC reference panels (351), was performed using 
IMPUTE2 algorithms (352). Analyses were restricted to autosomal variants by graded 
filtering with varying imputation quality according to allele frequency ranges, rarer 
genetic variants were required to have a higher imputation info score (info>0.3 for 
MAF>3%; info>0.6 for MAF 1-3%; info>0.8 for MAF 0.5-1%; info>0.9 for MAF 0.1-
0.5%) with MAF and info scores having been recalculated on an in-house derived 
‘European’ subset.” 
QC filtering of the UK Biobank data was conducted by Mitchell et al as 
previously described (350):  
“Individuals with mismatches between genetic and reported sex or individuals with sex 
chromosome aneuploidy were excluded. The sample was restricted to individuals of 
European ancestry as defined by an in-house k-means cluster analysis performed using 
the first 4 principal components (PCs), provided by UK Biobank, in R. The current 
analysis uses the largest cluster from this analysis. Estimated kinship coefficients, using 
the KING toolset (353), identified pairs of related individuals (349). An inhouse 
algorithm preferentially removed individuals related to the greatest number of other 
individuals, until no related pairs remained.”  
12,321,875 SNPs and 463,005 individuals passed QC and were included in the 
final dataset.  
The Rotterdam study 
Genotyping of the three RS cohorts was performed at the Genetics laboratory, 
department of Internal Medicine, Erasmus Medical College. The RS1 and RS2 
cohorts were genotyped using the Illumina HumanHap 550kv3 chip and the RS3 
cohort was genotyped using the Illumina HumanHap 610-Quad V1 chip. SNPs 
with a call rate <98% (i.e. SNPs missing in >2% of individuals), with a MAF <1% 
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or a Hardy-Weinberg p-value <10-6 were excluded, leaving 512,349, 455,389 and 
517,658 SNPs in RS1, 2 and 3, respectively (146,354). Duplicates and first/second-
degree relatives were identified using identical by state (IBS) probabilities greater 
than 97% in PLINK (146,354) and these individuals were excluded. Ethnic 
outliers were identified using an IBS distance >3SD and excluded. Individuals 
with sex mismatches with typed X-linked markers or excess autosomal 
heterozygosity were excluded. Additional genotypes were imputed using the 
Haplotype Reference Consortium (HRC)v1.1 reference panel and ‘minimac3’. 
Genotypes of 39,117,478 SNPs were available for 6,291 individuals in RS1, 2,157 
individuals in RS2 and 3,048 individuals in RS3. Additional analysis-specific 
post-imputation QC steps are described in Chapter 9 and Chapter 10.  
5.3.2. GWAS 
GWAS has been developed as a hypothesis-free scan of millions of genetic 
variants across the genome, with the aim of identifying common genetic variants 
robustly associated with a disease/phenotype, which may lead to the 
identification of novel causal genes for the disease/phenotype in question (355). 
GWAS tests whether the allele frequency for each genotyped SNP is related to a 
trait (either binary or quantitative), most commonly using an additive model (i.e. 
assuming a linear relationship with dosage of the effect allele) (355). GWAS of a 
binary outcome performs millions of individual logistic regression analyses, 
adjusted for a priori confounders, and a GWAS of a quantitative trait performs 
millions of linear regressions. The assumptions of these analyses are therefore the 
same as those for a standard linear regression model (i.e. homoskedasticity and 
normality of residuals) (356). In this thesis, I performed GWAS to generate 
summary statistics for pathway analyses (section 5.3.5) and latent causal variable 
analyses (LCV, Chapter 9). 
Accounting for population stratification 
Population stratification can occur because allele frequencies differ between 
populations with different ancestries. If the disease/trait also varies between 
 
 151 
these populations, the allele frequency can appear related to the disease/trait, 
even if it is not causal (or in linkage disequilibrium [LD] with the causal variant) 
(356). I performed GWAS in UK Biobank using a linear mixed model (LMM) 
within the software ‘BOLT’ (version 2.3) (357), using the MRC-Integrative 
Epidemiology Unit pipeline (358). The BOLT-LMM model is advantageous over 
standard linear regression modelling in that it can account for cryptic relatedness 
and population stratification and therefore related individuals do not need to be 
excluded, increasing power (357). The population structure, which is treated as a 
random effect in the linear mixed model, is modelled from 143,006 genotyped 
SNPs (selected based on a MAF>0.01, genotyping rate>0.015, Hardy-Weinberg 
equilibrium (HWE) p-value<10-4 and independence based on an r2 threshold of 
0.1, all calculated in PLINKv2.0) (358). The BOLT-LMM model is particularly 
advantageous in the UK Biobank population as all white Europeans can be 
included, instead of restricting to white British individuals (358,359). I adjusted 
for sex and genotyping chip in all GWAS analyses. To ensure population 
stratification was fully accounted for, I also adjusted for 10 PCs, generated using 
the software EigenSTRAT (360), which compares the allele frequencies within the 
study population to HapMap reference populations of different ethnicities (356).  
I performed GWAS of the individual radiographic OA sub-phenotypes (binary) 
in each RS population using the software ‘SNPtest’, using an additive model and 
adjusting for sex and 10 PCs. Post-GWAS QC in RS is described in Chapter 10. I 
performed GWAS separately for each cohort and then meta-analysed using a 
fixed-effect inverse-variance weighted meta-analysis in the software ‘EasyQC’ 
(361). I selected a standard logistic model over the linear mixed model in RS as 
BOLT-LMM is not recommended for sample sizes <5000 (362).  
I measured the potential effect of population stratification in each GWAS using 
the genomic inflation statistic, known as lambda genomic control (λGC) (363). 
This statistic measures the ratio of the median test statistic to the median test 
statistic of a null distribution, with a value of one representing no population 
stratification (363). A value much greater than one provides evidence for 
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population stratification. I also generated QQplots of the observed p-values 
against expected p-values from a χ2 distribution (364), to visually inspect for 
population stratification (deviation of most p-values from the χ2 distribution 
suggests population stratification), using the R ‘qqman’ package (365). 
5.3.3. Mendelian randomization 
Although every effort was made to collect data on all a priori confounders for 
analyses, there is still the possibility, as in any observational study, that 
unmeasured confounding or reverse causality may explain any associations 
observed, rather than a causal effect of BMD on OA.  
MR is a form of instrumental variable analysis that has been developed to 
determine whether a risk factor is causal, using data from large cohorts (366). 
This methodology is based on the concept of an RCT, the ‘gold standard’ method 
for determining a causal relationship (367). In well-designed, unbiased RCTs, 
patients are randomized to either receive an intervention (e.g. a drug) or to the 
control group (e.g. placebo). If successful randomization has occurred, the only 
difference between the groups should be whether they receive the intervention; 
all confounding variables should be evenly distributed between groups. The 
theory of MR is based on Mendel’s law of independent segregation of alleles 
during gamete formation. This leads to a random assortment of alleles in the 
offspring, which in theory means that the genotype determining a particular 
exposure of interest should not be associated with confounding variables (except 
in cases of assortative mating) (368,369). Therefore, if there are genetic variants 
that are robustly associated with the exposure (e.g. from GWAS), these variants 
can be used as instruments for the exposure of interest, to determine a causal 
effect of an exposure on an outcome, independent of confounding. Additionally, 
as alleles are randomly assigned at conception, they will not be influenced by the 
outcome and therefore reverse causality can be ruled out. If an exposure truly 
has a causal effect on an outcome, any genetic variant robustly associated with 
the exposure should be related to the outcome with an effect size proportional to 
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the SNP-exposure association and the causal effect of the exposure on the 
outcome (370).  
Assumptions of MR 
To accurately determine the causal effect using MR, three key assumptions must 
be met (Figure 35). The first key assumption is that the instrument (genetic 
variant(s)) is associated with the exposure of interest (IV1). To ensure an 
instrument meets this assumption, genetic variants are usually taken from the 
largest possible GWAS for the exposure (any SNP associated with the exposure 
with genome-wide significance). Although there may be additional variants 
associated with the phenotype above this stringent p-value threshold, the 
instrument is normally restricted to genome-wide significant SNPs to limit weak 
instrument bias, which will be described in more detail in the context of one-
sample (1S) and two-sample (2S) MR, below. The second assumption is that the 
instrument(s) is not associated with any confounders of the exposure-outcome 
relationship (IV2). This assumption can be tested for measured confounders by 
determining the association between the instrument(s) and all a priori 
confounders; instruments can be either the single SNPs or a PRS. The third key 
assumption of MR is that the instrument is not related to the outcome via a 
pathway independent of the exposure (IV3). This is known as the exclusion-
restriction criteria (371). When an instrument is associated with an outcome 










Where data were available for the exposure and the outcome in the same 
population (367,369), I performed 1SMR. In 1SMR, the causal effect of the 
exposure is determined either by a Wald ratio estimator (for a single SNP) or 
using two-stage least squares (2SLS) regression (367). The Wald ratio estimator is 
simply the beta of the instrument-outcome association divided by the beta of the 
instrument-exposure association (367), as displayed in Equation 3. 
 
Equation 3: Calculation of the Wald ratio estimator. 
 
Two-stage least-squares regression was used if multiple instruments were 
available for the exposure of interest. This was performed in three stages: 1) a 
regression of the exposure on the instruments was performed; 2) fitted values of 
the exposure were calculated; 3) the outcome was regressed on the fitted values 
of the exposure. I performed all analyses using the instrumental-variable 
regression (‘ivreg’) function of the Applied Econometrics with R package (372) or 
the Stata ‘ivreg2’ package (373). 
In 1SMR, I determined the strength of the instrument-exposure relationship 
using the F-statistic, which is displayed in both the Stata and R output. The F-







instruments and the proportion of variation in the exposure explained by the 
instrument (374). A value of less than 10 was used as evidence for weak 
instrument bias (367,375). In 1SMR, weak instrument bias would overinflate the 
estimate, biasing it towards the observational (confounded) estimate (374). I 
tested the IV2 assumption where data were available for relevant confounders, 
by determining the association between the instrument(s) and measured 
confounders using standard regression modelling. However, I was unable to test 
IV2 for unmeasured confounders. I tested IV3, in analyses where I included 
individual SNPs as instruments, using the Sargan test of overidentification, 
which determines if the estimates differ between the different instruments (376). 
If the estimates differ, this is evidence for heterogeneity: i.e. pleiotropy (377). 
1SMR is still vulnerable to confounding by population stratification. I therefore 
adjusted for 10 PCs in the 2SLS analysis, along with sex and genotyping chip. 
1SMR can be underpowered as analyses are limited to populations with 
measured exposure, outcome, and genotype data. 
Two-sample MR 
2SMR has since been developed to make use of publicly available summary 
statistics from large GWAS collaborations and to allow MR analyses when access 
to individual-level data is not possible (378,379). For 2SMR analyses, I extracted 
the summary statistics (effect size, SE, effect allele [EA] and alternative allele 
[NEA], effect allele frequency [EAF]) for the SNP-exposure and the SNP-outcome 
associations, for autosomal SNPs associated with the exposure at genome-wide 
significance, from published GWAS summary statistics. I performed LD-based 
clumping, using an r2 threshold of 0.001, with European reference data, so that 
only the most strongly associated SNP at each locus was retained. Exposure and 
outcome data were then harmonized to ensure the statistics correspond to the 
same effect allele. I excluded palindromic alleles with indeterminate allele 
frequencies (i.e. MAF>0.42).  
After harmonization, I calculated individual Wald ratios for each SNP and then 
generated an overall estimate for the causal effect by meta-analysing these Wald 
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ratio estimates. The meta-analysis was performed using fixed-effects inverse-
variance weighted (IVW) meta-analysis, i.e. a meta-analysis weighted by the 
inverse of the SE of the SNP-outcome association (379). I performed all 2SMR 
analyses in this thesis using the ‘TwoSampleMR’ package version 0.4.22 
(downloaded from http://www.mrbase.org/) (380).  
Numerous methods have been developed to test the IV3 assumption illustrated 
in Figure 35 and determine if horizontal pleiotropy is biasing results. I used MR-
Egger regression to generate an estimate of the causal effect which is not biased 
by horizontal pleiotropy. Unlike IVW regression, MR-Egger regression can have 
a value other than 0 for the intercept and this value represents the average effect 
of the instruments on the outcome not mediated by the exposure (381). 
Therefore, if this value is not zero, there is evidence that the exclusion-restriction 
criteria is invalid. The slope from the MR-Egger regression is a pleiotropy-robust 
estimate of the causal effect of the exposure on the outcome provided the InSIDE 
assumption holds: the instrument strength does not correlate with the degree of 
pleiotropy (381). In cases where the exposure is highly correlated with other 
covariates, this may be violated; for example, when analysing the effect of BMD 
on OA, the BMD SNPs are likely to be associated with BMI as well. As BMD and 
BMI are correlated, it is likely that as the strength of the SNP-BMD association 
increases, so does the strength of the SNP-BMI association. Another limitation of 
MR-Egger regression is low power (382). 
Additional methods have been developed more recently, such as the weighted-
median estimator. The IVW estimate is a weighted mean of the Wald ratios for 
each SNP (379) and is biased if any SNP is an invalid instrument (383). The 
weighted median estimate, however, is valid as long as at least 50% of SNPs are 
valid instruments (383). I therefore compared the IVW, weighted median and 
MR-Egger slope estimates for all analyses to determine if the causal effect 
estimates are likely to be biased by invalid instruments. If the effect estimates 
were similar across the three methods, I was more confident that the effect 
estimate generated was a good, unbiased, approximation of the causal effect of 




In analyses where I detected evidence for horizontal pleiotropy, I performed 
MVMR. MVMR determines the causal effect of one exposure (exp1) on an 
outcome when the instrument exerts a pleiotropic effect on another exposure(s) 
(exp2) (Figure 36). MVMR requires an additional instrument(s), robustly 
associated with exp2. This methodology is particularly useful when trying to 
determine the causal effect of exp1 on an outcome when exp1 and exp2 are highly 
correlated traits (377). I performed MVMR in a one-sample setting, by regressing 
exp1 on the instrument(s) for both exp1 and exp2 and generating predicted values 
for exp1 (exp1p). I repeated this process for exp2, generating exp2p. I then 
regressed the outcome on exp1p and exp2p, in a multivariable model including 
potential confounders (sex, genotyping chip and 10 PCs), to give a causal effect 
estimate for exp1 on the outcome, independent of exp2, and vice versa (377). It 
does not matter if any of the instrument(s) are associated with both exposures, as 
long as they are associated with at least one exposure. Sanderson-Windmeijer 
(SW) conditional F-statistics, generated in the Stata ‘ivreg2’ output, determined 
the conditional strength of the instruments, as the instrument must be able to 
jointly predict both exp1 and exp2 (377,384). It should be noted that MVMR can 
only account for pleiotropy if all pleiotropic variables and their instrument(s) are 





Figure 36: DAG summarizing the concept of MVMR. 
 
In MVMR, a genetic instrument (or instruments) robustly associated with each exposure 
is required. It is possible for the instruments to be associated with more than one exposure 
in the model if the instrument can jointly predict both exposures. MVMR will generate 
an estimate for the causal effect of exposure1 on the outcome, independent of exposure2 
and an effect estimate for exposure2 on the outcome, independent of exposure1. However, 
if any of the instruments are related to another exposure not included in the model, the 
effect estimate will still be biased by horizontal pleiotropy (in this instance, if exposure3 is 
not included in the model, the effect estimate generated for BMD will be independent of 
BMI but will still be biased).  
 
5.3.4. Polygenic risk scores 
Individual variants identified by GWAS normally only explain a small amount 
variance in the phenotype of interest. PRS sum the alleles for all genome-wide 
significant loci, generating a variable with increased variability. PRS were first 
used by Purcell et al in their GWAS of schizophrenia: due to a small sample size, 
their GWAS was underpowered to identify variants with small effects on disease 
risk and therefore they generated PRS to determine if this would explain a 
greater proportion of variability in schizophrenia risk (385). PRS can be weighted 
by the beta (i.e. the per-allele effect on the phenotype) from the GWAS, hence 
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giving greater weight to variants that have a greater effect on the phenotype, 
further increasing variability.  
As discussed in section 3.1, the two major radiographic features of OA 
(osteophytes and JSN) may have distinct relationships with BMD. I generated 
PRS using independent BMD loci, from a recent large-scale GWAS of eBMD 
(386), to determine if genetic burden for eBMD is differentially associated with 
the radiographic OA sub-phenotypes in the RS population (Chapter 9). PRS are a 
continuous variable, which I analysed using standard linear and logistic 
regression analyses. As SNPs are constant from conception, reverse causality and 
confounding are less of an issue in PRS models. However, population 
stratification still needs to be accounted for, as described in section 5.3.2. 
Therefore, I adjusted for 10 PCs in all PRS analyses.  
5.3.5. Pathway analysis 
In Chapter 10, I aimed to determine the variation in OA, and specifically OA sub-
phenotypes, explained by specific biological pathways known to influence both 
BMD and OA, such as the Wnt and TGFβ signalling pathways described in 
sections 2.1.3 and 3.3.2. The pathways selected and the methods for extracting a 
list of genes annotated to each pathway are described in detail in Chapter 10. I 
extracted variants related to each pathway using two methods: 
1. Using all variants within 20kb upstream and 20kb downstream of all 
genes in the pathway. 
2. Using all cis-expression quantitative trait loci (eQTLs) associated with 
gene expression levels in blood in the eQTLgen (significant) December 
2019 release data, downloaded from (https://www.eqtlgen.org/cis-
eqtls.html). 
Variants were restricted to independent SNPs (i.e. SNPs in linkage equilibrium) 
using the Plink ‘—indep-pairwise’ function and a pairwise LD<0.2. 
I considered generating PRS based on all variants linked to each pathway and 
determining the variation explained by each pathway using the r2 from a linear 
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regression of the PRS on each sub-phenotype. However, the disadvantage of 
generating PRS is that you must select an allele to count as the ‘effect allele’ when 
summing alleles across multiple loci. Therefore, I generated SNP-specific r2 
estimates using the formula published by Shim et al (Equation 4) (387). 
 
Equation 4: Calculation of SNP-specific r2.  
 
βSNP: per-allele effect estimate for the SNP on the sub-phenotype, estimated from a 
GWAS, SESNP: standard error for βSNP, EAF: effect allele frequency.     
 
I then summed values across all independent variants linked to each pathway to 
generate an estimate of the pathway-specific r2. 
5.4. Metabolomics 
Metabolomics is the study of metabolites within a sample. Unlike genetics, which 
are fixed at conception, metabolites represent the current cellular state within a 
particular tissue; they are the intermediate or end-stage products produced by 
metabolic processes of a cell, representing a mix of genetic and lifestyle factors 
(388).  
5.4.1. Determining plasma metabolomic profile using NMR 
spectroscopy 
Metabolomic profiling in all cohorts analysed was performed externally by 
Nightingale health (formerly Brainshake), Helsinki, Finland, using their custom-
designed platform. This is a high-throughput, reproducible, proton-nuclear 
magnetic resonance (NMR) spectroscopy platform which measures over 200 
metabolic traits in serum or plasma, representing systemic metabolism, including 
low-molecular weight molecules (LMWMs) such as amino acids, lipoproteins 
and lipid sub-factions (Figure 37) (389). Due to the inclusion of lipids and 
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(a mass of less than 1.5kDa is normally used to define a metabolite) (390,391), the 
measures generated by this platform are referred to as metabolic traits 
throughout this thesis. 
 
Figure 37: List of the metabolic traits quantified by the Nightingale health platform. 
 
Reproduced from (389). 
 
NMR utilises the magnetic properties of hydrogen ions (i.e. protons) within the 
molecules. Electromagnetic radiation emitted by the spectrometer excites the 
protons and the energy released as the protons return to equilibrium is recorded 
(390). A mathematical process called Fourier transformation generates the 
spectra (392,393), with x axis representing chemical shift and y axis representing 
intensity (390). The chemical shift of a proton, compared to the reference, gives 
information about the environment of a proton (i.e. the chemical structure of the 
molecule) (390). The intensity provides information about the molecule 
concentration. 
The methodology for the Nightingale NMR analysis has been published in detail 
in several reviews (389,392-394). The NMR spectroscopy was performed on a 96 
well plate, including two QC samples: one to measure the consistency of 
quantification and the other to measure performance of the spectrometer (389). 
Prior to analysis, blood samples were stored at -80°C within two hours of 
collection and thawed to 4°C overnight before analysis (390). Samples were then 
spun in a centrifuge to remove precipitate (3400xg) (392). 300µl of sample was 
mixed with 300µl of sodium phosphate buffer in NMR tubes and samples were 
heated to 37°C for analysis (394). Analyses were performed using a Bruker 
AVANCE III spectrometer at 500.36MHz (392,393). The metabolic traits were 
detected using three molecular windows (Figure 38): LIPO identified 
lipoproteins and LMWM identified LMWMs. Then lipids were extracted with 
0.15M saturated sodium chloride solution, 5ml methanol and 10ml 
dichloromethane and deuterochloroform, the sample was centrifuged at 4°C for 
20 minutes (2400xg) and the lipid extracts were moved to separate NMR tubes 
Image removed for copyright purposes  
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for detection by the LIPID window (at 22°C) (389,394). QC and quantification of 
metabolic traits were performed using proprietary software (395). The 
quantification of lipids and metabolites measured by standard clinical chemistry 
assays (such as total cholesterol, triglycerides) is comparable to routine clinical 
assays (395). 
 
Figure 38: The Nightingale health platform for determination of metabolomic profile. 
 
Reproduced from (389). 
 
5.4.2. Analysing metabolomic data 
The Nightingale platform generates a measure of the absolute concentration of 
each metabolic trait (normally in mmol/L, Figure 37) or a percentage for the ratio 
metabolic traits (e.g. apolipoprotein B: apolipoprotein A1). All measures 
represent continuous variables that were analysed in standard linear/logistic 
regression analysis, adjusting for covariates such as age and sex. A large 
proportion of the measures were skewed (Appendix 16). To reduce the 
complexity of interpreting some metabolic traits in log-transformed units and 
others on their original scale, analyses were performed with metabolic traits in 
their original units (or SD units). Regression analyses were performed with 
heteroskedasticity-robust SEs (section 5.1.2). However, sensitivity analyses were 
performed with log-transformed metabolic traits (where appropriate) to 
determine if results were biased by skewed metabolic traits. 
 
Image removed for copyright purposes  
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CHAPTER 6.  THE 
ASSOCIATION BETWEEN 






6.1. Background and aims 
As discussed in section 3.1, there is strong evidence to suggest that higher BMD 
is a risk factor for prevalent and incident knee OA (209,212-215,229,230,232,396-
398), whereas there is some evidence suggesting that high BMD is protective 
against knee OA progression (229,233). There are several reasons for this 
paradox. The first potential explanation is selection bias (also known as collider 
or index event bias). When studying OA progression based on a binary definition 
of any increase in overall OA severity in those with OA at baseline (i.e. KL>2), 
the analysis is restricted to cases. If a variable that causes both OA incidence and 
progression is not controlled for in a case-only analysis, an inverse association 
between the confounding variable and high BMD may be induced, causing a 
backdoor pathway from high BMD to OA progression (Figure 39 illustrates 
collider bias, using an analysis which has not been adjusted for fat mass as an 
example).  
 
Figure 39: Illustration of the theory of collider bias in a case-only study. 
 
The box around incident OA indicates that incident OA has been ‘conditioned on’ by 
restricting the analysis to those with OA at baseline. Fat mass has not been adjusted for 
in this analysis, leading to a backdoor pathway between BMD and progressive OA. The 
dashed line represents an induced negative association. Adjusting for fat mass in this 
example would ‘block’ this backdoor pathway. 
 
Another reason why basing the definition of OA progression on KL grade could 
lead to a potentially spurious inverse association between BMD and OA 
progression is that to progress from a KL grade of two to a grade of three, a knee 
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must go from displaying ‘possible’ to ‘definite’ narrowing of the joint space (32). 
Therefore, progression from grade two to three reflects incident JSN. Studies that 
have identified the relationship between BMD and radiographic sub-phenotypes 
of OA suggest that BMD is related to osteophytes, but not JSN (212,227,233). It is 
possible that high BMD is also only related to the progression of osteophytes and 
not progressive JSN; this would not be picked up in a study using overall KL 
change as an outcome. 
Alternatively, there may in fact be a protective effect of BMD against knee OA 
progression. One reason for this could be that individuals with higher BMD have 
lower bone turnover. As discussed in section 3.1.2, an analysis in the Chingford 
population without osteoporosis found that women with progressive OA had 
higher levels of uNTX-1 and uCTX-1, compared to women with non-progressive 
OA and women without OA, at three timepoints (244). This suggests that bone 
turnover may be specifically related to reduced OA progression. Further 
evidence for a relationship between bone turnover and OA progression was 
provided by Berry et al, who found that higher baseline P1NP, osteocalcin and 
CTX-1 were associated with a reduced rate of cartilage loss in 132 older 
Australians (399).  
In this chapter, I employ a novel approach to determine the relationship between 
high BMD and knee OA progression, by examining the HBM population and 
their relatives without HBM (section 2.3.2). By examining progression of the 
individual radiographic sub-phenotypes in this population, I can detect any 
differential associations which may explain the potential spurious associations 
observed in previous studies of overall OA. To limit the possibility of selection 
bias from performing a case only study, I analysed change in sub-phenotypes as 
a continuous variable and included individuals without features of OA at 
baseline, which also increased variability in the outcome and hence statistical 
power. As clinical severity (e.g. pain) may have differential relationships with 
OA risk factors, such as BMD, I also aimed to determine if HBM is associated 
with clinical symptoms of OA, i.e. pain, stiffness, functional limitation and 
reduced HR-QoL, and whether any such symptom is explained by radiographic 
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OA severity, which would provide insight into the potential clinical relevance of 




6.2. Methods  
6.2.1. Study population 
This analysis was performed in the HBM study population (section 2.3.2), who 
were still alive and contactable and consented to knee X-rays. The follow-up 
procedure is described in Chapter 4. Of the 437 individuals who originally 
consented at the eight participating centres, 254 (58%) were still alive and 
contactable, of whom 217 (85%) completed the questionnaire and 176 (69%) 
attended for follow-up radiographs. Derivation of the follow-up population and 









6.2.2. Assessing radiographic OA progression 
Methodology for grading radiographic OA progression is described in section 
4.4. Overall KL grade at the two timepoints was used to generate a binary 
variable for overall OA progression, using the standard definition of OA at 
baseline (KL>2) and an increase in grade at follow-up. This variable is limited as 
it does not consider how individuals with doubtful OA at baseline (KL=1) differ 
from those clear of OA at baseline (KL=0). It is also vulnerable to a ceiling effect 
as individuals with a KL grade of four at baseline cannot progress.  
I summed the semi-quantitative grades for osteophytes at the four regions (tibial 
and femoral, medial and lateral) and separately for JSN at the two regions 
(medial and lateral) to generate continuous outcome variables based on change 
in these summed scores between baseline and follow-up, with higher scores 
representing worsening osteophytes or JSN. Continuous measures of mJSW at 
the two timepoints were used to calculate reliable change index (RCI), which 
determines if the change in mJSW is meaningful over and above measurement 
error. Methodology for calculating RCI from mJSW measurements is outlined in 
Equation 5 and has been published elsewhere (400). 
  
Equation 5: Formula for generating RCI from mJSW measurements at two timepoints. 
 
 
The RCI is a Z-score and a level of 1.96 is used to denote a ‘true’ change over and 
above measurement error (400). A binary variable for true JSN was therefore 
generated for those with an RCI<-1.96. A summary of all radiographic variables 
and how they were derived is presented in Table 11. 
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Table 11: Variables generated by Kellgren-Lawrence grading and semi-quantitative sub-
phenotype grading using the OARSI atlas, and the derived variables used in this 
analysis. 




Progressive OA: KL grade >2 at baseline and an 
increase in grade at follow-up 
Incident OA: KL grade <2 at baseline and >2 at follow-
up 
Osteophytes 
Osteophyte progression: Sum of all semi-quantitative 
osteophyte grades at follow-up – sum at baseline 
 Medial femoral 0-3 
 Lateral femoral 0-3 
 Medial tibial 0-3 
 Lateral tibial 0-3 
JSN 
JSN progression: Sum of both semi-quantitative JSN 
grades at follow-up – sum at baseline 
 Medial 0-3 
 Lateral 0-3 
Subchondral sclerosis 
Incident sclerosis: no sclerosis (medial or lateral) at 
baseline and any sclerosis at follow-up 
 Medial 0, 1 
 Lateral 0, 1 
Chondrocalcinosis 0, 1 
Incident chondrocalcinosis: no chondrocalcinosis at 
baseline and chondrocalcinosis at follow-up 
mJSW continuous 
Change in mJSW: mJSW at follow-up – mJSW at 
baseline 
True JSN: Reliable change index <-1.96 
 
6.2.3. Determining clinical features of knee OA progression 
Knee pain, stiffness and limitation of function were assessed using the WOMAC 
index at follow-up (310), as described in section 4.2.1. HR-QoL was determined 
using the five-level EuroQol EQ5D questionnaire as described in section 4.2.1.  
6.2.4. Covariates 
Age and sex were considered a priori confounders. Baseline grades for 
continuous sub-phenotype outcomes were also adjusted for, to limit the 
possibility of a ceiling effect, due to those with higher baseline scores being less 
able to progress. Due to HBM cases being identified from routine DXA 
databases, the proportion of postmenopausal women and the proportion with a 
history of steroid use was higher than the relatives without HBM (197) and as 
these factors could be related to osteophyte development, these were 
investigated as potential confounders. History of hormone replacement therapy 
(HRT) use, PA and time between baseline and follow-up X-rays were also 
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investigated as potential confounders. As individuals with HBM have higher 
TBFM than their unaffected relatives, with a hypothesized causal pathway 
between HBM and TBFM via bone turnover (201), I investigated TBFM as a 
potential mediator of any observed associations. However, it is also possible that 
TBFM is a confounder, as there is strong evidence for a causal relationship 
between higher BMI and higher BMD (401). The directed acyclic graph (DAG) for 
the hypothesized causal pathway between HBM and osteophyte/ JSN 
progression is presented in Figure 41. 
 
Figure 41: DAG of the hypothesized causal pathway between HBM and OA sub-
phenotype progression, highlighting hypothesized confounders. 
 
Dashed lines represent induced associations due to participant selection. Arrows 
represent positive associations and capped lines represent inverse associations. 
 
6.2.5. Statistical analysis 
Associations between HBM status (binary) and binary OA incidence and 
progression variables were determined by multivariable logistic regression, 
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using GEE to account for clustering due to multiple knee radiographs per person, 
as described in section 5.1.2. Associations with continuous osteophyte and JSN 
progression variables were determined by multivariable GEE linear regression, 
with robust SEs due to non-normal distributions of outcome variables. Analyses 
were initially performed unadjusted (model 1), then adjusted for age and sex 
(and baseline score for continuous outcomes) (model 2), then additionally 
adjusting for height, menopause, and education (model 3). Finally, the 
mediating/confounding effect of TBFM was determined by additionally 
adjusting for TBFM in model 4.  
6.2.6. Sensitivity analyses 
I performed the following sensitivity analyses to assess the reliability of results: 
1) As TKRs were excluded from analyses but are likely to be performed due 
to severe OA, analyses of progressive OA were repeated, assuming that 
individuals with OA at baseline (KL>2) and a TKR at follow-up had 
progressive OA. Those with a KL score <2 at baseline and a TKR at follow-
up were coded as incident and progressive OA cases (assuming rapid OA 
progression led to a TKR within eight years of OA development). 
2) Person-level analyses, using the highest value for osteophyte/JSN scores 
of the two knees.  
3) Repeating analyses removing individuals reporting a cartilage operation 
(12 knees), knee lavage, washout, arthroscopy (16 knees) or a steroid 
injection (9 knees) in their follow-up questionnaire. 
4) An additional model adjusting for metal artefacts on DXA scans (section 
4.3.1). 
5) An additional model adjusting for bone size as assessed by maximal tibial 
plateau width. 
6) Removing individuals with positioning errors leading to loss of fat mass 
from the DXA image (section 4.3.2). 
7) Removing those visiting a different site for follow-up imaging. 
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8) To check that conclusions were not invalid due to skewed continuous 





6.3.1. Descriptives of the High Bone Mass radiographic 
follow-up population 
Follow-up and baseline radiographic data were available for 169 individuals, 
63% of whom had HBM. Those with follow-up data were more commonly 
female and more active at baseline and less commonly postmenopausal and 
diabetic at baseline (Table 12). However, there did not appear to be differential 
loss-to-follow-up between HBM cases and their relatives, and there was no 
evidence of a difference in baseline prevalence of knee OA or OA sub-
phenotypes or joint replacement between those with and without follow-up 




Table 12: Baseline descriptives of  individuals from the HBM cohort with and without 













 N (%)  
HBM cases  274 (62.7) 107 (63.3) 167 (62.3) 0.833 
Female sex  285 (65.2) 124 (73.4) 161 (60.1) 0.004 
     Postmenopausal  207 (74.2) 85 (68.6) 122 (78.7) 0.054 
History of smoking  244 (57.0) 85 (50.3) 159 (61.4) 0.023 
Alcohol consumption    
0.164 
     None 87 (20.3) 28 (16.6) 59 (22.7) 
     Occasional 52 (12.1) 23 (13.6) 29 (11.2) 
     Regular 217 (50.6) 94 (55.6) 123 (47.3) 
     Heavy 73 (17.0) 24 (14.2) 49 (18.9) 
Diabetes 44 (10.1) 10 (5.9) 34 (12.7) 0.022 
Physical activity categoryd    
0.030 
     Low 66 (17.4) 19 (11.6) 47 (21.9) 
     Moderate 129 (34.0) 58 (35.4) 71 (33.0) 
     High 184 (48.6) 87 (53.1) 97 (45.1) 
Joint replacement  47 (10.8) 16 (9.5) 31 (11.6) 0.490 
KOA (KL >2) 127 (32.2) 49 (29.5) 78 (34.2) 0.325 
Knee osteophyte  127 (32.2) 49 (29.5) 78 (34.2) 0.325 
Knee JSN 78 (19.9) 27 (16.3) 51 (22.5) 0.128 
Any subchondral sclerosis 17 (4.4) 4 (2.4) 13 (5.8) 0.111 
Any chondrocalcinosis 37 (9.6) 15 (9.2) 22 (9.9) 0.812 
 Mean (SD)  
Age, years  59.1 (15.4) 57.7 (12.3) 59.9 (17.1) 0.133 
Height, cm  168.8 (9.8) 167.7 (9.2) 169.5 (10.1) 0.072 
Weight, kg  84.5 (17.1) 82.6 (17.6) 85.6 (16.6) 0.074 
L1 Z-score 2.6 (2.1) 2.5 (2.0) 2.7 (2.3) 0.281 
Max total hip Z-score 2.0 (1.6) 2.0 (1.5) 2.1 (1.7) 0.846 
 
As expected, individuals with follow-up data and HBM were more commonly 
female (84% vs 55%), more commonly postmenopausal (74% vs 53%) and had a 
greater baseline BMD (mean TH-BMD 1.25g/cm2 vs 0.97g/cm2) and BMI (30.4 
kg/m2 vs 27.7 kg/m2) than individuals with follow-up data without HBM (Table 
13). Individuals with HBM were also less likely to drink regularly (weekly or 
more frequent) and had a greater loss of BMD between baseline and follow-up, 

















 N (%)  
Female sex 124 (73.3) 90 (84.1) 34 (54.8) 7.22x10-5 
 Postmenopausal at baseline 85 (68.5) 67 (74.4) 18 (52.9) 0.037 
 
Menopause transition during 
follow-up 
13 (10.8) 7 (8.1) 6 (17.7) 0.131 
 History of HRT use 55 (45.5) 44 (50.0) 11 (33.3) 0.151 
History of smoking  81 (50.6) 49 (49.0) 32 (53.3) 0.596 
Alcohol consumption     0.037 
 Never 15 (9.0) 7 (6.7) 8 (12.9)  
 Monthly or less 60 (35.9) 46 (43.8) 14 (22.6)  
 Weekly 49 (29.3) 29 (27.6) 20 (32.3)  
 Daily/ most days 43 (25.8) 23 (21.9) 20 (32.3)  
Physical activity at baseline    0.453 
     Low  19 (11.6) 11 (10.8) 8 (12.9)  
     Medium  58 (35.4) 33 (32.4) 25 (40.3)  
     High 87 (53.0) 58 (56.9) 29 (46.8)  
Education    0.061 
     Up to GCSE/ O level 67 (41.4) 50 (48.1) 17 (29.3)  
     A level or equivalent 37 (22.8) 22 (21.2) 15 (25.9)  
     Degree or equivalent 58 (35.8) 32 (30.8) 26 (44.8)  
 Mean (SD)  
Age at baseline, years  57.7 (12.3) 58.4 (12.6) 56.4 (11.7) 0.303 
Age at follow-up, years 65.9 (12.4) 66.7 (12.7) 64.7 (11.8) 0.312 
Height at baseline, cm  167.7 (9.2) 166.5 (8.0) 169.8 (10.6) 0.036 
Weight at baseline, kg  82.6 (17.6) 84.1 (17.6) 80.0 (17.4) 0.146 
BMI at baseline (kg/m2) 29.4 (5.9) 30.4 (6.2) 27.7 (5.0) 0.003 
TBFM (kg) 32.1 (10.9) 33.2 (11.3) 30.0 (10.0) 0.076 
Baseline TH Z-Score 2.03 (1.50) 2.96 (0.95) 0.46 (0.80) 8.55x10-39 
Baseline TH-BMD, g/cm2  1.15 (0.19) 1.25 (0.14) 0.97 (0.13) 1.03x10-26 
Change in TH-BMD, % per year -0.31 (0.92) -0.44 (0.94) -0.09 (0.84) 0.020 
Baseline L1 Z-Score 2.47 (1.96) 3.64 (1.25) 0.44 (1.14) 4.20x10-37 
Baseline L1-BMD, g/cm2  1.26 (0.22) 1.38 (0.15) 1.06 (0.14) 1.39x10-29 
Change in L1-BMD, % per year 0.02 (1.19) 0.02 (1.24) 0.02 (1.09) 0.994 
Maximum tibial plateau width at 
baseline, mm 
81.4 (7.2) 80.1 (6.3) 83.9 (8.0) 0.001 
Follow-up time, years  8.3 (1.0) 8.3 (0.7) 8.2 (1.3) 0.871 
 
6.3.2. Determining potential covariates 
Age, sex, educational attainment, height, and weight were a priori confounders. 
As highlighted in section 6.2.4, I investigated time between X-rays, menopause, 
PA, and HRT use as potential confounders, by determining the association 
between these variables and OA sub-phenotype progression. As there was some 
evidence for alcohol consumption differing between HBM cases and relatives 
without HBM (Table 13), I also determined the associations of alcohol 
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consumption with the outcomes (Table 14, Table 15). There was evidence for a 
greater odds of incident OA for women postmenopausal at baseline. Age was 
related to an increased odds of incident OA, chondrocalcinosis and subchondral 
sclerosis. Baseline weight was related to an increased odds of incident OA and to 
change in osteophyte and JSN scores. As BMD is a component of weight, TBFM 
was included in statistical models instead of weight. Time between X-rays was 






















Female 0.83 (0.38, 1.80) 0.637 0.62 (0.22, 1.72) 0.361 0.38 (0.12, 1.16) 0.088 
Alcohol consumption (baseline)  p for trend=0.188  p for trend=0.251  p for trend=0.864 
 None Ref  Ref  Ref  
 Occasional 3.16 (0.68, 14.63) 0.141 0.27 (0.05, 1.57) 0.145 0.81 (0.08, 8.15) 0.856 
 Regular 3.24 (0.87, 12.16) 0.081 0.42 (0.12, 1.49) 0.179 1.01 (0.27, 3.81) 0.987 
 Heavy 2.25 (0.51, 9.84) 0.282 0.38 (0.08, 1.80) 0.221 1.13 (0.17, 7.40) 0.902 
PA category (baseline)  p for trend=0.540  p for trend=0.545  p for trend=0.662 
 Low Ref  Ref  Ref  
 Medium 0.54 (0.19, 1.51) 0.238 0.54 (0.08, 3.42) 0.509 2.11 (0.25, 18.0) 0.494 
 High 0.94 (0.37, 2.35) 0.890 1.09 (0.21, 5.60) 0.917 2.03 (0.25, 16.6) 0.508 
Education  p for trend=0.982  p for trend=0.123  p for trend=0.294 
 up to GCSE/O level Ref  Ref  Ref  
 A level 0.69 (0.27, 1.82) 0.457 0.53 (0.17, 1.64) 0.271 0.77 (0.19, 3.16) 0.719 
 Degree 0.99 (0.46, 2.14) 0.979 0.40 (0.12, 1.30) 0.127 0.48 (0.12, 1.97) 0.308 
Postmenopausal (baseline) 3.40 (1.26, 9.14) 0.015 all cases postmenopausal at baseline 4.40 (0.54, 35.9) 0.166 
Premenopausal at baseline,  
postmenopausal at follow-up 
0.72 (0.19, 2.81) 0.641 all cases postmenopausal at baseline 0.85 (0.10, 6.89) 0.876 
History of HRT use (follow-up) 2.13 (0.93, 4.84) 0.072 0.65 (0.19, 2.25) 0.498 0.34 (0.07, 1.76) 0.201 
Age (baseline), years 1.06 (1.02, 1.09) 4.70x10-4 1.11 (1.06, 1.16) 2.71x10-5 1.08 (1.03, 1.13) 0.001 
Time between X-rays, years 0.78 (0.52, 1.15) 0.211 2.34 (1.20, 4.55) 0.013 1.43 (1.18, 1.74) 3.55x10-4 
Height (baseline), cm 1.01 (0.96, 1.05) 0.717 1.00 (0.94, 1.07) 0.977 1.00 (0.91, 1.09) 0.944 
Weight (baseline), kg 1.02 (1.01, 1.04) 0.013 1.01 (0.99, 1.03) 0.230 1.03 (1.00, 1.07) 0.056 
ORs are per unit increase for continuous covariates.   
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Table 15: Associations between covariates and progressive OA outcome variables in the HBM cohort follow-up population. 
 Change in osteophyte score Change in JSN grade 
 β (95% CI) p β (95% CI) p 
Female 0.38 (-0.09, 0.84) 0.111 -0.08 (-0.26, 0.10) 0.378 
Alcohol consumption at baseline  p for trend=0.860  p for trend=0.535 
 None Ref  
 Occasional -0.14 (-0.90, 0.61) 0.709 0.04 (-0.19, 0.27) 0.722 
 Regular 0.04 (-0.62, 0.69) 0.912 0.15 (-0.03, 0.34) 0.111 
 Heavy -0.19 (-0.91, 0.52) 0.592 -0.03 (-0.20, 0.13) 0.677 
Physical activity category at baseline  p for trend=0.458  p for trend=0.175 
 Low Ref Ref 
 Medium 0.15 (-0.41, 0.71) 0.601 0.25 (0.09, 0.41) 0.002 
 High 0.24 (-0.24, 0.72) 0.335 0.22 (0.08, 0.36) 0.002 
Educational attainment  p for trend=0.988  p for trend=0.273 
 up to GCSE/ O level Ref  Ref  
 A level -0.23 (-0.80, 0.35) 0.436 0.07 (-0.11, 0.24) 0.462 
 Degree 0.01 (-0.52, 0.54) 0.976 0.10 (-0.08, 0.27) 0.274 
Postmenopausal at baseline 0.16 (-0.47, 0.79) 0.609 -0.06 (-0.25, 0.12) 0.507 
Premenopausal at baseline,  
postmenopausal at follow-up 
0.80 (-0.52, 2.12) 0.236 0.24 (-0.16, 0.64) 0.242 
History of HRT use at follow-up 0.18 (-0.37, 0.72) 0.530 0.08 (-0.07, 0.23) 0.291 
Age at recruitment, years 0.01 (-4.77x10-3, 0.03) 0.154 4.04x10-3 (-7.82x10-4, 0.01) 0.101 
Time between X-rays, years 0.15 (-4.38x10-3, 0.29) 0.057 -0.01 (-0.06, 0.04) 0.784 
Height at recruitment, cm -0.02 (-0.04, 3.45x10-3) 0.095 4.63x10-3 (-4.11x10-3, 0.01) 0.299 
Weight at recruitment, kg 0.02 (0.01, 0.03) 0.002 0.01 (2.72x10-3, 0.01) 0.001 
Betas represent the difference in the mean change in osteophyte/JSN score between categories or per unit increase in continuous variables. ORs 
are the odds ratio compared to the reference category or per unit increase for continuous variables. E.g. a beta of 0.38 represents a 0.38-point 
higher mean change in osteophyte score in females compared to males and a beta of 0.02 represents a 0.02-point higher change in osteophyte 




6.3.3. HBM and radiographic OA progression 
OA progression based on KL grade 
I found limited evidence for a relationship between HBM and incident, but not 
progressive, OA as defined by overall KL grade (i.e. global OA incidence and 
progression, Figure 42). In analyses adjusted for age, sex, height, educational 
attainment, and menopause (model 3), HBM was associated with an over two-
fold odds of incident OA (OR=2.29 [1.00,5.26]). Additional adjustment for TBFM 
did not largely attenuate the effect size but widened the CIs (OR=2.17 [0.90,5.23]). 
However, incident OA analyses were restricted to 213 knees without OA (KL<2) 
at baseline and progressive analyses were even further restricted to the 76 knees 
eligible to progress due to the presence of OA at baseline. 
 
Figure 42: Associations between HBM status and global OA incidence and progression. 
 
Points represent ORs and horizontal bars represent 95% CIs. Model 1: Unadjusted; 
model 2: adjusted for age and sex; model 3: model 2 plus height, educational attainment, 





In age, sex, height, education, baseline score and menopause-adjusted analyses 
(model 3), individuals with HBM had greater changes in osteophyte score 
between baseline and follow-up (mean difference=0.50 [0.06,0.94], Figure 43). 
Further adjustment for TBFM explained approximately 10% of this relationship 
(TBFM-adjusted mean difference=0.44 [0.02,0.87]). Individuals with HBM also 
had a greater change in JSN score, with an age, sex, height, education, baseline 
score and menopause-adjusted mean difference of 0.17 (0.03,0.31). This 
association was robust to additional adjustment for TBFM (mean difference=0.16 
[0.02,0.29]). Determining ‘true’ JSN, based on RCI, individuals with HBM had a 
greater odds of ‘true’ JSN, which was not affected by adjustment for TBFM 
(ORmodel 4=9.72 [1.23,76.9]), although the CIs were wide reflecting the low 
numbers of individuals without HBM displaying this phenotype. I did not find 
evidence for an association between HBM and incident subchondral sclerosis or 




Figure 43: Associations between HBM status and incident and progressive OA sub-
phenotypes. 
 
Points for continuous outcomes represent the difference in mean outcome between 
individuals with and without HBM. Points for binary outcomes represent the OR for 
individuals with HBM compared to their relatives with normal BMD. Horizontal bars 
represent 95% CIs. Model 1: unadjusted; model 2: adjusted for age and sex (plus baseline 
score for continuous outcomes); model 3: model 2 plus height, educational attainment, 
and menopause; model 4: model 3 plus TBFM. N for reliable change in mJSW=278; N for 
incident chondrocalcinosis=274; N for incident subchondral sclerosis=287. 
 
6.3.4. HBM and clinical features of OA progression 
In unadjusted analyses, individuals with HBM had much greater WOMAC pain, 
stiffness, and functional limitation scores (mean differences=11.2 [5.4,17.0], 11.0 
[4.5,17.5] and 9.7 [4.8,14.7], respectively) and lower HR-QoL index values (mean 
difference=-0.09 [-0.14,-0.04]). Adjustment for age and sex (model 2) attenuated 
the strength of the relationship between HBM and WOMAC scores by 
approximately 30% (Figure 44). Relationships persisted after further adjustment 
for height, education, and menopause (model 3, mean differences=7.2 [0.7,13.6], 
6.9 [0.2,13.6] and 5.9 [0.8,11.0] and -0.07 [-0.13,-0.004] for pain, stiffness, limitation 
of function and HR-QoL, respectively).  
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Figure 44: Associations between HBM status and WOMAC pain, stiffness, and 
functional limitation subscale scores and HR-QoL measured by EQ5D. 
 
Points represent the mean difference in WOMAC scores or EQ5D values between 
individuals with HBM and relatives/spouses without HBM. Horizontal bars represent 
95% CIs. Results are from a person-level analysis, accounting for clustering in families. 
Model 1: unadjusted; model 2: adjusted for age and sex; model 3: model 2 plus height, 
educational attainment, and menopause; model 4: model 3 plus TBFM. 
 
I performed further analyses to determine which of TBFM, osteophyte severity, 
JSN severity, change in osteophytes or change in JSN were the strongest 
predictors of increased pain and reduced HR-QoL in HBM individuals (Figure 
45). Adjustment for osteophyte severity at follow-up attenuated the association 
between HBM and pain, stiffness, functional limitations and reduced HR-QoL by 
the greatest proportion, with follow-up osteophyte score attenuating the 
relationships by 58%, 67%, 55% and 37%, respectively. Osteophyte progression 
also attenuated the association between HBM and knee stiffness by 43%. 
Adjustment for TBFM and JSN severity and progression had little effect on the 
relationship between HBM and HR-QoL. Adjustment for TBFM attenuated 
associations between HBM and WOMAC scores by 15-20%, whilst JSN severity 





Figure 45: Associations between HBM status and WOMAC pain, stiffness, and functional limitation scores and HR-QoL, adjusting for 
radiographic OA sub-phenotypes. 
 
Points represent the mean difference in WOMAC scores or EQ5D values between individuals with HBM and relatives/spouses without HBM. 
Horizontal bars represent 95% CIs. Results are from a person-level analysis, accounting for clustering in families. Model 3: adjusted for age, 
sex, height, educational attainment, and menopause; model 4: model 3 plus TBFM. Follow-up osteophyte and JSN score is the highest of the two 




6.3.5. BMD and OA progression 
When analysing associations with TH-BMD as a continuous exposure, there was 
evidence for an association between TH-BMD and incident OA, with an age, sex, 
height, TBFM, menopause and education-adjusted (model 4) OR of 1.64 
(1.04,2.56) per SD increase in TH-BMD (Figure 46). ORs for the association with 
OA progression were similar, although CIs were much wider and overlapped the 
null, probably due to the small sample size (N=75). There was no evidence for an 
association between L1-BMD and incident or progressive OA (Figure 47). 
 
Figure 46: Associations between TH-BMD and global OA incidence and progression in 
the HBM cohort. 
 
Points represent ORs per SD increase in TH-BMD and horizontal bars represent 95% 
CIs. Model 1: Unadjusted; model 2: adjusted for age and sex; model 3: model 2 plus 




Figure 47: Associations between L1-BMD and global OA incidence and progression in 
the HBM cohort. 
 
Points represent ORs per SD increase in L1-BMD and horizontal bars represent 95% 
CIs. Model 1: Unadjusted; model 2: adjusted for age and sex; model 3: model 2 plus 
height, educational attainment, and menopause; model 4: model 3 plus TBFM. 
 
TH-BMD strongly predicted change in osteophyte score, with an SD increase in 
TH-BMD associated with a greater change in osteophyte score of 0.28 (0.05,0.51) 
(Figure 48). Evidence supported an association between TH-BMD and change in 
JSN score, although much weaker than that seen for osteophytes (β=0.09 [3x10-
3,0.18]). TH-BMD was also related to an increased odds of ‘true’ JSN (OR=2.07 
[1.14,3.77]). There was limited evidence for an association between L1-BMD and 
change in osteophyte score only, although CIs overlapped the null (0.17 [-






Figure 48: Associations between TH- BMD and incident and progressive OA sub-
phenotypes in the HBM cohort. 
 
Points for continuous outcomes represent the increase in outcome per SD increase in 
total hip BMD. Points for binary outcomes represent the OR per SD increase in total hip 
BMD. Horizontal bars represent 95% CIs. Model 1: unadjusted; model 2: adjusted for 
age and sex (plus baseline score for continuous outcomes); model 3: model 2 plus height, 
educational attainment, and menopause; model 4: model 3 plus TBFM. N for reliable 






Figure 49: Associations between L1-BMD and incident and progressive OA sub-
phenotypes in the HBM cohort. 
 
Points for continuous outcomes represent the increase in outcome per SD increase in L1-
BMD. Points for binary outcomes represent the OR per SD increase in L1-BMD. 
Horizontal bars represent 95% CIs. Model 1: unadjusted; model 2: adjusted for age and 
sex (plus baseline score for continuous outcomes); model 3: model 2 plus height, 
educational attainment, and menopause; model 4: model 3 plus TBFM. N for reliable 
change in mJSW=274; N for incident chondrocalcinosis=270; N for incident subchondral 
sclerosis=283. 
 
I next determined the relationship between change in TH-BMD and L1-BMD, 
between baseline and follow-up, and progression of OA and OA sub-
phenotypes. There was no evidence for a relationship between change in TH-
BMD and incident or progressive OA (Figure 50) or incidence or progression of 
OA sub-phenotypes (Figure 51). There was some evidence for an association 
between change in L1-BMD and OA progression in the unadjusted model 
(OR=0.64 [0.41,0.99]) (Figure 52). Adjustment for age, sex, menopause, education, 
height and TBFM (model 4) did not alter the point estimate but did widen the CIs 
to include the null. There was no evidence for an association between change in 





Figure 50: Associations between change in TH-BMD and global OA incidence and 
progression in the HBM cohort. 
 
Points represent ORs per SD increase in change in TH-BMD and horizontal bars 
represent 95% CIs. Model 1: Unadjusted; model 2: adjusted for age and sex; model 3: 
model 2 plus height, educational attainment, and menopause; model 4: model 3 plus 
TBFM. 
 
Figure 51: Associations between change in TH-BMD and incident and progressive OA 
sub-phenotypes in the HBM cohort. 
 
Points for continuous outcomes represent the increase in outcome per SD increase in 
change of TH-BMD. Points for binary outcomes represent the OR per SD increase in 
TH-BMD. Horizontal bars represent 95% CIs. Model 1: unadjusted; model 2: adjusted 
for age and sex (plus baseline score for continuous outcomes); model 3: model 2 plus 
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height, educational attainment, and menopause; model 4: model 3 plus TBFM. N for 
reliable change in mJSW=272; N for incident chondrocalcinosis=266; N for incident 
subchondral sclerosis=279. 
 
Figure 52: Associations between change in L1-BMD status and global OA incidence and 
progression in the HBM cohort. 
 
Points represent ORs per SD increase in change in L1-BMD and horizontal bars 
represent 95% CIs. Model 1: Unadjusted; model 2: adjusted for age and sex; model 3: 






Figure 53: Associations between change in L1-BMD and incident and progressive OA 
sub-phenotypes in the HBM cohort. 
 
Points for continuous outcomes represent the increase in outcome per SD increase in 
change of L1-BMD. Points for binary outcomes represent the OR per SD increase in L1-
BMD. Horizontal bars represent 95% CIs. Model 1: unadjusted; model 2: adjusted for 
age and sex (plus baseline score for continuous outcomes); model 3: model 2 plus height, 
educational attainment, and menopause; model 4: model 3 plus TBFM. N for reliable 
change in mJSW=273; N for incident chondrocalcinosis=269; N for incident subchondral 
sclerosis=282. 
 
6.3.6. Investigating dose-response relationships 
As one of the Bradford Hill criteria for assessing causality is the presence of a 
dose-response relationship between exposure and outcome, I next aimed to 
determine if there was a dose-response relationship between TH-BMD and 
change in osteophyte score, change in JSN score or WOMAC pain scores. 
Baseline TH-BMD Z-score was categorized into quartiles, separately for HBM 
and non-HBM individuals. A non-linear trend between quartile of TH-BMD and 
change in osteophyte score was observed in the HBM population, with mean 
change in osteophyte score increasing with increasing quartile until the highest 
BMD quartile (Figure 54). There was no evidence for an association between 




was there an association between TH-BMD quartile and change in JSN score in either population. There was strong evidence for a 
dose-response relationship between BMD and WOMAC pain score in HBM individuals only (p for trend <0.001). 
 
Figure 54: Association between quartiles of TH-BMD Z-score and (A) change in osteophyte score, (B) change in JSN score and (C) WOMAC 





6.3.7. Sensitivity analyses 
Including 18 knees with an incident TKR at follow-up as progressive OA cases 
did not affect conclusions drawn, nor did including three knees with no OA 
(KL<2) at baseline and a TKR at follow-up as incident OA cases (Figure 55).  
 
Figure 55: Association between HBM and incident and progressive OA including knees 
with TKR. 
 
Knees with OA at baseline (KL>2) and a TKR at follow-up were included as progressive 
OA cases. Knees without OA at baseline and a TKR at follow-up were including as 
incident and progressive cases. Adjusted for age, sex, menopause, educational 
attainment, height, and TBFM. Nincident=213 without including TKR, 216 including 
TKR. Nprogression=76 excluding TKR, 94 including TKR. 
 
In person-level analyses, effect sizes were weaker with wider CIs overlapping the null for 
the relationship with change in osteophyte score (βmodel 4=0.29 [-0.16,0.75]), although 
these analyses only included 140 individuals ( 
Figure 56). There was no evidence for an association between HBM and change 
in JSN score in person-level analyses, whilst the relationship between HBM and 
reliable change in mJSW was still present in person-level analyses and of a 




Figure 56: Person-level analyses of the associations between HBM and progression of OA 
sub-phenotypes. 
 
Change in osteophyte and JSN score represent the highest of the two knees. Reliable 
change in mJSW represents an RCI<-1.96 in either knee. Incident chondrocalcinosis and 
subchondral sclerosis represent any incident subchondral sclerosis or chondrocalcinosis 
in either knee. Model 1: unadjusted; model 2: adjusted for age and sex (and baseline score 
for change in osteophytes or JSN); model 3: model 2 plus height, menopause, and highest 
educational attainment; model 4: model 3 plus TBFM. N =140, NRCI=135. 
 
Removing individuals reporting knee procedures did not alter overall 
conclusions drawn, although this did weaken the evidence for an association 
between HBM and reliable change in mJSW (Figure 57). Weak evidence for a 
reduced odds of incident sclerosis in HBM individuals was also present after 




Figure 57: Analyses of associations between HBM and OA progression removing 
individuals who had reported knee procedures. 
 
Adjusted for age, sex, baseline score, height, menopause, highest educational attainment 
and TBFM. Ncartilage operation=12, Nknee lavage, washout, arthroscopy=16, Nsteroid injection=9. 
 
Additional adjustment for metal artefact grade (Figure 58) and maximal tibial 




Figure 58: Associations between HBM and incident and progressive OA sub-phenotypes 
with additional adjustment for metal artefacts on DXA scans. 
 
Model 1: unadjusted; model 2: adjusted for age and sex (and baseline score for change in 
osteophytes or JSN); model 3: model 2 plus height, menopause, and highest educational 






Figure 59: Associations between HBM and incident and progressive OA sub-phenotypes 
with additional adjustment for maximal tibial plateau width. 
 
Model 1: unadjusted; model 2: adjusted for age and sex (and baseline score for change in 
osteophytes or JSN); model 3: model 2 plus height, menopause, and highest educational 
attainment; model 4: model 3 plus TBFM.  
 
Removing 10 individuals with TB DXA positioning errors, which can lead to loss 
of TBFM, slightly weakened the evidence for an association with reliable change 
in mJSW, but otherwise did not alter conclusions (Figure 60), nor did removing 




Figure 60: Associations between HBM and incident and progressive OA sub-phenotypes, 
with and without individuals with TB DXA positioning errors. 
 
Adjusted for age, sex, menopause, educational attainment, height, and TBFM (model 4). 
 
Figure 61: Associations between HBM and incident and progressive OA sub-phenotypes, 
with and without individuals attending a different site for follow-up. 
 
Adjusted for age, sex, menopause, educational attainment, height, and TBFM (model 4). 
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Evidence for a positive relationship between HBM and osteophyte and JSN 
progression were observed when using a Poisson model (Figure 62), although 
CIs overlapped the null (βΔosteophyte= 1.72 [0.88,3.38] and βΔJSN=1.97 [0.99,3.93]). 
The magnitude of effect was greater for change in JSN, rather than change in 
osteophytes, when using a Poisson model.  
 
Figure 62: Associations between HBM and change in osteophyte and JSN scores using a 
Poisson model. 
 
Points represent the difference in predicted count between individuals with and without 
HBM. Model 1: unadjusted; model 2: adjusted for age and sex (and baseline score for 
change in osteophytes or JSN); model 3: model 2 plus height, menopause, and highest 





6.4.1. Summary of findings 
This is the first study to evaluate change in sub-phenotypes of knee OA in a 
population with HBM. I have identified increased osteophyte development in 
individuals with HBM, compared to their relatives without HBM, reflecting both 
initial appearance and subsequent growth of osteophytes. The same direction of 
effect was observed for JSN, but of weaker magnitude. Furthermore, I have 
identified that individuals with HBM have worse clinical symptoms of knee OA 
(pain, stiffness, and limitation of function) and reduced HR-QoL, which is mainly 
explained by osteophyte severity. These results are consistent with the one 
general population study which identified a positive relationship between LS-
BMD and progression of knee osteophytes (232). 
6.4.2. Context of findings 
The relationship between high BMI and knee OA is widely acknowledged 
(78,100). Individuals with HBM have increased TBFM compared to their relatives 
without HBM (201), with development of HBM likely preceding fat 
accumulation due to its genetic origin (203). One could therefore hypothesize 
that increased TBFM mediates the association between HBM and OA 
progression through increased joint loading, or other metabolic pathways. 
However, the observed association between HBM and increased osteophyte 
development was not attenuated by adjustment for TBFM. This finding is 
consistent with one earlier population-based study of North American women in 
whom those with low BMD and low BMI had the lowest KL grades, those with 
high BMD and high BMI had the highest KL grades, and those with low BMI and 
high BMD had similar KL grades to those with high BMI and low BMD, 
suggesting that the underlying biological pathway leading to increased 
osteophyte development in individuals with higher BMD is independent of 
adiposity (217).   
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Previous analyses of this HBM population identified an increased presence of 
enthesophytes, reflecting a ‘bone-forming’ phenotype (402). Increased osteophyte 
development over an average of eight years provides further evidence for this 
phenotype. As both BMD and knee OA are highly heritable (403,404), one 
possible explanation for this ‘bone-forming’ phenotype is pleiotropy, whereby 
the same genetic variants contribute to both phenotypes: genetic analyses in the 
OAI and JoCo populations identified a positive association between four BMD-
associated SNPs and knee OA (262). Such pleiotropy could reflect a causal 
pathway between BMD and knee OA (i.e. vertical pleiotropy), where BMD 
mediates the relationship between the variants and knee OA, a hypothesis 
supported by a recent MR study (261), or shared underlying biological pathways 
contributing to both phenotypes. Individuals with HBM have an over-
representation of common BMD-associated variants, including those which 
annotate to bone-forming pathways e.g. Wnt signalling (203), which, as discussed 
in section 3.3.2, is also linked to OA. However, a more recent genome-wide 
analysis did not find evidence for a genetic correlation specifically between FN-
BMD and knee OA (137).  
Differences in subchondral bone texture may explain the positive, albeit weaker, 
association between HBM and JSN progression (207). Higher trabecular number 
and thickness plus reduced trabecular separation in subchondral bone have been 
linked to medial JSN progression (405). Individuals with HBM have greater 
trabecular density at both the tibia and radius (200); it is currently unknown 
whether HBM individuals have altered subchondral trabecular bone texture 
predictive of JSN progression.  
An alternative explanation is enhanced endochondral ossification, due to an 
enrichment of variants annotated to genes involved in this process (203). 
Endochondral ossification not only contributes to osteophyte formation (406), but 
also reestablishment of endochondral ossification at the tidemark, which leads to 
tidemark duplication, reducing the area of non-calcified cartilage (18). However, 
lack of evidence for a relationship between HBM and incident chondrocalcinosis 
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suggests that calcification of cartilage is not key to OA pathogenesis in HBM 
individuals. 
In contrast to my analysis, Zhang et al found that risk of knee OA progression 
declined with increasing BMD in the Framingham cohort (229). One possible 
explanation for this opposite direction of effect is that authors defined knee OA 
progression as change in KL score in those with prevalent knee OA at baseline. 
To have prevalent knee OA an individual must present with osteophytes, and to 
increase KL grade, JSN must occur (30). Therefore, progression from KL=2 to 
KL=3 relies solely on incident JSN, not worsening of osteophyte grade. Using an 
increased KL grade to define progression is also vulnerable to bias due to a 
ceiling effect, as those with a KL grade of 4 at baseline cannot progress. Another 
potential explanation for the observed inverse association in the Framingham 
study is ‘collider bias’, as this analysis was restricted to those with OA at baseline 
(i.e. case only), thereby potentially inducing a negative correlation between BMD 
and any other variable that influences incident OA. If any such variable is also 
associated with progression and is not appropriately controlled for in the 
analysis, a ‘backdoor pathway’ from high BMD to knee OA progression can be 
induced. This can manifest as a negative association, when in fact there is none, 
or even a true positive association (236). Although adjusting for baseline score 
could also induce collider bias, reassuringly the results did not change between 
model 1 and model 2. 
The weak evidence for an association between HBM and incident OA in this 
analysis corroborates results from two population-based studies, where an 
increased risk of incident OA was observed in those with higher BMD (232,234). 
The weak evidence, with CIs overlapping the null after adjustment for TBFM, is 
likely due to a lack of power to detect this association due to the small sample 
size and the fact that the study prevalence of OA was already 33% at baseline, 
reducing the number of possible incident cases. The small sample size may also 
explain why I did not observe an association between change in TH-BMD and 
OA sub-phenotype progression, despite previous studies relating bone loss to 
prevalent radiographic OA (209) and cartilage loss (407). Unfortunately, I am 
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unable to make any firm conclusions about relationships between HBM and 
subchondral sclerosis, which one may expect to be key to OA pathogenesis in 
HBM individuals, due to the rarity of this phenotype and the lower reliability of 
gradings.  
The finding that individuals with HBM suffer worse clinical symptoms of OA, 
independent of TBFM, is consistent with a recent MR analysis which identified a 
causal relationship between FN-BMD and hospital-diagnosed knee OA, even 
after excluding BMI-associated SNPs from the instrument (261). OA is often 
diagnosed clinically due to symptoms, such as pain, rather than by radiography 
(10) and therefore hospital-diagnosed knee OA is likely to reflect symptomatic 
OA, confirmed by radiographic changes. One Bradford-Hill criterion supporting 
causal inference is a dose-response relationship (408) and I found increased 
WOMAC pain scores with increasing TH-BMD quartile, although this 
relationship was only present in individuals with HBM. The observation that 
adjustment for osteophyte severity at follow-up attenuated the association 
between HBM and pain to a greater extent than adjustment for JSN is consistent 
with the findings of Cicuttini et al, who observed that the odds of ever having 
knee pain was increased in middle-aged women with osteophytes compared to 
those without osteophytes, and this association was stronger than the association 
between knee JSN and knee pain (409). However, Neogi et al found that JSN, 
rather than osteophytes, was more strongly related to knee pain in individuals 
with knees discordant for pain (410). 
6.4.3. Strengths of this research 
The HBM study is the largest population of individuals with relatively rare, 
unexplained, generalized HBM (197). Detailed data were collected at baseline 
and follow-up, allowing for adjustment for a priori confounding variables. I 
analysed change in OA sub-phenotypes separately as well as using KL score, 
which allowed the identification of the strong relationship with osteophyte 
development and the weaker relationship with change in JSN. I analysed change 
in osteophytes and JSN as continuous measures, increasing statistical power to 
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detect associations, and reducing the possibility of a ceiling effect by increasing 
the range of possible values to 0-6 for JSN and 0-12 for osteophytes. 
6.4.4. Methodological issues and limitations 
The method of identifying individuals from NHS DXA databases meant that the 
average age of the population at baseline was 59 years, ranging from 18 to 90. 
This meant a large proportion of participants were not able to be followed-up 
due to death or poor health. Follow-up X-rays could only be performed at seven 
(albeit the largest) of the original 13 centres, again reducing the size of the follow-
up population. Some individuals were able to visit a different centre, but these 
individuals had to be removed in a sensitivity analysis to confirm that 
differences in X-ray methodology between baseline and follow-up were not 
explaining observed associations. Due to the small sample size, I could not 
evaluate change in osteophyte score in individuals with osteophytes at baseline 
(i.e. progression) separately from those with no osteophytes at baseline (i.e. 
incidence). The stronger magnitude of effect observed for osteophytes, compared 
to JSN, may purely reflect the greater range of possible values, rather than a 
stronger effect of BMD on osteophyte progression compared to cartilage loss. I 
did not read baseline and follow-up radiographs paired and I did observe some 
negative scores for change in osteophytes and change in JSN, which were 
included in analyses. Removing these values as ‘measurement error’ would have 
biased results as there is likely to be the same proportion of measurement error 
in the opposite direction, for which I would not be able to account, and may 
explain why a stronger magnitude of effect was observed for JSN, compared to 
osteophytes, when using the Poisson model. Reassuringly, the proportion with 
negative values did not differ between HBM and relatives (data not shown). 
Radiographic grading of OA sub-phenotypes is subjective; I tried to limit 
subjectivity by using an established atlas (29). There was good intra-rater and 
inter-rater agreement for the osteophyte and JSN measures and no evidence of a 
systematic over-estimation of JSN/osteophytes. Agreement was lower for 
subchondral sclerosis, but I was not able to draw any clear conclusions about the 
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relationship between HBM and incident sclerosis due to the rarity of this sub-
phenotype. Due to the complexity of the statistical models, age was included as a 
continuous covariate, under the assumption that it was linearly associated with 
the outcomes. Although HBM is thought to be largely genetically-determined 
(203) and therefore a causal relationship between BMD and knee OA progression 
is inferred, I cannot rule out the possibility that genetic pleiotropy may explain 
the overlap between BMD and osteophyte progression rather than a causal 
relationship. Finally, the majority of the HBM population is female, limiting 
generalizability to male populations. 
6.4.5. Future work 
There are four key areas of further work to address. The first is to determine if 
the relationship between high BMD and knee osteophyte progression is a true 
causal relationship. To do this, a GWAS of osteophyte progression in a large 
sample with multiple available radiographs would first need to be performed. 
Summary statistics could then be used for 2SMR analyses. Unfortunately, this 
analysis was beyond the scope of this PhD. Secondly, the analyses presented in 
this current chapter should be repeated with hip OA sub-phenotypes as 
outcomes, to determine if there is an association between HBM and generalized 
osteophyte progression or whether this is knee-specific (Chapter 7). Thirdly, 
bidirectional analyses should be performed to determine whether the observed 
association between HBM and knee OA subphenotype prevalence/progression 
represents a true causal pathway between BMD and OA, or whether shared 
underlying biology contributing to both phenotypes explains observational 
relationships (Chapter 9). Finally, it is important to determine the underlying 
pathways which contribute to OA sub-phenotype development in HBM (Chapter 
10).  
6.4.6. Conclusions  
In this chapter, I have found evidence that individuals with HBM have increased 
knee osteophyte and JSN development over eight years, independent of 
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adiposity, and that a greater number and/or size of osteophytes explains the 
association between HBM and knee pain, stiffness and functional limitation and 
reduced HR-QoL.  
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CHAPTER 7.  THE 
ASSOCIATION BETWEEN 






7.1. Background and aims 
As discussed in section 3.1.1, higher BMD has been associated with prevalent hip 
OA in several cross-sectional analyses (208-211,411,412). However, these analyses 
are complicated by the fact that BMD is often measured at the hip (208-211) and 
therefore it is hard to determine whether higher BMD is a cause, or feature, of 
hip OA. Arokoski et al identified that FN-BMD was 4% higher in the hip scoring 
higher for OA in men with discordant hips (218), reflecting a greater FN volume, 
assessed by MRI. Hip osteophytes can grow across the FN, in a process known as 
buttressing, which can lead to an increased FN size (226). Despite this, Chaganti 
et al identified a relationship between TH cortical volumetric BMD (measurement 
of which is not artefactually elevated by bone size) and hip OA in 3,886 men 
from MrOS (210). Alternatively, BMD can be measured at the LS (208,210,211), 
which is commonly artefactually elevated by the presence of spinal osteophytes, 
a feature of spinal OA. However, Nevitt et al found that the relationship between 
LS-BMD and severe hip OA persisted after adjustment for spinal osteophytes. 
They additionally found a relationship between BMD of the calcaneus (which is 
less likely to be affected by artefactual elevation due to OA) and hip OA in over 
4,000 women from SOF, although of lower magnitude than see for hip BMD 
(208).  
The limitation of not being able to determine the temporal relationship between 
higher BMD and OA development in cross-sectional analyses can be overcome 
by studying the HBM population. As discussed in section 3.1.1, individuals with 
HBM have a greater odds of hip OA than their relatives without HBM and 
general population controls, reflecting a greater odds of osteophytosis, but not 
JSN (226). As HBM reflects a generalized phenotype (section 2.3.2), it is unlikely 
to be an artefact of osteophytosis (197).  
As discussed in section 3.1.2, fewer analyses have been performed to determine 
the relationship between BMD and hip OA incidence and progression. In Chapter 
6, I identified a strong relationship between HBM and worsening knee 
osteophytosis over an average of eight years, with some evidence that knee JSN 
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incidence and/or progression is increased in HBM individuals. In this chapter, 
studying the same population, I aim to determine the relationship between HBM 
and change in radiographic features of hip OA over eight years, as well as 




7.2.1. Study population 
These analyses were performed in the HBM study population (section 2.3.2), who 
were still alive after eight years, able to be contacted and who consented to pelvic 
X-rays. Participants aged under 40 years did not have pelvic X-rays and baseline 
pelvic X-rays were not performed on those who attended the Oxford centre. In 
total, 363 individuals, aged 40 years or older at baseline, had attended one of the 
seven centres which was then able to perform follow-up X-rays. Of these 
individuals, 207 (57%) were still alive and consenting to contact in 2016, of whom 
149 (72%) completed the postal questionnaire and attended for follow-up 








7.2.2. Radiographic OA progression 
Methodology for grading radiographic hip OA progression is described in 
section 4.4. Croft score at baseline and follow-up was used to generate a binary 
variable for overall OA progression, using Croft>3 to define OA at baseline and 
an increase in grade at follow-up. As discussed in Chapter 6, using continuous 
variables for change in OA sub-phenotypes, instead of binary variables for any 
progression, avoids the limitations associated with performing a case-only 
analysis. I therefore summed the semi-quantitative grades for osteophytes at the 
four regions (inferior and superior, acetabulum and femur) and JSN at the two 
regions (medial and superior) to generate continuous outcome variables based 
on change in these summed scores between baseline and follow-up, with higher 
scores representing worsening osteophytes or JSN. Continuous measures of 
mJSW at the two timepoints were used to calculate RCI, as outlined in Chapter 6. 
Table 16 presents a summary of all radiographic variables analysed.  
  
Table 16: Variables generated by Croft scoring and semi-quantitative sub-phenotype 
grading using the OARSI atlas, and derived variables. 




Progressive OA: Croft score >3 at baseline and an 
increase in grade at follow-up 
Incident OA: Croft score <3 at baseline and >3 at 
follow-up 
Osteophytes 
Change in osteophyte score: Sum of all semi-
quantitative osteophyte grades at follow-up minus the 
sum at baseline 
 Superior femoral 0-3 
 Medial femoral 0-3 
 Superior acetabular 0-3 
 Medial acetabular 0-3 
JSN 
Change in JSN score: Sum of both semi-quantitative 
JSN grades at follow-up minus the sum at baseline 
 Superior 0-3 
 Medial 0-3 
Subchondral sclerosis 
Incident sclerosis: no sclerosis (femoral or acetabular) 
at baseline and any sclerosis at follow-up 
 Femoral 0, 1 
 Acetabular 0, 1 
Subchondral cysts 0, 1 
Incident cysts: no cyst at baseline and cyst at follow-
up 
Superior mJSW Continuous 
Change in mJSW: mJSW at follow-up minus mJSW at 
baseline 




7.2.3. Clinical features of hip OA progression 
Hip pain, stiffness and limitation of function were determined using the 
WOMAC questionnaire, as outlined in section 4.2. 
7.2.4. Covariates 
Age and sex were considered a priori confounders, as well as baseline 
radiographic sub-phenotype grade for osteophyte and JSN outcomes. Height and 
TBFM were included in the final model to determining their potential 
confounding or mediating effect. Time between baseline and follow-up, 
menopausal status and HRT use, history of smoking, baseline PA, education and 
steroid use were all investigated as potential confounders by determining their 
relationships with the OA sub-phenotype outcomes.  
7.2.5. Statistical analysis 
Statistical analysis was performed as outlined for knee OA (sub-phenotype) 
progression (Chapter 6). Distributions of continuous outcomes are presented in  
Figure 64-Figure 66. Due to the lower numbers with complete data for hip, 
compared to the knee, analyses, less variables were included in the statistical 
models to reduce complexity. Model 1 was unadjusted, model 2 was adjusted for 
age, sex, baseline score and follow-up time and model 3 was additionally 





Figure 64: Distribution of change in osteophyte score between baseline and follow-up in 
the HBM cohort. 
 
 










7.2.6. Sensitivity analyses 
I performed the following sensitivity analyses to determine the reliability of 
results: 
1. As hips with THR were excluded from analysis, but THRs are likely to be 
performed due to severe OA, analyses were repeated including those with 
a Croft grade <3 at baseline and a non-fracture-related THR at follow-up, 
and counting these as incident and progressive OA cases (assuming rapid 
OA progression led to a THR within eight years of OA development). 
Individuals with Croft>3 at baseline and a non-fracture related THR at 
follow-up were included as progressive cases. 
2. Person-level analyses, using the sum of the osteophyte/JSN scores from 
the two hips and any incident OA in either hip.  
3. Additional adjustment for metal artefacts on DXA scans (section 4.3.1). 
4. Removal of individuals with positioning errors leading to loss of fat mass 
from the DXA image (section 4.3.2). 
5. Removal of those visiting a different site for follow-up imaging. 
6. Poisson regression analyses, recoding negative values as 0, to check that 
conclusions were not invalid due to skewed outcome variables. 
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7. Additional adjustment for FN area (measured at follow-up) to check that 
associations between HBM and OA sub-phenotype progression were not 





7.3.1. Descriptives of the HBM radiographic hip OA follow-
up population 
Complete baseline and follow-up radiographic data were available for 145 
individuals, with 64% having HBM. There was no difference in the proportion of 
HBM individuals in the population with or without follow-up data. Those with 
follow-up data were younger, were less likely to have had hip OA at baseline, to 
have ever smoked, to be postmenopausal, but they were more physically active 
(Table 17).  
 
Table 17: Baseline descriptives of those with and without complete radiographic hip 












 N (%)  
High Bone Mass  237 (65.3) 92 (63.5) 145 (66.5) 0.548 
Female  240 (66.1) 105 (72.4) 135 (61.9) 0.039 
     Postmenopausal  197 (84.2) 81 (77.1) 116 (89.9) 0.008 
History of smoking  208 (58.8) 74 (51.0) 134 (64.1) 0.014 
Alcohol consumption    0.154 
     None 79 (22.3) 25 (17.2) 54 (25.7) 
     Occasional 41 (11.6) 17 (11.7) 24 (11.4) 
     Regular 185 (52.1) 85 (58.6) 100 (47.6) 
     Heavy 50 (14.1) 18 (12.4) 32 (15.2) 
Physical activity category    0.009 
     Low 58 (18.1) 16 (11.4) 42 (23.2) 
     Moderate 112 (34.9) 47 (33.6) 65 (35.9) 
     High 151 (47.0) 77 (55.0) 74 (40.9) 
Hip Osteoarthritis (Croft>3) 87 (27.5) 28 (19.9) 59 (33.7) 0.006 
Any hip osteophyte  248 (77.5) 102 (71.3) 146 (82.5) 0.017 
Moderate hip osteophyte 82 (26.0) 30 (21.6) 52 (29.6) 0.110 
Hip joint space narrowing 98 (30.8) 36 (25.5) 62 (35.0) 0.068 
 Mean (SD)  
Age, years  62.8 (12.0) 59.6 (10.2) 64.9 (12.6) <0.001 
Height, cm  168.1 (9.7) 167.6 (9.5) 168.4 (9.8) 0.476 
Weight, kg  83.4 (16.5) 82.1 (16.9) 84.2 (16.1) 0.222 
L1 Z-score 2.7 (2.1) 2.5 (2.0) 2.9 (2.1) 0.069 
Maximum total hip Z-scorea 2.1 (1.5) 2.1 (1.5) 2.1 (1.5) 0.953 




Of the 136 individuals who also had complete covariate data, HBM individuals 
were more commonly female and postmenopausal, with a higher BMI at baseline 
and higher TBFM at follow-up (Table 18). As expected, mean baseline TH and 
L1-BMD were higher in HBM individuals compared to relatives without HBM. 
Relatives without HBM were more highly educated and were taller at baseline.  
 
Table 18: Descriptives of the radiographic hip follow-up population with complete 










 N (%)  
Female gender 98 (72.1) 73 (84.9) 25 (50.0) <0.001 
 Postmenopausalb 75 (76.5) 59 (80.8) 16 (64.0) 0.087 
 Menopause transition during follow-
up period 
11 (11.2) 6 (8.2) 5 (20.0) 0.177 
 History of HRT usef  49 (50.0) 39 (53.4) 10 (40.0) 0.508 
History of smokingf  66 (48.9) 42 (49.4) 24 (48.0) 0.874 
Physical activity categoryb     
     Low  14 (10.7) 9 (11.0) 5 (10.2)  
     Medium  46 (35.1) 26 (31.7) 20 (40.8) 0.567 
     High 71 (54.2) 47 (57.3) 24 (49.0)  
Education categoryf     
     Up to GCSE/ O level 55 (42.0) 42 (50.0) 13 (27.7)  
     A level or equivalent 26 (19.9) 17 (20.2) 9 (19.2) 0.019 
     Degree or equivalent 50 (38.2) 25 (29.8) 25 (53.2)  
 Mean (SD)  
Age, yearsb  59.2 (10.2) 60.2 (9.9) 57.5 (10.6) 0.136 
Height, cmb  167.8 (9.6) 166.1 (8.4) 170.8 (10.8) 0.005 
Weight, kgb  81.5 (17.0) 82.1 (16.0) 80.6 (18.7) 0.619 
BMI (kg/m2)b 28.9 (5.5) 29.8 (5.6) 27.5 (5.1) 0.017 
TBFM (kg)f 31.6 (10.6) 33.0 (10.9) 29.1 (9.5) 0.035 
TH-BMD, g/cm2 b 1.143 (0.182) 1.242 (0.129) 0.976 (0.131) <0.001 
L1-BMD, g/cm2 b 1.255 (0.215) 1.377 (0.149) 1.049 (0.141) <0.001 
FN areaf, cm2 5.28 (0.52) 5.20 (0.52) 5.40 (0.51) 0.029 
Follow-up time, years  8.2 (1.0) 8.2 (0.7) 8.2 (1.4) 0.817 
bassessed at baseline, fassessed at follow-up. 
 
7.3.2. Prevalence, incidence, and progression of hip OA sub-
phenotypes 
Due to the rarity of baseline OA in this population (6.5%), it was not possible to 
analyse overall OA progression (Table 19). Incidence and prevalence of both 
subchondral sclerosis and subchondral cysts were too low to analyse (N<5) and 
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the prevalence of true JSN, based on RCI, was too low in the non-HBM relatives 
to draw any meaningful conclusions. 
 
Table 19: Proportion of all hips with baseline, follow-up, incident, and progressive OA 
(sub-phenotypes) in the HBM cohort follow-up population. 











OA (Croft>3)       
 Baseline 285 22 (7.7) 179 13 (7.3) 106 9 (8.5) 
 Follow-up 275 33 (12.0) 173 24 (13.9) 102 9 (8.8) 
 Incident 257 18 (7.0) 162 15 (9.3) 95 3 (3.2) 
 Progressive 18 5 (27.8) 11 2 (18.2) 7 3 (42.9) 
Hip replacement (identified on radiograph) 
 Baseline 290 5 (1.7) 184 5 (2.7) 106 0 
 Follow-up 290 15 (5.2) 184 11 (6.0) 106 4 (3.8) 
 Incident 285 10 (3.5) 179 6 (3.4) 106 4 (3.8) 
Subchondral sclerosis     
  Baseline 285 4 (1.4) 179 3 (1.7) 106 1 (0.9) 
 Follow-up 275 4 (1.5) 173 3 (1.7) 102 1 (1.0) 
 Incident 273 3 (1.1) 171 2 (1.2) 102 1 (1.0) 
Subchondral cysts       
 Baseline  283 1 (0.4) 178 0 105 1 (1.0) 
 Follow-up  275 5 (1.8) 173 3 (1.7) 102 2 (2.0) 
 Incident  275 5 (1.8) 173 3 (1.7) 102 2 (2.0) 
Osteophyte score       
 Baseline 285  179  106  
      0  203 (71.2)  126 (70.4)  77 (72.6) 
      1-4  75 (26.3)  50 (27.9)  25 (23.6) 
      >5  7 (2.5)  5 (2.8)  4 (3.8) 
 Follow-up 275  173  102  
      0  161 (58.6)  94 (54.3)  67 (65.7) 
      1-4  105 (38.2)  73 (42.2)  32 (31.4) 
      >5  9 (3.3)  6 (3.5)  3 (2.9) 
 Delta 275  173  102  
      <1  201 (73.1)  121 (69.9)  80 (78.4) 
      1  48 (17.5)  32 (18.5)  16 (15.7) 
      >1  26 (9.5)  20 (11.6)  6 (5.9) 
JSN score       
 Baseline 285  179  106  
      0  253 (88.8)  160 (89.4)  93 (87.7) 
      1-2  27 (9.5)  16 (8.9)  11 (10.4) 
      >3  5 (1.8)  3 (1.7)  2 (1.9) 
 Follow-up 275  173  102  
      0  241 (87.6)  149 (86.1)  92 (90.2) 
      1-2  28 (10.2)  20 (11.6)  8 (7.8) 
      >3  6 (2.2)  4 (2.3)  2 (2.0) 
 Delta 275  173  102  
      <1  261 (94.9)  161 (93.1)  100 (98.0) 
      1  12 (4.4)  10 (5.8)  2 (2.0) 
      >1  2 (0.7)  2 (1.2)  0 (0.0) 
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WOMAC at follow-up      
 Pain 145 0 (0, 25) 92 10 (0, 35) 53 0 (0, 15) 
 Function 145 3.6 (0, 25) 92 
10.7 (0, 
30.4) 













145 16 (11.0) 92 13 (14.1) 53 3 (5.7) 
 
7.3.3. Determining covariates 
To determine which of the potential covariates (highlighted in section 7.2.4) 
should be included in analyses, associations between the potential covariates and 
the three main outcomes (change in osteophyte score [continuous], change in JSN 
score [continuous] and incident OA [binary]) were determined by GEE linear (for 
continuous variables) and logistic (for binary outcomes) regression. Low 
numbers meant very few associations were observed, including lack of evidence 
for associations with a priori confounders sex and weight (Table 20). There was 
evidence for a greater mean change in JSN score in those with a history of steroid 
use and a much higher odds of incident OA. Follow-up time was strongly related 
to change in JSN score. This was not attenuated by adjustment for assessment 
centre (β=0.04 [0.02,0.06]), meaning this relationship does not reflect systematic 
differences in follow-up time between study centres. I therefore decided to 
include age, sex, baseline score (for the continuous outcomes) and follow-up time 
(except for cross-sectional WOMAC variables for which follow-up time was not 
included) in the first adjusted model (model 2) before adjusting for height and 




in sensitivity analyses (section 7.3.8). 
 
Table 20: Associations between potential covariates and hip OA outcomes in the HBM cohort. 
 
 Change in osteophyte score Change in JSN grade Incident OA 
 β (95% CI) p β (95% CI) p OR (95% CI) p 
Female 0.221 (-0.135, 0.576) 0.224 -0.010 (-0.129, 0.109) 0.868 2.08 (0.58, 7.52) 0.262 
Ever smoked 0.014 (-0.308, 0.335) 0.934 0.019 (-0.084, 0.123) 0.714 1.75 (0.59, 5.18) 0.316 
Alcohol consumption at baseline     
    None Ref  Ref  Ref  
    Occasional 0.621 (0.066, 1.180) 0.028 0.081 (-0.064, 0.227) 0.273 5.57 (0.53, 59.1) 0.154 
    Regular 0.180 (-0.125, 0.484) 0.248 0.051 (-0.032, 0.133) 0.231 3.08 (0.38, 25.4) 0.295 
    Heavy 0.538 (-0.199, 1.270) 0.152 0.049 (-0.180, 0.279) 0.673 0.89 (0.05, 14.6) 0.933 
Physical activity category at baseline     
    Low Ref  Ref  Ref  
    Medium -0.227 (-0.905, 0.450) 0.511 -0.010 (-0.290, 0.270) 0.943 0.62 (0.11, 3.49) 0.584 
    High -0.153 (-0.786, 0.480) 0.636 -0.037 (-0.304, 0.230) 0.785 0.40 (0.07, 2.27) 0.303 
Education     
    up to GCSE/ O level Ref  Ref  Ref  
    A level -0.037 (-0.365, 0.291) 0.826 -0.003 (-0.124, 0.119) 0.966 1.16 (0.30, 4.57) 0.828 
    Degree -0.107 (-0.543, 0.329) 0.631 0.012 (-0.121, 0.146) 0.856 0.59 (0.16, 2.22) 0.439 
Postmenopausal at baseline -0.154 (-0.754, 0.447) 0.616 -0.028 (-0.207, 0.151) 0.759 7.71 (0.98, 60.7) 0.052 
History of HRT use at follow-up 0.191 (-0.184, 0.566) 0.318 -0.007 (-0.128, 0.113) 0.906 1.71 (0.48, 6.08) 0.409 
History of steroid use at follow-up 0.553 (-0.071, 1.180) 0.082 0.305 (0.100, 0.509) 0.004 8.01 (2.37, 27.1) 0.001 
Age at baseline, years 0.004 (-0.013, 0.021) 0.622 0.005 (-0.001, 0.010) 0.104 1.08 (1.04, 1.12) 3x10-4 
Follow-up time, years 0.002 (-0.060, 0.064) 0.944 0.047 (0.029, 0.066) 5x10-7 1.72 (0.92, 3.20) 0.089 
Height at baseline, cm -0.009 (-0.025, 0.007) 0.273 -0.002 (-0.006, 0.003) 0.536 0.96 (0.90, 1.02) 0.145 




7.3.4. HBM and global radiographic hip OA incidence and 
progression 
Out of 290 hips with repeat radiographs, hip OA was observed in 7.7% of all hips 
at baseline and 12.0% of all hips at follow-up (Table 19). Out of the 257 hips 
without OA at baseline, 7.0% developed OA. There was no clear evidence that 
HBM was associated with an increased odds of overall incident OA measured by 
Croft score, before (model 1: OR=2.54 [0.66,9.71], Figure 67) or after adjustment 
for age, sex, and follow-up time (model 2: 1.65 [0.41,6.70]). Due to the low 
prevalence of hip OA at baseline in the population with follow-up data, I was 
unable to analyse a binary variable for overall hip OA progression based on a 
Croft>3. Using a Croft score >1 to define OA at baseline, 82 hips were eligible to 
progress, of which 16 had a higher Croft score at follow-up (12 with HBM). The 
fully adjusted OR for hip OA progression (model 3) was 4.14 (0.81,21.3). 
7.3.5. HBM and the combined incidence and progression of 
radiographic hip OA sub-phenotypes 
Of the total population analysed, 28.8% had at least one osteophyte at baseline, 
rising to 41.5% at follow-up (Table 19). JSN was much less prevalent than 
osteophytes at baseline and follow-up (11.3% and 12.4%, respectively). In 
unadjusted analyses, individuals with HBM had a greater change in osteophyte 
and JSN score between baseline and follow-up than those without HBM 
(βosteophyte=0.30 [0.05,0.54], p=0.019 and βJSN=0.09 [0.01,0.16], p=0.019, β reflects the 
mean difference in change in score between those with and without HBM). These 
associations persisted after adjustment for age, sex, follow-up time, baseline 
score, height and TBFM (model 3,Figure 67). HBM was not associated with 





Figure 67: Associations between HBM and incident OA and change in OA sub-
phenotypes. 
 
Points for continuous outcomes represent the difference in mean outcome between 
individuals with and without HBM (e.g. a beta of 1 for change in osteophyte score would 
represent a 1-point greater increase in summed osteophyte score, which is the equivalent 
of the appearance of one additional osteophyte or the increase in size of an osteophyte 
already present). Points for binary outcomes represent the OR for individuals with HBM 
compared to their relatives without HBM. Horizontal bars represent 95% CIs. 
Model 1: unadjusted, model 2: adjusted for age, sex, and follow-up time (plus baseline 
score for continuous outcomes), model 3: model 2 plus height and TBFM. 
Nincident OA=248; Ncontinuous outcomes=263. 
 
7.3.6. HBM and clinical features of hip OA  
HBM was associated with 12-point (95% CI: 5,18) higher WOMAC pain scores 
and 13-point (7,19) higher function scores in unadjusted analyses. Adjustment for 
age, sex, height and TBFM attenuated these relationships by approximately one-
third to one-half (βpain=6.4 [-1.4,14.2], p=0.105 and βfunction=8.3 [0.7,15.8], p=0.032, 
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β represents the difference in mean WOMAC score between those with and 
without HBM). Further adjustment for osteophyte or JSN score at follow-up did 
not appear to explain these relationships (Figure 68). There was some weak 
evidence supporting an increased odds of self-reported hip replacement in 
individuals with HBM who completed the follow-up questionnaire, compared to 
those without HBM (age, sex, height and TBFM-adjusted OR=4.27 [0.94,19.5], 
p=0.061, N=148). 
 
Figure 68: Associations between HBM status and WOMAC pain, stiffness, and function 
subscales. 
Points represent the mean difference in WOMAC scores between individuals with HBM 
and relatives/spouses without HBM. Horizontal bars represent 95% CIs. Person-level 
analysis, accounting for clustering in families. Model 1: unadjusted, model 2: adjusted 
for age, sex and follow-up time, model 3: model 2 plus height and TBFM, model 4: model 





7.3.7. BMD and hip OA progression 
No evidence was detected to support an association of baseline TH or L1-BMD with odds of incident OA or change in sub-
phenotype scores (Table 21). However, there was evidence for associations of baseline TH and L1-BMD with WOMAC pain, 
stiffness and functional limitation scores (Table 21), although CIs overlapped the null after adjustment for TBFM. Magnitudes of 
associations were stronger for TH, compared to L1, BMD.  
 
Table 21: Associations of L1 and TH-BMD with radiographic and clinical features of OA progression in the HBM cohort. 
   Model 1 Model 2 Model 3 
Outcome Exposure N β LCI UCI P Β LCI UCI P β LCI UCI P 
Incident OA 
L1-BMD 245 1.39 0.65 2.97 0.398 1.34 0.57 3.14 0.495 1.34 0.56 3.23 0.513 
TH-BMD 245 1.04 0.53 2.05 0.907 1.08 0.50 2.36 0.844 1.07 0.47 2.40 0.876 
Change in JSN score 
L1-BMD 259 0.03 -0.01 0.06 0.137 0.03 -0.01 0.06 0.161 0.03 -0.01 0.07 0.184 
TH-BMD 259 0.00 -0.05 0.05 0.953 0.01 -0.04 0.05 0.784 0.01 -0.04 0.05 0.726 
Change in osteophyte score 
L1-BMD 259 0.11 -0.03 0.26 0.132 0.11 -0.04 0.25 0.145 0.11 -0.04 0.27 0.152 
TH-BMD 259 0.10 -0.04 0.25 0.170 0.11 -0.03 0.26 0.132 0.12 -0.03 0.28 0.107 
WOMAC pain 
L1-BMD 125 4.20 0.24 8.16 0.038 3.67 -0.03 7.37 0.052 2.04 -1.75 5.82 0.291 
TH-BMD 125 4.84 0.23 9.45 0.040 4.96 0.45 9.47 0.031 3.60 -0.87 8.07 0.115 
WOMAC stiffness 
L1-BMD 125 4.87 0.38 9.35 0.033 4.37 0.01 8.74 0.050 2.90 -1.74 7.55 0.220 
TH-BMD 125 5.32 0.30 10.3 0.038 5.29 0.41 10.2 0.033 4.10 -0.78 8.98 0.100 
WOMAC functional limitation 
L1-BMD 125 5.11 1.35 8.87 0.008 4.70 1.20 8.21 0.009 2.80 -0.98 6.59 0.147 
TH-BMD 125 5.49 0.91 10.1 0.019 5.55 1.08 10.0 0.015 4.16 -0.27 8.59 0.066 




7.3.8. Sensitivity analyses 
Including six individuals with an incident THR and with a Croft score<3 at 
baseline in the analysis of incident OA did not alter conclusions drawn. Neither 
did removing 10 hips from individuals who visited a different site for follow-up 
radiographs (Figure 69), additional adjustment for TB DXA artefact (Figure 69) or 
removing 10 hips from individuals with DXA positioning errors (Figure 69). 
Conclusions were unchanged when performing a person-level analysis 
accounting for within-family clustering, although CIs were wider due to the 
lower numbers (Figure 70). When recoding the 21 hips with negative scores for 
change in osteophytes, and the 4 hips with negative scores for JSN, as 0 to enable 
use of a Poisson model, the association between HBM and change in JSN score 
was stronger (but with wider CIs) than the association with change in 
osteophytes (model 3: IRRosteophyte=2.10 [1.09,4.02] and IRRJSN=115 [10,1313]). 
Additional adjustment for FN area (as a measure of bone size) marginally 
attenuated effect estimates (βosteophyte 0.26 [0.01,0.52] attenuated to 0.21 [-0.02,0.44] 
and βJSN 0.08 [0.01,0.16] to 0.07 [4x10-3,0.13]). Additional adjustment for history of 
steroid use (assessed at baseline) did not alter conclusions.  
 





Adjusted for age, sex, follow-up time, height, TBFM, and baseline score for the 
continuous outcomes.  
 
Figure 70: Associations between HBM and incident OA and change in OA sub-
phenotypes in person-level analyses. 
 
Points for continuous outcomes represent the difference in mean outcome between 
individuals with and without HBM. Points for binary outcomes represent the OR for 
individuals with HBM compared to their relatives with normal BMD. Horizontal bars 
represent 95% CIs. 
Model 1: unadjusted, model 2: adjusted for age, sex, and follow-up time (plus baseline 
score for continuous outcomes), model 3: model 2 plus height and TBFM. Nincident 





7.4.1. Summary of findings 
In this chapter, I have presented evidence for increased hip osteophyte and JSN 
development, over an average of eight years, in individuals with HBM, 
compared to their relatives without HBM. Furthermore, I present evidence that 
individuals with HBM have more hip pain and limitation of function, which 
provides further evidence for more severe OA in this HBM population, although 
these clinical relationships were independent of radiographic features of OA. 
This analysis extends the previous findings of increased radiographic and clinical 
features of knee OA progression in this population (Chapter 6), suggesting that 
HBM is related to generalized OA progression, although the magnitudes of effect 
were weaker than seen at the knee.  
7.4.2. Context of this research 
Few studies have determined the association between BMD and hip OA 
incidence or progression. Bergink et al observed a relationship between FN-BMD 
and both hip OA incidence and progression in the Rotterdam study population 
(235). This chapter has extended these findings by determining the relationship 
between high BMD and the incidence and/or progression of individual 
radiographic sub-phenotypes. Barbour et al identified weak evidence for 
worsening osteophytes with increasing BMD in JoCo, but no evidence for a 
relationship with JSN progression (231), which is inconsistent with the observed 
(albeit weak) relationship between HBM and change in JSN score. Hochberg et al 
identified a dose-response relationship between BMD and subsequent incidence 
of OA in SOF (413). However, this relationship was no longer present when 
defining incidence based on JSN alone. In this chapter, I did not observe strong 
evidence for an association between HBM and incident hip OA, possibly due to 
low numbers, but the direction of effect was consistent with previous findings.  
The observed relationship between HBM and hip pain is consistent with studies 
of cohorts sampled from the general population, which have identified a higher 
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BMD in those reporting hip pain (208). The severity of OA sub-phenotypes did 
not appear to explain the relationship between HBM and hip pain or functional 
limitations, suggesting that HBM individuals have an increased risk of clinical 
OA independent of radiographic severity. The WOMAC questionnaire measures 
pain over the past 48 hours, which may explain why radiographic OA severity 
did not explain current pain, as pain could increase during stages of rapid OA 
progression not captured by radiographs (414). An analysis of the Framingham 
and OAI populations found that fewer than 25% of individuals with 
radiographic hip OA reported hip pain, and fewer than 20% of individuals 
reporting hip pain had radiographic hip OA (415). It is possible that more pain 
and functional limitations in the HBM population could reflect other conditions 
of the hip (e.g. bursitis (416)), features of a mild skeletal dysplasia, or 
inflammation not detected on the radiograph.  
Increased TBFM in the HBM population (201) did not appear to explain the 
relationship between HBM and change in radiographic OA sub-phenotypes. 
Adjustment for FN area, as a measure of bone size, only explained a small 
proportion of the relationship. Unfortunately, measures of FN width are not 
available in the HBM population, a risk factor for hip OA progression (417). It is 
plausible that HBM individuals would have greater FN width due to greater 
bone mass, meaning measures of FN area may not equate to FN width in this 
population. Another factor which may mediate the relationship between HBM 
and development of hip OA sub-phenotypes are differences in hip shape. HBM 
individuals more commonly have features of cam-type deformity (section 1.2.5), 
compared to their relatives without HBM (418). There is evidence to suggest that 
cam-type deformities are related to end-stage hip OA, suggesting that cam-type 
deformity is a risk factor for hip OA progression (419,420).  
As discussed in section 2.3.4, HBM is likely to be caused by the polygenic 
inheritance of multiple BMD loci (203), or the monogenic inheritance of rare 
variants (205), indicating that HBM precedes OA development. However, the 
possibility that biological pleiotropy, rather than a causal effect, explains the 
current results cannot be ruled out. Previous observations of a greater prevalence 
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of pelvic enthesophytes in the HBM population led to the hypothesis that HBM 
individuals may have a genetic predisposition to form extra bone (402). The 
stronger effect size for the relationship between HBM and change in hip 
osteophyte score, compared to change in hip JSN score, further suggests a ‘bone-
forming’ phenotype in this population. The genetic correlation between hip OA 
and LS-BMD (137) is further evidence for pleiotropy. 
7.4.3. Strengths  
The HBM study constitutes the largest population of individuals with extreme, 
unexplained, generalized HBM (11). I analysed change in OA sub-phenotypes 
separately, which allowed me to detect the stronger relationship with osteophyte 
development compared to change in JSN. I analysed change in osteophytes and 
JSN as continuous measures, increasing statistical power to detect associations, 
and reducing the possibility of a ceiling effect by increasing the range of possible 
values from 0-6 for JSN and 0-10 for osteophytes, and eliminating the possibility 
of selection bias in a case-only analysis.  
7.4.4. Limitations  
The method of identifying individuals from NHS DXA databases ascertained a 
predominantly female and older population, such that a relatively large 
proportion were unable to be followed-up after eight years, due to death or poor 
health. Hence there was a lower baseline prevalence of radiographic hip OA in 
the population able to be followed-up, meaning power to assess hip OA 
incidence and progression, based on overall Croft score, was limited. 
Radiographs and DXA scans were performed using standard protocols at each 
centre but were not standardized across centres. However, as 97% of individuals 
re-attended the same centre for follow-up, this is unlikely to affect the measures 
for change in radiographic features. Furthermore, measuring change in sub-
phenotype variables did not separate hip OA sub-phenotype progression from 
incidence since these results had to be pooled to optimise sample size. As I did 
not read baseline and follow-up radiographs paired, I did observe a few negative 
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scores for change in osteophytes (8%) and change in JSN (1.5%), which were 
included in analyses, because removing these values as ‘measurement error’ 
would have biased results, as there was likely to have been the same proportion 
of measurement error overinflating change, for which I would not have been able 
to account (hence the reasoning for not basing conclusions on the Poisson 
analysis). Radiographic grading of OA sub-phenotypes is subjective, which I 
limited using an established atlas (19), although the intra-rater and inter-rater 
reliability were low for a few variables, attenuating the conclusions I can draw 
from this analysis. As I was blinded to timepoint, it is unlikely that I 
systematically under-graded at baseline and over-graded at follow-up, meaning 
measurement error is unlikely to explain these results. WOMAC scores were 
only collected at follow-up and therefore I cannot draw conclusions about the 
relationship between HBM and symptomatic OA progression. 
7.4.5. Future work 
As highlighted in Chapter 6, it is important to determine if the relationship 
between high BMD and hip osteophyte development is a true causal 
relationship. In Chapter 9, I determine the causal effect of BMD on hip OA, using 
multivariable analyses to determine if the causal effect is independent of BMI. To 
determine if BMD has a causal effect on OA (sub-phenotype) progression, a 
GWAS of hip OA (sub-phenotype) progression in a large sample with multiple 
available radiographs would first need to be performed. Summary statistics 
could then be used for 2SMR analyses. Unfortunately, this analysis was beyond 
the scope of this PhD. Bidirectional analyses should additionally be performed to 
determine whether the observed association between HBM and hip OA 
subphenotype prevalence/progression represents a true causal pathway between 
BMD and hip OA sub-phenotypes, or whether there may be shared underlying 
biology contributing to both phenotypes (i.e. pleiotropy, Chapter 9). Finally, it is 
important to determine the underlying pathways which contribute to hip OA in 
people with high BMD (Chapter 10), as knowledge of the underlying biological 




I have found evidence for associations between HBM and worsening 
radiographic sub-phenotypes of hip OA over eight years. I have found evidence 
for a greater clinical severity of hip OA in HBM individuals, compared to their 
relatives without HBM. These associations are independent of the elevated TBFM 
observed in HBM individuals. Further analyses are required to determine the 
BMI-independent causal role of BMD in hip OA progression, and to identify the 




CHAPTER 8.  USING 
METABOLOMICS TO 
DETERMINE THE ROLE OF 





8.1. Background and aims 
8.1.1. The association between bone and metabolism 
A positive relationship between BMD and BMI is widely accepted, reflecting the 
beneficial effect of increased loading on the skeleton; MR analysis provided 
evidence for a causal pathway from higher BMI to increased BMD (401). Obesity 
is a component of the metabolic syndrome (MetS), along with hyperglycaemia, 
dyslipidaemia, and high blood pressure (421). Several studies have investigated 
the link between MetS and BMD (422-424). These studies have produced 
conflicting results, suggesting that individuals with MetS could have lower, 
higher or no difference in BMD compared to those without MetS (422-424). 
Reasons for these inconsistencies could include the differential relationships of 
each of the MetS components with BMD; a study in the RS population found a 
positive relationship between elevated glucose and FN-BMD, a positive 
relationship between high-density lipoprotein cholesterol (HDLc) and FN-BMD 
in women only and an inverse relationship between waist circumference and FN-
BMD in men only (425). More recently, MR analyses have suggested an inverse 
effect of low-density lipoprotein cholesterol (LDLc) on BMD estimated from heel 
ultrasound (eBMD); the same association was not observed for HDLc or 
triglycerides (426).  
This recent MR analysis found some evidence for a causal pathway between 
eBMD and LDLc (i.e. bidirectional relationships between eBMD and LDLc) (426). 
Bone is suggested to play a role in regulating energy metabolism. Osteocalcin is a 
measure of osteoblast function and thus bone formation (427-429). Osteocalcin 
deficient mice have increased blood glucose, reduced insulin levels, and an 
increase in FM compared to wildtype mice (202). In human populations, 
osteocalcin has been inversely associated with FM and blood glucose levels 
(430,431). Further evidence for a metabolic effect of high BMD was provided by 
investigating the HBM population, as discussed in section 2.3.2. 
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Several human metabolomic studies of BMD have been performed (432-438), but 
only one has used the targeted metabolomics platform developed by Nightingale 
health outlined in section 5.4 (434), allowing analyses to be reproduced in other 
populations. This study, performed in the ALSPAC adolescent population 
outlined in section 5.2.3, identified inverse relationships between tibial cortical 
BMD and concentrations of lipoprotein, lipid, and fatty acid traits, as well as a 
strong inverse relationship with citrate. However, only the association with 
citrate met the Bonferroni-corrected p-value threshold after adjustment for FM 
and LM (434). Consistent with an inverse relationship between BMD and citrate, 
a non-targeted metabolomics analysis in a smaller Japanese population observed 
higher serum citrate in postmenopausal women with low BMD, defined by a T-
score<-1, compared to those with a T-score>-1 (437). 
8.1.2. OA and metabolism 
As discussed in section 1.2.5, BMI is a strong risk factor for OA. With regards to 
the relationship between MetS and OA risk, a systematic review concluded that 
there was insufficient evidence to draw conclusions on the relationship between 
MetS and hand OA, and that there was no evidence to suggest a relationship 
between MetS and hip and knee OA, although the majority of studies were cross-
sectional (439). In a more recent analysis of the Chingford cohort, the individual 
components of MetS (hypertriglyceridemia, low HDLc, hypertension and high 
fasting glucose levels) were associated with painful interphalangeal OA, but not 
knee OA, independent of BMI (440). An MR analysis including the UK Biobank 
population (N=376,435) and the Malmo Diet and Cancer Study (N=27,691) 
provided evidence for a protective effect of LDLc on hip/knee OA (441). This MR 
analysis did not find evidence for a causal effect of HDLc, triglyceride levels or 
fasting plasma glucose on OA risk (441). 
Several metabolomics studies have been performed of OA, mainly in animal or 
small case-control settings (388). Several of these studies have determined 
metabolic profile of SF (442-445). Xu et al extracted cartilage samples from 
osteophytes of postmenopausal women undergoing TKR and compared the 
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metabolic profiles of these samples to those extracted from the lateral posterior 
femoral condyle. They identified 28 metabolic variations, many of which 
corresponded to amino acids, including elevated phenylalanine and proline in 
the osteophyte samples (446). Whilst this tissue-specific analysis will capture 
localised metabolic dysregulation, SF and cartilage cannot be easily sampled 
from large cohorts.  
Of the studies determining circulating metabolic profile (i.e. plasma or serum), 
Zhai et al identified an increased branched chain amino acid (BCAA) to histidine 
ratio in the serum of female knee OA cases, compared to controls, from 
TwinsUK. This association replicated in a population of knee OA cases and 
controls from the Chingford cohort (447). Zhang et al also identified an increased 
plasma BCAA to histidine ratio in knee OA cases sampled from the mixed sex 
Newfoundland OA study, compared to controls sampled from the Complex 
Diseases in the Newfoundland Population: Environment and Genetics study. 
This ratio, however, did not predict TKR in a separate population sampled from 
TASOAC, but lysophosphatidylcholine to phosphatidylcholine ratio did predict 
TKR (448). In another analysis, Zhang et al identified lower levels of plasma 
arginine in knee OA patients undergoing TKR, compared to controls, which 
replicated in a separate case-control study (449). However, none of these 
metabolomics studies have determined which circulating metabolic traits are 
associated with the individual radiographic OA sub-phenotypes. As discussed in 
Chapter 3, the sub-phenotypes of bone formation and cartilage loss may have 
different associations with BMD and therefore may display different associations 
with metabolic traits. 
8.1.3. Aims  
The cross-sectional association between HBM and knee OA was attenuated by 
approximately 50% by adjustment for BMI (227). This could be explained by 
confounding, as BMI is a common cause of both BMD and OA. However, HBM is 
at least in part genetically determined (203) and in the HBM population, 
adjustment for TH-BMD partially attenuated the relationship between HBM and 
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TBFM, whereas adjustment for TBFM only minimally attenuated differences in 
BMD between HBM individuals and their relatives without HBM, suggesting a 
causal pathway between HBM and TBFM (201). HBM could therefore be 
associated with dysregulation of metabolic pathways, via reduced bone turnover 
(201). I aim to identify metabolic traits cross-sectionally associated with BMD 
(Aim 1, Figure 71) and OA (Aim 2, Figure 71) in the HBM cohort. These 
metabolic traits may mediate the relationship between BMD and OA, possibly 
identifying pathways involved in OA pathogenesis. Due to the suggested role of 
osteocalcin in insulin sensitivity and adiposity (202), I aim to determine if BTMs 
(section 2.1.4) alter metabolic profiles (Aim 3, Figure 71) , which could mediate 
the association between HBM and OA phenotypes, as HBM individuals have 
reduced bone turnover (201). Finally, I aim to assess the generalizability of any 
observed results in cohorts more representative of the general population. 
 
Figure 71: Simplified DAG of hypothesized pathways between HBM, bone turnover and 
OA sub-phenotypes and the hypothesized mediating effect of metabolic pathways. 
 
Red arrows indicate an inverse relationship and green arrows represent a positive 
relationship. The possible direct effect of bone turnover on OA sub-phenotypes is 








8.2.1. Study population 
Initial analyses were performed in the HBM study population, described in 
section 2.3.2. Metabolomic profiling was performed on 354 individuals, of whom 
229 (65%) were HBM cases and 125 (35%) were relatives/spouses without HBM. 
Individuals with metabolomic data were recruited from eight of the original 
centres: Bristol, Cardiff, Bath, Hull, Gwent, Birmingham, Sheffield, and 
Cambridge.  
8.2.2. Metabolomics 
Metabolic profiling of the HBM cohort was performed using the Nightingale 
Health NMR platform (section 5.4.1).  
Data cleaning and quality control 
Analytical outliers 
Histograms were produced for all metabolic traits to detect potential analytical 
outliers (those which were several orders of magnitude greater than all other 
measurements and make all other measurements indistinguishable on a 
scatterplot). Although potential outliers were detected (i.e. measurements >7SD 
above or below the mean), that could be removed in later sensitivity analyses 
(section 8.2.5), no analytical outliers were detected. Some metabolic traits, 
particularly the lipoprotein measures, were heavily zero-skewed. This may not 
represent true zero concentrations, but a failure to detect the true concentration 
(450). These zero values were therefore set to missing. Several of the lipoprotein 
subclass measures were undetectable in many individuals, ranging from 3% 
missing for the extra-large HDL lipoproteins to 95% for the large and medium 
HDL lipoproteins (Table 22). The general pattern also appeared to be an increase 
percentage of missing data in those without HBM compared to those with HBM. 
Due to the large amount of missing data for the lipoprotein subclass measures, I 
excluded these variables from all analyses. 
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Table 22: Number of individuals with available data for each of the metabolic traits in the 
HBM cohort. 
Metabolic Trait  NHBM (%) Nno HBM (%) Ntotal (%) 
Extremely large VLDL 187 (82) 87 (70) 274 (77) 
Extra-large VLDL 153 (67) 65 (52) 218 (62) 
Large VLDL 125 (55) 53 (42) 178 (50) 
Medium VLDL 141 (62) 51 (41) 192 (54) 
Small VLDL 87 (38)  39 (31) 126 (36) 
Very small VLDL 64 (28) 36 (16) 100 (28) 
IDL 96 (42) 42 (34) 138 (39) 
Large LDL 58 (25) 19 (15) 77 (22) 
Medium LDL 32 (14) 7 (6) 39 (11) 
Small LDL 32 (14) 8 (6) 40 (11) 
Extra-large HDL 222 (97) 120 (96) 342 (97) 
Large HDL 15 (7) 1 (1) 16 (5) 
Medium HDL 16 (7) 0 (0) 16 (5) 
Small HDL 222 (97) 119 (95) 341 (96) 
Lipoprotein particle size 229 (100) 125 (100) 354 (100) 
Cholesterol    
 Total 229 (100) 125 (100) 354 (100) 
 VLDL 229 (100) 125 (100) 354 (100) 
 Remnant 229 (100) 125 (100) 354 (100) 
 LDL 229 (100) 125 (100) 354 (100) 
 HDL  229 (100) 125 (100) 354 (100) 
 HDL2 30 (13) 3 (2) 33 (9) 
 HDL3 229 (100) 125 (100) 354 (100) 
 Esterified  229 (100) 125 (100) 354 (100) 
 Free 229 (100) 125 (100) 354 (100) 
Glycerides and phospholipids 229 (100) 125 (100) 354 (100) 
Fatty acids    
 Degree of unsaturation 34 (15) 9 (7) 43 (12) 
 Docosahexaenoic acid 18 (8) 0 (0) 18 (5) 
 Linoleic acid 34 (15) 9 (7) 43 (12) 
 MUFA 34 (15) 9 (7) 43 (12) 
 n-3 fatty acids 34 (15) 9 (7) 43 (12) 
 n-6 fatty acids 34 (15) 9 (7) 43 (12) 
 PUFA 34 (15) 9 (7) 43 (12) 
 Saturated fatty acids 34 (15) 9 (7) 43 (12) 
 Total fatty acids 34 (15) 9 (7) 43 (12) 
Apolipoproteins 229 (100) 125 (100) 354 (100) 
Glycolysis-related metabolites    
 Glucose  228 (99.6) 119 (95) 347 (98) 
 Lactate 228 (99.6) 119 (95) 347 (98) 
 Citrate 229 (100) 125 (100) 354 (100) 
Amino acids    
 Alanine  229 (100) 125 (100) 354 (100) 
 Histidine  229 (100) 125 (100) 354 (100) 
 Isoleucine  229 (100) 125 (100) 354 (100) 
 Leucine  229 (100) 125 (100) 354 (100) 
 Valine  229 (100) 125 (100) 354 (100) 
 Phenylalanine  216 (94) 119 (95) 335 (95) 
 Tyrosine  229 (100) 125 (100) 354 (100) 
Ketone bodies    
 Acetate 228 (99.6) 122 (98) 350 (99) 
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 Acetoacetate  228 (99.6) 125 (100) 353 (99.7) 
 Beta-hydroxybutyrate 229 (100) 125 (100) 354 (100) 
Fluid balance    
 Creatinine 229 (100) 120 (96) 349 (99) 
 Albumin 229 (100) 125 (100) 354 (100) 
Inflammation    
 Glycoprotein acetylation  229 (100) 125 (100) 354 (100) 
Metabolic traits in bold correspond subclasses of metabolic traits. Numbers were the same 
for all lipoprotein measures within these subclasses. MUFA: monounsaturated fatty acid, 
PUFA: polyunsaturated fatty acid. 
 
Storage issues and sample degradation 
Unfortunately, due to the time lapse between collection of blood samples and 
analysis (average 8 years), some samples had degraded, and the quality of the 
data was reduced (450). Nightingale Health provide variables for quality control 
tags for sample issues:  
• Low glucose/high lactate: samples kept at room temperature during 
blood collection result in glucose metabolism to lactate or pyruvate. I set 
glucose and lactate concentrations to missing for individuals with this tag. 
• Abnormal macromolecule A: this tag means that signals from abnormal 
proteins and macromolecules have been detected and accurate 
quantification of phenylalanine, acetate, and acetoacetate has not 
occurred. I therefore set phenylalanine, acetate, and acetoacetate 
concentrations to missing for individuals with this tag.  
• Low glutamine/high glutamate: this tag is given when glutamine appears 
to have degraded, normally due to samples being left at room temperature 
or being subjected to multiple freeze-thaw cycles. All but three samples 
had this tag, so glutamine was not analysed.  
Due to differences in facilities available at the different HBM centres, some sites 
were unable to freeze samples in the required amount of time for accurate 
metabolomic analysis (Bristol, Cardiff, Bath, Gwent, N=28). I analysed 
differences in metabolite concentrations between sites where the samples could 
be frozen correctly, and those where there was a delay in freezing, using GEE to 
account for clustering within families. Mean concentration of most metabolites 
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were lower in the group where samples were stored correctly (Figure 72). This 
was not explained by differences in HBM prevalence, age, or social status (IMD) 
between the sites. Individuals from sites where samples could not be stored 
correctly were excluded from further analysis, leaving the final maximum 
sample numbers for each metabolite provided in Appendix 17.  
 
Figure 72: Differences in metabolic trait concentrations between samples that were 




To limit the number of statistical tests and thus reduce the risk of chance 
findings, I initially analysed 23 metabolic traits, which included the amino acids, 
ketone bodies, glycolysis-related metabolites and one summary variable from 
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each lipid family (e.g. total triglycerides, total cholesterol). I aimed to perform 
further sub-group analyses if any associations were observed for the summary 
variables. 
Comparing associations to previously published work  
To check the reliability of the data, I compared associations with BMI, stratified 
by gender, to previously published results from adolescents (342), and 
differences in metabolic traits between those individuals ever taking statins and 
those individuals who had never taken a statin, to those previously published 
(451). Results were generally consistent with previously published data, despite a 
smaller sample size. A summary of these analyses is provided in Appendix 18.  
8.2.3. Assessment of HBM, BMD and bone turnover 
The definition of HBM is described in section 2.3.2, and the protocol for assessing 
TH, LS, and TB-BMD by DXA scanning is described in section 4.3. Non-fasted 
P1NP and total osteocalcin were measured as markers of bone formation and β-
isomer of CTX-1 (β-CTX) was measured as a marker of bone resorption. Plasma 
was separated and frozen within 4 hours to −80°C and BTM concentrations were 
measured by electrochemiluminescence immunoassays (Roche Diagnostics), 
performed by Professor Bill Fraser and Dr Jonathan Tang at the University of 
East Anglia Medical School. Detection limits were 4.0, 0.6 and 0.01 µg/L for 
P1NP, osteocalcin and β-CTX, respectively. Reference ranges were supplied by 
UK Supra Regional Assay Service laboratory (reference range 0.1‐0.5µg/L for β-
CTX, 20‐110µg/L for P1NP and 6.8‐32.2µg/L for osteocalcin). Intra-assay 
coefficients of variation (CV), provided by Professor Fraser and Dr Tang, were 
<2%, <2% and <4%, for P1NP, osteocalcin and β-CTX, respectively. Inter-assay 
CVs were <3%, <5% and <5%, respectively.  
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8.2.4. OA outcome variables 
OA sub-phenotypes were defined as described in the published papers based on 
baseline HBM analyses (226-228). The OA outcomes analysed are summarized in 
Table 23. 
 
Table 23: OA outcome variables analysed in the metabolomics analysis in the HBM 
cohort and their derivation. 
Variable Description 
Any hip osteophyte 
Any superior acetabular, lateral femoral or medial femoral 
osteophyte grade >1 
Any hip JSN Any JSN grade >1 
Any knee osteophyte Any medial or lateral osteophyte grade >1 
Any knee JSN Any medial or lateral JSN grade >1 
Any DIP osteophyte Osteophyte grade >1 at the DIP joint 
Any DIP JSN JSN grade >1 at the DIP joint 
Any CMC osteophyte Osteophyte grade >1 at the CMC joint 
Any CMC JSN JSN grade >1 at the CMC joint 
 
8.2.5. Statistical analysis 
Many of the metabolic traits displayed a skewed distribution (Appendix 19). 
However, from previous experience working with metabolomic data, log 
transformation does not alter the conclusions drawn, compared to when a model 
with robust SEs is used (Figure 73), but can make the results more difficult to 
interpret. Some metabolic traits did not display a normal distribution when log 
transformed (I checked all other transformations using the Stata ‘gladder’ 





Figure 73: Comparison of robust SE and log-transformed methods of analysis for the 
association between HBM and the 23 metabolic traits analysed. 
 
Points represent the mean difference in metabolic traits in SD units for the robust SE 
model and in SD units of the log transformed variable for the log transformed model. 
Adjusted for age and sex. 
 
Although most metabolic traits were measured in units of mmol/L, the range of 
values varied between metabolic traits, for example concentrations of the amino 
acid tyrosine ranged from 0.03 to 0.12mmol/L, whereas the concentration of 
glucose ranged from 1.41 to 13.1mmol/L. Therefore, to present data in a way that 
can allow comparisons between metabolic traits, I performed initial analyses 
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with standardized metabolic traits. However, when comparing associations 
between populations, for example when comparing HBM and ALSPAC 
populations, as HBM is such an extreme and smaller population, I additionally 
analysed the metabolic traits in their original units.  
Accounting for clustering 
Methods for dealing with within-family clustering in the HBM population are 
discussed in section 5.1.2. Associations between continuous BMD/BTM variables 
and continuous metabolic traits were determined by GEE linear regression. For 
analyses of binary outcomes (i.e. OA sub-phenotype variables), analyses were 
performed using GEE logistic regression. Hip and knee OA analyses were 
performed on all available hip and knee x-rays, using GEE to account for within-
person clustering rather than within-family. As only one hand radiograph was 
available per person, analyses of hand OA sub-phenotypes accounted for within-
family clustering. 
Correction for multiple testing  
Although analyses were restricted to the 23 key metabolic traits, there was still a 
need to correct the significance threshold for multiple testing. As the metabolic 
traits assessed were highly correlated, I determined the significance threshold 
based on matrix spectral decomposition of a correlation matrix between the 
variables (452,453). The 23 metabolic traits generated 20 independent variables, 
so I set the p-value threshold at 0.05/20=0.003. 
Determining models for analysis  
Analyses were initially performed unadjusted. Age, sex, height, and weight were 
considered a priori confounders, so I performed further analyses using two 
additional models: model 2: adjusted for age, sex, and height and model 3: 
additionally adjusted for weight. Age was not linearly associated with some 
variables, so I categorized age into quintiles. Due to the large number of tests for 
multiple exposures/outcomes performed, I explored the need for adjustment for 
additional covariates such as menopause and use of glucocorticoids or 
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bisphosphonates for any metabolites associated with BMD, bone turnover or OA 
sub-phenotypes (Figure 74). 
Sensitivity analyses 
I excluded individuals with a metabolic trait concentration at least 7SD above or 
below the mean concentration. I excluded samples with any of the QC tags 
(rather than just setting particular metabolic traits as missing) provided by 
Nightingale Health (except low glutamine/high glutamate as glutamate was not 
analysed), outlined in section 8.2.2, in a separate analysis. 
 
Figure 74: DAGs of hypothesized relationships between BMD/ bone turnover/OA sub-




8.2.6. Determining the generalizability of observed 
associations 
The Rotterdam study 
I determined generalizability for analyses with BMD exposures and OA 
outcomes by replicating analyses for metabolic traits of interest in RS, described 
in section 5.2.2. Metabolomic profiling was performed on RS1 individuals who 
attended the fourth assessment, using the Nightingale health platform. Although 
the mean age of the RS population was slightly higher than the HBM population 
(75 (6) vs 59 (15) years), RS represents the largest population with detailed OA 
sub-phenotype data and metabolomic assessment in a population of male and 
female older adults. L1 and FN-BMD were assessed by DXA at the same outcome 
assessment clinic. Methods for performing X-rays, and assessment of 
radiographs for OA sub-phenotypes, have previously been described 
(232,454,455). I generated variables for any osteophyte and any JSN at the hip, 
knee, DIP and CMC joints of either hand/knee, as described for the HBM 
population (section 8.2.4). Associations between BMD variables (exposures) and 
metabolic traits (outcomes) were determined by linear regression and 
associations with OA outcomes were determined by logistic regression. Analyses 
were adjusted for age, sex, height, and weight. 
ALSPAC 
I assessed generalizability for the analyses of BTMs by replicating analyses for 
metabolic traits of interest in the ALSPAC populations, described in section 5.2.3. 
The ALSPAC mother’s population was selected as it represents the largest 
population of adults with measurement of β-CTX and metabolic traits using the 
Nightingale health platform. The offspring population was also assessed to 
determine generalizability to a younger age range. In the ALSPAC populations, 
fasted β-CTX concentration was measured. Plasma was separated and frozen 
within 4 hours to −80°C and β-CTX concentration measured by 
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electrochemiluminescence immunoassay (Roche Diagnostics), with a detection 
limit of 0.01µg/L. Intra‐ and inter‐assay CVs were <4% and <5%, respectively.  
Analyses of ALSPAC populations were performed using linear regression. For 
the mother's cohort, the final model was adjusted for age, height, weight, 
menopausal status, and fasting time prior to sample collection (<8 or ≥8 hours). 
Height and weight were measured contemporaneous to blood sampling. To 
determine HRT use and use of other medications affecting bone turnover, 
ALSPAC women were asked if they were taking hormone replacement, and to 
list all current medications, from which I determined bisphosphonate and oral 
glucocorticoid use. Women were considered postmenopausal if they had not had 
a period in the last 12 months or if their periods had stopped due to 
hysterectomy, ablation/resection, chemotherapy, or other medical reasons (456). 
As only 14 mothers reported bisphosphonate use and 12 oral glucocorticoid use, 
I removed these mothers in a sensitivity analysis. For the offspring population, 
model 3 was adjusted for age, sex, height, weight, Tanner stage, and time of 
sample collection (AM or PM). Tanner pubertal stage was assessed by line 
drawings (457,458) using a paper questionnaire sent to all participants prior to 





8.3.1. Descriptives of the HBM population included in these 
analyses 
354 individuals from the HBM population had metabolomics analysis performed 
on their baseline blood samples. 229 (65%) had HBM, 231 (65%) were female and 
the mean age was 58.7 (15.1) years. Of these 354 individuals, 326 had their blood 
samples collected at a site with the ability to freeze the samples. A flowchart 
detailing the derivation of the sample for analyses is presented in Figure 75. A 
comparison of the individuals with metabolomic data included in these analyses, 
and those with metabolomic data but not included, is presented in Table 24. Of 
the 326 individuals, 320 had complete covariate data and were analysed. 
Descriptive statistics comparing those with and without HBM are presented in 
Appendix 20. Summary statistics for each of the 23 metabolic traits initially 
analysed are presented in Table 25. 
 





Table 24: Characteristics of HBM cohort included in the metabolomics analysis, those not 
















  N (%)   
HBM  198 (62) 31 (91) 129 (63) 0.003 
Female  206 (64) 25 (74) 137 (67) 0.525 
Postmenopausal  154 (75) 12 (55) 100 (79) 0.045 
Radiographic knee 
OA (KL>2) 
101 (33) 8 (29) 53 (33) 0.877 
Radiographic hip 
OA (Croft >3) 
71 (27) 7 (32) 31 (26) 0.865 
Any joint 
replacement 
35 (11) 4 (12) 16 (8) 0.464 
History of HRT use 86 (45) 8 (40) 49 (44) 0.919 
History of steroid 
use 




10 (3) 4 (14) 5 (3) 0.007 
History of fracture 135 (42) 15 (44) 74 (37) 0.454 
History of smoking 172 (54) 18 (60) 99 (54) 0.798 
  Mean (SD)   
Age, years  59.1 (15.0) 54.7 (15.2) 59.1 (15.3) 0.270 
Height, cm  168.7 (9.9) 167.8 (10.1) 168.0 (8.9) 0.623 
Weight, kg  84.5 (17.0) 81.8 (14.2) 83.5 (17.8) 0.591 
Total hip BMD Z-
score 
2.07 (1.61) 2.92 (2.02) 2.07 (1.64) 0.020 
L1 BMD Z-score 2.53 (2.14) 3.50 (1.98) 2.80 (2.22) 0.033 




Table 25: Summary statistics for the 23 metabolic traits analysed in the HBM cohort. 
Metabolic trait N Mean (SD) Median (IQR) 
Cholesterol  
 Total cholesterol 320 0.610 (0.364) 0.497 (0.395, 0.722) 
Glycerides and phospholipids 
 Total triglycerides 320 0.671 (0.239) 0.606 (0.507, 0.777) 
 Phosphoglycerides 320 0.336 (0.173) 0.289 (0.235, 0.395) 
 Sphingomyelins 320 0.210 (0.114) 0.190 (0.167, 0.220) 
 Cholines 320 0.689 (0.408) 0.617 (0.528, 0.736) 
Apolipoproteins  
 Apolipoprotein-A1 320 0.546 (0.053) 0.540 (0.510, 0.577) 
 Apolipoprotein-B 320 0.299 (0.103) 0.279 (0.234, 0.337) 
Glycolysis related metabolites 
 Glucose 313 3.753 (1.333) 3.420 (3.090, 3.899) 
 Lactate 313 1.228 (0.515) 1.130 (0.944, 1.412) 
 Citrate 320 0.130 (0.023) 0.128 (0.115, 0.143) 
Amino acids 
 Alanine 320 0.316 (0.060) 0.314 (0.277, 0.349) 
 Histidine 320 0.025 (0.009) 0.024 (0.020, 0.028) 
 Isoleucine  320 0.045 (0.016) 0.042 (0.034, 0.053) 
 Leucine  320 0.067 (0.021) 0.064 (0.054, 0.075) 
 Valine 320 0.141 (0.041) 0.136 (0.115, 0.161) 
 Phenylalanine 302 0.061 (0.011) 0.059 (0.054, 0.066) 
 Tyrosine 320 0.051 (0.012) 0.049 (0.043, 0.057) 
Ketone bodies 
 Acetate 316 0.122 (0.080) 0.114 (0.101, 0.129) 
 Acetoacetate 319 0.011 (0.008) 0.009 (0.007, 0.013) 
 β-hydroxybutyrate 320 0.144 (0.067) 0.127 (0.107, 0.158) 
Fluid balance 
 Creatinine  315 0.060 (0.014) 0.058 (0.052, 0.065) 
 Albumin 320 0.079 (0.007) 0.078 (0.075, 0.082) 
Inflammation  
 Glycoprotein acetyls 320 1.308 (0.214) 1.291 (1.159, 1.444) 
 
8.3.2. Associations with BMD variables 
 
HBM status 
In unadjusted analysis, there was some evidence for higher mean concentrations 
of citrate, phenylalanine and β-hydroxybutyrate in individuals with HBM, and 




However, only the associations with alanine and β-hydroxybutyrate met the 
corrected p-value threshold. After adjustment for potential covariates age, sex, 
height, and weight, HBM was still strongly associated alanine, with an effect size 
of -0.38SD ([95% CI -0.61,-0.16], p=0.001, effect size=difference in mean 
concentrations between individuals with and without HBM). Mean 
apolipoprotein-A1 concentration was lower in individuals with HBM (-0.10SD [-
0.20,-3x10-3], p=0.04), but this association was not robust to correction for 
multiple testing. There was evidence of an increased concentration of the ketone 
body β-hydroxybutyrate in HBM cases, with an effect size of 0.30SD (0.06,0.54), 
p=0.02. Full results are tabulated in Appendix 21. 
 




Points represent the SD difference in mean metabolic trait concentration between those 
with and without HBM. Horizontal bars represent 95%CIs.  
 
Adjustment for additional potential covariates menopause, bisphosphonate use, 
and oral glucocorticoid use did not alter the strength of associations between 
HBM and apolipoprotein-A1, alanine or β-hydroxybutyrate (data not shown). 
TB-BMD 
In unadjusted analyses, TB-BMD appeared negatively associated with total 
cholines, citrate and tyrosine and positively associated with creatinine, but these 
associations did not meet the corrected p-value threshold (Figure 77). After 
adjustment for age, sex, height and weight, TB-BMD remained weakly negatively 
associated with cholines, with an SD increase in TB-BMD associated with 0.1SD 
lower total cholines (-0.19,-0.01), p=0.03. TB-BMD remained negatively associated 
with tyrosine concentration (-0.19 [-0.32,-0.07], p=0.003). Adjustment for 
menopause, bisphosphonate use, and oral glucocorticoid use did not alter these 
associations. Additional negative associations between TB-BMD and 
phosphoglycerides, alanine and leucine were observed, but were not robust to 





Figure 77: Associations between total body BMD and metabolic traits in the HBM 
cohort. 
 
Points represent the SD increase in metabolic trait concentration per SD increase in TB-
BMD. Horizontal bars represent 95% CIs. 
 
L1-BMD 
In unadjusted analyses, L1-BMD was inversely associated with alanine and 
positively associated with β-hydroxybutyrate, although neither association was 
robust to correction for multiple testing (Figure 78). After adjustment for age, sex, 
height, and weight, L1-BMD remained inversely associated with alanine (β=-0.17 
[-0.26,-0.08], p=2x10-4, β=SD change in alanine concentration per SD increase in 
L1-BMD). This association was robust to additional adjustment for 
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bisphosphonate use, glucocorticoid use, and menopausal status. Full results are 
tabulated in Appendix 23. 
 
Figure 78: Associations between L1-BMD and metabolic traits in the HBM cohort. 
 
Points represent the SD increase in metabolic trait concentration per SD increase in L1-
BMD. Horizontal bars represent 95% CIs. 
 
Maximum TH-BMD 
There was no strong evidence for an association between TH-BMD and any 
metabolic trait in unadjusted analyses (Figure 79). Negative associations with 
total cholesterol, phosphoglycerides, apolipoprotein-A1 and glucose were 
present only after adjustment for weight. None of these associations were robust 
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to correction for multiple testing. These could be evidence of potential collider 
bias, as weight might be a common effect of both HBM and increased blood 
glucose and total cholesterol. Full results are tabulated in Appendix 24. 
 
Figure 79: Associations between maximal total hip BMD and metabolic traits in the 
HBM cohort. 
 
Points represent the SD increase in metabolic trait concentration per SD increase in TH-
BMD. Horizontal bars represent 95% CIs. 
 
Sensitivity analyses 
The results of the sensitivity analyses are tabulated in Appendix 21-Appendix 24. 
When >7SD outliers were removed, CIs were narrowed for the association 
between L1-BMD and cholines, but the effect size was reduced -0.15SD (-
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0.32,0.03) vs -0.06SD (-0.12,-3x10-3). The same pattern was seen for the association 
between TB-BMD/TH-BMD and cholines when outliers were removed. When 
samples with quality control tags (low glucose, high lactate, abnormal 
macromolecule A, low protein content or high ethanol) were removed (NHBM=3, 
Nno HBM=6), the associations of HBM and L1-BMD with alanine were partially 
attenuated (-0.38SD vs -0.26SD and -0.17SD vs -0.11SD, respectively). Removing 
the tagged samples widened the CIs for the association between TB-BMD and 
alanine and the null value was included (-0.08 [-0.19,0.03]). Evidence for 
associations between TB-BMD and phosphoglycerides, cholines, leucine and 
glycoprotein acetyls were weakened when tagged samples were removed (CIs 
just overlapped the null). The inverse association between HBM and 
apolipoprotein-A1 was attenuated by removal of tagged samples. Evidence for 
associations between TH-BMD and apolipoprotein-A1 and phosphoglycerides 
was also weakened by removing samples with QC tags.  




There was strong evidence for an increased odds of any hip osteophyte with 
increasing glucose concentration in unadjusted and age, sex, and height-adjusted 
analyses (ORmodel 2=1.51 [1.16,1.98], p=0.002, Figure 80). Adjustment for weight 
did not attenuate the association, with an SD increase in glucose associated with 
49% increased odds of hip osteophytes. There was some evidence for a decreased 
odds of hip osteophytes per SD increase in acetoacetate and an increased odds 
per SD increase in glycoprotein acetyls (ORmodel 3=0.67 [0.47,0.96], p=0.03 and 1.29 




Figure 80: Associations between metabolic traits and any hip osteophyte in the HBM 
cohort. 
 
Points represent the OR for hip osteophytes per SD increase in metabolic trait 
concentration. Horizontal bars represent 95% CIs. 
 
JSN  
Evidence for associations between the metabolic traits and odds of hip JSN was 
very weak (Figure 81). The only metabolic traits where CIs did not overlap the 
null value were cholines (ORmodel 3=1.23 [1.03,1.48], p=0.02) and creatinine 




Figure 81: Associations between standardized metabolic traits and hip JSN in the HBM 
cohort. 
 
Points represent the OR for hip JSN per SD increase in metabolic trait concentration. 




I did not observe evidence for associations between any of the metabolic traits 
and any knee osteophyte (Figure 82). This was the same before and after 





Figure 82: Associations between standardized metabolic traits and any knee osteophyte in 
the HBM cohort. 
 
Points represent the OR for knee osteophytes per SD increase in metabolic trait 
concentration. Horizontal bars represent 95% CIs. 
 
JSN 
There was some evidence for an association between an SD increase in both 
sphingomyelins and cholines and a 20-30% increased odds of any knee JSN 
(p=0.03 and 0.01, respectively, Figure 83). I found some evidence that higher 
lactate concentration was associated with decreased odds of knee JSN (ORmodel 
3=0.57 [0.36,0.91], p=0.02. In unadjusted analyses, citrate was strongly associated 
with an increased odds of knee JSN, but the association was attenuated by 
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approximately 50% when adjusting for age, sex and height and CIs overlapped 
the null.  
 
Figure 83: Associations between standardized metabolic traits and knee JSN in the HBM 
cohort. 
 
Points represent the OR for knee JSN per SD increase in metabolic trait concentration. 




Evidence for associations between metabolic traits and osteophytes at the DIP or 
CMC joints was weak, with the CIs overlapping the null when adjusted for age 
and sex, for all metabolic traits except lactate, for which there was some evidence 
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for a reduced odds of DIP osteophytes with increasing lactate concentration in all 
three models (ORmodel 3=0.66 [0.49,0.89], p=0.006, Figure 84, Figure 85). 
 
Figure 84: Associations between standardized metabolic traits and DIP osteophytes in the 
HBM cohort. 
 
Points represent the OR for any DIP osteophyte per SD increase in metabolic trait 





Figure 85: Associations between standardized metabolic traits and CMC osteophytes in 
the HBM cohort. 
 
Points represent the OR for any CMC osteophyte per SD increase in metabolic trait 
concentration. Horizontal bars represent 95% CIs. 
 
JSN 
After adjustment for age and sex, there was evidence for a reduced odds of DIP 
JSN with increasing glucose and tyrosine concentrations (ORmodel 3=0.65 
[0.46,0.90] and 0.74 [0.58,0.94], respectively, p<0.02, Figure 86). Odds of CMC 
JSN, however, were higher with increasing total cholesterol and apoliprotein-A1 
concentrations, although CIs were wide and the p-value was greater than the 
corrected threshold (ORmodel 3=1.61 [1.08,2.40], p=0.02 and 1.86 [1.03,3.36], p=0.04, 
respectively, Figure 87). 
 
 264 
Figure 86: Associations between standardized metabolic traits and DIP JSN in the HBM 
cohort. 
 
Points represent the OR for DIP JSN per SD increase in metabolic trait concentration. 





Figure 87: Associations between standardized metabolic traits and CMC JSN in the 
HBM cohort. 
 
Points represent the OR for CMC JSN per SD increase in metabolic trait concentration. 
Horizontal bars represent 95% CIs. 
 
Sensitivity analyses 
Removing >7SD outliers weakened evidence for an association between 
acetoacetate and hip osteophytes, and attenuated associations between 
sphingomyelins/cholines and hip and knee JSN. An inverse association between 
acetate and hip JSN was apparent after the removal of outliers (full results 
provided in Appendix 25-Appendix 32).  
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8.3.4. Replication of BMD and OA associations in the 
general population 
To determine the generalizability of any BMD or OA sub-phenotype-associated 
metabolic trait to the general population, I sought replication in a cohort sampled 
from the general population. The RS1 population had data for all radiographic 
sub-phenotypes and metabolomics data cross-sectionally for 2,801 individuals. 
As I did not identify any metabolic traits associated with BMD or OA sub-
phenotypes at the Bonferroni-corrected p-value threshold, I attempted to 
replicate analyses for any metabolic traits associated with either TH/L1-BMD (as 
these were measured in the RS population) or any OA sub-phenotype at a 
suggestive p-value threshold (i.e. p<0.05) in the HBM cohort (Table 26).  




Table 26: Summary of results of metabolomics analyses in the HBM cohort and the metabolic traits selected for replication. 
 BMD OA 
Selected for Replication 

















Acetoacetate     -        1 
Acetate             0 
Alanine -  -          1 
Albumin             0 
Apolipoprotein A1             1 
Apolipoprotein B             0 
Beta hydroxybutyrate +            Data not available 
Citrate             0 
Creatinine      -       1 
Glucose     +     -   1 
Glycoprotein acetyls     +        1 
Histidine             0 
Isoleucine             0 
Lactate        - -    1 
Leucine             0 
Phenylalanine             0 
Total cholesterol             0 
Triglycerides             0 
Sphingomyelins             0 
Cholines  -           Data not available 
Phosphoglycerides             0 
Tyrosine  -        -   1* 
Valine             0 
‘-‘ represents an inverse association identified at p<0.05, ‘+’ represents a positive association at p<0.05. Blank boxes represent no identified 






Descriptives of the study population 
2,801 individuals from RS1 who attended the 4th outcome assessment (RS1-4) had 
metabolomic data. Descriptives of the RS1-4 population are presented in Table 
27. 
 
Table 27: Descriptives of the RS1-4 population with metabolomics data. 
 Mean (SD) 
Age (years) 75.0 (5.8) 
Height (cm) 166.4 (9.2) 
Weight (kg) 75.9 (13.2) 
L1-BMD 0.998 (0.197) 
Total hip BMD 1.109 (0.122) 
 N (%) 
Female 1,491 (57.9) 
Hip osteophyte 1,599 (86.1) 
Hip JSN 1,020 (54.9) 
Knee osteophyte 1,215 (69.5) 
Knee JSN 879 (50.3) 
DIP osteophyte 1,635 (66.1) 
DIP JSN 266 (10.8) 
CMC osteophyte 1,132 (45.8) 
CMC JSN 303 (12.3) 
Osteophytes/ JSN represent an OARSI grade>1. 
 
The metabolic traits assessed in RS1 are summarised in Table 28. 
 
Table 28: Summary of the metabolic traits assessed for associations with BMD or OA 
sub-phenotypes in the RS1-4 population. 
Metabolic trait (mmol/l) N Mean SD Median LQ UQ 
Glucose  2,801 4.817 1.180 4.506 4.208 4.983 
Lactate  2,801 0.791 0.290 0.727 0.594 0.913 
Alanine  2,801 0.293 0.069 0.285 0.244 0.331 
Tyrosine  2,801 0.060 0.011 0.059 0.053 0.066 
Acetoacetate  2,801 0.037 0.021 0.033 0.024 0.046 
β-hydroxybutyrate 2,801 0.095 0.074 0.071 0.055 0.107 
Creatinine  2,801 0.072 0.019 0.069 0.060 0.081 
Glycoprotein acetyls  2,801 1.303 0.159 1.285 1.195 1.392 
 
BMD 
In unadjusted analyses, there was strong evidence for a positive association 
between both FN and L1-BMD and alanine, the opposite direction to that 
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observed in HBM (Table 29). The magnitudes of these associations were 
strengthened by adjustment for age, sex, and height. Additional adjustment for 
weight attenuated the association between FN-BMD and alanine by over 50% 
and CIs overlapped the null (β=-0.03 [-0.02,0.08], p=0.2). There was still some 
weak evidence for an association between L1-BMD and alanine, although the 
magnitude of the association was attenuated by approximately 50% (0.05 
[0.01,0.09], p=0.02). In original units, this is equivalent to a 0.26mmol/L increase 
in alanine per 1g/cm2 increase in L1-BMD (95%CI 0.04,0.48), compared to a 
0.04mmol/L (0.02,0.07) decrease per 1g/cm2 observed in the HBM population. 
OA 
Associations of glucose, acetoacetate and glycoprotein acetyls with any hip 
osteophyte, lactate with any knee JSN, lactate with any DIP osteophyte and 
glucose with any DIP JSN did not replicate in RS (Table 29). There was some 
evidence for a reduced odds of hip JSN with increasing creatinine concentration. 
This association was the same direction, but of weaker magnitude, to that 
observed in the HBM population (ORHBM per 0.01mmol/L increase=0.76 
[0.62,0.94] vs ORRS1=0.91 [0.86,0.97]). There was weak evidence for a reduced 
odds of DIP JSN per SD increase in tyrosine concentration in RS. This was the 
same direction and of similar magnitude to the association observed in the HBM 





Table 29: Results of metabolomics replication analyses in the RS1-4 population and comparison with effect sizes in the HBM cohort. 
   Model 1 Model 2 Model 3 HBM Model 3 
Exposure Outcome N β (95% CI) p β (95% CI) p β (95% CI) p N β (95% CI) p 
FN-BMD Alanine 2,576 0.06 (0.02, 0.10) 0.002 0.08 (0.03, 0.12) 0.001 0.03 (-0.02, 0.08) 0.201 315 -0.08 (-0.19, 0.03) 0.153 
L1-BMD Alanine 2,576 0.07 (0.03, 0.11) 4x10-4 0.10 (0.06, 0.14) 4x10-6 0.05 (0.01, 0.09) 0.019 318 -0.17 (-0.26, -0.08) 3x10-4 
  N OR (95% CI) p OR (95% CI) p OR (95% CI) p  OR (95% CI) p 
Glucose  Hip osteophyte 1,823 0.99 (0.87, 1.13) 0.829 0.98 (0.87, 1.12) 0.740 0.99 (0.88, 1.15) 0.928 507 1.49 (1.14, 1.96) 0.004 
Acetoacetate Hip osteophyte 1,823 1.01 (0.89, 1.16) 0.884 0.97 (0.86, 1.11) 0.648 0.97 (0.85, 1.11) 0.634 519 0.67 (0.47, 0.96) 0.031 
Glycoprotein acetyls Hip osteophyte 1,823 0.92 (0.8, 1.05) 0.230 0.93 (0.81, 1.06) 0.252 0.94 (0.82, 1.07) 0.336 521 1.29 (1.01, 1.64) 0.042 
Creatinine Hip JSN 1,823 0.93 (0.85, 1.02) 0.138 0.85 (0.77, 0.95) 0.004 0.86 (0.77, 0.95) 0.005 511 0.72 (0.54, 0.95) 0.019 
Lactate Knee JSN 1,746 0.93 (0.85, 1.02) 0.141 0.95 (0,86, 1.04) 0.271 0.94 (0.85, 1.03) 0.185 588 0.57 (0.36, 0.91) 0.020 
Lactate DIP osteophyte 2,419 1.04 (0.95, 1.13) 0.423 1.06 (0.97, 1.15) 0.236 1.05 (0.96, 1.14) 0.333 312 0.66 (0.49, 0.89) 0.006 
Glucose  DIP JSN 2,419 1.08 (0.96, 1.21) 0.176 1.09 (0.96, 1.22) 0.167 1.05 (0.92, 1.19) 0.408 312 0.65 (0.46, 0.90) 0.011 
Tyrosine DIP JSN 2,419 0.89 (0.77, 1.01) 0.079 0.89 (0.78, 1.02) 0.100 0.85 (0.74, 0.98) 0.025 319 0.74 (0.58, 0.94) 0.015 
β represents the SD increase in metabolic trait concentration per SD increase in BMD. ORs are per SD increase in metabolic trait 
concentration. Model 1: unadjusted, model 2: adjusted for age, sex, and height, model 3: model 2 plus weight.  
 






Bone formation markers 
P1NP 
P1NP was not associated with any of the cholesterol, glyceride, phospholipid or 
apolipoprotein, ketone body, fluid balance or inflammation measures in any 
model (Figure 88). Weak evidence for a positive association with citrate was 
observed (βmodel 3=0.11 [4x10-3,0.21], p=0.04). A positive association with alanine 
of magnitude 0.14SD (0.02,0.26) (model 3) was observed, but this was not robust 
to correction for multiple testing (p=0.03). Full results are tabulated in Appendix 
33. 
 
Figure 88: Associations between P1NP and metabolic traits in the HBM cohort. 
  
Points represent the SD increase in metabolic trait concentration per SD increase in 





There was some evidence for negative associations of osteocalcin with total 
triglycerides and lactate in all models, but these associations were not robust to 
correction for multiple testing (Figure 89). There was slightly stronger evidence 
of a positive association with citrate (βmodel 3=0.14 [0.03,0.24], p=0.01), but this did 
not reach the corrected significance threshold in any model. After adjustment for 
all covariates, CIs for the association between osteocalcin and creatinine were 
narrower and no longer overlapped the null value (0.19 [3x10-3,0.37], p=0.047). 
Full results are tabulated in Appendix 34. 
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Figure 89: Associations between plasma osteocalcin and metabolic traits in the HBM 
cohort. 
Points represent the SD increase in metabolic trait concentration per SD increase in 




β-CTX was strongly inversely associated with triglycerides and positively 
associated with citrate in all models (βmodel 3=-0.13 [-0.21,-0.05], p=0.002 and 0.19 
[0.07,0.30], p=0.002, respectively) (Figure 90). There was weaker evidence for 
negative associations between β-CTX and phosphoglycerides, apolipoprotein-B 
and glucose, but these were of weak magnitude (magnitude ~-0.1SD, all p>0.003). 




Figure 90: Associations between plasma β-CTX and metabolic traits in the HBM cohort. 
 
Points represent the SD increase in metabolic trait concentration per SD increase in β-
CTX. Horizontal bars represent 95% CIs. 
 
Adjustment for additional potential covariates menopause, bisphosphonate use, 
and oral glucocorticoid use did not attenuate the association between β-CTX and 
citrate (0.19 [0.07,0.30], p=0.001) or triglycerides (-0.15 [-0.23,-0.06], p=4x10-4).  
Determining differences in associations between HBM individuals 
and those with normal BMD 
I next investigated differences in associations of β-CTX and citrate/triglycerides, 
between HBM individuals and the relatives without HBM, using stratified 
analyses and model 3. Mean citrate in the HBM cases was 0.132 (0.025)mmol/L 
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vs 0.127 (0.019)mmol/L in the relatives without HBM. Mean triglyceride 
concentrations were 0.672 (0.210)mmol/L and 0.670 (0.281)mmol/L, respectively. 
The sample size was small for each stratum (198 with HBM, 122 without), which 
led to wide CIs due to a lack of power. An interaction between HBM status and 
β-CTX was observed for citrate, but not for triglycerides (Figure 91, Figure 92). 
When combining all three BTMs in the same model, only β-CTX remained 
independently associated with citrate.  
 








I performed additional analyses of the triglyceride sub-types; results are 
presented in Table 30. β-CTX was inversely associated with all triglyceride sub-
variables (triglycerides in VLDL, LDL and HDL), particularly VLDL 
triglycerides. The association between osteocalcin and triglycerides appeared 
driven by VLDL. β-CTX was independently (of other BTMs) associated with 
total, VLDL and LDL triglycerides. After adjustment for other BTMs, there was 





Table 30: Associations between BTMs and triglyceride subclass variables in individuals with HBM. 
  Model 1 Model 2 Model 3 Model 4 






 VLDL  -0.15 (-0.23, -0.07) 2.06x10-4 -0.14 (-0.23, -0.06) 0.001 -0.15 (-0.23, -0.07) 4.09x10-4 -0.15 (-0.28, -0.01) 0.039 
LDL  -0.09 (-0.16, -0.03) 0.006 -0.08 (-0.16, -0.01) 0.027 -0.09 (-0.16, -0.02) 0.012 -0.13 (-0.25, -0.02) 0.023 









 VLDL  -0.13 (-0.23, -0.04) 0.007 -0.13 (-0.22, -0.04) 0.006 -0.13 (-0.22, -0.04) 0.006 -0.12 (-0.27, 0.03) 0.126 
LDL  -0.04 (-0.17, 0.09) 0.533 -0.04 (-0.17, 0.10) 0.587 -0.04 (-0.16, 0.08) 0.532 -0.04 (-0.20, 0.11) 0.570 





 VLDL  -0.05 (-0.16, 0.05) 0.314 -0.05 (-0.16, 0.06) 0.370 -0.06 (-0.16, 0.05) 0.279 0.13 (1.03x10-3, 0.25) 0.048 
LDL  0.04 (-0.08, 0.15) 0.550 0.04 (-0.08, 0.17) 0.502 0.04 (-0.08, 0.16) 0.532 0.14 (0.02, 0.26) 0.018 
HDL  -0.02 (-0.13, 0.08) 0.641 -0.02 (-0.13, 0.09) 0.764 -0.02 (-0.12, 0.08) 0.660 0.09 (0.01, 0.17) 0.035 
β represents the increase in triglycerides in SD per SD increase in BTMs.  
Model 1: unadjusted; model 2: adjusted for age and sex; model 3: model 2 plus height, weight, menopause, bisphosphonate, and oral 
glucocorticoid use; model 4: adjusted as per model 3 plus other BTMs. 
 
Sensitivity analyses 
Results of sensitivity analyses are provided in Appendix 33-Appendix 35. Removing 7SD outliers did not affect any of the 
associations between the BTMs and metabolic traits. Removing QC tagged samples did not affect any of the associations between 
β-CTX and the metabolic traits. There was some evidence for an inverse association between osteocalcin and apolipoprotein-B (-
0.08 [-0.13,-0.02], p=0.01) after tagged samples were removed. Evidence for an association between P1NP and alanine was 




8.3.6. Replication in the ALSPAC population 
Descriptives of the study population 
I aimed to assess whether bone resorption is similarly associated with citrate and 
triglycerides in peri-menopausal women with normal BMD (mean TH-BMD T-
score +0.24 [1.6]) and adolescents, from the ALSPAC cohorts, in whom citrate 
and β-CTX had been contemporaneously measured. Derivation of the ALSPAC 
sample sizes is presented in Figure 93. Of 3,664 mothers with mean age 47.9 
(4.4)years, 77% were pre-menopausal. Median β-CTX and mean citrate 
concentrations were 0.25 (0.18-0.35)µg/L and 0.09 (0.03)mmol/L, respectively. Of 
2,492 adolescents, with mean age 15.4 (0.3)years, 53% were female. Median β-
CTX and mean citrate concentrations were 0.94 (0.66-1.39)μg/L and 0.11 




Figure 93: Flowchart detailing the derivation of the ALSPAC maternal (left) and 




Table 31: Descriptives of the ALSPAC maternal and adolescent populations included in 
this analysis. 
 Maternal Adolescent 
 N=3,664 N=2,492 
 Mean (SD) 
Age (years) 47.9 (4.4) 15.4 (0.3) 
Height (cm) 164.1 (6.1) 169.6 (8.4) 
Weight (kg) 71.2 (14.2) 61.9 (11.5) 
BMI (kg/m2) 26.4 (5.1) 21.5 (3.4) 
TBFM (kg) 26.2 (9.7)  
TBLM (kg) 41.0 (4.7)  
TH-BMD (g/cm2) 1.03 (0.14)  
TH-BMC (g) 32.1 (5.1)  
TBLH-BMD  1.035 (0.088) 
Plasma citrate (mmol/L) 0.09 (0.03) 0.11 (0.02) 
 Median (IQR) 
β-CTX (μg/L) 0.25 (0.18, 0.35) 0.94 (0.66, 1.39) 
Total triglycerides (mmol/L) 0.92 (0.71, 1.23) 0.82 (0.69, 1.02) 
Triglycerides in VLDL (mmol/L) 0.51 (0.35, 0.77) 0.51 (0.40, 0.67) 
Triglycerides in LDL (mmol/L) 0.16 (0.13, 0.19) 0.12 (0.10, 0.14) 
Triglycerides in HDL (mmol/L) 0.13 (0.11, 0.15) 0.10 (0.09, 0.11) 
 N (%) 
Gender (Female) 3,664 (100.0) 1,308 (52.5) 
Postmenopausal 849 (23.2)  
Oestrogen replacement use 158 (4.3)  
Tanner Stagea   
      <Stage 5  1,261 (50.6) 
      Stage 5  1,231 (49.4) 
Bisphosphonate use 14 (0.4)  
Oral glucocorticoid use 12 (0.3)  
Fasted <8 hours 673 (18.4)  
Time of sample collection (AM)  1,404 (56.3) 
Alcohol consumption   
      Less than once weekly 1,052 (43.0) 1,607 (76.0) 
      At least once weekly 1,394 (57.0) 509 (24.0) 
aTanner stage below 5 represents an adolescent still going through puberty. 
 
Among ALSPAC mothers, a strong positive association was seen between β-CTX 
and citrate, robust to confounder adjustment (model 3, Table 32). This 
relationship was 60% lower than that seen in HBM individuals (fully adjusted 
βHBM=0.05 [0.02,0.08] vs βALSPAC=0.02 [0.01,0.03], β=mmol/L increase in citrate 
per 1μg/L increase in β-CTX). The association between β-CTX and triglycerides 
also replicated in ALSPAC mothers (Table 32). 
In adolescents, in analyses adjusted for age, sex, height, weight, Tanner stage and 
time of sample collection (model 3), a 1μg/L increase in β-CTX was associated 
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with a 0.022 (0.020,0.024) mmol/L increase in citrate (Table 32). The magnitude of 
the association between β-CTX and citrate in adolescents was less than 50% of 
that in HBM individuals. Inverse associations between β-CTX and total, LDL and 
HDL triglycerides were observed in the adolescent population (Table 32), but 
with a much smaller effect size than seen in the adult populations. After full 





Table 32: Associations between β-CTX and citrate and triglycerides in the ALSPAC maternal and adolescent populations. 
β represents the change in citrate or triglycerides in mmol/L per 1μg/L increase in β-CTX. 
Model 1: unadjusted; model 2: adjusted for age (and sex in the adolescent and HBM populations); model 3: adjusted for age, height, weight, 
menopause, less than 8 hours of fasting in the maternal population and age, sex, height, weight, Tanner stage and time of sample collection in 
the adolescent population. Model 3 adjusted for age, sex, height, weight, menopause, bisphosphonate, and oral glucocorticoid use for the HBM 
population. TGs=triglycerides. 
 
  Model 1 Model 2 Model 3 






















Citrate 0.055 0.026, 0.083 1.89x10-4 0.048 0.022, 0.075 2.95x10-4 0.050 0.024, 0.076 1.71x10-4 
Total TGs -0.288 -0.445, -0.131 3.32x10-4 -0.298 -0.465, -0.130 5.03x10-4 -0.276 -0.434, -0.118 6.03x10-4 
VLDL TGs -0.239 -0.375, -0.102 0.001 -0.247 -0.392, -0.101 0.001 -0.228 -0.365, -0.090 0.001 
LDL TGs -0.025 -0.041, -0.009 0.002 -0.026 -0.043, -0.009 0.002 -0.025 -0.041, -0.009 0.003 























Citrate 0.026 0.020, 0.032 1.28x10-16 0.022 0.016, 0.028 5.10x10-12 0.020 0.013, 0.026 1.95x10-9 
Total TGs -0.414 -0.530, -0.298 3.31x10-12 -0.502 -0.624, -0.380 1.17x10-15 -0.354 -0.471, -0.237 3.03x10-9 
VLDL TGs -0.356 -0.453, -0.259 8.33x10-13 -0.409 -0.512, -0.307 7.28x10-15 -0.274 -0.372, -0.176 4.00x10-8 
LDL TGs -0.017 -0.030, -0.005 0.008 -0.035 -0.049, -0.022 1.95x10-7 -0.030 -0.043, -0.016 1.60x10-5 

























Citrate 0.018 0.016, 0.019 4.39x10-106 0.023 0.021, 0.025 1.06x10-93 0.022 0.020, 0.024 2.10x10-74 
Total TGs -0.024 -0.047, -0.002 0.034 -0.010 -0.043, 0.022 0.535 0.041 0.007, 0.076 0.019 
VLDL TGs -0.001 -0.020, 0.018 0.919 -0.021 -0.050, 0.007 0.141 0.028 -0.002, 0.058 0.068 
LDL TGs -0.012 -0.015, -0.009 3.61x10-13 0.007 0.003, 0.011 3.16x10-4 0.007 0.003, 0.012 0.001 





8.4.1.  BMD, bone turnover and metabolic traits 
Summary of findings 
In this chapter, I have provided evidence for a positive association between β-
CTX and plasma citrate, and consistent but weaker associations between 
osteocalcin/P1NP and citrate. Furthermore, β-CTX and osteocalcin both 
demonstrated inverse associations with plasma triglycerides in individuals with 
unexplained HBM, despite adjustment for a range of confounders. Associations 
between the bone resorption marker, β-CTX, and citrate and total plasma 
triglycerides were independent of the two bone formation markers, osteocalcin 
and P1NP. This positive association between β-CTX and citrate was further 
observed in peri-menopausal women and adolescents from ALSPAC (Table 33). I 
also found evidence for associations between HBM/L1-BMD and reduced serum 
alanine, but the opposite direction of effect was observed in the general 
population (Table 33). 
 
Table 33: Summary of key findings of this chapter. 












Β-CTX RS ALSPAC 
Acetoacetate  -      0  
Alanine -       1a  
Citrate       +  1 
Creatinine   -     1  
Glucose  +    -  0  
Glycoprotein acetyls  +      0  
Lactate    - -   0  
Triglycerides       -  1b 
Tyrosine      -  1  






Citrate is synthesized in mitochondria from acetyl-CoA and oxaloacetate during 
the Krebs cycle, where most remains, regulating energy production (459,460). 
Hence, soft tissue cellular metabolism is not considered a major source of plasma 
citrate (460). Approximately 80% of citrate is stored in bone and 2% of bone 
content is citrate (461). Citrate, found between hydrated layers of bone mineral 
and which binds to the surface of apatite crystals, is thought to prevent formation 
of larger crystals, thereby maintaining bone structural properties (462,463). 
Human osteoblasts can produce citrate; it is hypothesized that citrate is 
incorporated into bone directly from osteoblast secretion, and that, as bone is 
resorbed and both bone collagen and mineral are degraded, citrate is released 
into the circulation generating the major source of plasma citrate (464). This 
concurs with the positive relationships I observed between citrate and both age 
and bone resorption, and an inverse association recently identified between β-
CTX and citrate in a smaller sample from the ALSPAC adolescent population 
(434). Due to its suggested association with bone mineral, plasma citrate may 
provide information on turnover of bone mineral during bone resorption. 
Stronger citrate-β-CTX associations in the context of HBM compared with 
individuals with normal BMD may simply reflect the greater quantity of bone in 
the HBM skeleton and therefore a greater source of citrate. It has been previously 
shown that HBM individuals have increased cortical volumetric BMD measured 
by pQCT, possibly due to reduced bone turnover allowing more time for 
secondary mineralization (200). Alternatively, the mineral platelets may be 
structured differently in HBM, contributing to increased bone strength (200), 
which may result in citrate being released more readily during bone resorption.  
Triglycerides  
The inverse association between β-CTX and triglycerides in the adult HBM and 
peri-menopausal populations is consistent with previous findings from the 
European Male Ageing Study; mean β-CTX concentrations were lower in male 
individuals with serum triglyceride concentrations above 150mg/dL, 
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independent of other components of the metabolic syndrome such as 
hyperglycaemia (465). As I observed, increased osteocalcin has been associated 
with reduced triglycerides in adults (465,466). The metabolic impact of 
osteocalcin has further been demonstrated in animal studies, where osteocalcin-
deficient mice display a distinct metabolic phenotype with greater accumulation 
of fat mass and higher serum triglyceride levels (202). In my analyses, the inverse 
association between osteocalcin and triglycerides was not independent of β-CTX. 
It is important to note that I determined associations between total osteocalcin 
and serum triglycerides, rather than the uncarboxylated form proposed to be 
metabolically active (202). Yet, the finding that β-CTX, rather than osteocalcin, 
was independently associated with triglycerides raises the possibility that β-CTX 
influences triglycerides via a separate pathway from osteocalcin. As this analysis 
is cross-sectional, I am unable to determine if higher β-CTX causes decreased 
triglyceride levels or vice versa, yet a recent analysis did not find evidence of a 
causal pathway between triglycerides and BMD after accounting for pleiotropy, 
consistent with the lack of any causal effect of triglycerides on bone turnover 
(467). 
In adolescents, I observed the opposite direction of effect between β-CTX and 
triglycerides: β-CTX was positively related to triglycerides after adjustment for 
weight. This is unlikely to be explained by collider bias as weight is unlikely to 
be a common outcome in this analysis. One possible explanation is that during 
adolescence, increased bone resorption likely reflects bone modelling during 
growth rather than bone remodelling, as indicated by the positive association 
between β-CTX and periosteal circumference previously reported in this 
adolescent population (468). Pubertal growth may increase both bone modelling 
and fat storage concurrently, with higher associated plasma triglyceride levels. 
Whilst in mature adults, bone remodelling predominates and hence the direction 




Alanine is a non-essential amino acid, widely used for protein synthesis, and 
forms a source of energy in muscles (469). Alanine is released into the circulation 
by the breakdown of muscle tissue (for example during prolonged periods of 
fasting) and is taken up by the liver to be used as a substrate in gluconeogenesis 
(470). An analysis of dietary protein intake in female participants from TwinsUK 
observed a positive relationship between alanine intake and forearm and LS-
BMD, but not FN-BMD (471). In vitro studies suggest that alanine is able to 
stimulate insulin secretion, promoting osteoblast differentiation, hence leading to 
increased bone formation (471). This is consistent with the positive relationship 
between L1-BMD and alanine observed in the RS1 population and the weak but 
positive association between P1NP and alanine in the HBM population, but 
inconsistent with the inverse association between HBM and alanine. The 
discrepancy in observed relationships could reflect systematic, unmeasured 
differences in fasting time prior to sample collection (i.e. HBM cases may have 
been more likely to eat closer to the time of sample collection), increased alanine 
metabolism by the liver in individuals with HBM or reduced muscle breakdown 
in HBM individuals (HBM females have been previously shown to have a greater 
LM than their non-HBM relatives (201)). The magnitude of the association 
between HBM and alanine was weakened by removing samples with QC tags, 
including low glucose, which reflects glucose metabolism to pyruvate due to 
incorrect sample storage. This occurs via a pathway involving alanine. However, 
associations were still present after removing these samples and therefore this is 
unlikely to explain the inverse relationship with HBM.  
8.4.2. Metabolic traits and OA sub-phenotypes 
I did not find evidence for associations between any of the BMD or BTM-
associated metabolic traits and OA sub-phenotypes. However, I did observe 
weak evidence for associations between three metabolic traits (creatinine, 
tyrosine and apolipoprotein-A1) and OA sub-phenotypes, with a consistent 
direction of effect in both the HBM and RS1 populations (Table 33). None of 
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these metabolic traits were BCAAs or histidine, the ratio of which has previously 
been related to OA risk (447,448). None of the associations met the Bonferroni-
corrected p-value threshold in either population; I therefore cannot rule out the 
possibility that these are chance findings.  
8.4.3. Strengths of this research 
As far as I am aware, this is the first study to determine the metabolic profiles of 
bone turnover and OA sub-phenotypes. Additional strengths include the unique 
HBM population, allowing me to determine differences in metabolic traits 
between those with and without HBM, plus the ability to evaluate 
generalizability of findings in large population-based cohorts. All cohorts had 
detailed phenotypic data which allowed adjustment for a range of potential 
confounders. The metabolomics platform used is highly reproducible (395), 
allowing comparison between populations.  
8.4.4. Limitations of this research 
The major limitation of this work is the possible degradation of the HBM 
samples, leading to reduced reliability of metabolic trait measurements. HBM 
study samples had been stored at -80ᵒC for up to ten years before metabolomics 
analysis; however, previous studies suggest that long-term storage is unlikely to 
significantly affect citrate measurements (472). The effect of different storage 
conditions and freeze-thaw cycles on metabolic trait concentrations may affect 
lipids, alanine and glucose (473); reassuringly the association between β-CTX and 
plasma triglycerides replicated with a similar effect size in the ALSPAC maternal 
cohort, but this could explain the inconsistency in direction of effect for alanine 
between the HBM and RS populations. As HBM index cases were recruited 
before their relatives, the samples were stored for longer, allowing more time for 
sample degradation. However, this is unlikely to explain the inverse relationship 
between HBM and alanine as multiple freeze-thaw cycles are likely to increase, 
rather than decrease, alanine concentration (473). Concentrations of most 
metabolic traits assessed for replication in RS1 were similar between the HBM 
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and RS1 populations, although concentrations for most metabolic traits were 
slightly lower in the HBM population. Mean concentration of total cholesterol 
was almost eight times lower in the HBM population compared to the RS1 
population and therefore no conclusions can be made on the relationship 
between total cholesterol and BMD, BTMs or OA sub-phenotypes in the HBM 
population.  
Although I hypothesized that metabolic traits would be on the causal pathway 
between BMD/bone turnover and OA, this cross-sectional study is unable to 
examine directions of causality. BTM measurements provide a measurement of 
current bone turnover at the time of assessment only. BTMs are affected by 
fasting time, with β-CTX levels increasing with fasting (474). A weaker 
association was observed between β-CTX and citrate in those ALSPAC mothers 
with shorter fasts. The samples collected from the HBM population were not 
collected when fasting.  
8.4.5. Future work 
The aim of this chapter was to identify metabolic traits which mediate the 
relationship between BMD and OA. I did not identify any metabolic traits 
associated with both BMD and OA, so did not perform mediation analyses. One 
could conclude that metabolic pathways do not mediate the relationship between 
BMD and OA. Although a metabolic effect of bone turnover has been observed in 
animal studies (202), MR studies in children do not provide evidence for a causal 
effect of BMD on BMI (401), suggesting that bone turnover may not have a 
metabolic effect in humans. In Chapter 9, I will perform MR to determine the 
causal effect of BMD on BMI in adults. Lack of evidence for associations of 
metabolic traits with BMD and OA could alternatively be due to the issues with 
the sample degradation in the HBM population. Additionally, it may be that 
metabolic traits may not mediate the relationship between BMD and OA in a 
population with extreme elevations in BMD, but there may be metabolic 
pathways mediating this relationship in the general population. Replication of 
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the full analysis (rather than just metabolic traits of interest) is required to 
confirm that there are no metabolic traits associated with both BMD and OA.  
To determine if circulating citrate levels truly represent bone turnover, analyses 
are required to determine change in circulating citrate levels in response to 
osteoporosis treatments, for example by determining changes in circulating 
citrate levels during bisphosphonate treatment. This chapter provides limited 
data as to how β-CTX relates to citrate and triglycerides in adult men, or adults 
with low bone mass, so further analyses are required in these populations. 
Further analyses are required to determine the direction of association between 
alanine and LS-BMD in other population-based cohorts and cohorts with low 
BMD. MR could be performed to determine causality for metabolic traits 
associated with BMD, BTMs or OA, for example to determine if dietary alanine 
intake has a causal effect on BMD.  
8.4.6. Conclusions 
As none of the identified metabolic traits were associated with both bone and OA 
phenotypes, I was unable to perform the mediation analyses originally planned. 
However, in this chapter, I have provided strong evidence for a relationship 
between bone turnover and circulating citrate, which was stronger in the HBM 
population compared to the general population, providing novel hypotheses 
about differences in the structure of bone mineral between individuals with and 
without HBM. Given that citrate binds to apatite nanocrystals (462), one could 
hypothesize that circulating citrate may reflect breakdown of bone mineral. 
Further studies are justified to explore whether plasma citrate concentration is 
altered by factors known to modulate bone resorption, such as bisphosphonates, 
to determine the direction of causality and whether measuring circulating citrate 




CHAPTER 9.  USING GENETICS 
TO DETERMINE THE 
CAUSAL ROLE OF BONE IN 
OSTEOARTHRITIS   
 
 291 
9.1. Background and aims 
As discussed in Chapter 3,Chapter 6 and Chapter 7, several large population-
based studies have identified positive relationships between BMD and OA of the 
hip (208-211,412) and knee (209,212-215,217,396-398). Furthermore, the fact that 
HBM individuals have an increased odds of radiographic OA at these joints 
(226,227), is highly suggestive of a causal effect of BMD on OA, due to the 
temporal relationship between HBM development and OA onset. As discussed 
in section 1.2.5, BMI is a risk factor for OA. Although BMI explained 
approximately 50% of the association between HBM and knee OA, the 
association persisted (227), suggesting that BMD influences OA via BMI-
independent pathways.  
A positive relationship between BMD and BMI is well-established. The skeleton 
adapts to the increased load placed upon it by a higher BMI, reducing fracture 
risk. Therefore, a causal pathway between BMI and BMD is widely accepted. 
However, a causal pathway between BMD and BMI is plausible, via the 
metabolic effects of bone turnover (Chapter 2, Chapter 8). However, analyses of a 
population of children suggested that there is no causal pathway between FN- or 
LS-BMD and BMI (401), although this finding is yet to be replicated in an adult 
population. 
Recent MR analyses have determined a causal role of both BMI and BMD on risk 
of hip and knee OA (139,261,441). MR estimates for the relationship between 
BMD and OA may be biased by relationships of the instrument to a confounder 
of the BMD-OA relationship, i.e. BMI, as BMD SNPs may be related to BMI due 
to the strong correlation between these two phenotypes. Funck-Brentano et al 
tried to eliminate this bias by removing any SNPs nominally associated with BMI 
from their analyses (261). On the other hand, Hackinger et al identified a genetic 
correlation between LS-BMD and OA (137), which suggests shared biological 
pathways contribute to both BMD and OA development. If this is the case, one 
would expect to see bidirectional causal relationships between BMD and OA. 
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However, another potential explanation for the genetic correlation could be the 
presence of spinal osteophytes artefactually elevating LS-BMD.  
I hypothesize that there will be bidirectional relationships between BMD and 
BMI, BMD and OA and BMI and OA (Figure 94) and therefore aim to test these 
relationships using MR. I will perform both 1S and 2SMR, to determine reliability 
of estimates, using the largest possible data sources to increase power. I then aim 
to use formal MVMR methods, to determine the direct (i.e. unconfounded) causal 
pathways between these variables, and latent causal variable (LCV) analysis to 
determine if BMD has a causal effect on OA, independent of shared genetic 
aetiology.   
 
Figure 94: Hypothesized relationships between BMD, BMI, and OA.  
 
Thicker arrows represent stronger hypothesized relationships. 
 
In addition to determining the BMI-independent causal role of BMD on hip and 
knee OA, I will examine the causal role of BMD in the individual radiographic 
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OA sub-phenotypes, and whether BMD is specifically causally related to the 
bony sub-phenotypes (i.e. osteophytes and subchondral sclerosis) rather than 
JSN. Therefore, my final aim of this chapter is to determine the relationship 
between PRS for eBMD and radiographic hip and knee OA sub-phenotypes, 
using individual-level data from the RS population. I am unable to perform 
formal 1SMR in RS as I do not have access to BMD data for the full sample. 
However, PRS analysis allows the determination of a causal effect, without 





9.2.1. Bidirectional and multivariable MR analyses 
Data sources 
GEFOS 
The Genetic Factors for Osteoporosis (GEFOS) consortium was a collaboration of 
17 discovery cohorts (n=32,961) from North America, Europe, East Asia, and 
Australia and 34 replication populations (n=50,933) to identify genetic variants 
associated with FN-BMD and LS-BMD (204). Full methodology has been 
published elsewhere (204). This analysis represents the largest GWAS to-date of 
FN-BMD and therefore FN-BMD genome-wide significant loci from this analysis 
were selected to instrument eBMD in UK Biobank in 1SMR (as an instrument for 
eBMD not generated in UK Biobank does not exist). More recently, the GEFOS 
consortium has performed a GWAS of eBMD in 426,824 individuals from UK 
Biobank (386). Summary statistics from this GWAS were used for 2SMR. 
GIANT 
BMI summary statistics for 2SMR were taken from the GWAS meta-analysis 
performed by the Genetic Investigation of Anthropometric Traits (GIANT) 
consortium. This meta-analysis was performed in two stages: stage one including 
80 BMI GWAS (n=234,069) and stage two including an additional 34 GWAS 
(n=88,137) (475). This represents the largest BMI GWAS which does not include 
the UK Biobank population and I could therefore use the summary statistics for 
2SMR with UK Biobank-derived outcome statistics. 77 SNPs were associated 
with BMI at genome-wide significance in the mixed-sex European populations, 





The Genetics of Osteoarthritis (GO) consortium is a collaboration of cohorts 
aiming to identify novel genetic variants for OA. The most recent published GO 
GWAS meta-analysed UK Biobank and arcOGEN (77,052 cases, 378,169 controls) 
(141). ArcOGEN is a population of UK-based Europeans with clinically 
diagnosed knee and/or hip OA (131). More recently, the GO consortium has 
expanded to include additional cohorts and the total sample size is now >800,000 
from 13 international cohorts, with full details of cohort specific GWAS 
published elsewhere (476). This has allowed the largest GWAS meta-analysis for 
OA, excluding UK Biobank individuals, to be performed, generating summary 
statistics to be used for 2SMR when the SNP-exposure summary statistics have 
been generated in the UKBB population. (i.e. eBMD).  
 





Table 34: Summary of all MR analyses performed. 
 
Exposure  Outcome 
 Source  Source 
1S eBMD 
Individual-level eBMD in UKBB  
I:FN-BMD SNPs from GEFOS (204) 
Knee 
OA 
Individual-level HD knee OA status in UKBB 
2S eBMD 




Summary statistics from GO consortium GWAS based on 
radiographic, clinical evaluation, joint replacement, self-reported or 
HD knee OA, excluding UKBB  
N=44,001 ca, 301,541 co (476) 
1S eBMD 
Individual-level eBMD in UKBB 
I:FN-BMD SNPs from GEFOS  
Hip 
OA 
Individual-level HD hip OA status in UKBB 
2S eBMD 




Summary statistics from GO consortium GWAS based on 
radiographic, clinical evaluation, joint replacement, self-reported or 
HD hip OA, excluding UKBB  
N=25,237 ca, 272,284 co 
1S eBMD 
Individual-level eBMD in UKBB 
I:FN-BMD SNPs from GEFOS  
BMI Individual-level BMI data in UKBB 
2S eBMD 
Summary statistics from GEFOS UKBB eBMD GWAS  
N=426,824  
BMI 
Summary statistics from GIANT European BMI GWAS 
N=339,224 (475) 
1S BMI  
Individual-level BMI data in UKBB 
I: BMI SNPs from GIANT  
Knee 
OA 








Summary statistics from UKBB and arcOGEN GWAS HD knee OA 
N=24,955 ca, 378,169 co (141) 
1S BMI  
Individual-level BMI data in UKBB 
I: BMI SNPs from GIANT  
Hip 
OA 
Individual-level HD hip OA status in UKBB 
2S BMI 




Summary statistics from UKBB and arcOGEN GWAS of HD hip 
OA 
N=15,704 ca, 378,169 co  
1S BMI  
Individual-level BMI data in UKBB 
I: BMI SNPs from GIANT  




Summary statistics from GIANT European BMI GWAS 
N=339,224  
eBMD  





Individual-level data on HD knee OA in UKBB 
I: knee OA SNPs from the GO consortium meta-analysis (excluding 
UKBB)  
 




Summary statistics from GO consortium GWAS of knee OA, 
excluding UKBB  
N=44,001 ca, 301,541 co  
eBMD  





Individual-level data on HD knee OA in UKBB 
I: knee OA SNPs from the GO consortium meta-analysis (excluding 
UKBB) 




Summary statistics from UKBB and arcOGEN GWAS of HD knee 
OA 
N=24,955 ca, 378,169 co 
BMI  





Individual-level data on HD hip OA in UKBB 
I: hip OA SNPs from the GO consortium meta-analysis (excluding 
UKBB) 




Summary statistics from GO consortium GWAS of hip OA, 
excluding UKBB 
N=25,237 ca, 272,284 co 
eBMD  





Individual-level data on HD hip OA in UKBB 
I: hip OA SNPs from the GO consortium meta-analysis (excluding 
UKBB) 




Summary statistics from UKBB and arcOGEN GWAS of HD hip 
OA 
N=15,704 ca, 378,169 co  
BMI 
Summary statistics from GIANT European BMI GWAS 
N=339,224  






1SMR, as described in section 5.3.3, was performed in the UK Biobank 
population, which is described in detail in section 5.2.1. Analyses were restricted 
to individuals of white British ethnicity. 
eBMD assessment 
BMD was estimated by ultrasound measurement of the calcaneus using a Sahara 
Clinical Bone Sonometer, from a combination of speed of sound (SOS) and 
broadband ultrasound attenuation (BUA) (477). As described by Morris et al, men 
with an eBMD measurement <0.18 or >1.06g/cm2 were excluded, whilst women 
with a value <0.12 or >1.025g/cm2 were excluded (386). 
Hospital-diagnosed OA ascertainment 
Hospital-diagnosed hip and knee OA were determined from hospital episode 
statistics (HES) data (478), using International Statistical Classification of 
Diseases and Related Health Problems (ICD) 9/10 codes previously reported 
(Table 35) (141). Those with arthropathies at other joints and inflammatory 
polyarthropathies were excluded from the control population. A complete list of 
exclusion codes for controls is presented in Appendix 36.   
Physical activity assessment 
Total weekly metabolic equivalent task (MET) minutes were calculated based on 
IPAQ responses (section 4.2), completed via touchscreen questionnaire at the 





Table 35: ICD codes used to identify cases of hospital-diagnosed hip and knee OA in UK 
Biobank. 
Joint  Code Description 
 ICD10 ICD9  
Hip M16  “Coxarthrosis” 
 M160  “Primary coxarthrosis, bilateral” 
 M161  “Other primary coxarthrosis” 
 M169  “Coxarthrosis, unspecified” 
 M1905  “Primary arthrosis of other joints (pelvic region and thigh)” 
 M1995  “Arthrosis, unspecified (pelvis region and thigh)” 
  71535 
“Osteoarthrosis, localized, primary or secondary, pelvic region and 
thigh” 
  71515 “Osteoarthrosis, localized, primary, pelvic region and thigh” 
Knee M17  “Gonarthrosis” 
 M170  “Primary gonarthrosis, bilateral” 
 M171  “Other primary gonarthrosis” 
 M179  “Gonarthrosis, unspecified” 
 M1906  “Primary arthrosis of other joints (lower leg)” 
 M1996  “Arthrosis, unspecified (lower leg)” 
  71536 “Osteoarthrosis, localized, primary or secondary, lower leg” 
  71516 “Osteoarthrosis, localized, primary, lower leg” 
 
Statistical analysis 
1SMR was performed using the instrumental-variable regression (‘ivreg’) 
function of the AER package (372). Exposures were instrumented by an 
unweighted PRS, generated as the sum of the dosage for exposure-increasing 
alleles (data sources provided in Table 34). Analyses were adjusted for sex, 
genotyping chip and 10 PCs. Continuous exposures (eBMD/BMI) were 
standardized prior to analysis. Effect estimates for binary outcomes (hip/knee 
OA) represent risk differences. I therefore performed additional two stage 
regression, first regressing the instruments on the exposure, generating predicted 
values of the exposure, then regressing the predicted values of the exposure on 
the binary outcomes using a logistic regression model. This gave an estimate of 
the OR per SD increase in the exposure, allowing comparison with 2SMR 





2SMR was performed as described in section 5.3.3. SNP-exposure and SNP-
outcome summary statistics are presented in Appendix 37-Appendix 42. Steiger 
filtering was performed to exclude SNPs which explained a greater proportion of 
the variance in the outcome than the exposure variable (480). SNP-specific r2 
were estimated from the sample size and p-value using the ‘get_r_from_pn’ 
function for linear variables, and using the log OR, effect allele frequency and 
case prevalence and the ‘get_r_from_lor’ function for binary traits. Seven eBMD 
SNPs were excluded due to a larger r2 for hip OA, four eBMD SNPs for knee OA 
and two for BMI. Two BMI SNPs explained a greater proportion of variance in 
hip OA risk, one for knee OA risk and 15 explained a greater proportion of the 
variance in eBMD. One knee OA SNP was excluded due to a greater r2 for eBMD. 
All Steiger filtered SNPs are listed in Appendix 37-Appendix 42.  
Sensitivity analyses 
A summary of how the MR assumptions, outlined in section 5.3.3, were tested is 
provided in Figure 95.  
 





As I hypothesized that BMI is a confounder of the BMD-OA relationship (i.e. a 
common causes of both phenotypes), I determined the independent effect of 
BMD on OA outcomes by performing 1SMVMR, including PRS for both BMI and 
BMD as instruments, as described in section 5.3.3. Analyses were adjusted for 
sex, genotyping chip and 10 PCs.  
Latent Causal Variable model 
The LCV model, developed by O’Connor and Price, estimates the causal effect of 
one trait on another trait when the two traits are genetically correlated (481). The 
genetic correlation between the two traits is modelled as a latent variable, and 
the genetic correlation between the latent variable and each trait is assessed (481). 
A perfect genetic correlation between the latent variable and one of the traits 
suggests a fully genetically causal effect of that trait on the other trait (481). If the 
trait has a partial causal effect on the (outcome) trait of interest (i.e. the genetic 
correlation between the latent variable and the (exposure) trait is less than 1), 
partial causality can be estimated using the genetic causality proportion (GCP), 
with a value of 0 representing no causal effect and a value closer to 1 
representing a stronger causal effect (481). Although this method is unable to 
determine bidirectional relationships between traits, as I hypothesized that any 
observed causal effect of OA on BMD is likely to reflect shared genetic aetiology, 
rather than a true causal effect of OA on BMD, I deemed this method 
appropriate. 
Three datasets were required to run this model: genome-wide summary statistics 
for SNP-BMD associations, genome-wide summary statistics for SNP-OA 
associations and LD scores. The LD scores were generated from the 1,000 
Genomes European population and were download from 
https://data.broadinstitute.org/alkesgroup/LDSCORE/ (eur_w_ld_chr.tar.bz). 
To maximise sample size for the OA summary statistics, whilst limiting to a fully 
European population, I aimed to use OA GWAS summary statistics generated 
from UK Biobank. I could not use the eBMD summary statistics for the SNP-
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exposure relationships due to the large sample overlap, and thus used the 
GEFOS European FN/LS-BMD GWAS summary statistics (which are adjusted 
for weight) (482). I therefore performed GWAS of both hospital-diagnosed hip 
and knee OA, adjusting for weight, within UK Biobank. GWAS was performed 
as described in section 5.3.2 and the published protocol (358). 410,052 individuals 
were included in the GWAS of knee OA and 400,516 in the GWAS of hip OA. 
QQplots are provided in Figure 96.  
I removed the MHC region (Chr6, 28.5-33.5Mb) from both sets of summary 
statistics, as well as SNPs with a MAF<0.05, as recommended by the authors 
(481). Analyses were restricted to SNPs present in both datasets. Alleles were 
harmonized so that the beta corresponded to the same effect allele. Betas were 
then transformed by dividing by their SE. Analyses were performed using the 
‘RunLCV.R’ script provided by the authors 
(https://github.com/lukejoconnor/LCV). 
 
Figure 96: QQplots of p-values from weight-adjusted GWAS of hospital-diagnosed hip 






9.2.2. BMD PRS 
Selection of genetic variants 
Genetic variants were selected from the largest GWAS of BMD to date, the 
Morris eBMD GWAS (386). Non-autosomal SNPs were excluded.  
Study population 
These analyses were performed in the RS population, outlined in section 5.2.2. 
Generation of PRS 
Dosages for eBMD SNPs were extracted from VCF files of HRC version1.1-
imputed genotype data using the vcftools software (483), with the ‘—recode –
recode-INFO-all’ option. This was performed separately for each chromosome and 
for each cohort. The ‘vcf-concat’ command was then used to combine all SNPs 
across the 22 chromosomes into one file. ‘vcf-query’ was used to extract the 
dosage from the ‘info’ column.  
Dosage data for the extracted SNPs were then imported into R. As vcftools 
extracts dosage based on the alternative allele, the dosage was converted to the 
dosage for the reference allele by subtracting the dosage from two, unless the 
reference allele was the BMD-decreasing allele, in which case the dosage of the 
alternative allele was used. The dosage was then multiplied by the beta for the 
BMD-increasing allele from the GWAS (386). Scores were generated using the 
‘rowSums()’ command on the weighted BMD-increasing allele dosage. PRS were 
generated using independent SNPs identified by clumping, using the 
TwoSampleMR ‘clump_data’ function. This was 362 SNPs, of which eight had a 
MAF<0.001, an imputation info score<0.8 or an HWE p-value<1x10-6 and were 
excluded. 
Outcome measures 




Table 36: Summary of OA outcomes analysed in the Rotterdam study population. 
Prevalent  
Hip osteophyte score 
Sum of inferior and superior femoral and acetabular 
osteophyte grades across the left and right hips 
Hip JSN score Sum of left and right semi-quantitative hip JSN grades 
Hip subchondral 
sclerosis 
Subchondral sclerosis observed at either hip (binary) 
Knee osteophyte score 
Sum of osteophyte grades across the medial and lateral, 
tibial and femoral regions, across both knees 
Knee JSN score Sum of medial and lateral grades across both knees 
Knee subchondral 
sclerosis 
Subchondral sclerosis observed at either knee (binary) 
Progressive 
Change in summed 
knee osteophyte score Follow-up scores were calculated as above for prevalent 
scores and the baseline score subtracted from the score 
at follow-up (RS1-3 for knees) Change in summed 
knee JSN score 
 
Covariates 
PRS analyses in the RS population were adjusted for age at baseline, sex and 10 
PCs. For analyses of progressive OA sub-phenotypes, follow-up time was 
included as a covariate. 
Statistical analysis 
In each RS cohort, PRS were normally distributed (Figure 97). Summed 
osteophyte and JSN scores were analysed as continuous outcomes, despite being 
skewed (Figure 98, Figure 99), using linear regression models. Analyses were 
performed separately in each cohort. Results for the three cohorts were then 










Figure 98: Histograms of prevalent OA variables in the three Rotterdam study cohorts. 
 
 






9.3.1. MR analyses to determine causal pathways between 
BMD, BMI, and OA 
MR analyses of bidirectional causal pathways between BMD and 
OA 
In 1SMR, eBMD was causally related to both hip and knee OA, with an SD 
increase in eBMD related to a 0.8% (0.1,1.4) increased probability of having hip 
OA and 1.7% (0.9,2.5) increased probability of having knee OA (Table 37). This 
was equal to approximately 28% increased odds for hip OA and 40% increased 
odds for knee. The F-statistic confirmed sufficient instrument strength (F>3000). 
However, the BMD risk score was related to BMI, violating the second 




Table 37: Results of 1S univariable and MVMR in UK Biobank. 
sdestimate represents the SD increase in outcome per unit increase in exposure. Estimates for binary exposures represent the SD increase in 
outcome per doubling in risk of exposure. rdEstimates for binary outcomes represent the risk difference per SD increase in exposure. ORs are per 
SD increase in exposure. 
  
     Two-stage least-squares regression Two-stage linear-logistic regression 






eBMD Hip OA 3,390 190,408 0.008 (0.001, 0.014)rd 0.016 1.28 (1.05, 1.57) 0.016 
eBMD Knee OA 3,483 194,638 0.017 (0.009, 0.025)rd 3x10-5 1.40 (1.20, 1.63) 3x10-5 
BMI Hip OA 4,201 333,828 0.015 (0.010, 0.021)rd 6x10-8 1.60 (1.35, 1.91) 7x10-8 
BMI Knee OA 4,446 341,686 0.036 (0.029, 0.043)rd <2x10-16 2.01 (1.76, 2.29) <2x10-16 
BMI eBMD 2,952 218,700 0.073 (0.037, 0.109)sd 6x10-5   
Hip OA eBMD 107 190,408 1.10 (0.36, 1.84)sd 0.003   
Hip OA BMI 197 333,828 0.54 (0.01, 1.07)sd 0.048   
Knee OA eBMD 49 194,638 4.16 (2.74, 5.57)sd 8x10-9   






eBMD Hip OA 275 190,175 0.007 (0.001, 0.013)rd 0.027 1.26 (1.03, 1.54) 0.027 
BMI Hip OA 211 190,175 0.013 (0.006, 0.020)rd 6x10-4 1.49 (1.19, 1.87)  5x10-4 
eBMD Knee OA 275 194,404 0.015 (0.008, 0.023)rd 1x10-4 1.36 (1.16, 1.59) 1x10-4 
BMI Knee OA 211 194,404 0.034 (0.025, 0.043)rd 3x10-13 1.93 (1.62, 2.30) 3x10-13 
Hip OA eBMD 7.5 190,175 1.12 (0.35, 1.89)sd 0.004   
BMI eBMD 43 190,175 0.084 (0.040, 0.128)sd 2x10-4   
Knee OA eBMD 1.2 194,404 5.76 (2.62, 8.89)sd 3x10-4   
BMI eBMD 1.4 194,404 -0.195 (-0.392, 0.001)sd 0.052   
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Table 38: Associations between the four 1SMR PRS instruments and potential confounders in UK Biobank. 
 
Score 
BMD BMI Hip OA Knee OA 
Age, years -3x10-3 (-0.01, 3x10-3) -5x10-3 (-0.01, 4x10-4) 0.01 (-0.01, 0.02) 5x10-4 (-0.02, 0.02) 
Height, cm 0.03 (0.02, 0.04) 0.01 (-7x10-5, 0.01) -0.01 (-0.03, 1x10-3) -0.15 (-0.17, -0.13) 
Weight, kg 0.04 (0.03, 0.06) 0.32 (0.31, 0.33) -2x10-3 (-0.03, 0.02) 0.33 (0.29, 0.37) 
BMI, kg/m2 0.01 (2x10-3, 0.01) 0.11 (0.11, 0.11) 4x10-3 (-4x10-3, 0.01) 0.16 (0.15, 0.18) 
eBMD, g/cm2 0.004 (0.004, 0.004) 2x10-4 (1x10-4, 3x10-4) 5x10-4 (2x10-4, 0.001) 2x10-3 (2x10-3, 3x10-3) 
Hip OA 1.01 (1.00, 1.01) 1.01 (1.01, 1.02) 1.07 (1.06, 1.08) 1.02 (1.00, 1.04) 
Knee OA 1.01 (1.00, 1.01) 1.02 (1.01, 1.02) 1.05 (1.02, 1.08) 1.06 (1.05, 1.07) 
Physical Activity, total weekly MET-minutes -2.82 (-7.56, 1.93) 2.77 (--1.30, 6.84) -0.39 (-11, 10) -0.48 (-16, 15) 
HRT use, ever 1.00 (1.00, 1.00) 1.00 (1.00, 1.00) 1.00 (1.00, 1.01) 1.00 (0.99, 1.01) 
Estimates for continuous covariates represent the per-allele unit increase (e.g. a value of 0.03 for height represents a per-allele increase in height 
of 0.03cm). Estimates for binary variables represent the per-allele OR. Estimates in italics represent the association between the PRS and the 
variable that the PRS instruments. 
 
In 2SMR, IVW provided evidence for a causal effect of eBMD on hip OA (OR per SD increase=1.09 [1.03,1.16]), which was relatively 
consistent (in magnitude) across the three MR methods (Figure 100). Leave-one-out analysis did not suggest that any individual 
SNP was driving this relationship (Appendix 43). Excluding two SNPs more strongly related to BMI than eBMD did not alter 
results (Table 39). Evidence for a causal effect on knee OA was weaker (ORIVW=1.04 [1.00,1.09]), but did not appear to be driven by 
a particular SNP (Appendix 43). When restricting to 10 SNPs also associated with FN-BMD with genome-wide significance 
(p<5x10-8) in GEFOS, the magnitude of effect was stronger for hip OA (ORIVW=1.40 [1.12,1.74]), but this effect estimate was less 
consistent with the MR-Egger and weighted median estimates (Table 39, Figure 101). Evidence for a causal effect on knee OA, 
however, was more consistent (in magnitude) across the three methods (ORIVW=1.21 [1.01,1.44], Figure 102).  
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Table 39: Full two-sample MR results. 
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aNumber of SNPs after Steiger filtering. bThe rs12209223 OA-risk increasing allele was identified in a GWAS of height, with the same allele 
associated with an increased height. 
Effect sizes for binary exposures represents the SD increase per doubling in OA risk. Effect sizes for BMD and BMI analyses represent the SD 
increase in outcome per SD increase in exposure. 
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Figure 101: Plot of two-sample MR results for the causal effect of eBMD on hip OA, 
restricted to 10 SNPs also associated with FN-BMD at genome-wide significance. 
 
 
Figure 102: Plot of two-sample MR results for the causal effect of eBMD on knee OA, 




There was evidence for a causal pathway between hip OA and higher eBMD in 
1SMR (SD increase per doubling in odds of hip OA=1.10 [0.36,1.84]) (Table 37), 
but not 2SMR (Figure 100). Evidence for a causal effect of knee OA on eBMD was 
provided by 1SMR (β=4.15 [2.74,5.56]) and 2SMR (β=0.13 [0.03,0.23]), with a 
positive effect observed for all three 2SMR methods, albeit of weak magnitude, 
with wide CIs overlapping the null for the MR-Egger regression (Figure 100). 
The leave-one-out analysis identified a stronger positive effect when removing 
rs143384, a 5’ UTR variant in GDF5 (Appendix 43). The knee, but not hip OA, 
PRS was related to BMI, potentially invalidating IV2 (Table 38). The other two 
knee OA SNPs are an intronic variant in FTO and an intergenic variant mapped 
to TMEM18, suggesting that the observed causal effect of knee OA on eBMD was 
mediated by a pleiotropic effect on BMI.  
Using MR to determine bidirectional relationships with BMI 
1SMR provided evidence that BMI has a strong causal effect on hip and knee OA, 
with an SD increase in BMI associated with a 1.5% (1.0,2.1) increased risk of hip, 
and 3.6% (2.9,4.3) increased risk of knee, OA (Table 37). 2SMR suggested that 
BMI is causally related to hip and knee OA, with an SD increase in BMI related to 
a 56 (31,87)% increased odds of hip, and a 69 (48,93)% increased odds of knee, 
OA. These results were consistent across the three 2SMR methods, apart from the 
causal effect of BMI on knee OA estimated by MR-Egger, which was 
approximately 30% weaker, albeit in the same direction (Figure 100). Leave-one-
out analysis did not identify any individual SNPs driving this effect (Appendix 
43).  
There was strong evidence from 1SMR that the causal pathway between BMI and 
knee OA was bidirectional, with weaker evidence for hip OA (Table 37). 
Additional adjustment for total weekly PA did not attenuate these relationships 
(data not shown). 2SMR, however, provided inconsistent evidence for a causal 
effect of hip OA on BMI and did not provide evidence for a causal pathway from 
knee OA to BMI (Figure 100). The leave-one-out analysis suggested that the 
removal of rs12209223 had a particularly strong effect on the observed 2SMR 
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results for the effect of hip OA on BMI (Appendix 43). The A allele, associated 
with an increased risk of hip OA, has been associated with height with genome-
wide significance (484). I therefore repeated the 2SMR of hip OA on BMI, 
excluding this SNP. There was evidence for a causal effect of BMI on hip OA (SD 
increase in BMI per doubling in odds of hip OA=0.03 [0.01,0.04]), with results 
still inconsistent between the IVW/weighted median estimates and the MR-
Egger estimate (Table 39).   
I could not perform bidirectional 1SMR for BMD-BMI as the FN-BMD SNPs were 
taken from a GWAS adjusted for weight, which meant the SNPs may be 
inversely related to weight, but 2SMR, using summary statistics from a GWAS 
not adjusted for weight, did not identify a causal effect of eBMD on BMI (Figure 
100). There was robust evidence for a causal effect of BMI on eBMD in 1SMR, 
with an SD increase in BMI causing a 0.07 (0.04,0.11) SD increase in eBMD (Table 
37). This estimate was similar to that from 2SMR, for which the effect size was 
consistent across methods. The MR-Egger intercept revealed weak evidence of 
horizontal pleiotropy (Figure 100, Table 39), although the MR-Egger estimate 
was stronger than the IVW estimate, suggesting that the pleiotropic effect was 
weakening the causal effect estimate. The leave-one-out analysis did not identify 
any outlying SNPs (Appendix 43). 
Using MVMR to determine the BMI-independent causal effect of 
eBMD on OA 
Overall, 1SMR and 2SMR provided consistent evidence that BMI is a confounder 
of the relationship between BMD and hip/knee OA. I therefore used 1SMVMR to 
examine the causal effect of eBMD on OA, accounting for shared relationships 
with BMI. Following adjustment for BMI, eBMD was found to be an independent 
causal risk factor for both hip and knee OA (risk difference=0.007 [0.001,0.013] 
and 0.015 [0.008,0.023], respectively, Table 37). This was equivalent of 26% and 
36% increased odds per SD increase in BMD, respectively, and similar in 
magnitude to that observed in MR analyses not accounting for BMI. BMI was a 
much stronger risk factor, compared to BMD, for both hip and knee OA (Table 
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37). SW conditional F-statistics were >200 for both instruments, suggesting that 
these results are not biased by weak instruments.  
I aimed to determine the BMI-independent effect of OA on BMD. MVMR 
provided evidence for a BMI-independent causal effect of OA on eBMD 
(βhip=1.12 [0.35,1.89] and βknee=5.76 [2.62,8.89], Table 37). The causal effect of BMI 
on BMD was independent of hip OA (β=0.08 [0.04,0.13]). However, when 
conditioning on knee OA, an inverse effect of BMI on BMD was observed (β=-
0.20 [-0.39,1x10-3]). However, of note, these results are vulnerable to weak 
instrument bias as conditional F statistics were 7.5 and 1.2 for hip and knee OA, 
respectively. 
Summary of findings from bidirectional MR 
A full summary of all MR analyses is presented in Figure 103. Overall, MR 
provided evidence for causal pathways from BMI to BMD, hip, and knee OA. 
MR did not provide evidence for a causal effect of eBMD on BMI. There was 
strong evidence for a causal effect of BMD on both hip and knee OA in 1SMR, 
although the magnitude of effect was much weaker for 2SMR. There was 
evidence for a causal pathway from knee OA to eBMD, but evidence was less 




Figure 103: Summary of results of MR analyses for hip OA (left) and knee OA (right). 
 
Effect estimates represent the SD increase in outcome per SD increase in exposure for BMD-BMI and BMD-BMI analyses, the OR per SD 




Using LCV analyses to determine the true causal effect of BMD on 
OA  
To determine if shared underlying genetic aetiology fully explains the observed 
causal effect of BMD on OA, I performed LCV modelling using weight-adjusted 
summary statistics for both FN/LS-BMD and hip/knee OA. LCV analyses 
identified evidence for genetic correlations between BMD (both FN and LS) and 
OA at both the hip and knee, ranging from rho=0.16 for the correlation between 
FN-BMD and hospital-diagnosed hip OA, to rho=0.23 for the genetic correlation 
between LS-BMD and hip OA (Table 40). There was evidence for a partial causal 
effect of BMD at both sites on OA at both sites, independent of genetic 
correlation and weight, with the largest magnitude of causal effect observed for 
FN-BMD and knee OA, with a genetic causality proportion of 0.64. 
 
Table 40: Results of latent causal variable modelling of the genetic correlation between 
FN/ LS-BMD and hip/knee OA, as well as the estimate of the genetic causality 
proportion. 
Trait 1 Trait 2 Rho (SE) GCP (SE) p-value 
FN-BMD Hospital-diagnosed hip OA 0.16 (0.02) 0.56 (0.07) 3x10-20 
 Hospital-diagnosed knee OA 0.19 (0.07) 0.64 (0.21) 1x10-7 
LS-BMD Hospital-diagnosed hip OA 0.23 (0.08) 0.57 (0.21) 0.002 
 Hospital-diagnosed knee OA 0.20 (0.07) 0.59 (0.25) 0.003 
Rho represents the genetic correlation between the two traits, estimated by LD score 
regression. The GCP is an estimate of the genetic component of trait 1 which is causal for 
trait 2. A value closer to 1 represents stronger causality of trait 1 on trait 2. A negative 





9.3.2. Using PRS to determine the role of bone in radiographic OA sub-phenotype prevalence and 
progression 
There was no strong evidence of relationships between the PRS and prevalent hip or knee OA sub-phenotypes in RS (Table 41). 
Follow-up OA sub-phenotype data was only available for the RS1 population, limiting the sample size for progression analyses. 
However, there was some evidence of a positive relationship between the eBMD PRS and both change in summed knee 
osteophytes and summed knee JSN (Table 41). 
 
Table 41: Associations between eBMD PRS and radiographic OA sub-phenotypes in the Rotterdam study cohorts. 
   Unadjusted Adjusted 
 Outcome N β 95% CI p Β 95% CI p 
Prevalent 
Hip JSN score 8,773 0.032 -0.015,0.080 0.180 0.030 -0.016,0.077 0.204 
Hip osteophyte score 7,594 -0.023 -0.191,0.146 0.792 -0.040 -0.204,0.124 0.636 
Hip subchondral sclerosis 7,156 1.161 0.975,1.384 0.094 1.168 0.980,1.393 0.083 
Knee JSN score 5,635 0.059 -0.011,0.128 0.099 0.064 -0.005,0.133 0.071 
Knee osteophyte score 7,524 0.172 -0.066,0.410 0.157 0.183 -0.052,0.418 0.126 
Knee subchondral sclerosis 5,233 1.046 0.781,1.400 0.762 1.047 0.777,1.411 0.764 
Progressive 
Change in knee JSN score 1,549 0.110 0.015,0.205 0.024 0.109 0.014,0.204 0.024 
Change in knee osteophyte score 2,717 0.193 0.015,0.371 0.034 0.190 0.014,0.367 0.035 





9.4. Discussion  
9.4.1. Summary of findings 
In this chapter, I have found strong evidence for a causal effect of BMD on hip 
and knee OA using 1SMR, which was relatively consistent with 2SMR. MVMR 
confirmed that the effect of BMD on OA is independent of BMI. These results 
also suggest that there is a bidirectional causal effect between OA and eBMD. I 
have confirmed strong causal effects of BMI on eBMD, hip and knee OA, with no 
causal effect of eBMD on BMI. The observed causal effect of BMI on eBMD in this 
adult population is consistent with a previous analysis of a paediatric population 
(mean age 10), where a causal effect of BMI on FN-BMD was observed (401). As 
seen in this current analysis, Kemp et al found no evidence for a causal effect of 
BMD on BMI (401). The strong causal effect of BMI on both hip and knee OA 
corroborates previous MR analyses (139,261,441).  
9.4.2. Context of this work 
I observed a causal effect of BMD, measured from heel ultrasound scans, on hip 
and knee OA, consistent with previous MR analyses which identified a causal 
effect of FN and LS-BMD on hip and knee OA (139,261). This suggests that BMD 
has a causal effect on OA, regardless of the site or method of measurement. 
However, the magnitude of effect of eBMD on OA was larger in 2SMR restricted 
to SNPs associated with FN-BMD. There are two potential explanations for a 
stronger effect of BMD on OA when restricting to FN-BMD loci. The first is that 
FN-BMD is measured by DXA, which is a more specific measure of BMD than 
the estimates generated from heel ultrasound. Heel ultrasound measures may be 
influenced by factors such as FM, which could lead to the inclusion of 
instruments not specific to BMD, increasing heterogeneity of the individual-SNP 
Wald ratios in 2SMR. An alternative explanation is that a large proportion of 
bone at the FN is cortical, whereas bone at the heel is predominantly trabecular 
(485,486). Increased cortical BMD could correlate with increased density or 
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thickness of the subchondral bone plate, creating greater pressure on the 
underlying cartilage.  
I have found some evidence for reverse causality in the relationship between 
eBMD and OA. The positive direction of effect is as expected from artefactual 
elevation, rather than loss of bone mass due to reduced PA. However, 
as I do not expect BMD measurements at the heel to be artefactually elevated by 
features of OA, the observed causal effect of OA on eBMD in 1SMR may reflect 
biological pleiotropy (i.e. the same underlying biological pathways may be 
contributing to both phenotypes). As discussed in section 3.3.2, consistent with 
shared biological mechanisms contributing to both BMD and OA, Hackinger et al 
identified a genetic correlation between LS-BMD (but not FN) and OA (137) and 
identified a novel locus in SMAD3 from the cross-phenotype meta-analysis of 
OA and LS-BMD (137). SMAD3 is part of the TGFβ signalling pathway, which 
regulates osteoblast differentiation. Evidence for a role of this pathway in OA 
pathogenesis in discussed in section 3.3.2. As discussed in section 3.3.2, other 
pathways with roles in both BMD development and OA aetiology include the 
Wnt and BMP signalling pathways. However, it should be noted that the knee 
OA PRS was also related to BMI, suggesting a pleiotropic effect of the instrument 
on BMI could also explain the observed causal effect of knee OA on eBMD. 
I did find stronger, more consistent, evidence for an effect of eBMD on OA, as 
opposed to vice versa. This could reflect the stronger instrument for eBMD, but 
the LCV analyses using the full set of summary statistics provided further 
evidence for a causal pathway between BMD and OA, independent of genetic 
correlation (and confounding by weight). Overall, this suggests that bone may 
still have a direct effect on OA, for example via increased joint loading, or 
structural differences in the subchondral bone, which have been linked to 
progression of JSN (405). The sub-phenotype analyses in RS were inconclusive, 
although evidence for relationships between the eBMD PRS and change in knee 
scores (both osteophytes and JSN) was stronger than evidence for associations 
with prevalent scores, providing further evidence for a role of BMD in knee OA 
progression, including JSN progression and osteophyte development (discussed 
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in Chapter 6). This finding suggests that BMD may be an ongoing factor in the 
pathogenesis of OA, rather than its initiation. 
9.4.3. Strengths of this work 
I have utilised the largest datasets possible to maximize the power to detect 
causal effects. I have ensured that there is no overlap between the exposure and 
outcome populations. I have utilised the availability of individual-level data in 
UKBB to perform 1SMR to strengthen evidence, as well as radiographic sub-
phenotype data to investigate the association between higher genetically 
predicted eBMD and OA sub-phenotypes. 
9.4.4. Limitations  
I was unable to use eBMD instruments for 1SMR, as they were identified in the 
same population used for analyses; reassuringly F-statistics suggested that the 
FN-BMD instrument was of reasonable strength. The OA outcomes for 1SMR 
were based on hospital-diagnosis; it is unclear how hospital diagnosis relates to 
radiographic features of OA, such as JSN, which are commonly used as clinical 
trial outcomes. Using a severe phenotype as the outcome means reduced power 
in GWAS, as the phenotype is rare and a composite of structural features and 
pain, leading to fewer genome-wide significant loci and a greater chance of 
weak-instrument bias (as highlighted by the much smaller F-statistics for the OA 
instruments). The OA outcomes from the GO consortium included a range of 
definitions of hip and knee OA, including hospital diagnosis, radiographic 
evidence, and self-reported OA definitions. Heterogeneity in phenotype, 
reflecting a combination of pain and structural symptoms, reduces the power to 
detect loci in GWAS. The ORs from 1SMR are estimates and SEs are likely 
underestimated (479), therefore caution should be taken when interpreting CIs. 
There may be additional risk factors related to the genetic variants which I did 
not include in the MVMR model. Most individuals included were of white 
European ancestry, limiting generalizability to other ethnicities. PRS analysis 
using FN or LS-BMD loci could not be performed in RS as it is part of GEFOS.  
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9.4.5. Future work 
The results of this work provide evidence for both a causal role of BMD on hip 
and knee OA, and shared underlying biology contributing to both phenotypes. 
In Chapter 10, I will investigate the contribution of biological pathways (e.g. Wnt 
signalling, TGFβ signalling) to both BMD and OA risk. I will select pathways 
involved in both bone formation and bone resorption and compare the 
contribution of variation in these pathways to both eBMD and OA risk. To 
perform formal MR analyses of the BMI-independent causal effect of BMD on 
OA sub-phenotypes and their progression, GWAS summary statistics are 
required for these sub-phenotypes. This was beyond the scope of this PhD, but 
LCV analyses to determine if there is a causal effect of BMD on particular OA 
sub-phenotypes, independent of genetic correlation, would make an important 
contribution to our knowledge of the role of bone in OA pathogenesis. 
9.4.6. Conclusions  
I have found evidence for a BMI-independent causal effect of BMD on hip and 
knee OA, and some evidence for a bidirectional causal effect which I hypothesize 
to reflect shared underlying genetic aetiology. I have confirmed strong causal 
effects of BMI/BMD on hip and knee OA. Further analyses are required to 
determine the shared pathways contributing to both BMD and OA, and to 
determine the mechanisms by which higher BMD causes OA.  
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CHAPTER 10.  THE ROLE OF 






10.1. Background and aims 
As discussed in sections 1.2.2 and 3.2, bone turnover is involved in OA 
pathogenesis via subchondral bone remodelling. A role of the Wnt and TGFβ 
signalling pathways in OA pathogenesis is widely accepted (section 3.3.2), but it 
is currently unclear to what extent these pathways contribute to OA risk, and 
whether the role of these pathways is direct (via their role in chondrocyte 
differentiation) or mediated by their role in bone formation. The first aim of this 
chapter is to use UK Biobank data to determine the contribution of genetic 
variation in the Wnt (and specifically canonical Wnt) and TGFβ superfamily 
signalling pathways, as well as a pathway specific to osteoclast differentiation, to 
variation in OA phenotypes. I aim to determine the specific contribution of the 
OPG-RANK-RANKL system, which, as discussed in section 2.1, is responsible for 
regulating bone resorption by osteoclasts and is the drug target for Denosumab. I 
aim to compare the variance in OA and in eBMD explained by these pathways 
and determine if the variance in OA explained by these pathways is altered by 
conditioning on eBMD (Aim 1, Figure 104). If the variance explained is 
unchanged by conditioning on eBMD, this would suggest that the effect of these 
pathways on OA risk is direct, for example mediated by an effect on 
chondrocytes and thus JSN (left pathway, Aim 1, Figure 104). However, if the 
variance explained is reduced when conditioning on eBMD, this would suggest 
the effect is mediated by bone (right pathway, Aim 1, Figure 104). Subsequently, 
I aim to use RS data to determine the contribution of genetic variation in these 





Figure 104: Diagrams summarising the key aims of this chapter. 
 
Arrows represent causal pathways, with dashed arrows representing hypothesized causal 
pathways.  
 
Although the pathway analyses outlined above will be performed to determine 
the contribution of variation in these pathways to OA risk and severity of 
radiographic OA sub-phenotypes, these analyses will not provide information on 
whether overactivation or inhibition of signalling via these pathways contributes 
to OA pathogenesis. One method to determine this is to measure a key inhibitor 
of a pathway and determine the relationship of levels of the inhibitor with OA. 
The Wnt inhibitor sclerostin has been measured in the HBM population. 
Previous analyses have shown that individuals with HBM have elevated plasma 
sclerostin levels, which may reflect the greater number of osteocytes present, as 
indicated by a positive causal effect of BMD on plasma sclerostin concentration 
in a subsequent MR analysis (487,488). As discussed in section 3.3.2, Wnt 
antagonists such as sclerostin may have a role in OA pathogenesis. However, 
there have been few studies investigating the association between circulating 
sclerostin and OA, and these have used small populations of patients undergoing 
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TJR and healthy controls, thus not investigating individual sub-phenotypes 
(489,490). These studies have conflicting findings, with one finding little evidence 
of an association between OA and serum sclerostin (490), and the other finding 
reduced sclerostin levels in those with a higher radiographic severity of OA 
(489). Therefore, the second aim of this chapter is to determine cross-sectional 
associations between plasma sclerostin and OA sub-phenotypes (osteophytes, 
JSN, subchondral sclerosis and chondrocalcinosis) at the hip, knee, and hand in 





10.2.1. Contributions of genetic variation in bone pathways to 
OA risk 
Study population 
Analyses with hospital-diagnosed OA outcomes were performed in the UK 
Biobank population (section 5.2.1), that had data for eBMD and at least one 
hospital-diagnosed OA variable. Analyses with radiographic OA outcomes were 
performed using baseline data for the three RS populations. 
Outcomes 
Derivation of hospital-diagnosed OA variables in UK Biobank and measurement 
of eBMD, as well as radiographic OA variables in RS, are described in Chapter 9. 
Radiographic OA sub-phenotypes were binarised based on the presence of any 
osteophyte or any JSN at each joint (i.e. summed score >1). ICD codes used to 
derive hospital-diagnosed hand OA are presented in Table 42 (261). 
 
Table 42: ICD codes used to identify cases of hospital-diagnosed hand OA in UK 
Biobank. 
Joint  Code Description 
 ICD10 ICD9  
Hand M151  “Heberden nodes (with arthropathy)” 
 M152  “Bouchard nodes (with arthropathy)” 
 M154  “Erosive (osteo)arthrosis” 
 M180  “Primary arthrosis of first carpometacarpal joints, bilateral” 
 M181  “Other primary arthrosis of first carpometacarpal joint” 
 M189  “Arthrosis of the first carpometacarpal joint, unspecified” 
 M1904  “Primary arthrosis of other joints (hand)” 
 M1994  “Arthrosis, unspecified (hand)” 
  71534 “Osteoarthrosis, localized, primary or secondary, hand” 





GWAS of eBMD and hospital-diagnosed OA in UK Biobank 
To generate SNP-outcome effect estimates to calculate pathway-specific r2, I 
performed GWAS of eBMD and hospital-diagnosed hip, knee, and hand OA in 
UK Biobank, restricting the OA GWAS to those with eBMD data, so that the 
sample size was the same when adjusting for eBMD, ensuring that any change in 
effect size for a SNP was not due to sample size differences. 12,321,875 SNPs 
were analysed with sample sizes ranging from 222,952 for hand OA to 241,487 
for eBMD (all white Europeans). Pre-GWAS QC of genetic data is described in 
section 5.3.1. GWAS were performed as described in section 5.3.2. Conditional 
GWAS were performed for OA at each joint, adjusting for eBMD. QQplots to 
assess population stratification are presented in Figure 105 and Figure 106, and 
Miami plots comparing unadjusted with eBMD-adjusted analyses are presented 




Figure 105: QQplots from GWAS of hospital-diagnosed hand (top), hip (middle) and 





Figure 106: QQplot from GWAS of eBMD in UK Biobank, restricted to individuals with 
data for hospital-diagnosed OA in at least one joint. 
 
 
GWAS of OA sub-phenotypes in RS 
To extract estimates for the effect of pathway-annotated SNPs on osteophytes 
and JSN at each joint, GWAS in the three RS cohorts were performed as 
described in section 5.3.2. Post-GWAS QC was performed using ‘EasyQC’ 
software (version 9.2): SNPs with a MAF<0.05, duplicate IDs, mismatched alleles 
compared to the reference HRCv1.1 dataset (downloaded from 
https://www.uni-regensburg.de/medizin/epidemiologie-
praeventivmedizin/genetische-epidemiologie/software/) or with an allele 
frequency difference >0.2 from the reference dataset were excluded. Meta-
analyses were then performed, for 5,282,396 SNPs common to all three 
populations, as described in section 5.3.2. QQplots for all analyses, after meta-
analysis, are provided in Figure 107. QQplots for each population are provided 




Figure 107: QQplots for the GWAS meta-analysis of each radiographic OA sub-





Extracting pathway-specific variants 
To ensure only independent loci were included to calculate pathway-specific r2, I 
used LD pruning to generate a list of independent SNPs within the UK Biobank 
cleaned genotype data (QC procedure described in section 5.3.1). This allowed 
SNP r2 estimates to be summed across a pathway without having to account for 
LD between variants. For RS, I performed pruning on the SNPs included in the 
meta-analysis, using the largest population (RS1). Pruning was performed using 
the Plink ‘indep-pairwise’ function, with a window size of 50kb, a step size of five 
and an r2 threshold of 0.2. 
I downloaded the latest version of the relevant Kegg pathways for homo sapiens 
(Figure 108-Figure 110) (491). I extracted a list of all genes from the Kegg 
pathway and then downloaded the genome position for each gene from NCBI 
gene (https://www.ncbi.nlm.nih.gov/gene/), using the ‘hg19’ assembly. I used 
two approaches to determine pathway-specific variants: one based on all SNPs 
within 20kb upstream and downstream of all genes (location-based) and one 
based on all cis-eQTLs (<1Mb from the gene) associated with expression of 
pathway genes in blood, identified by the eQTLGen Consortium (492) 
(expression-based). For the expression-based approach, I wrote R code to search 
for all genes in the pathway in the file downloaded from eQTLGen (‘2019-12-11-
cis-eQTLsFDR0.05-ProbeLevel-CohortInfoRemoved-BonferroniAdded (1).txt.gz’, 
downloaded 15th May 2020). To check for genes that were missed due to 
alternative gene names, I downloaded the Ensembl IDs for genes not discovered 
in the file and searched for those. This did not identify any additional SNPs.  
Once I had generated the list of pathway-specific variants, I filtered these on the 
list of independent loci generated by LD pruning, and calculated the SNP-
specific r2 estimates for the filtered variants in R. Non-biallelic SNPs in UK 




Figure 108: KEGG pathway map used to generate a list of genes involved in overall Wnt signalling and canonical Wnt signalling. 
 
Downloaded from https://www.kegg.jp/kegg-bin/highlight_pathway?scale=1.0&map=hsa04310&keyword=wnt. The grey dashed line represents 
the nucleus.   
Image removed for copyright purposes  
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Figure 109: KEGG pathway used to identify genes in the osteoclast differentiation pathway.  
 
 
Downloaded from https://www.kegg.jp/kegg-bin/highlight_pathway?scale=1.0&map=hsa04380&keyword=osteoclast.  
Image removed for copyright purposes  
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Figure 110: KEGG pathway map used to generate TGFβ and BMP pathway-specific gene lists.  
 
 
A gene was annotated to the BMP-specific pathway if signalling was via the BMP receptors, as highlighted in blue. A gene was annotated to 
TGFβ-specific signalling if it was involved in signalling by TGFβ, Activin or Nodal receptors, as highlighted in yellow. Genes such as ERK and 








Calculation of pathway-specific r2 
The proportion of the variance explained by each SNP was calculated as the 
variance explained by an individual SNP (2β2EAF(1-EAF)), divided by the total 
phenotypic variance, as described in section 5.3.5. For eBMD, the total 
phenotypic variance was the SD of eBMD in the GWAS population, squared. For 
OA variables, the total phenotypic variance was estimated using the equation 
provided on page 160. The proportion of variance explained by each SNP was 
then summed across the pathway to generate the pathway r2.  
10.2.2. The relationship between circulating sclerostin and 
OA sub-phenotypes 
Measurement of plasma sclerostin 
Plasma sclerostin concentrations in the HBM population were assessed from 
blood samples, collected at baseline, by ELISA immunoassay by Professor Bill 
Fraser and Dr Jonathan Tang. Individuals whose samples were collected at a site 
without the correct storage facilities to immediately freeze the samples were 
excluded from these analyses. Intra- and inter-assay CVs, provided by Professor 
Fraser and Dr Tang, were <5% and <13%, respectively. 
Radiographic sub-phenotype outcomes 
I used baseline binary variables for any osteophyte and any JSN of grade >1, at 
each joint, as described in section 8.2.4. Subchondral sclerosis and 
chondrocalcinosis of the hip and knee were assessed as present or absent. OA 
was defined as a KL grade >2 at the knee and a Croft score >3 at the hip. 
Statistical analysis 
Person-level analyses were performed, using GEE logistic regression, to 
determine the association between plasma sclerostin (standardized) and binary 
OA sub-phenotype variables, accounting for within-family clustering. Analyses 
were initially performed unadjusted (model 1), before adjusting for age and sex 
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(model 2) and then additionally height and weight (model 3). Finally, P1NP was 
added to model 3 to determine if observed associations were independent of 
current levels of osteoblast activity. Measurement of P1NP is described in section 
8.2.3. As I analysed 12 prevalent outcome variables, I performed Bonferroni 
correction to give a significance threshold of 0.004, to investigate the potential 
role of chance observations. I additionally adjusted for creatinine in a sensitivity 
analysis, to determine if renal function explained results. 
Association of sclerostin loci with OA phenotypes 
Two loci were associated with plasma sclerostin levels at genome-wide 
significance in a recent meta-analysis of 10,584 individuals (488). The association 
of these two SNPs with OA at the hand, hip and knee was assessed in the latest 
GO meta-analysis (section 9.2.1). Summary statistics for the two SNPs were 
provided by Dr Lorraine Southam, Helmholtz University, with permission of the 
GO steering committee. I performed IVW to generate an estimate of the causal 
effect of plasma sclerostin on OA at each site, although with only two SNPs I was 
unable to perform additional analyses such as MR-Egger to determine if results 





10.3.1. Contribution of variation in bone pathways to OA risk 
Descriptive characteristics of the UK Biobank population included in these 
analyses are presented in Table 43. 
 
Table 43: Descriptive characteristics of the UK Biobank population analysed. 
  N (%) 
Female 135,874 (54.4) 
Hospital-diagnosed OA  
 Hand 1,623 (0.7) 
 Hip 7,519 (3.2) 
 Knee 13,005 (5.4) 
  Mean (SD) 
eBMD (g/cm2) 0.540 (0.124) 
Age (years) 56.3 (8.0) 
 
Table 44 presents the variance in each outcome (columns) for each pathway 
(rows) using the two annotation methods. The total variance explained by all 
SNPs, annotated to any of the pathways by location, was 22% for eBMD, 16% for 
hand OA, 17% for hip OA and 16% for knee OA. Variance explained by all 
eQTLs across the pathways was 15% for eBMD and 6% for OA at all joints. The 
number of SNPs annotated to each pathway varied, mainly due to the number of 
genes annotated to each pathway: only three genes were annotated to OPG-
RANK-RANKL whereas 139 genes contributed to the Wnt signalling pathway. 
Estimates for pathways with many annotated genes were therefore higher than 
those with few annotated genes. Therefore, it was unsurprising that the largest r2 
for all phenotypes was for the Wnt signalling pathway (location-based r2=0.075, 
0.064, 0.066 and 0.065 for eBMD, hand, hip, and knee OA, respectively). eBMD 
had higher r2 values than OA at any site, across all pathways and both methods, 
suggesting that these pathways explain a greater proportion of variance in eBMD 
compared to OA risk. Using the location-based approach, BMP signalling 
explained more variance in eBMD than canonical Wnt signalling, despite fewer 
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annotated SNPs (0.060 vs 0.048). This pattern was not seen for the OA 
phenotypes. As expected, the r2 for eBMD and the OPG-RANK-RANKL 
pathway, specific to bone resorption, was twice that of the OA phenotypes (0.004 
vs 0.002). Of the three OA phenotypes, the total r2 was slightly higher for hip, 
compared to hand and knee OA, although differences between sites were small 
for all pathways. 
 
Table 44: Variance in eBMD and hospital-diagnosed OA in UK Biobank explained by 














0.075 0.064 0.066 0.065 
Canonical Wnt 
NSNPs=9,364 
0.048 0.041 0.042 0.042 
TGFβ 
NSNPs=7,353 
0.047 0.034 0.034 0.034 
BMP 
NSNPs=7,550 
0.060 0.035 0.035 0.034 
Osteoclast differentiation 
NSNPs=7,876 
0.044 0.034 0.036 0.036 
OPG-RANK-RANKL 
NSNPs=339 
0.004 0.002 0.002 0.002 
All 
NSNPs=36,270 





0.085 0.022 0.024 0.024 
Canonical Wnt 
NSNPs=2,975 
0.070 0.013 0.014 0.014 
TGFβ 
NSNPs=2,186 
0.021 0.010 0.011 0.012 
BMP 
NSNPs=2,419 
0.026 0.012 0.011 0.012 
Osteoclast differentiation 
NSNPs=4,916 
0.038 0.024 0.022 0.026 
All 
NSNPs=12,318 
0.150 0.058 0.058 0.062 
 
When calculating pathway-specific r2 based on blood eQTLs for genes in each 
pathway, despite fewer SNPs than using the location-based approach, the 
variance in eBMD explained by the Wnt signalling pathway was greater (8.5% vs 
7.5%, Table 44). This pattern was not seen for OA. The r2 for the osteoclast 
differentiation pathway was similar for eBMD despite 38% fewer SNPs (location-
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based r2=0.044, expression-based r2=0.038). The largest r2 for hand and knee OA 
were seen for eQTLs annotated to the osteoclast differentiation pathway (0.024 
and 0.026, respectively), and for hip OA the largest contributor was the Wnt 
signalling pathway (0.024). r2 values were similar across OA at the three joints.  
The contribution of variation in genetic pathways mediated by 
BMD 
I next aimed to determine if adjustment for eBMD changed the variance in OA 
risk explained by each pathway, to determine if the contribution of each pathway 
to OA risk was mediated by BMD or represented a direct effect on OA risk. I 
used summary statistics from a GWAS for each OA phenotype adjusted for 
eBMD. As the SE of the SNP-outcome effect could be increased or decreased by 
adjustment for a covariate, and yet the total phenotypic variance would be the 
same, I calculated the denominator for the OA outcomes using SEs and betas 
from unadjusted analyses. If eBMD mediates the effect of a pathway on OA risk, 
one would expect the betas to decrease in magnitude upon adjustment and 
therefore the estimated r2 would decrease. However, adjustment for eBMD made 
no difference to the variance in OA risk explained by each pathway (Figure 111), 









Figure 111: Comparison of r2 values for each OA phenotype, with and without adjustment for eBMD, in UK Biobank.  
 




10.3.2. Contribution of variation in bone pathways to OA 
sub-phenotypes 
I next aimed to determine if the variation explained by these pathways differs 
between osteophytes and JSN, to determine the role of these pathways in the 
pathogenic processes of OA. Descriptive characteristics of the RS population, 
with complete data for both sub-phenotypes at least one joint and included in the 
GWAS meta-analysis, are presented in Table 45. 
 
Table 45: Descriptive characteristics of the Rotterdam Study population analysed. 
  Mean (SD) 
Age 64.7 (9.1) 
  N (%) 
Female 5,621 (57.3) 
Hand  
 Any osteophyte 6,708 (77.2) 
 Any JSN 1,598 (18.4) 
Hip  
 Any osteophyte 4,739 (63.7) 
 Any JSN 2,052 (27.6) 
Knee  
 Any osteophyte 3,263 (57.8) 
 Any JSN 1,600 (28.3) 
 
Table 46 displays the r2 estimates for each sub-phenotype, at each joint, in the 
total RS population. Sample sizes were much smaller in RS than UK Biobank 
analyses, which appears to have caused inflated beta estimates and thus r2 
estimates, as evidenced by the ~0.2 greater summed r2 for knee sub-phenotypes 
compared to hip/hand sub-phenotypes, where the sample size was smaller by 
2,000-3,000 individuals. Results are therefore not comparable to those presented 
in section 10.3.1, or between joints. There was no consistent pattern, across joints, 





















0.251 0.277 0.359 0.335 0.227 0.247 
Canonical Wnt 
NSNPs=1,091 
0.136 0.165 0.207 0.187 0.127 0.140 
TGFβ 
NSNPs=620 
0.095 0.089 0.097 0.115 0.068 0.080 
BMP 
NSNPs=672 
0.100 0.089 0.116 0.120 0.081 0.082 
Osteoclast differentiation 
NSNPs=1,320 
0.188 0.175 0.233 0.244 0.153 0.152 
OPG-RANK-RANKL 
NSNPs=30 
0.003 0.005 0.003 0.004 0.004 0.003 
All pathway SNPs 
NSNPs=4,032 





0.203 0.261 0.324 0.299 0.209 0.234 
Canonical Wnt 
NSNPs=1,048 
0.115 0.157 0.199 0.184 0.129 0.136 
TGFβ 
NSNPs=848 
0.113 0.121 0.171 0.155 0.093 0.110 
BMP 
NSNPs=843 
0.135 0.100 0.177 0.182 0.100 0.111 
Osteoclast differentiation 
NSNPs=1,803 
0.236 0.232 0.334 0.307 0.223 0.219 
All pathway eQTLs 
NSNPs=4,248 




10.3.3. The role of sclerostin in OA 
I next utilised the availability of measured plasma sclerostin in the HBM 
population to determine if circulating levels of this Wnt inhibitor are related to 
radiographic OA sub-phenotypes (Aim 2, Figure 104). 
Participant characteristics 
In the HBM population, 362 individuals had at least one hip, knee, or hand 
radiograph, plus measured plasma sclerostin and covariate data. 64% had HBM. 
Descriptive characteristics of these 362 individuals are presented in Table 47. The 
mean plasma sclerostin concentration was 83.2 (41.1) pmol/L (standard range 0-
80pmol/L).   
 
Table 47: Characteristics of the HBM study population analysed. 
 N (%) 
High Bone Mass  232 (64) 
Sex (Female) 239 (66) 
Hand DIP osteophyte 217 (60)  
DIP JSN 146 (41)  
CMC osteophyte 231 (64)  
CMC JSN 159 (44) 
Knee Osteophyte 115 (34)  
Subchondral sclerosis 13 (4)  
JSN 63 (19)  
Chondrocalcinosis 28 (9) 
 OA (KL>2) 117 (35) 
Hip  Osteophyte 227 (77)  
Subchondral sclerosis 12 (4)  
JSN 92 (31)  
Bilateral JSN 32 (11)  
Chondrocalcinosis 19 (7) 
 OA (Croft >3) 78 (27) 
 Mean (SD) 
Age (years) 59.6 (14.7) 
Plasma sclerostin (pmol/L) 83.2 (41.1) 
Height (cm) 168.7 (9.7) 




Cross-sectional associations between plasma sclerostin and OA 
sub-phenotypes 
In unadjusted analyses, higher plasma sclerostin was positively associated with 
OA at the hip and knee, presence of osteophytes of any severity in the DIP, CMC, 
knee, and hip, as well as any JSN at the knee, and any chondrocalcinosis at the 
knee and hip. The strongest associations were observed for the hand osteophyte 
variables (ORDIP=1.59 [1.25,2.03] and ORCMC=1.62 [1.24,2.12], OR per SD increase 
in plasma sclerostin (Figure 112)). Associations of plasma sclerostin with hip OA, 
osteophytes and chondrocalcinosis, and knee chondrocalcinosis, were not robust 
to correction for multiple testing. After adjustment for age and sex, the 
associations between plasma sclerostin and hip OA, hand and hip osteophytes, 
and hip and knee chondrocalcinosis were attenuated by over 50%, with CIs 
overlapping one. CIs for the association between plasma sclerostin and OA and 
osteophytes in the knee joint just overlapped one, but this was further attenuated 
in model 3. However, a strong inverse association between plasma sclerostin and 
CMC JSN became apparent in model 2 (OR=0.68 [0.53,0.87]), which persisted 
after adjustment for height, weight and P1NP. Adjustment for maximum TH-
BMD (instead of P1NP) did not alter results, nor did adjustment for creatinine 
(data not shown).  
In summary, these observational analyses provide evidence for a reduced odds 
of JSN at the CMC joint with increasing plasma sclerostin, but there was no 
evidence for a relationship with JSN at the hip or knee. This was the opposite 
direction of effect compared to osteophytes at the hip or knee, where there was 
very weak evidence (CIs overlapping one) for an increased odds of osteophytes 






Figure 112: Cross-sectional associations between plasma sclerostin and OA-sub-
phenotypes of the hip, knee, and hand in the HBM cohort. 
 
Points represent ORs per SD increase in plasma sclerostin concentration. Horizontal 
bars represent 95% CIs. N=361 for hand OA variables, 334 for knee variables, 294 for 
hip variables. 
 
Associations between sclerostin loci and OA phenotypes 
Having observed strong evidence for an inverse relationship between plasma 
sclerostin and thumb JSN in observational analyses, I next aimed to determine if 
sclerostin loci were associated with a reduced odds of thumb OA, to try and 
determine if cross-sectional relationships reflected a causal pathway. There was 




in the GO consortium (OR=0.97 [0.95,1.00], p=0.033). This allele was also 
associated with higher plasma sclerostin levels. Effect sizes were consistent 
between thumb and finger OA (ORthumb=0.97 [0.93,1.00], p=0.033 and 
ORfinger=0.97 [0.94,1.00], p=0.086). There was some evidence of a weak protective 
effect of the rs215226 A allele on knee OA (0.99 [0.97,1.00], p=0.044). There was no 
evidence for an association between the rs215226 loci and hip OA risk, or 
between the rs7241221 loci and OA (Table 48). IVW estimates were consistent 
with a potential protective effect of sclerostin against hand OA, although CIs 




Table 48: Summary statistics for the two sclerostin loci from the largest GO consortium meta-analysis to date, and results of MR analysis. 
SNP 
OA Serum sclerostin 
Phenotype  EA NEA EAF Cases Controls OR 95% CI P EAF Β SE p 
rs215226 
Hand OA 
 A G 0.591 21,208 285,124 0.974 0.951,0.998 0.033 0.597 0.205 0.014 5x10-49 
rs7241221  G A 0.775 21,208 285,124 1.002 0.974,1.031 0.910 0.772 0.109 0.017 4x10-11 
IVW meta-analysis       0.901 0.809,1.003 0.056     
rs215226 
Finger OA 
 A G 0.585 10,818 255,841 0.970 0.936,1.004 0.086      
rs7241221  G A 0.768 10,818 255,841 0.997 0.958,1.038 0.902      
IVW meta-analysis       0.880 0.753,1.028 0.108      
rs215226 
Thumb OA 
 A G 0.589 10,559 236,671 0.965 0.933,0.997 0.033      
rs7241221  G A 0.771 10,559 236,671 1.004 0.966,1.044 0.832      
IVW meta-analysis       0.870 0.742,1.019 0.084      
rs215226 
Hip OA 
 A G 0.597 36,523 317,638 0.995 0.977,1.013 0.562      
rs7241221  G A 0.779 36,523 317,638 0.994 0.974,1.016 0.617      
IVW meta-analysis       0.970 0.896,1.052 0.464      
rs215226 
Knee OA 
 A G 0.598 63,502 335,819 0.986 0.972,1.000 0.044      
rs7241221  G A 0.782 63,502 335,819 1.003 0.986,1.019 0.741      




10.4. Discussion  
In this chapter, I have estimated the variance explained in OA phenotypes by key 
pathways in bone regulation and determined that the effect of genetic variation 
in these pathways on hospital-diagnosed OA risk is unchanged when using 
summary statistics from GWAS adjusted for eBMD, suggesting that these 
pathways have a direct effect on OA development. Furthermore, I have 
identified evidence for a reduced odds of thumb JSN with increasing plasma 
sclerostin in the HBM population, further suggesting a role of inhibition of the 
Wnt signalling pathway in OA pathogenesis. 
10.4.1. Pathway analyses 
The variance explained in eBMD was consistently higher across all pathways 
compared to each hospital-diagnosed OA phenotype. One potential explanation 
is that the OA phenotype represents a combination of pain and structural 
progression. I hypothesize that the pathways analysed contribute to OA 
pathogenesis via structural progression, overall reducing the magnitude of effect 
of the pathway-specific SNPs on OA, reducing the r2 estimate. The difference in 
r2 between eBMD and hospital-diagnosed OA was greater when pathway-
specific variants were identified by their effect on gene expression (i.e. eQTLs), 
compared to location. This suggests that circulating levels of factors expressed by 
pathway-specific genes have a stronger role in maintaining eBMD rather than 
joint homeostasis, particularly for the Wnt signalling pathway. However, it 
should be noted that the phenotypic variance represents variance in actual 
measured eBMD but variance in risk for OA, which may limit comparability. 
The total proportion of variance explained by all pathways, when SNPs were 
selected based on location, was slightly higher for hip, compared to knee, OA. 
This is consistent with the greater heritability estimates for hip, compared to 
knee, OA discussed in section 1.2.5. Knee OA is thought be more strongly 
influenced by risk factors with a modifiable component, such as obesity, than hip 
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OA (10). When SNPs were selected based on location, Wnt signalling made the 
greatest contribution to variation in OA risk at all three joints. However, when 
selecting SNPs based on eQTL effects, osteoclast differentiation contributed a 
similar proportion to Wnt signalling. This suggests that genes contributing to 
osteoclast differentiation are more highly expressed in the blood than genes 
contributing to Wnt signalling. This is likely explained by the fact that these cells 
share a common precursor with macrophages, and these precursors circulate in 
the blood (493). As discussed in section 2.1.1, M-CSF, a component of the 
osteoclast differentiation pathway, contributes to the proliferation, 
differentiation, and survival of several cells from the monocyte lineage (161). 
This highlights a limitation of selecting SNPs purely based on their regulation of 
gene expression in one tissue, if comparing cell-specific pathways.  
Despite a similar number of annotated SNPs, the variance in eBMD explained by 
the BMP-specific pathway was greater than the TGFβ-specific pathway, 
suggesting that the BMP-specific pathway is a greater contributor to variation in 
BMD. A novel variant in SMAD9 was identified through whole exome 
sequencing in the HBM study (205). The SMAD9 mutation identified in the HBM 
study was predicted to reduce the inhibitory activity of SMAD9 on BMP 
signalling, providing evidence for a key role of the BMP signalling pathway in 
determining bone mass (205). Further evidence for a stronger role of the BMP-
specific pathway is that more of the loci identified in the recent eBMD GWAS 
were annotated to BMP genes, compared to TGFβ genes (386). 
The lack of attenuation of proportion of variance explained in hospital-diagnosed 
OA by the osteoclast-specific pathways when conditioning on eBMD suggests 
that osteoclasts have a direct role in joint homeostasis, as well as bone 
remodelling. This is consistent with previous in vitro evidence that peripheral 
blood mononuclear cells (PBMCs) from OA patients showed enhanced 
differentiation into osteoclasts compared to PBMCs from individuals without OA 
(494). The relationship between bone turnover and OA is discussed in detail in 
section 3.2; however, as discussed previously, most studies are based on the 
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relationship of systemic bone turnover, which may not reflect bone remodelling at 
the local joint level. As discussed in section 1.2.2, subchondral bone remodelling 
is a key pathogenic feature of OA (18). Consistent with a key role of osteoclasts in 
subchondral bone remodelling, a cross-sectional analysis found that women with 
symptoms of knee OA, taking the bisphosphonate alendronate which inhibits 
osteoclasts, had less subchondral bone attrition, compared to women with 
symptoms not taking alendronate (495). It is possible that osteoclasts contribute 
to the early stages of OA pathogenesis, as rats treated with alendronate showed 
reduced subchondral bone loss and osteophyte formation, but still developed 
subchondral sclerosis (496). A comparison of r2 values for osteoclast 
differentiation between OA incidence and progression would be a method of 
testing this hypothesis. In addition to a role of osteoclasts in subchondral bone 
remodelling, in vitro evidence suggests that osteoclasts are able to degrade both 
calcified and non-calcified cartilage, via the action of Cathepsin-K and MMPs 
(497). As discussed in section 3.3.2, Cathepsin-K, mainly expressed by 
osteoclasts, is able to cleave type II collagen (301) and in vitro studies suggest that 
Cathepsin-K is able to activate MMP9 secreted by osteoclasts (498).  
Due to the large, unfeasible estimates of the r2 generated for the sub-phenotype 
analyses (i.e. sum of variance explained >40% for all sub-phenotypes), I am 
unable to draw any conclusions for the proportion of variance in OA sub-
phenotypes explained by these pathways. It is possible that the equation for 
estimating the r2 from effect estimates and SEs is only suitable when the sample 
size is large enough that SNPs not associated with the outcome have negligible 
beta estimates. However, it should be noted that the variance explained would be 
expected to be larger for a more specific phenotype, such as osteophytes or JSN, 
compared to a composite phenotype such as hospital-diagnosed OA.  
10.4.2. Wnt antagonism and OA 
Observational analyses in the HBM population suggest that reduced Wnt 
antagonism may be a factor in thumb OA pathogenesis. Although the population 
is enriched by individuals with elevated plasma sclerostin levels and a higher 
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prevalence of OA, the association between plasma sclerostin and OA in the HBM 
population is unlikely to be explained by collider bias, as elevated BMD is more 
likely to be a common cause, rather than a common outcome. It is currently 
unclear whether circulating sclerostin correlates with joint level expression, or 
whether circulating sclerostin can have a direct effect on the joint. Circulating 
sclerostin is thought to be predominantly produced by osteocytes and the 
elevated circulating sclerostin levels in HBM individuals is evidence supporting 
this hypothesis (487). It is therefore unlikely that osteocyte-derived sclerostin 
levels mediate the relationship between high BMD and OA risk, as one would 
expect to see a positive relationship between circulating sclerostin and OA. As 
the opposite direction of effect was observed, it is possible that serum sclerostin 
is a marker of joint level sclerostin expression and pleiotropic effects of the Wnt 
signalling pathway on BMD and OA. Results of the lookup of the two genome-
wide significant loci in the thumb OA GWAS agree with a protective effect of 
sclerostin, with the allele associated with increased sclerostin at the B4GALNT3 
locus associated with a reduced odds of thumb OA at nominal significance 
(p<0.05). However, there was no evidence for an association between the 
GALNT1 locus and thumb OA. B4GALNT3 encodes a galatosaminyltransferase, 
responsible for glycosylation of target molecules; it has been hypothesized that 
this enzyme may modify sclerostin, protecting it from degradation (488).  
Consistent with differential effects of sclerostin on cartilage vs bone, Chan et al 
measured reduced SOST expression in the subchondral bone adjacent to the area 
of meniscectomy in two animal models of OA, but increased expression in 
cartilage (278). This pattern was confirmed in human cartilage samples from OA 
patients (278). In vitro analyses suggested that SOST downregulated 
MMP/ADAMTS production and inhibited GAG release from cartilage samples 
in response to IL-1α stimulation, indicating a mechanism by which sclerostin 
may reduce cartilage degradation in response to initial joint damage (278). In a 
SOST knockout mouse model, higher expression of catabolic enzymes, as well as 
markers of chondrocyte hypertrophy, were observed, providing further evidence 
for a role of sclerostin in protecting against cartilage degeneration (277). Studies 
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of human OA joints found that sclerostin expression in the subchondral bone 
was inversely related to severity of cartilage degeneration (281), and in a mouse 
knockout model, a greater subchondral bone mass, but no cartilage abnormality, 
was observed (279), suggesting that the protective role of sclerostin against JSN is 
mediated by reduced subchondral density.  
Evidence for an inverse relationship between serum sclerostin and thumb JSN, as 
well as previous evidence that FRZB may be protective against cartilage loss 
(499), and the evidence that canonical Wnt signalling can inhibit chondrocyte 
differentiation and hypertrophy (500), overall suggests that targeting the Wnt 
signalling pathway may be an effective strategy for OA therapies. However, this 
would have to be at a joint level, through intra-articular injection, to avoid side 
effects such as decreased BMD. Any therapeutic targeting this pathway should 
retain a balance between Wnt signalling and inhibition, as chondrocyte-specific 
inhibition of β-catenin signalling led to cartilage loss in a mouse model (501) and 
SOST overexpressing mice had enhanced cartilage loss compared to wildtype 
mice (280). A phase-2a RCT of intra-articular injection of a small-molecule Wnt 
inhibitor, Lorecivivint, showed promising results, in terms of reducing pain and 
maintaining mJSW in the knee of individuals with unilateral knee OA (502). In 
vivo and in vitro studies suggest that this molecule inhibits two intranuclear 
kinases, independent of β-catenin, inhibiting expression of Wnt pathway genes, 
leading to chondrogenesis and inhibition of IL-1β-induced MMP expression and 
pro-inflammatory cytokine production (503). Further trials are required to 
determine whether intra-articular injections of Wnt inhibitors are beneficial for 
other joints. 
10.4.3. Strengths  
This represents the first analysis aimed at quantifying the variance in BMD and 
OA explained by key bone pathways, and at determining the relationship 
between plasma sclerostin and OA sub-phenotypes. I used detailed pathway 
maps from a publicly available database to extract all genes currently annotated 
to these pathways and two different methods to identify genetic variants linked 
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to these genes. LD pruning restricted analyses to the same independent loci 
across phenotypes for comparability and allowed a pathway-specific r2 to be 
simply calculated by summing SNP r2 estimates.  
10.4.4. Limitations 
The BOLT-LMM model used for GWAS of binary traits in UK Biobank may 
overestimate SNP-outcome effects and underestimate p-values for rare variants 
when the outcome is a binary trait with a case proportion <10% (359), which was 
the case for the GWAS of hospital-diagnosed OA outcomes. Simulations suggest 
that the knee and hip OA GWAS, with case proportions >3%, may have an 
inflated type-1 error rate for genome-wide significant loci only (359), but only 
one SNP, used to calculate the r2 for knee OA, reached genome-wide significance. 
For the rarer hand OA phenotype, any SNP with a MAF<0.01 may have an 
inflated test statistic (359), but as SNPs with a lower MAF contribute less to the 
total numerator, it is unlikely that these SNPs would have largely overinflated 
the r2 estimate. 
For some pathways, there were differences in variance explained between the 
eQTL-based and position-based approaches. This in part can be explained by the 
fact that there were often fewer eQTLs within 1Mb than SNPs within 20Kb of the 
gene, particularly in UK Biobank where lower frequency variants were retained. 
Selecting SNPs purely based on an association with expression of a gene excludes 
variants that may have other functions in gene regulation, such as missense and 
alternative splicing variants. Conversely, for eBMD, despite eQTLs only 
including a third of the number of SNPs compared to selection based on location, 
the r2 was larger and similar for the Wnt and osteoclast differentiation pathways, 
respectively. The range from which cis-eQTLs were selected was larger than 
when I selected based on position, suggesting that limiting to 20Kb upstream or 
downstream of the gene is too conservative. A 1Mb threshold was used to 
determine cis from trans eQTLs (492), but including all SNPs within this 
threshold may include eQTLs for non-pathway genes. Therefore, time-
permitting, these analyses should be repeated using multiple thresholds for the 
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location-based approach, comparing the r2 generated to that generated using 
eQTLs. This pattern was not observed for hospital-diagnosed OA, though, 
suggesting that the additional cis-eQTLs selected are annotated to genes that play 
a more important role in eBMD variation than OA risk. Alternatively, an eQTL 
can be associated with expression of multiple genes and it is possible that the 
higher r2 reflects the inclusion of an eQTL for a key gene from another pathway. 
In future, until more data are available for regulatory functions for all SNPs, a 
combination of SNPs within a certain distance upstream/downstream of a gene 
plus all eQTLs (cis and trans) would be the most comprehensive way to select all 
variants linked to a pathway. It would be useful to exclude eQTLs annotated to 
multiple genes in sensitivity analyses. 
The eQTLGen eQTLs are loci associated with expression of genes in blood, rather 
than specific tissues. As the pathways analysed have been selected based on their 
role in bone and joint development, they may not be expressed in blood, 
meaning that eQTLs were not available for certain genes in the pathway which 
may have a key role in OA pathogenesis (e.g. SOST). This was particularly 
noticeable for the OPG-RANK-RANKL system. It is unclear if gene expression 
levels for these pathway genes would correlate with expression levels in the 
blood and therefore eQTLs representing bone and joint-level expression of genes 
in the pathway would be desirable for future analyses, to determine how much 
variation in tissue-specific expression of genes in these pathways contributes to 
BMD/OA. I was unable to determine the interaction between pathways and 
whether interactions may increase the variance explained. There is evidence for 
interactions between these pathways, for example the BMP2 regulation of 
canonical Wnt signalling discussed in section 3.3.2. 
The fact that the beta estimates for hospital-diagnosed OA did not change after 
adjustment for eBMD could just reflect a lack of association between the SNPs 
and eBMD, rather than a lack of mediation of effect by eBMD. Alternatively, it 
could reflect such small effect sizes on the risk difference scale that attenuation 
was negligible (e.g. the maximum unadjusted β for knee OA was 0.0559 and the 
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maximum adjusted β was 0.0565). The lack of attenuation could be explained by 
the fact that I was only able to adjust for eBMD, rather than FN-BMD, which, as 
discussed in Chapter 9, has a stronger effect on OA risk. DXA assessment is 
currently underway in a subset of UK Biobank, which will allow these analyses 
to be repeated adjusting for FN-BMD. 
A lack of CIs around the r2 estimate means that it is unclear how precise the r2 
estimates are. This makes it difficult to draw any conclusions about differences 
between phenotypes when estimates are very close. To determine precision of 
these estimates, one would have to perform data simulations and generate CIs by 
bootstrapping, which was beyond the scope of this PhD.  
Finally, the sclerostin analyses were cross-sectional and, as there are currently 
only two SNPs to instrument plasma sclerostin, MR analyses were 
underpowered to determine if this represents a causal protective effect, or 
whether this relationship could be explained by unmeasured confounding. The 
HBM study represents the only population (that I am aware of) to have data for 
OA sub-phenotypes and plasma sclerostin measurements, limiting 
generalizability.  
10.4.5. Future directions 
Although these results suggest that the effect of variation in these pathways on 
OA risk is not mediated by BMD, there is still a possibility that the effect could be 
mediated by other bone parameters, such as bone shape. As described in section 
1.2.5, alterations in the shape of the hip, such as cam-type deformities, are a key 
risk factor for hip OA. However, phenotypes such as hip shape have not yet been 
derived in the UK Biobank population and I was therefore unable to determine 
the contribution of hip shape to the variation in hip OA explained by these 
pathways, but this analysis could be performed in the future. 
The advantage of the individual SNP r2 analysis was not having to pick a 
reference allele or allele weighting which I would have had to with PRS. 
However, new methods are being developed through the software ‘PRSice’ 
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(https://www.prsice.info/quick_start_prset/), which generate a pathway-
specific PRS based on GWAS summary statistics for the trait of interest. It will 
therefore be interesting to generate pathway specific PRS, using summary 
statistics for both BMD and OA from a separate population to determine the 
reference allele. I could then determine the variance explained in eBMD and OA 
sub-phenotypes in UK Biobank by these PRS and whether these estimates are 
comparable to the estimates from the individual SNPs. 
Measurement of plasma sclerostin is currently underway in all OAI individuals 
who provided blood samples at baseline. This will allow replication of the 
observational analyses for the relationship between circulating sclerostin and 
each OA sub-phenotype. As longitudinal data are available for the OAI cohort, I 
will be able to determine if circulating sclerostin is associated with incidence 
and/or progression of OA sub-phenotypes. OAI sclerostin measurements will 
contribute to an updated GWAS meta-analysis of plasma sclerostin, which 
should have more power to detect additional loci for plasma sclerostin, 
increasing the strength of the instrument for MR studies.  
Finally, when the relevant data is available to perform GWAS of OA progression, 
I could repeat the r2 analyses. This will allow the determination of whether the 
contribution of variation in the bone pathways differs between prevalent and 
progressive disease, potentially providing further information on the role of 
these pathways in OA pathogenesis. 
10.4.6. Conclusions  
In this chapter, I have determined the contribution of key bone pathways to OA 
at the hip, knee, and hand, and that the variance explained in OA by each 
pathway is not explained by eBMD, suggesting that these pathways contribute to 
OA pathogenesis directly, rather than via BMD. I have determined a potential 
role of Wnt inhibition in protecting against hand OA, although further analyses 
are required to replicate the association and to determine if this represents a true 
causal effect.   
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CHAPTER 11.  THE ROLE OF 






11.1. Background and aims 
Insulin-like growth factor-1 (IGF-1) is a hormone involved in skeletal growth and 
development (504). Most circulating IGF-1 is produced by the liver in response to 
growth hormone stimulation (504). IGF-1 can also be produced by specific 
tissues, including chondrocytes (504,505). In vitro studies of animal cartilage have 
suggested that IGF-1 is able to stimulate proteoglycan synthesis (506), upregulate 
type II collagen expression and downregulate MMP13 expression (507), all of 
which suggests that IGF-1 may be protective against cartilage degeneration. 
However, the observation that IGF1 is expressed by osteoblasts and osteoclasts, 
but not osteocytes, in human osteophyte tissue, suggests a role of IGF-1 in 
osteophyte formation (508). 
Epidemiological evidence of an association between circulating IGF-1 and OA is 
currently inconclusive (509), with the largest population-based study so far 
identifying a positive association between IGF-1 concentration and bilateral knee 
OA (510). Consistent with a positive association between circulating IGF-1 and 
OA risk, individuals with acromegaly (a disorder of excess growth hormone 
production) are at an increased risk of developing secondary OA (509). In 
contrast, polymorphisms in the IGF1 gene, associated with lower IGF-1 levels, 
have been linked to a higher prevalence of OA (366,367). 
In this chapter, I will utilise the large-scale availability of data for serum IGF-1 in 
the UK Biobank population, to determine the association between IGF-1 and 
hospital-diagnosed OA at the hand, hip, and knee. I aim to determine if 
adjustment for eBMD attenuates any relationship, as BMD may be a mediator of 
the effect of IGF-1 on OA, due to its role in regulating osteoblastogenesis (511). A 
lack of attenuation by adjustment for eBMD suggests a direct influence of IGF-1 
on the joint, highlighting another pathway contributing to the shared aetiology of 
BMD and OA. I will also determine if adjustment for BMI alters the relationship 
between IGF-1 and OA, as an inverse relationship between IGF-1 and BMI has 
been observed (512), which could reflect the key role of the IGF-1 axis in growth 
(504) or regulating adiposity (513). 
 
 361 
Secondly, I aim to use MR to determine the causal effect of circulating IGF-1 on 
OA at each joint. The MR analyses will use IGF-1-associated SNPs identified in 
the Cohorts for Heart and Aging Research in Genetic Epidemiology (CHARGE) 
meta-analysis, which also performed a GWAS of IGF binding protein-3 (IGF-
BP3) (514). IGF-BP3 binds to circulating IGF-1, regulating the bioavailability of 
IGF-1 (504). Out of eight IGF-1-associated SNPs, three were also associated with 
IGF-BP3 levels. Finally, I will use MVMR to determine if any observed causal 





11.2. Methods  
11.2.1.  Study population 
UK Biobank 
The UK Biobank population is described in section 5.2.1. 421,527 individuals had 
complete data for the observational analyses. Observational analyses were not 
restricted on ethnicity. After exclusion of related individuals, individuals of non-
white European ancestry, and sex-mismatches, 332,059 (79%) had genetic data 
and were included in MR analyses. Figure 113 details the derivation of these 
sample sizes. 
 
Figure 113: Flowchart detailing sample size derivation for the observational and MR UK 








11.2.2. IGF-1 assessment 
Serum IGF-1 was assessed in UK Biobank at baseline using the Liaison XL 
chemiluminescent immunoassay (Diasorin Ltd). Biomarker data were 
downloaded in April 2019. Average within-laboratory coefficients of variation 
were 6.0% for low, 5.3% for medium and 6.2% for high concentrations (515). QC 
procedures have been published previously (516). 
11.2.3. Outcomes 
Hospital-diagnosed hip, knee and hand OA were determined from HES data 
using ICD codes previously reported for hip and knee (141) and hand (261) OA, 
as described in sections 9.2 and 10.2.1.  
11.2.4. Covariates 
Age, sex, BMI, ethnicity, HRT use and PA were hypothesized confounders of the 
association between IGF-1 and OA. Ethnic background was ascertained by 
touchscreen questionnaire at the initial assessment centre and was categorised as 
White, Mixed (White and Black Caribbean, White and Black African, White, and 
Asian or any other Mixed background), Asian or Asian British, Black or Black 
British, Chinese or other ethnic group. HRT use (ever used) was ascertained by 
touchscreen questionnaire.  
11.2.5. Statistical analysis 
Observational 
Serum IGF-1 concentration was positively skewed by a few outliers (Figure 114) 
and therefore I log-transformed IGF-1 for observational analyses, as this 
appeared to improve the distribution (Figure 115). Associations between log-
transformed IGF-1 concentration and binary OA outcomes were determined 
using multivariable logistic regression. Analyses were performed using four 
models: [1] unadjusted; [2] adjusting for age and sex, [3] additionally adjusting 
for ethnicity and HRT and [4] additional adjustment for BMI. Coefficients were 
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transformed by the natural logarithm of two to generate an OR per doubling in 
IGF-1 concentration. Additional analyses were performed stratified by sex to 
determine sex-specific effects. I performed sensitivity analyses excluding 
individuals with hospital-diagnosed acromegaly (ICD10 code E220, ICD9 code 
2530) or with an arthropathy related to an endocrine disorder (ICD10 code M145, 
ICD9 code 7130) (N=94). Individuals for whom serum IGF-1 was measured from 
an aliquot other than the first aliquot (N=43,728) were also removed as a 
sensitivity analysis, as sample dilution issues have been reported by UK Biobank 
and the dilution increases with increasing aliquot (516). 
 









Genotyping and imputation  
Genotyping and imputation in UK Biobank are described in section 5.3.1. 
IGF-1 instrument selection 
The eight SNPs, associated with IGF-1 at genome-wide significance from the 
CHARGE meta-analysis, were used to instrument IGF-1 (514). These SNPs, and 
their associations with IGF-1 and hand, hip and knee OA in UK Biobank are 
presented in Table 49. SNP-exposure summary data for 2SMR were extracted 
from the Teumer et al meta-analysis (514). Two of these SNPs were also 
associated with IGF-BP3 levels and another one was identified from a bivariate 
analysis of IGF-1 and IGF-BP3. The CHARGE study employed a sample-size 
weighted Z-score based meta-analysis to manage assay heterogeneity across 
cohorts, which does not generate a beta or SE (514). Hence betas and SEs, 
provided by the CHARGE consortium, were estimated from p-values using the 





Table 49: IGF-1 instruments and their associations with IGF-1 and hip and knee OA in UK Biobank. 
SNP EA 
IGF-1 Hip OA Knee OA Hand OA 
Beta SE P OR SE p OR SE p OR SE P 
rs1065656* G 0.050 0.003 4x10-84 0.987 0.015 0.392 1.019 0.012 0.116 1.000 0.033 0.996 
rs2153960 A 0.048 0.003 6x10-76 1.025 0.016 0.125 1.023 0.013 0.061 1.010 0.034 0.774 
rs509035 A 0.054 0.003 5x10-102 0.998 0.015 0.897 1.011 0.012 0.342 0.999 0.033 0.981 
rs646776* T -0.029 0.003 3x10-25 0.939 0.016 2x10-4 0.992 0.013 0.543 1.051 0.039 0.181 
rs700753* G 0.113 0.002 <1x10-300 0.982 0.015 0.234 0.984 0.011 0.155 0.987 0.032 0.687 
rs780093 C 0.060 0.002 1x10-135 1.041 0.016 0.007 1.021 0.012 0.066 0.967 0.030 0.280 
rs934073 G 0.035 0.003 4x10-43 1.011 0.016 0.471 1.000 0.012 0.988 1.017 0.034 0.608 
rs978458 C -0.074 0.003 6x10-172 0.953 0.015 0.003 0.983 0.012 0.180 0.991 0.034 0.794 
IGF-1 PRSa 0.058 0.001 <1x10-300 1.018 0.006 0.001 1.010 0.004 0.019 0.993 0.012 0.539 
Associations adjusted for sex, genotyping chip and 10 PCs. Betas represent the per-effect allele increase in standardized IGF-1.  






1SMR was performed as described in section 5.3.3. Analyses were performed 
using the individual SNPs as instruments and then using an unweighted PRS to 
instrument IGF-1. Analyses were adjusted for sex, genotyping chip and 10 PCs. 
IGF-1, not log-transformed to aid interpretation, was standardized prior to 
analysis. The assumptions of MR are outlined in section 5.3.3 and Figure 116 
summarizes how these assumptions were tested. To limit potential horizontal 
pleiotropy, I repeated analyses, firstly excluding the SNPs also associated with 
IGF-BP3 at genome-wide significance (rs700753, rs646776, rs1065656) and 
secondly using just the intronic IGF1 SNP (rs978458) as the instrument. Power 
calculations for 1SMR were performed using mRnd 
(http://cnsgenomics.com/shiny/mRnd/) (518). Power estimates are presented 
in Table 50.  
 









Hand OA (K=0.007)a    
 OR=0.95 0.06 0.06 0.05 
 OR=0.90 0.08 0.07 0.06 
 OR=0.80 0.16 0.13 0.08 
 OR=0.70 0.30 0.24 0.12 
 OR=0.60 0.48 0.39 0.17 
Hip OA (K=0.03)    
 OR=1.05 0.08 0.06 0.06 
 OR=1.10 0.17 0.11 0.10 
 OR=1.20 0.50 0.30 0.26 
 OR=1.30 0.83 0.57 0.51 
 OR=1.40 0.97 0.82 0.75 
Knee OA (K=0.05)    
 OR=1.05 0.10 0.07 0.05 
 OR=1.10 0.24 0.15 0.14 
 OR=1.20 0.70 0.45 0.39 
 OR=1.30 0.96 0.78 0.72 
 OR=1.40 1.00 0.95 0.92 
All power calculations estimated based on an R2xz (i.e. the proportion of variance in the 
exposure explained by the instrument) of 0.01 and a type-1 error rate of 0.05. 
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K=proportion of cases within the MR population. aK=0.010 for females and 0.004 for 
males. 
 
Figure 116: Assumptions of MR and how they were tested in both one-sample and two-




Methodology for 2SMR is described in section 5.3.3. SNP-exposure summary 
statistics were extracted from the CHARGE meta-analysis (Appendix 46) (514). 
To provide estimates of the SNP-outcome association, hip and knee OA 
summary statistics for the IGF-1 SNPs were extracted from the GWAS meta-
analysis of UK Biobank and arcOGEN (Appendix 46) (141). For hand OA, I 
performed a GWAS of hospital-diagnosed hand OA in UK Biobank, using 
methods described in sections 5.3.2 and 10.2.1, and extracted the IGF-1 SNPs 
from the summary statistics (Appendix 46). Steiger filtering did not identify any 
SNPs explaining a greater proportion of variation in OA compared to IGF-1. 




To determine the BMI-independent causal effect of IGF-1 on OA, I performed 
1SMVMR. Methodology for MVMR is described in section 5.3.3. An unweighted 
BMI PRS was generated as described in section 9.2.1 (475). Associations of the 
BMI SNPs with BMI in UK Biobank are presented in Appendix 47. MVMR was 
also performed with height (instead of BMI) as a covariate, instrumented by 
height SNPs (Appendix 48) from the GIANT meta-analysis of 253,288 individuals 
(484). In MVMR, SW conditional F-statistics were calculated for IGF-1 and BMI to 
determine conditional instrument strength (377). 
Factorial MR 
To determine the additive effects of BMI and IGF-1 on OA risk, the MR 
population was stratified based on whether the PRS for IGF-1 was above/equal 
to or below the median. The same was performed for BMI PRS. The population 
was then categorised into four groups: 1) those below the median for IGF-1 PRS 
and below the median for BMI PRS; 2) those above/equal to the median for IGF-
1 PRS and those below the median for BMI PRS; 3) those below the median for 
IGF-1 PRS and those above the median for BMI and 4) those above the median 
for both IGF-1 and BMI PRS. Logistic regression analyses were then performed 
with PRS category as the exposure and OA variables as the outcome, adjusting 





11.3.1. Descriptives of the study population 
The mean age of the observational and MR populations was 56.4 (SD 8.1) and 
56.5 (8.0) years, respectively, and 54% were female (Table 51). The mean IGF-1 
concentration was 21.5 (6) nmol/L for both populations. Of the observational 
population, 3.1% had hospital-diagnosed hip, 5.4% had hospital-diagnosed knee, 
and 0.7% had hospital-diagnosed hand, OA. Proportions for the MR population 
were 3.2%, 5.4%, and 0.7%, respectively. 
 
Table 51: Descriptive characteristics of the UK Biobank population included in the 






 Mean SD Mean SD 
Age (years) 56.4 8.1 56.5 8.0 
Height (cm) 168.6 9.2 168.9 9.2 
Weight (kg) 77.9 15.8 78.0 15.8 
BMI (kg/m2) 27.3 4.7 27.3 4.7 
IGF-1 (nmol/L)a 21.3 17.6, 24.9 21.3 17.6, 24.9 
 N % N % 
Female 227,738 54.0 178,699 53.8 
     HRT use 84,341 37.0 67,181 37.6 
Ethnicity     
     White  401,844 95.3 332,059 100 
     Black/ Black British 6,500 1.5   
     Asian/ Asian British 6,489 1.5   
     Chinese  1,335 0.3   
     Mixed 1,619 0.4   
     Other 3,740 0.9   
Hospital-diagnosed OA     
     Hip 12,425 3.1 9,951 3.2 
     Knee 22,278 5.4 17,338 5.4 
     Hand 2,727 0.7 2,165 0.7 
aValues represent the median and IQR. 
 
11.3.2. Observational results 
In unadjusted analyses, increasing IGF-1 concentration was associated with 
lower odds of hip, knee, and hand OA (Table 52), with the largest effect seen for 
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hand OA (OR per doubling in IGF-1=0.61 [0.57,0.65], p=2x10-58). Adjustment for 
age and sex reduced the strength of all associations, but there was still evidence 
for a protective effect of IGF-1 on all outcomes. However, IGF-1 was strongly 
inversely associated with BMI in the UK Biobank population, with an SD higher 
IGF-1 concentration associated with a 0.13SD lower BMI. Further adjustment for 
ethnicity and HRT use did not alter observed associations. When I added BMI to 
the model, there was still evidence of a protective effect of IGF-1 on hand OA, 
albeit of weaker magnitude (OR=0.87 [0.82,0.93], p=4x10-5). The association with 
knee OA was fully attenuated by adjustment for BMI. I observed some evidence 
for an increased odds of hospital-diagnosed hip OA, based on results from model 
4 (OR=1.04 [1.01,1.07], p=0.014), and evidence of an interaction between log-
transformed IGF-1 and BMI on odds of hip OA, with a stronger magnitude of 
effect of IGF-1 on hip OA with increasing BMI (OR for interaction term=1.02 
[1.01,1.03], p=2x10-6, representing the increase in effect of IGF-1 on hip OA per 
1kg/m2 increase in BMI). The addition of eBMD to model 4, in a subset of 222,386 
individuals with eBMD data, did not attenuate the relationship with hip OA 
(OR=1.06 [1.02,1.11], p=0.008). 
 
Table 52: Results from observational analyses of associations between IGF-1 and hospital-
diagnosed OA in UK Biobank. 
 
When I stratified BMI-adjusted analyses by sex, the association between IGF-1 
and hip OA was only present in the female population (ORF=1.07 [1.03,1.12] vs 
ORM=1.00 [0.95,1.05]). The inverse association between IGF-1 and hand OA was 
present, with a similar magnitude, in both sexes. Restricting analyses to 377,602 
individuals whose IGF-1 was measured from the first aliquot did not alter 
conclusions drawn. Observational results were the same when individuals with 
 Hip OA (N=398,965) Knee OA (N=408,872) Hand OA (N=389,308) 
Model OR 95% CI P OR 95% CI P OR 95% CI p 
1 0.71 0.69, 0.74 6x10-108 0.68 0.66, 0.69 2x10-250 0.61 0.57, 0.65 1x10-58 
2 0.94 0.91, 0.97 3x10-4 0.80 0.78, 0.82 7x10-74 0.80 0.75, 0.86 6x10-11 
3 0.94 0.91, 0.97 4x10-4 0.81 0.80, 0.83 2x10-64 0.82 0.77, 0.88 3x10-9 
4 1.04 1.01, 1.07 0.014 0.99 0.96, 1.01 0.223 0.87 0.82, 0.93 4x10-5 
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hospital-diagnosed acromegaly or endocrine-related arthropathies were removed 
(Table 53).  
 
Table 53: Observational associations between IGF-1 and hospital-diagnosed OA in UK 
Biobank, after removing individuals with acromegaly or endocrine-related arthropathies. 
 
11.3.3. MR results 
In 1SMR, using individual IGF-1-associated SNPs as instruments, I found 
evidence for an increased odds of hip OA with increasing IGF-1 concentration 
(OR per SD increase in IGF-1=1.20 [1.01,1.43], p=0.033, Table 54). Combining 
genotypes for the eight SNPs in a PRS strengthened the instrument (F-statistic: 
3774 vs 563) and the evidence for a causal effect of IGF-1 on hip OA (OR=1.35 
[1.13,1.63], p=0.001, Table 54, Figure 117). An effect of IGF-1 on knee OA was also 
observed when using the IGF-1 PRS instrument (OR=1.19 [1.03,1.37], p=0.019, 
Figure 117). Although I found no evidence of a causal effect of IGF-1 on hand 
OA, these analyses were likely underpowered due to the rarity of hospital-
diagnosed hand OA (Table 50). Evidence for a causal effect of IGF-1 on hip and 
knee OA was stronger when excluding the three SNPs also associated with IGF-
BP3 at genome-wide significance (ORhip=1.57 [1.21,2.02], p=0.001 and ORknee=1.30 
[1.07,1.58], p=0.008, Table 54). The Sargan statistic was reduced from 30.5 
(p<0.001) to 4.4 (p=0.35), suggesting that results were less biased by pleiotropy 
when excluding IGF-BP3 SNPs. The causal effect of IGF-1 also persisted when I 
restricted the instrument to the single intronic IGF1 SNP, although CIs were 
wider (ORhip=1.93 [1.25,2.97], p=0.003 and ORknee=1.26 [0.90,1.76], p=0.179). When 
stratifying by sex, there was stronger evidence for an effect of IGF-1 on hip OA in 
females than males (ORF=1.42 [1.12,1.80] vs ORM=1.27 [0.94,1.71], Figure 118),
 Hip OA (N=398,928) Knee OA (N=408,832) Hand OA (N=389,282) 
Model OR 95% CI P OR 95% CI P OR 95% CI p 
1 0.71 0.69, 0.73 5x10-110 0.68 0.66, 0.69 4x10-252 0.61 0.57, 0.65 2x10-58 
2 0.94 0.91, 0.97 1x10-4 0.80 0.78, 0.82 8x10-75 0.80 0.75, 0.86 6x10-11 
3 0.94 0.91, 0.97 1x10-4 0.81 0.79, 0.83 2x10-65 0.82 0.77, 0.88 3x10-9 




although analysis in males had lower power (Table 50).  
 
Table 54: Results of 1SMR of the causal role of circulating IGF-1 on hospital-diagnosed OA in UK Biobank. 
 Individual SNPs (all 8 SNPs) Allele score Allele score (excluding IGF-BP3 SNPs) IGF1 SNP only 
 OR (CI) p OR (CI) p OR (CI) p OR (CI) p 
Hand (N=306, 748) 0.90 (0.63, 1.29) 0.564 0.88 (0.60, 1.31) 0.539 0.99 (0.57, 1.70) 0.958 1.13 (0.45, 2.87) 0.795 
Hip (N=314, 499) 1.20 (1.01, 1.43) 0.033 1.35 (1.13, 1.63) 0.001 1.57 (1.21, 2.02) 0.001 1.93 (1.25, 2.97) 0.003 
Knee (N=321, 930) 1.11 (0.97, 1.26) 0.129 1.19 (1.03, 1.37) 0.019 1.30 (1.07, 1.58) 0.008 1.26 (0.90, 1.76) 0.179 
 
When determining the causal relationship using 2SMR, although CIs widened, effect sizes were similar (Figure 117), with findings 
consistent with a positive effect of IGF-1 on hip OA (OR=1.26 [0.99,1.61], p=0.065). Weighted median analyses further suggested a 
positive effect of IGF-1 on OA risk, but estimates were much weaker, with CIs overlapping the null (Figure 119). The MR-Egger 
estimate differed in direction of effect (Figure 119), suggesting horizontal pleiotropy (OR=0.61 [0.29,1.30], p=0.25, intercept p-
value=0.1). Cochran’s Q value also suggested pleiotropy (Q=19.6, p=0.007). Further evidence for pleiotropy was supported by the 
stronger evidence for a causal effect when rs700753 and rs10655656 were removed in leave-one-out analysis (Figure 120); these two 
SNPs were also associated with IGF-BP3. When removing these SNPs, the causal effect estimate for IGF-1 became stronger 
(OR=1.49 [1.21,1.83], p=1x10-4) and consistent in direction with the MR-Egger estimate (OR=5.88 [0.70,49], p=0.2, p for intercept=0.3, 
Figure 121). Cochran’s Q was also reduced when these three SNPs were removed (Qhip=4.4, p=0.35). The effect of IGF-1 on hip OA 




Figure 117: Comparison of observational and MR results for the association between 
IGF-1 and hospital-diagnosed OA. 
 




Figure 118: Observational and one-sample MR results for hip OA in UK Biobank, 
stratified by sex. 
Points represent the OR per SD increase in IGF-1 concentration. Horizontal bars 




Figure 119: Comparison of IVW, weighted median and MR-Egger estimates for the 
causal effect of IGF-1 on hospital-diagnosed OA, using all eight IGF-1-associated SNPs.  
Points represent the OR per SD increase in IGF-1 concentration. Horizontal bars 
represent 95% CIs. 
 





Figure 121: Results from two-sample MR analysis of IGF-1 on hospital-diagnosed hip 




Evidence for a causal effect of IGF-1 on knee OA was weak in 2SMR using all 
eight SNPs, and inconsistent in direction between the IVW and MR-Egger 
estimates (Figure 119). The rs700753 SNP appeared to have a large effect on the 
estimates (Figure 122), and after excluding this SNP and the other two SNPs 
associated with IGF-BP3 at genome-wide significance, there was stronger 
evidence for a causal effect from IVW analysis (OR=1.33 [1.10,1.60], p=0.003) 
which was consistent in direction with the MR-Egger estimate (OR=2.09 [0.21,21], 
p=0.6, Figure 123). Evidence for heterogeneity was also weaker (Q reduced from 
14.9, p=0.038 to 5.9, p=0.206, MR-Egger intercept p-value=0.7). There was no 
evidence for a causal effect of IGF-1 on hospital-diagnosed hand OA in 2SMR 
(Figure 119). There was equally no evidence for a causal effect of IGF-BP3 on hip 
or knee OA using 2SMR, but some evidence for a protective effect of IGF-BP3 on 
hand OA (Table 55). 1SMR was not possible as IGF-BP3 has not been measured 




Figure 122: Results of leave-one-out analysis for the causal effect of IGF-1 on knee OA. 
 
 
Figure 123: Results from two-sample MR analysis of IGF-1 on hospital-diagnosed knee 







Table 55: Two-sample MR results for the causal effect of IGF-BP3 on hospital-diagnosed 
OA outcomes. 
 
When checking the assumptions of 1SMR, I found evidence for an association 
between the IGF-1 PRS and both BMI and HRT use (Table 56), violating the 
assumption that an instrument is independent of confounders of the exposure-
outcome relationship (IV2). Despite a strong inverse relationship between BMI 
and measured IGF-1, the association between the IGF-1 PRS and BMI was 
positive. I performed additional 1SMR, adjusting for HRT use, which did not 
attenuate the association between IGF-1 and hip OA (data not shown).  
 
Table 56: Associations between the IGF-1 PRS and potential mediators/confounders of 
the IGF-1-OA relationship in UK Biobank. 
Beta represents the unit increase in PRS per one-year increase in age and age at 
menopause or the difference between sexes. For BMI, beta represents the unit increase in 
BMI per unit increase in PRS. For HRT, beta represents the log odds of ever taking HRT 
per unit increase in PRS. Adjusted for sex, genotyping chip and 10 PCs. 
 
I hypothesized that BMI could mediate the effect of IGF-1 on hip OA; therefore, I 
performed MVMR to determine the causal effect of IGF-1 on hospital-diagnosed 
OA, independent of BMI.
  IVW Weighted median MR-Egger 
  OR 95% CI p OR 95% CI p OR 95% CI P 
All SNPs 
(NSNPs=5) 
Hand  0.88 0.75, 1.02 0.090 0.82 0.69, 0.97 0.021 0.72 0.52, 0.99 0.136 
Hip  1.00 0.90, 1.10 0.965 1.01 0.94, 1.08 0.808 1.15 0.99, 1.33 0.156 





Hand  0.85 0.64, 1.13 0.272       
Hip 1.03 0.95, 1.11 0.491       
Knee  0.97 0.91, 1.03 0.375       
Covariate Beta 95% CI p 
Age (years) -1.08x10-4 -0.001, 0.001 0.787 
Male -0.004 -0.017, 0.009 0.537 
BMI (kg/m2) 0.017 0.008, 0.025 1x10-4 
HRT (ever used) 0.008 0.003, 0.014 0.002 
Age at menopause -0.002 -0.004, 3.89x10-4 0.104 




I used the IGF-1 and BMI PRS’ as instruments and found evidence for an independent causal pathway between IGF-1 and hip OA 
(OR=1.32 [1.09,1.58], p=0.004), with weaker evidence for a causal effect on knee OA (OR=1.14 [0.99,1.31], p=0.078, Figure 117). 
Evidence for a causal effect of IGF-1 on both hip and knee OA was stronger after excluding the IGF-BP3 SNPs (ORhip=1.49 
[1.16,1.93] and ORknee=1.22 [1.00,1.48]). The effect sizes for the causal role of IGF-1 on hip and knee OA were unchanged when 
performing MVMR with height instead of BMI (Table 57). Like univariable MR, when stratifying by sex, a stronger effect of IGF-1 
on hip OA was seen in females (ORF=1.39 [1.10,1.76] vs ORM=1.21 [0.90,1.63], Figure 118).  
 
Table 57: One-sample results and multivariable MR results for the causal effect of IGF-1 on OA in UK Biobank. 
Risk differences are per SD increase in IGF-1. 
 Univariable MR MVMR: IGF-1 and BMI 
 Genetically predicted IGF-1 Genetically predicted IGF-1 Genetically predicted BMI 
 risk difference 95% CI p risk difference 95% CI p risk difference 95% CI p 
Hand OA -0.001 -0.004, 0.002 0.534 -0.001 -0.004, 0.002 0.554 -0.001 -0.003, 0.002 0.601 
Hip OA 0.009 0.004, 0.015 0.001 0.009 0.003, 0.014 0.003 0.015 0.010, 0.021 <0.001 
Knee OA 0.009 0.001, 0.016 0.019 0.006 -0.001, 0.014 0.081 0.035 0.029, 0.042 <0.001 
  MVMR: IGF-1 and height 
 Genetically predicted IGF-1 Genetically predicted IGF-1 Genetically predicted height 
Hand OA -0.001 -0.004, 0.002 0.534 -0.001 -0.004, 0.002 0.542 -3x10-5 -0.002, 0.001 0.968 
Hip OA 0.009 0.004, 0.015 0.001 0.009 0.003, 0.015 0.002 0.001 -0.002, 0.005 0.344 




11.3.4. Factorial MR to determine the additive effect of high 
IGF-1 and high BMI 
I next performed factorial MR to identify any additive effect of IGF-1 and BMI on 
OA. Those with a BMI and IGF-1 PRS above the median had the greatest odds of 
hip OA (OR=1.12 [1.06,1.18], p=1x10-4), compared to those with scores below the 
median (Figure 124), suggesting an additive effect of higher serum IGF-1 and 
higher BMI on hip OA risk. No difference in the odds of knee OA was apparent 
between those with a high BMI PRS and low IGF-1 PRS vs. those with a high IGF-
1 PRS and high BMI PRS (Figure 124), suggesting that IGF-1 may not contribute 
to knee OA risk. Results were similar when stratified by sex (Figure 125). 
 
Figure 124: Factorial MR analyses of the interaction between IGF-1 and BMI on hip and 
knee OA risk in UK Biobank. 
 
Points represent the OR for individuals in each BMI/IGF-1 PRS category compared to 
those with a BMI PRS below the median and an IGF-1 PRS below the median (reference 






Figure 125: Factorial MR analyses of the interaction between IGF-1 and BMI on hip and 







11.4.1. Summary of findings 
I have found evidence for a causal effect of higher circulating IGF-1 on the risk of 
hospital-diagnosed hip OA in a large population of white European adults. This 
effect is independent of BMI. Both observational and MR analyses suggest that 
the effect of IGF-1 on hip OA is greater in those with a higher BMI, suggesting 
BMI modifies the effect of IGF-1 on hip OA. I detected evidence for a causal role 
of IGF-1 as a risk factor for knee OA, though this was weaker than that for hip 
OA.  
11.4.2. Context of this research 
This is the first study to use MR to determine the causal relationships between 
IGF-1 and OA at the hand, hip, or knee. Two prior studies have identified a 
positive relationship between a microsatellite polymorphism in the IGF1 
promoter and radiographic hip OA (519,520). This polymorphism was related to 
lower serum IGF-1 concentrations in a subset of 50 individuals (521), but the 
authors could not conclude that the SNP was the causal variant, or in LD with a 
variant causing OA (520). 
The lack of observational evidence for an association between IGF-1 and knee 
OA is consistent with a previous case-control study (Framingham Osteoarthritis 
Study) of both incident and progressive radiographic knee OA (522), and a cross-
sectional analyses in the Baltimore Longitudinal Study of Aging (523). Lloyd et al 
identified a positive association between IGF-1 and radiographic knee OA in 
Chingford women, but only for severe, bilateral knee OA (510). The phenotype of 
hospital-diagnosed OA in this analysis is likely to reflect more severe 
radiographic or clinically apparent (i.e. painful) OA. UK Biobank lacks data on 
whether cases had bilateral or unilateral disease, which may contribute to the 
inconsistency in findings. Furthermore, Lloyd et al found weak evidence for 




contrasts with the protective association between IGF-1 and hand OA observed. 
Although the age-standardized prevalence of radiographic hand OA was 27% in 
the US Framingham population (524), UK hospital-diagnosis was much rarer, 
likely due to the lack of surgical management options for hand OA, so that 
individuals are unlikely to be referred to secondary care for assessment, meaning 
the MR analyses of hand OA were underpowered to confirm or refute the 
reported effect.  
Consistent with a role of the IGF-1/IGF-BP axis on hip OA risk, a GWAS of hip 
OA identified two loci near IGFBP3 associated with a decreased odds of hip OA 
and decreased circulating IGF-BP3 (not IGF-1) (525). In vivo functional studies 
suggest IGFBP3 overexpression in cartilage from patients with knee OA results in 
decreased aggrecan and increased MMP-13 expression (525). The two OA-
associated SNPs near IGFBP3 were not instruments in my analyses, nor in LD 
with any of the instruments used. The 2SMR analyses did not suggest a causal 
effect of circulating IGF-BP3 on hip OA risk.  
The lack of consistency between the observational and MR results may reflect the 
difference in exposures; for observational analyses, the exposure was current 
measured IGF-1 levels, whereas for MR analyses, the exposure was genetically 
predicted IGF-1 levels (371). Different relationships of measured IGF-1 and the 
IGF-1 PRS with BMI may be explained by a negative feedback loop, whereby 
higher IGF-1 levels throughout the lifecourse lead to a higher body mass which, 
over a sustained period of time, may reduce IGF-1 production by the liver (512). 
However, the BMI PRS was not associated with current IGF-1 levels (β=3x10-4 
[95%CI: -4x10-3, 4x10-3]). I therefore hypothesize that higher IGF-1 throughout the 
life-course may drive the progression of OA, and the MVMR analyses suggest 
that this effect is not mediated by BMI. One potential pathway is via increased 
BMD, a reported risk factor for hip OA (207). IGF-1 contributes to skeletal 
development and increases BMD by promoting MSC differentiation into 
osteoblasts (511). However, adjustment for eBMD did not attenuate the 
observational relationship between IGF-1 and hip OA. An alternative 




hip shape. IGF-1 is important for endochondral bone formation (526) and several 
genes linked to endochondral bone formation were identified in a recent GWAS 
meta-analysis of hip shape (527). Variation in hip shape is associated with hip 
OA (section 1.2.5). As I observed a stronger effect of IGF-1 on hip OA in females, 
I further hypothesize that IGF-1 levels could lower circulating oestrogen levels, 
leading to increased OA risk, as oestrogen may be protective against OA (528). 
However, the IGF-1 PRS was not related to menopausal age (data not shown).  
Another potential explanation for the differences between the observational and 
MR results could be additional unmeasured confounding, biasing the 
observational analyses (371). The potential for confounders to strongly bias 
observational results is highlighted by the difference in direction of effect 
observed for hip OA, before and after adjustment for BMI. As long as the 
instrument used for MR analysis meets the three key assumptions of MR, the MR 
estimate is not biased by confounding (367) and therefore I can have more 
confidence in the estimates generated by MR.  
11.4.3. Strengths of this work 
A major strength of this analysis is the availability of data for IGF-1 concentration 
and hospital diagnosis of OA for over 400,000 individuals, making this the most 
well-powered study to determine the observational relationship between IGF-1 
and OA. I also had genotype data for over 300,000 individuals, which meant I 
had 80% power to detect a causal OR of at least 1.28. The availability of genetic 
data meant that I was able to perform 1SMVMR analysis to determine if there is a 
BMI-independent causal effect of IGF-1 on hip OA. 
11.4.4. Methodological issues and limitations 
The outcome was hospital-diagnosed OA, which is likely to represent a more 
extreme and progressive OA phenotype. Although I excluded controls with other 
diagnosed arthropathies, there may still be controls with radiographic or clinical 
features of OA which have not been diagnosed, although this is likely to bias the 




meaning I am unable to draw conclusions from these analyses. I am unable to 
determine if the effect of IGF-1 is independent of IGF-BPs, as IGF-BPs have not 
been measured in UKBB. The summary statistics for the SNP-IGF-1 associations 
for 2SMR were estimated from p-values and therefore betas may not accurately 
reflect the true SNP-exposure association. However, these effect estimates were 
not used for 1SMR, which generated consistent results. I did not generate the 
BMI instrument from the largest GWAS of BMI, as a large proportion of 
individuals included in this meta-analysis were from UK Biobank and I was 
concerned about overestimating causal effect estimates due to ‘winner’s-curse 
bias’ (529,530). Dichotomizing the population based on their PRS may not be the 
most efficient method for performing factorial MR (531). I therefore cannot rule 
out a possible unobserved interaction between IGF-1 and BMI on knee OA risk. 
The MR analyses were restricted to those of white European ancestry, limiting 
the generalizability to other ethnicities. The overall UKBB population is also 
predominantly white British, with a higher prevalence of homeowners and non-
smokers, with a lower BMI and fewer self-reported health concerns than the 
general population (532), again limiting the generalizability of the observational 
results. There is also the possibility that ‘survivor bias’ may explain the 
associations observed; if higher IGF-1 levels are related to a lower mortality risk, 
those with higher IGF-1 levels will be surviving long enough to develop chronic 
diseases, such as OA. However, evidence suggests that IGF-1 levels are not 
related to all-cause mortality (533,534). The UK Biobank population is limited by 
latent population structure (geographical variation in allele frequencies) even 
after restricting to white European individuals and adjusting for PCs and 
assessment centre (535), which may confound the relationship between IGF-1 
and hospital-diagnosed hip OA.  
11.4.5. Future work 
Further MR analyses are required to determine if IGF-1 is related to radiographic 
features of OA, and their progression, in a large cohort of individuals from the 




hip/knee OA; previous studies have identified IGF1 gene expression in 
osteoblasts and osteoclasts from human osteophyte tissue, suggesting that the 
role of IGF-1 in OA pathogenesis is via osteophyte formation (508). 
Unfortunately, to the best of my knowledge, total serum IGF-1 has not been 
measured in a large cohort with radiographic data, such as RS, and therefore I 
was unable to determine the relationship between IGF-1 and radiographic OA 
sub-phenotypes. It also remains to be determined whether circulating IGF-1 
concentrations correlate with tissue-specific levels. 
As discussed earlier, the stronger effect estimates for MR, compared to 
observational analyses, suggests that lifetime exposure to higher IGF-1 levels has 
a greater effect on hip and knee OA risk compared to IGF-1 levels measured at a 
single timepoint in adulthood. However, an RCT is required to determine if 
interventions to reduce IGF-1 levels in older adults reduces the incidence and 
progression of hip and knee OA, as earlier interventions could interfere with 
growth and skeletal development.  
Finally, as discussed earlier, IGF-1 may affect hip OA risk through alterations in 
hip morphology. It is therefore important to determine the relationship between 
IGF-1 levels and hip shape in a cohort of individuals without OA (e.g. an 
adolescent cohort).  
11.4.6. Conclusions  
I have identified robust evidence that higher concentrations of serum IGF-1 are a 
causal risk factor for hip OA in a large UK population, with some evidence for a 
causal role in knee OA, and no evidence for an association with hand OA. 
MVMR analyses suggest that this causal role is independent of BMI, consistent 
with the observational analyses for hip, but not knee, OA. Further study is 











In this chapter, I will summarise the key results and how these add to the current 
knowledge of OA pathogenesis, and my hypotheses for biological mechanisms in 
OA. I will then discuss the next steps and translational potential of this work. 
12.1. Summary of key findings and further hypotheses 
12.1.1. HBM is associated with radiographic hip and knee OA 
sub-phenotype progression 
The overall aim of this PhD was to determine the role of bone in the pathogenesis 
of OA. This could be separated into five key aims, as summarized in Figure 19, 
Page 99. Prior to this work, higher BMD was an established risk factor for 
prevalent OA of the hip and knee, with sparse and inconclusive evidence for a 
role of BMD in hip and knee OA progression (discussed in section 3.1). The 
major limitation of these previous analyses has been the categorization of OA 
progression based on change in overall KL grade, which, as discussed in Chapter 
6, mainly reflects incident JSN at the knee. My first key aim was therefore to 
determine the role of BMD in hip and knee OA progression, including 
progression of the radiographic sub-phenotypes, by analysing a unique 
population with extreme elevations in BMD, and their relatives without HBM.  
In Chapter 6 and Chapter 7, I provide evidence that HBM is related to worsening 
(i.e. the combined incidence and/or progression) of both knee and hip 
osteophytes and JSN, independent of TBFM. Based on the previous observations 
of cross-sectional relationships between HBM and knee/hip OA representing 
relationships with osteophytes, rather than JSN (226-228), and the observation 
that HBM individuals have more enthesophytes than individuals without HBM 
(402), it was hypothesized that HBM individuals have a propensity to form more 
bone (207). This hypothesis, in combination with the observation that individuals 
with atrophic hip OA have lower BMD and an increased fracture risk (454), 
suggests that HBM individuals are more likely to develop hypertrophic OA but 




between HBM and worsening of JSN at both the hip and knee refutes this 
hypothesis and suggests that HBM individuals experience cartilage degeneration 
after osteophyte formation. The relationship with worsening of osteophytes was 
stronger than the relationship with JSN, which could reflect either the greater 
variability of osteophyte scoring, or the hypothesized ‘bone-forming’ phenotype 
of HBM (402). The fact that at an association between HBM and worsening of 
JSN was observed though is an interesting finding as there is limited evidence to 
suggest that BMD is a risk factor for incident/progressive JSN. Observed 
associations were stronger at the knee, compared to the hip, which could reflect 
the slightly larger sample size for the knee OA analyses (as individuals under the 
age of 40 were included), or a greater role of BMD in knee OA pathogenesis. As I 
treated my outcome as a continuous variable and my analyses were therefore not 
restricted to individuals with OA at baseline, my analyses were less likely to be 
biased by collider bias. The fact that I observed the opposite direction of effect 
from the previous knee OA studies, which were case-only analyses, suggests that 
collider bias is the explanation for the previously observed protective effect 
(229,233). 
Published analyses of the role of BMD in hip/knee OA progression have mainly 
been limited to large cohorts, allowing sufficient numbers to perform analyses of 
individuals with OA at baseline (229,232,233,235). Although these analyses are 
longitudinal, with BMD measurement preceding follow-up, the possibility that 
BMD is artefactually elevated (i.e. by spinal osteophytes or buttressing of 
osteophytes at the hip) cannot be ruled out. HBM individuals have been 
specifically selected based on generalized BMD elevations, and baseline DXA 
scans were inspected to rule out artefactual elevations by features of OA (197). 
HBM is genetically determined, by either an over-representation of polygenic 
variants associated with BMD (203), or rare monogenic variants (196,205). 
Therefore, a true temporal relationship can be inferred, suggestive of a causal 




HBM was additionally associated with severity of OA symptoms at both the hip 
and knee, with a stronger magnitude of effect at the knee. Symptoms were only 
assessed cross-sectionally, so I could not draw any conclusions about progression 
of symptoms. The HBM relationship with symptoms at the knee was explained 
by severity of osteophytes at follow-up, whereas the severity of pain at the hip 
was independent of severity of radiographic features. JSN severity did not 
attenuate the relationship between HBM and knee symptoms by the same 
magnitude as osteophytes, suggesting that osteophytes are a greater contributor 
to pain at the knee. It has been hypothesized that osteophyte formation is an 
attempt to stabilize the joint, protecting from further damage (19). However, 
evidence suggesting a strong contribution of osteophytes to OA symptoms in 
HBM individuals suggests that osteophytosis may be a pathogenic, rather than 
protective, feature.  
Possible explanations for an observational association between HBM and OA 
sub-phenotype incidence/progression include a true causal pathway, reverse 
causality, unmeasured confounding bias, or shared developmental pathways (i.e. 
shared genetic aetiology). The temporal relationship between HBM and OA 
development means reverse causality is an unlikely explanation. Additional 
analyses to determine a true causal pathway from shared genetic aetiology are 
described in sections 12.1.3-12.1.5. 
12.1.2. Metabolomics analysis in the HBM population did not 
identify any metabolic mediators of the HBM-OA 
relationship 
A causal effect of HBM on OA could be mediated by metabolic consequences of 
the HBM phenotype. As HBM is related to elevated FM, which is hypothesized 
to be a consequence of genetically-determined HBM and low bone turnover 
(201), I hypothesized that metabolic traits may mediate the HBM-OA 
relationship, reflecting altered metabolic regulation in HBM individuals by 




to identify metabolic traits associated with both HBM/BMD/bone turnover and 
OA sub-phenotypes, with the aim of then determining whether these metabolic 
traits mediate the relationship between HBM and OA, ultimately identifying 
metabolic pathways which may be involved in OA pathogenesis in HBM 
individuals, and thus potential druggable targets. However, possibly due to 
sample degradation resulting from long-term storage of blood samples 
(discussed in section 12.2.2), no metabolic traits were identified that were 
associated with both HBM/BMD/BTMs and OA variables.  
However, albeit not related to OA pathogenesis, I did identify a strong 
relationship between bone resorption (assessed by current CTX-1 levels) and 
circulating citrate. This relationship was independent of bone formation markers 
and replicated in two cohorts sampled from the general population (a cohort of 
mixed-sex adolescents and a cohort of adult women). The relationship was 
stronger in HBM individuals than either general population cohort or relatives 
without HBM. The presence of citrate in bone has already been established, with 
a hypothesized role in regulating the structure of bone mineral (460,462,463). The 
fact that citrate was, albeit cross-sectionally, associated with current levels of 
bone resorption in three populations, of different age and gender composition, is 
consistent with the knowledge that bone is a major source of plasma citrate (460). 
This represents the first analysis to compare associations between bone 
resorption levels and plasma citrate between individuals with high BMD and 
those with normal BMD. A stronger relationship between bone resorption and 
citrate in HBM individuals could reflect prolonged secondary mineralization in 
HBM individuals (200), with more mineral associated with more citrate, or could 
reflect differences in bone mineral structure in HBM, allowing citrate to be more 
readily released into the circulation. I therefore hypothesize that citrate could be 
a specific marker of turnover of bone mineral. Further analyses are required to 
determine the response of circulating citrate to interventions aimed at reducing 




12.1.3. Evidence for a BMI-independent causal effect of BMD 
on hip and knee OA 
BMI is perhaps the strongest confounder of any relationship between HBM and 
worsening features of OA, via increased joint loading, or increased adiposity 
increasing adipokine production which may be detrimental to the joint (84,85). In 
Chapter 9, I investigated the causal role of BMD on OA at the hip and knee, 
extending previous analyses (139,261) by using multivariable MR, and I found 
evidence for a causal role of BMD on hip and knee OA, independent of BMI. 
Bidirectional MR analyses confirmed that BMI is a confounder (i.e. common 
cause of both BMD and hip/knee OA). The fact that a causal effect of eBMD on 
BMI was not observed, in addition to no evidence for a relationship between 
plasma osteocalcin and total cholesterol and only weak evidence for inverse 
relationships between osteocalcin and serum triglycerides and glucose in the 
metabolomics analysis (section 12.1.2), suggests that the endocrine effect of 
osteocalcin observed in mice (202) may not translate to humans. However, 
methodological issues with the metabolomics data restricts the conclusions that 
can be made from these data. 
MR provided some, yet inconclusive, evidence for a causal effect of OA on BMD, 
representing the first MR analysis to examine this direction of causality. Possible 
explanations for a true causal effect of OA on BMD include artefactual elevation, 
although this was unlikely to be the case for eBMD, or reduced PA due to pain, 
but this would have led to a detrimental effect on BMD. I hypothesized that 
weak evidence for causal effects of OA on BMD was an artefact of the shared 
underlying biological pathways (such as Wnt and TGFβ signalling, discussed in 
section 3.3.2) and I employed the latent causal variable methodology to 
determine the genetic correlation of BMD and OA, as well as the proportion of 
genetic effect on BMD causal for OA. For this analysis, I used summary statistics 
from BMD and OA GWAS adjusted for weight, to take account of confounding. 




and hip/knee OA reflecting the shared genetic aetiology (section 12.1.4), as well 
as a causal effect of BMD on OA.  
12.1.4. Key pathways in bone metabolism appear to 
contribute independently to OA risk 
I hypothesized that the genetic correlation between BMD and OA was explained 
by the contribution of key bone and cartilage regulatory pathways to both 
phenotypes. Prior to this work, it was known that key pathways involved in 
osteoblast and osteoclast function, such as the Wnt signalling pathway, have a 
role in OA pathogenesis, but the exact contribution of these pathways had not 
been quantified. In Chapter 10, I attempted to quantify the contribution of 
genetic variation in key pathways to OA risk in Chapter 10. I selected three key 
pathways in bone development and metabolism which have been implicated in 
the pathogenesis of OA, namely Wnt signalling, the TGFβ superfamily and the 
osteoclast differentiation pathway, as discussed in section 3.3.2. I used GWAS 
summary statistics to estimate SNP-specific r2 for all independent SNPs 
annotated to each pathway, either by their location within ±20kb of a pathway 
gene, or by an association with gene expression in blood. These analyses 
suggested that the contribution of genetic variation in these pathways is similar 
between OA at the hand, hip, and knee, but lower than the contribution to eBMD 
variation. Adjustment for eBMD did not affect r2 estimates, suggesting that these 
pathways have a direct role in OA pathogenesis. When identifying pathway-
specific variants based on genetic location, the Wnt signalling pathway was the 
greatest contributor to variation in OA risk, whereas when selecting pathway-
specific variants based on effect on gene expression in the blood, the osteoclast 
differentiation pathway explained a similar proportion of the variance in OA risk 
to that explained by Wnt signalling.  
Additionally, in Chapter 10, I determined cross-sectional associations between 
plasma sclerostin and radiographic OA sub-phenotypes in the HBM population, 




increasing plasma sclerostin concentration, which was not explained by 
adjustment for age, sex, height, weight, or current levels of bone formation. I 
further determined the relationship between the two known loci for plasma 
sclerostin levels (488) and OA at the thumb base, with evidence suggesting that 
the observed cross-sectional relationship may reflect a causal effect of plasma 
sclerostin on reduced odds of thumb OA, although there was heterogeneity in 
estimates between the two SNPs. This adds to the body of evidence suggesting a 
protective role of Wnt inhibition in OA pathogenesis (536). 
12.1.5. Circulating IGF-1 is a risk factor for hip and knee OA 
IGF-1 regulates skeletal growth, and serum levels are related to periosteal 
expansion and BMD (511). Mechanisms of action include regulation of 
osteoblastogenesis, as well as regulation of chondrocyte differentiation and 
hypertrophy at the growth plate (511). Due to the role in both osteoblast and 
chondrocyte regulation, in Chapter 11, I aimed to clarify the role of IGF-1 in OA 
pathogenesis by determining the association between serum IGF-1 and hospital-
diagnosed OA at the hand, hip and knee in the UK Biobank population. Several 
observational analyses of the relationship between IGF-1 and OA have been 
performed, using much smaller sample sizes, and have generated conflicting 
results (509). Possible explanations for these conflicting results include 
phenotype heterogeneity, the lack of adjustment for key covariates such as BMI, 
or measurement of current IGF-1 levels which may not reflect IGF-1 levels 
throughout the lifecoure. I therefore utilised genetic loci related to IGF-1 levels to 
perform MR to determine the effect of genetically predicted IGF-1 on OA risk, as 
well as levels assessed at one timepoint in UK Biobank. 
In the observational analyses, prior to adjustment for BMI, IGF-1 levels appeared 
inversely related to hospital-diagnosed OA at the three joints. For hand OA, this 
relationship persisted after adjustment for BMI, whereas the association with 
knee OA was attenuated, and IGF-1 became positively related to hip OA. 




IGF-1 was positively related to BMI, suggesting that IGF-1 has differing 
relationships with BMI at different stages of the lifecourse. Subsequent MR 
analyses, including MVMR accounting for BMI, provided evidence for a causal 
effect of higher serum IGF-1 on hip OA, with weaker evidence for knee OA, and 
no evidence for a causal effect on hand OA, suggesting that higher IGF-1 levels 
throughout the lifecourse are involved in the pathogenesis of hip and knee OA. 
This study represented the largest analysis of observational relationships 
between IGF-1 and OA, and the first MR study to quantify the causal effect of 
IGF-1 on OA, independent of confounding and reverse causality. I did not 
observe attenuation of results when adjusting for eBMD, suggesting that BMD 
does not contribute to this relationship, thus meaning the IGF-1 axis could be 
another source of shared biology between BMD and OA. 
12.1.6. Hypothesized mechanisms 
Figure 126 summarizes the results discussed in sections 12.1.1-12.1.5 and my 
hypotheses for mechanisms behind the relationship between HBM and 




Figure 126: Summary of hypotheses to explain the relationship between HBM and prevalent and progressive OA. 
 





As well as the hypothesized direct effect of altered joint biomechanics due to 
increased loading by high BMD, a true causal pathway between high BMD and 
worsening OA sub-phenotypes could be explained by low bone turnover (201), 
which may contribute to a denser subchondral bone, creating greater pressure on 
the cartilage. However, although denser subchondral bone with lower bone 
turnover may contribute to subsequent disease progression, these features are 
not believed to initiate the disease process (18). Structure of the underlying 
subchondral trabecular bone could be altered in HBM individuals, as increased 
trabecular density at both the tibia and radius has been observed (200). 
Trabecular bone integrity of subchondral bone, with thinning of vertical, but 
thickening of horizontal, trabeculae has been linked to JSN progression, 
suggesting a role of trabecular bone in cartilage loss (537). Another analysis 
suggested that higher trabecular number and thickness plus reduced trabecular 
separation is linked to medial JSN progression (326), which would explain the 
relationship between HBM and development of JSN over eight years.  
In addition to the Wnt signalling, TGFβ superfamily and osteoclast 
differentiation pathways and the IGF-1 axis, enhanced endochondral ossification 
could contribute to osteophyte formation and OA pathogenesis in HBM 
individuals, and to shared genetic aetiology. In a recent GWAS of TH/L1-BMD 
in HBM individuals and individuals with low bone mass, two established BMD 
loci annotated to genes involved in endochondral ossification (MEF2C and 
SOX6) were identified (203). Endochondral ossification occurs in developing 
osteophytes (406). Re-establishment of endochondral ossification at the tidemark 
can lead to formation of additional tidemarks, advancing the area of calcified 
cartilage and reducing the articular cartilage (18), which could explain the 




12.2. Main strengths and limitations 
Analysis-specific strengths and limitations are discussed in the relevant results 
chapter. In this section, I will summarise the key strengths and limitations of the 
overall thesis. 
12.2.1. Strengths 
The major strength of the work presented in this thesis is the range of methods 
used, analysing the most appropriate data source for each research question. 
Although the HBM population was small, it allowed the study of differences in 
radiographic OA sub-phenotypes in individuals with extremely elevated BMD, 
against their family members with normal or low BMD. The fact that HBM is 
likely to have a predominantly genetic aetiology allows inferences about the 
temporal relationship between HBM and OA to be made, so results are unlikely 
to be explained by reverse causality. The availability of OA sub-phenotype data 
for a larger sample size in the RS population allowed replication of analyses in 
the general population and allowed some genetic analyses of OA sub-
phenotypes. The availability of genotype data for over 400,000 individuals in UK 
Biobank allowed well-powered genetic analyses for causal inference.  
12.2.2. Limitations 
The two key limitations of this work are loss-to-follow-up in the HBM 
population, reducing power and potentially biasing results for the progression 
analyses, as well as the lack of radiographic measures in UK Biobank.  
As referrals for DXA scans are normally due to conditions or medications related 
to older age, the HBM population at baseline was relatively old, so after 10 years 
there was a large drop-out due to death or ill health (only 58% of individuals 
recruited at the relevant sites were able to be followed-up, including 57% of those 
aged over 40 years at baseline). Fortunately, the proportion of individuals with 
HBM did not differ between those with or without follow-up data, suggesting 




However, there is also the concern that HBM individuals were more engaged 
with the study at baseline than their relatives without HBM, meaning that those 
with HBM still alive were more likely to participate in follow-up, regardless of 
health, whereas individuals without HBM were more likely to participate in 
follow-up if they were healthy and more altruistic, leading to a healthy-selection 
bias in the relative population, which could potentially cause spurious 
associations between HBM and worsening OA. Perhaps of some concern was the 
fact that, out of the follow-up population, relatives without HBM were more 
highly educated than HBM individuals, although adjustment for education did 
not alter conclusions. As well as possible selection bias, loss-to-follow-up led to 
very small sample sizes for the analyses of change in OA sub-phenotypes. 
Analyses of binary variables were underpowered (power <80%), generating CIs 
overlapping the null.  
The hospital-diagnosed OA phenotypes assessed in UK Biobank are unlikely to 
be comparable to radiographic OA definitions (based on KL/Croft score), as 
presentation to primary care and referral to secondary care likely reflects factors 
such as pain and referral practices, with radiographic evidence often being used 
to confirm a diagnosis upon presentation to secondary care. Therefore, hospital-
diagnosed OA is likely to reflect a severe, painful phenotype. Hospital-diagnosed 
hand OA was the least common phenotype in UK Biobank, whereas, as 
discussed in section 1.2.4, prevalence estimates for radiographic hand OA in any 
joint of the hand are higher than those for radiographic hip or knee OA (37-39). 
This is likely to reflect the lack of surgical procedures for hand OA, meaning GPs 
will be less likely to refer a hand OA patient to secondary care, compared to a hip 
or knee OA patient. Hospital-diagnosed OA phenotypes are therefore less useful 
when trying to identify mechanisms driving the structural progression of OA, 
and thus drug targets to reduce progression. Analyses of BMD in UK Biobank 
were also limited to BMD estimated from a combination of speed of sound and 
broadband ultrasound attenuation at the heel. The estimated correlation between 




a moderate genetic correlation between eBMD and FN-BMD (positive) and 
fracture risk (negative) (477). However, as discussed in Chapter 9, the 
composition of cortical vs trabecular bone differs between the hip and the heel, 
and these two different types of bone may have different roles in OA 
pathogenesis.  
12.3. Future work 
12.3.1. Examining the relationship between plasma sclerostin 
and OA sub-phenotypes in OAI  
I have found strong cross-sectional evidence for an association between plasma 
sclerostin and reduced odds of thumb JSN. However, this association requires 
replication in the general population. As discussed in section 10.4.5, sclerostin 
measurements are underway in OAI, which could be used to replicate analyses 
of cross-sectional associations between plasma sclerostin and OA sub-
phenotypes and perform longitudinal analyses of incident and progressive sub-
phenotypes. The OAI population will be included in an updated GWAS meta-
analysis of plasma sclerostin, which will hopefully be better powered to detect 
additional loci. If additional SNPs for sclerostin are identified, the MR analyses 
could be repeated with a stronger instrument, again increasing power.  
12.3.2. Additional MR analyses to further assess pleiotropy 
I have provided evidence for a BMI-independent causal effect of BMD on OA, 
although I have also found evidence for a direct effect of key pathways in bone 
development on OA risk. To further examine the pathways contributing to 
pleiotropy in the MR analyses of BMD on OA, I could annotate the Morris eBMD 
SNPs to the biological pathways analysed in Chapter 10, via their annotated 
gene. These annotations could be used to perform MR of eBMD on OA and 
determine if effect estimates differ across biological pathways. Evidence for 




effect on OA risk, not mediated by BMD) for specific pathways will be further 
evidence that these pathways have a direct effect on OA. Restricting to eBMD 
instruments not annotated to these pleiotropic pathways may give a pleiotropy-
robust estimate of the causal effect of BMD on OA.  
The low power of the MR-Egger method meant that CIs were very wide for 
analyses with few SNPs, limiting interpretability. Additionally, given the 
evidence for a direct effect of key bone pathways in OA pathogenesis generated 
in Chapter 10, and the inconsistency in results between the IVW, weighted 
median and MR-Egger methods for the causal effect of eBMD on knee OA 
(section 9.3.1), further analyses are required to determine the pleiotropy-
independent causal effect of BMD on OA. Since performing the analyses 
presented in this thesis, additional MR methods have been developed to generate 
pleiotropy-robust estimates of the causal effect in MR (539). These include 
methods to identify and remove, or downweight, outlier SNPs (539). If all SNPs 
are valid IVs, one would expect the Wald ratio estimate to be consistent across 
SNPs (539). However, if a SNP is associated with the outcome via a pathway not 
including the exposure (i.e. horizontal pleiotropy), and is thus an invalid 
instrument, the Wald ratio will differ from the estimates provided by valid 
instruments (539). MR pleiotropy residual sum and outlier (MR-PRESSO) is an 
example of a method which has recently been developed to identify and remove 
outliers, which identifies outliers by comparing the residuals for each SNP from 
the regression line to the expected residual when there is no horizontal 
pleiotropy (540). 
12.3.3. Additional pathways to consider 
I selected key signalling pathways in bone development for the pathway 
analyses, as there is evidence for a role of these pathways in OA pathogenesis, 
and the biology of these pathways is well understood. However, other key 
pathways remain which should be investigated in the future. As I hypothesize 




individuals with HBM, repeating pathway analyses with genes linked to 
endochondral ossification, and comparing variance explained between the OA 
sub-phenotypes, would be an important extension to this analysis. Other 
pathways identified based on the Morris annotated genes (386), such as 
adipogenesis, could likewise be investigated. Furthermore, to extend the analysis 
of the role of osteoclast pathways in OA pathogenesis, and determine if 
osteoclast pathways do have a direct role in OA pathogenesis or whether this is 
mediated by bone turnover, one could perform a GWAS of CTX-1 to identify 
genetic variants associated with bone resorption. These variants could then be 
used in an MR analysis of the causal effect of bone resorption on prevalent and 
progressive OA, using methods described in section 12.2.2 to identify pleiotropy 
(i.e. an effect of the variants on OA not mediated by bone resorption).  
12.3.4. Bone shape 
This work has focused on the role of bone mass in the pathogenesis of OA and 
has not focused on the role of bone shape. As discussed in Chapter 1, cam 
deformities of the hip are a risk factor for OA. More recently, associations 
between three OA loci and subtle variations in hip shape, such as a wider upper 
femur, were identified, suggesting a contribution of subtle variations in hip 
shape in the general population to OA pathogenesis (541). At the knee, 
relationships between the ratio of medial femoral to tibial subchondral surface 
area and incident symptoms have been observed (542). Analyses of the role of 
bone shape in OA pathogenesis were beyond the scope of this PhD. 
12.3.5. Radiographic phenotyping in UK Biobank 
Looking further ahead, the full data release from the UK Biobank imaging study 
is expected in 2022. This imaging study aims to recruit 100,000 individuals from 
the original population for various scans, including hip and knee DXA (343). This 
will allow the largest possible GWAS of DXA-assessed BMD to be performed 
(without adjustment for weight), which can be used to determine if FN-BMD 




could be used to assess osteophytes and JSN in UK Biobank, as long as this 
method is validated against grading from radiographs, and automated due to the 
scale of the task. This will remove the limitation of only having a severe, clinical 
measure of OA, and will allow most analyses performed in this thesis to be 
repeated with either a larger sample size or with more specific phenotypes. This 
will be particularly useful for repeating the pathway analyses to determine the 
variance explained in each OA sub-phenotype, as this larger sample size should 
generate more accurate estimates of the proportion of variance explained.  
12.4. Translational potential 
This work has highlighted the potential to target bone pathways to reduce 
structural progression of OA. The contribution of the Wnt signalling pathway to 
variance in OA risk, as well as the observed inverse relationship between 
sclerostin and thumb JSN, reiterates the potential benefit of Wnt inhibition in 
reducing structural OA progression (536). However, any treatment for OA must 
be balanced with the potential adverse impact on BMD and fracture risk, 
particularly in those more vulnerable to fracture, as the osteoporosis treatment 
Romosozumab aims to reduce, rather than increase, sclerostin levels (543). As the 
effect of IGF-1 on OA was of low magnitude and likely to reflect an effect across 
the lifecourse, targeting the IGF-1 axis is unlikely to be beneficial due to the key 
role of IGF-1 in skeletal growth and development (504).  
Targeting osteoclast pathways may be the best option, as reducing osteoclast 
function could lead to both BMD increases and reduced OA progression, as 
highlighted by the promising results for the RCT of the Cathepsin-K inhibitor, 
MIV-711, discussed in section 3.3.2. However, further analyses are required to 
determine the exact mechanism by which osteoclast differentiation contributes to 
OA, and whether this pathway contributes specifically to disease incidence or 
progression, as this will affect timing of any intervention. Also, development of 
the Cathepsin-K inhibitor, Odanacatib, developed as an osteoporosis treatment, 




cardiovascular events in those taking the drug (544), suggesting that targeting 
Cathepsin-K may lead to adverse effects on other systems. Alternatively, 
targeting pathways involved in endochondral ossification may be beneficial in 
reducing osteophyte formation and thus pain.  
It will be important to test any potential treatment in groups with different sub-
phenotypes of OA and in those with progressive vs non-progressive disease. For 
example, when patients from the trial of risedronate were stratified by 
progressors and non-progressors, as defined by change in mJSW, lower 
subchondral trabecular bone loss at the knee in those taking the highest dose of 
risedronate was observed in the progression group only (545), suggesting that 
bisphosphonates may only be effective in individuals with progressive disease, 
consistent with the theory that subchondral bone turnover is a key feature in the 
pathogenesis of early-stage disease (18). As the ultimate aim of OA drug trials is 
to reduce progression in those who already have the disease, interventions 
targeting risk factors for disease progression rather than incidence will have the 
greatest benefit for OA patients. Further genetic analyses of OA progression 
would be beneficial to identify genetic loci associated with disease progression, 
which could inform development of drugs to specifically reduce progression in 
those who already have the disease, the ultimate aim of OA drug trials.  
Circulating citrate levels may have translational potential as an additional 
biomarker of bone resorption, should levels be shown to be responsive to 
therapies known to reduce bone turnover. As citrate may reflect release of 
inorganic bone mineral into the circulation, measurement of citrate in 
osteoporosis may provide further information on the resorption process, in 
addition to CTX-1 which reflects breakdown of the organic phase of the bone 
matrix.  
12.5. Conclusions  
In this thesis, I have identified a strong positive relationship between HBM and 




years. I have confirmed a BMI-independent causal role of BMD on OA risk and 
provided evidence that this is not fully explained by the shared underlying 
biological pathways contributing to both BMD and OA. It remains to be 
determined if the association between BMD and hip/knee OA sub-phenotype 
progression represents a BMI-independent causal effect, although adjustment for 
TBFM did not attenuate the relationships between HBM and hip/knee OA sub-
phenotype progression.  
I have attempted to quantify the role of key bone pathways in variance in OA 
risk, with results suggesting that the Wnt signalling, TGFβ superfamily and 
osteoclast differentiation pathways have a direct role in OA pathogenesis. I have 
provided evidence for a role of the Wnt inhibitor sclerostin in reducing odds of 
OA specifically at the thumb. This result requires replication in a cohort 
generalizable to the general population and further analyses to determine 
causality. Finally, I have provided evidence that circulating levels of IGF-1 are a 
risk factor for both hip and knee OA. Further work is required to determine if 
intervening on IGF-1 levels in later life reduces OA risk.  
Overall, this work has furthered our knowledge of the role of bone in OA 
pathogenesis, highlighting BMD as a potential interventional target to reduce 
structural progression, as well as highlighting specific pathways for further 
analyses to determine their exact role in pathogenesis (e.g. the IGF-1 axis, 
osteoclast differentiation), which can potentially be translated to novel druggable 
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Appendix 1: Manuscript generated from the results of the analysis of the relationship 















































Appendix 2: Manuscript generated from the results of the analysis of the relationship 














































































































Appendix 4: Manuscript based on results of Mendelian randomization of IGF-1 and 
















































Appendix 5: Abstract based on results of multivariable MR analyses, accepted for poster 





Appendix 6: Abstract based on IGF-1 results, accepted for oral presentation at the OARSI 

































































































































Appendix 8: Inter- and intra-rater reliability statistics for the standardization set of knee radiographs. 
 Inter-rater Intra-rater 
 ICC 95% CI   ICC 95% CI   
Medial minimal JSW 0.787 0.689, 0.885   0.955 0.933, 0.977   
Maximum tibial plateau width 0.986 0.979, 0.993   0.994 0.991, 0.997   
 Unweighted Weighted Unweighted Weighted 
 kappa 95% CI kappa 95% CI Kappa 95% CI kappa 95% CI 
KL grade 0.607 0.479, 0.739 0.861 0.787, 0.890 0.803 0.734, 0.909 0.952 0.946, 0.959 
Medial femoral osteophyte 0.521 0.406, 0.560 0.614 0.573, 0.697 0.745 0.670, 0.867 0.865 0.822, 0.878 
Lateral femoral osteophyte 0.772 0.666, 0.957 0.951 0.920, 0.961 0.683 0.652, 0.765 0.919 0.881, 0.945 
Medial tibial osteophyte 0.628 0.459, 0.777 0.839 0.798, 0.853 0.669 0.579, 0.711 0.853 0.806, 0.884 
Lateral tibial osteophyte 0.533 0.453, 0.636 0.792 0.688, 0.870 0.822 0.755, 0.849 0.899 0.839, 0.972 
Medial JSN 0.636 0.459, 0.689 0.86 0.626, 0.928 0.652 0.630, 0.786 0.867 0.782, 0.892 
Lateral JSN 0.517 0.265, 0.550 0.684 0.366, 0.848 0.747 0.474, 0.926 0.826 0.698, 0.910 
Medial subchondral sclerosis 0.483 -0.131, 1   0.792 0.396, 1.000   
Lateral subchondral sclerosis 1 1,1   0.659 0.036, 1.000   




Appendix 9: Intra-rater reliability statistics for knee variables after first grading attempt. 
 N Unweighted Weighted 
  Kappa 95% CI Kappa 95% CI 
KL 69 0.544 0.409, 0.694 0.828 0.736, 0.898 
medial femoral osteophyte 69 0.838 0.638, 0.963 0.947 0.861, 0.989 
medial tibial osteophyte 69 0.82 0.691, 0.937 0.917 0.847, 0.973 
lateral femoral osteophyte 69 0.645 0.359, 0.858 0.877 0.628, 0.967 
lateral tibial osteophyte 69 0.71 0.498, 0.884 0.845 0.689, 0.943 
medial JSN 69 0.418 0.149, 0.661 0.704 0.377, 0.886 
lateral JSN 69 0.242 0, 0.496 0.796 0,0.895 
medial sclerosis 69 0.489 -0.111, 1   
lateral sclerosis 69 0.660 0.038, 1   
Chondrocalcinosis 69 0.850 0.561, 1   
Any OA (>=2) 69 0.820 0.684, 0.957   
Severe OA (>=3) 69 0.573 0.337, 0.808   
Any osteophyte (>=1) 69 0.820 0.684, 0.957   
Moderate osteophyte (>=2) 69 0.832 0.647, 1   
Any JSN (>=1) 69 0.422 0.184, 0.659   
Moderate JSN (>=2) 69 1 1,1   
Any sclerosis 69 0.653 0.209, 1   
  ICC 95% CI   
minimal JSW 139 0.995 0.993, 0.998   






Appendix 10: Intra-rater reliability statistics between second and third gradings of the 10% 
sample. 
 N Unweighted weighted 
  Kappa 95% CI Kappa 95% CI 
KL 69 0.762 0.643, 0.879 0.923 0.875, 0.963 
medial femoral osteophyte 69 0.811 0.610, 0.955 0.942 0.868, 0.988 
medial tibial osteophyte 69 0.822 0.664, 0.935 0.912 0.806, 0.970 
lateral femoral osteophyte 69 0.817 0.578, 1 0.962 0.854, 1 
lateral tibial osteophyte 69 0.909 0.729, 1 0.945 0.810, 1 
medial JSN 69 0.752 0.474, 0.941 0.887 0.643, 0.978 
lateral JSN 69 0.327 0, 0.496 0.855 0.795, 0.900 
medial sclerosis 69 0.660 0.038, 1   
lateral sclerosis 69 1 1, 1   
Chondrocalcinosis 69 1 1, 1   
Any OA (>=2) 69 0.877 0.759, 0.994   
Severe OA (>=3) 69 0.818 0.619, 1   
Any osteophyte (>=1) 69 0.877 0.759, 0.994   
Moderate osteophyte (>=2) 69 0.939 0.821, 1.000   
Any JSN (>=1) 69 0.758 0.560, 0.956   
Moderate JSN (>=2) 69 1 1, 1   





Appendix 11: Analyses of agreement of baseline measurements of minimal joint space width 
and maximal tibial plateau width between myself and Dr Hardcastle. 
 
Appendix 9a: Scatterplot of Dr Hardcastle's original mJSW measurements and my 
measurements for the same radiographs. 
 
 
Appendix 9b: Scatterplot of Dr Hardcastle's original maximal tibial plateau width 






Appendix 9c: Bland Altman plot displaying agreement between myself and Dr Hardcastle for 
measurements of mJSW. 
 
 
Appendix 9d: Bland Altman plot displaying agreement between myself and Dr Hardcastle 















Appendix 12: Standard operating procedure for measuring hip minimal joint space width. 

















Appendix 13: Correlation between the HipMorf baseline mJSW measurements and the 
BoneFinder baseline mJSW measurements. 
 
 
Appendix 14: Bland-Altman plot presenting agreement between the BoneFinder and 






Appendix 15: Inter- and intra-rater reliability statistics for the standardization set of hip radiographs. 
 Inter-rater Intra-rater 
 Unweighted Weighted Unweighted weighted 
 kappa 95% CI Kappa 95% CI kappa 95% CI kappa 95% CI 
Croft score 0.477 0.288, 0.622 0.799 0.671, 0.865 0.698 0.541, 0.811 0.863 0.751, 0.938 
Superior femoral osteophyte 0.584 0.333, 0.735 0.844 0.647, 0.917 0.81 0.623, 0.945 0.925 0.875, 1 
Inferior femoral osteophyte 0.544 0.317, 0.745 0.838 0.717, 0.928 0.89 0.698, 1 0.956 0.847, 1 
Superior acetabular osteophyte 0.369 0.227, 0.561 0.692 0.528, 0.833 0.81 0.661, 0.935 0.926 0.856, 0.983 
Inferior acetabular osteophyte 0.48 0.177, 0.783   0.88 0.717, 1   
Superior JSN 0.813 0.643, 1 0.859 0.732, 0.972 0.782 0.538, 0.943 0.828 0.617, 0.968 
Medial JSN 0.662 0.454, 0.826 0.835 0.662, 0.924 0.7 0.525, 0.937 0.831 0.695, 0.942 
Acetabular subchondral sclerosis -0.035 -0.093, 0.023   0.651 0.205, 1   
Femoral subchondral sclerosis -0.028 -0.083, 0.027   0.304 -0.076, 0.683   
















































Appendix 17: Final numbers with available measurements after excluding those samples that were not immediately frozen after collection and 
summary data for each of the metabolic traits. 
 All samples immediately frozen Removing 7SD outliers 
Metabolic traits N Mean SD Median LQ UQ N Mean SD 
Lipoprotein particle size          
Mean diameter for VLDL particles (nm) 326 38.35 1.05 38.32 37.57 39.06    
Mean diameter for LDL particles (nm) 326 23.53 0.42 23.55 23.26 23.82    
Mean diameter for HDL particles (nm) 326 9.30 0.10 9.30 9.23 9.36    
Cholesterol          
Serum total cholesterol (mmol/l) 326 0.61 0.37 0.50 0.40 0.72    
Total cholesterol in VLDL (mmol/l) 326 0.14 0.15 0.10 0.04 0.18    
Remnant cholesterol (nonHDL, nonLDL cholesterol) (mmol/l) 326 0.20 0.23 0.13 0.04 0.27    
Total cholesterol in LDL (mmol/l) 326 0.07 0.12 0.03 0.01 0.07    
Total cholesterol in HDL (mmol/l) 326 0.35 0.06 0.34 0.30 0.39    
Total cholesterol in HDL3 (mmol/l) 326 0.35 0.06 0.34 0.30 0.39    
Esterified cholesterol (mmol/l) 326 0.34 0.28 0.28 0.19 0.44    
Free cholesterol (mmol/l) 326 0.27 0.10 0.25 0.21 0.30    
Glycerides and Phospholipids          
Serum total triglycerides (mmol/l) 326 0.67 0.24 0.61 0.51 0.78    
Triglycerides in VLDL (mmol/l) 326 0.49 0.20 0.43 0.35 0.58    
Triglycerides in LDL (mmol/l) 326 0.07 0.03 0.06 0.05 0.07    
Triglycerides in HDL (mmol/l) 326 0.07 0.01 0.06 0.06 0.07    
Total phosphoglycerides (mmol/l) 326 0.34 0.17 0.29 0.23 0.40    
Phosphatidylcholine and other cholines (mmol/l) 326 0.33 0.16 0.29 0.23 0.37    
Sphingomyelins (mmol/l) 326 0.21 0.11 0.19 0.17 0.22 325 0.20 0.07 
Total cholines (mmol/l) 326 0.69 0.40 0.62 0.53 0.74 325 0.67 0.25 
Apolipoproteins          
Apolipoprotein AI (g/l) 326 0.55 0.05 0.54 0.51 0.58    
Apolipoprotein B (g/l) 326 0.30 0.10 0.28 0.23 0.34    
Ratio of apolipoprotein B to apolipoprotein AI 326 0.54 0.15 0.51 0.44 0.60    
Glycolysis-related metabolites          
Glucose (mmol/l) 319 3.77 1.36 3.42 3.10 3.91    
Lactate (mmol/l) 319 1.23 0.52 1.13 0.94 1.42 318 1.22 0.48 
Citrate (mmol/l) 326 0.13 0.02 0.13 0.11 0.14    
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Amino acids          
Alanine (mmol/l) 326 0.32 0.06 0.31 0.28 0.35    
Histidine (mmol/l) 326 0.02 0.01 0.02 0.02 0.03    
Branched-chain          
Isoleucine (mmol/l) 326 0.04 0.02 0.04 0.03 0.05    
Leucine (mmol/l) 326 0.07 0.02 0.06 0.05 0.08    
Valine (mmol/l) 326 0.14 0.04 0.14 0.11 0.16 325 0.14 0.04 
Aromatic          
Phenylalanine (mmol/l) 308 0.06 0.01 0.06 0.05 0.07 307 0.06 0.01 
Tyrosine (mmol/l) 326 0.05 0.01 0.05 0.04 0.06    
Ketone bodies          
Acetate (mmol/l) 322 0.12 0.08 0.11 0.10 0.13 320 0.12 0.03 
Acetoacetate (mmol/l) 325 0.01 0.01 0.01 0.01 0.01 324 0.01 0.01 
3hydroxybutyrate (mmol/l) 326 0.14 0.07 0.13 0.11 0.16    
Fluid balance          
Creatinine (mmol/l) 321 0.06 0.01 0.06 0.05 0.07    
Albumin (mmol/l) 326 0.08 0.01 0.08 0.07 0.08    
Inflammation          
Glycoprotein acetylation (mmol/l) 326 1.31 0.21 1.29 1.16 1.43    




Appendix 18: Comparing metabolomic associations in HBM to previously published 
work. 
To check the reliability of the metabolomic data, I compared associations with 
BMI, stratified by gender, to previously published results from adolescents (342). 
I performed linear regression modelling, with standardized metabolic traits as 
the exposure and BMI as the outcome, adjusting for age at blood sample 
collection, stratifying by gender and with robust SEs (Figure). Overall results 
were consistent, in direction of effect and difference in magnitude between men 
and women, with the previously published results (provided in Figure 2 of 
Wurtz et al (342)). The sample size was much smaller for HBM (206 HBM women 
and 114 men vs 6,468 women and 6,196 men, meaning CIs were wider and some 
results were null. The only difference between the HBM results and those 
previously published was a stronger association between BMI and glycoprotein 
acetyls in HBM women compared to men, whereas the opposite pattern was seen 
in the Wurtz population. This could reflect the much smaller sample size for 
HBM men or the older age of the HBM men compared to the adolescents and 





Figure 1: Associations between BMI and metabolic traits in the HBM population, 
stratified by gender. 
Points represent the SD increase in metabolic trait per 1kg/m2increase in BMI. 
 
I analysed differences in metabolic traits between those individuals ever taking 
statins and those individuals who had never taken a statin and compared results 
to those previously published (451). I created a variable for statin use based on 
recorded medications at baseline. I identified statins based on a BNF code of 
02.12(s). Other lipid-lowering medications (ezetimibe and fibrates) were 
identified based on free-text responses. I assessed differences in mean 
concentrations of metabolic traits between those who had ever taken a lipid-
lowering medication and those who had never taken one, in SD units, using 
linear regression, adjusting for age and sex, and using robust SEs (Figure). 
Sample sizes were much smaller in HBM and therefore results were closer to the 
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null. However, the direction of associations with statins were similar to the 
published literature (Presented in Figures 1 and 3 of Wurtz et al (451)).  
 
 
Figure 2: Associations between statin use and metabolic traits in the HBM population. 
Points represent the mean difference in SD units between those taking statins and those 



















Appendix 20: Descriptive characteristics of the HBM metabolomics study population, 
















difference  Mean (SD) Mean (SD) Mean (SD) 
Age (years) 59.1 (15.0) 61.6 (13.7) 55.0 (16.2) 1.26x10-4 
Height (cm) 168.7 (9.9) 166.9 (8.9) 171.7 (10.5) 1.45x10-5 
Weight (kg) 84.5 (17.0) 84.9 (16.8) 84.0 (17.4) 0.664 
BMI (kg/m2) 29.7 (5.6) 30.5 (5.8) 28.4 (4.9) 0.001 
L1-BMD 1.28 (0.22) 1.40 (0.16) 1.08 (0.16) 1.34x10-50 
L1-BMD Z-score 2.53 (2.14) 3.85 (1.34) 0.36 (1.25) 5.36x10-69 
Max TH-BMD 1.15 (0.21) 1.25 (0.18) 0.99 (0.14) 3.13x10-34 
Max TH-BMD Z-score 2.07 (1.61) 3.02 (1.16) 0.53 (0.89) 1.55x10-57 
Physical Activity  
(MET-minutes/week) 
3740.5 
(4414.6) 3479.0 (3293.0) 4155.7 (5760.0) 0.804 
  Median (IQR) Median (IQR)  
β-CTX (μg/L)a 
0.18 (0.12, 
0.27) 0.17 (0.12, 0.25) 0.20 (0.11, 0.28) 0.214 
P1NP (μg/L)a 
33.0 (25.0, 
44.0) 32.0 (23.0, 44.0) 34.0 (26.0, 44.0) 0.339 
Osteocalcin (μg/L)a 
16.9 (13.8, 
21.7) 16.6 (13.1, 21.2) 18.0 (14.6, 23.0) 0.007 
  N (%) N (%)  
Female 206 (64.4) 152 (76.8) 54 (44.3) 3.69x10-9 
Postmenopausalb 159 (77.2) 130 (85.5) 29 (53.7) 1.70x10-6 
History of bisphosphonate use 10 (3.1) 8 (4.0) 2 (1.6) 0.231 
History of oral glucocorticoid 
use 
66 (20.6) 
48 (24.2) 18 (14.8) 0.042 
Prior/current smoking 172 (53.9) 114 (57.6) 58 (47.5) 0.080 
Alcohol Consumption     
0.002 
     None 78 (24.4) 57 (28.8) 21 (17.2) 
     Occasional 32 (10.0) 22 (11.1) 10 (8.2) 
     Regular 160 (50.0) 99 (50.0) 61 (50.0) 
     Heavy 50 (15.6) 20 (10.1) 30 (24.6) 
ap-value represents difference in log-transformed concentrations due to skewed 
distributions; bindividuals currently going through menopause included in this category. 
Max TH BMD is the highest recorded BMD from the left and right hips. Total weekly 
MET-minutes is calculated as the energy requirement of each activity type multiplied by 
duration and summed across all three activity types. History of oral glucocorticoid use is 





Appendix 21: Full results of the metabolomics analysis with HBM as the exposure. 
  Model 1 Model 3 Excluding outliers Excluding tagged samples 
Outcome N Β LCI UCI p β LCI UCI p N β LCI UCI p N β LCI UCI p 
Acetoacetate 319 0.098 -0.036 0.232 0.153 0.140 -0.010 0.291 0.068 318 0.087 -0.024 0.198 0.124 311 0.116 -0.036 0.269 0.136 
Acetate 316 0.018 -0.207 0.244 0.873 0.173 -0.215 0.561 0.383 314 0.016 -0.065 0.096 0.703 311 0.154 -0.246 0.554 0.451 
Alanine 320 -0.369 -0.582 -0.157 0.001 -0.382 -0.607 -0.156 0.001 320 -0.382 -0.607 -0.156 0.001 311 -0.255 -0.465 -0.046 0.017 
Albumin 320 -0.196 -0.418 0.026 0.083 0.006 -0.249 0.262 0.962 320 0.006 -0.249 0.262 0.962 311 0.075 -0.160 0.311 0.529 
Apolipoprotein A1 320 -0.127 -0.222 -0.032 0.009 -0.100 -0.196 -0.003 0.042 320 -0.100 -0.196 -0.003 0.042 311 -0.060 -0.148 0.029 0.190 
Apolipoprotein B 320 -0.036 -0.210 0.139 0.688 -0.062 -0.228 0.105 0.468 320 -0.062 -0.228 0.105 0.468 311 0.028 -0.126 0.182 0.724 
Beta hydroxybutyrate 320 0.309 0.109 0.509 0.002 0.299 0.057 0.542 0.015 320 0.299 0.057 0.542 0.015 311 0.266 0.023 0.508 0.032 
Citrate 320 0.194 0.017 0.370 0.031 -0.001 -0.194 0.193 0.994 320 -0.001 -0.194 0.193 0.994 311 0.016 -0.178 0.211 0.868 
Creatinine 315 -0.067 -0.300 0.166 0.573 0.149 -0.078 0.375 0.198 315 0.149 -0.078 0.375 0.198 311 0.167 -0.057 0.391 0.144 
Glucose 313 -0.031 -0.271 0.209 0.800 -0.096 -0.330 0.137 0.418 313 -0.096 -0.330 0.137 0.418 311 -0.099 -0.332 0.134 0.405 
Glycoprotein acetyls 320 0.109 -0.119 0.337 0.348 -0.018 -0.266 0.231 0.890 320 -0.018 -0.266 0.231 0.890 311 0.061 -0.170 0.292 0.606 
Histidine 320 0.057 -0.121 0.235 0.532 0.103 -0.089 0.296 0.292 319 0.054 -0.103 0.211 0.503 311 0.145 -0.040 0.330 0.125 
Isoleucine 320 -0.082 -0.319 0.155 0.498 -0.033 -0.291 0.224 0.799 320 -0.033 -0.291 0.224 0.799 311 0.002 -0.257 0.261 0.986 
Lactate 313 -0.147 -0.373 0.079 0.202 -0.098 -0.437 0.240 0.569 312 0.006 -0.274 0.287 0.964 311 -0.093 -0.432 0.245 0.590 
Leucine 320 -0.176 -0.419 0.067 0.156 -0.128 -0.420 0.163 0.389 320 -0.128 -0.420 0.163 0.389 311 -0.058 -0.347 0.231 0.694 
Phenylalanine 302 0.229 0.006 0.451 0.044 0.011 -0.270 0.292 0.937 301 -0.087 -0.299 0.126 0.423 295 0.026 -0.257 0.308 0.858 
Total cholesterol 320 -0.040 -0.173 0.093 0.556 -0.059 -0.179 0.061 0.336 320 -0.059 -0.179 0.061 0.336 311 0.011 -0.095 0.117 0.844 
Triglycerides 320 -0.024 -0.250 0.202 0.835 0.021 -0.185 0.227 0.843 320 0.021 -0.185 0.227 0.843 311 0.122 -0.074 0.318 0.224 
Sphingomyelins 320 -0.180 -0.447 0.087 0.187 -0.286 -0.636 0.064 0.109 319 -0.127 -0.286 0.033 0.120 311 -0.274 -0.638 0.090 0.140 
Cholines 320 -0.173 -0.420 0.075 0.172 -0.285 -0.612 0.041 0.087 319 -0.135 -0.280 0.009 0.066 311 -0.263 -0.603 0.078 0.130 
Phosphoglycerides 320 -0.050 -0.203 0.103 0.521 -0.099 -0.229 0.032 0.138 320 -0.099 -0.229 0.032 0.138 311 -0.051 -0.184 0.083 0.455 
Tyrosine 320 -0.001 -0.240 0.237 0.991 -0.194 -0.464 0.076 0.160 320 -0.194 -0.464 0.076 0.160 311 -0.139 -0.401 0.123 0.299 





Appendix 22: Full results of the metabolomics analysis with TB-BMD as the exposure. 
  Model 1 Model 3 Excluding outliers Excluding tagged samples 
Outcome N β LCI UCI p β LCI UCI p N β LCI UCI p N β LCI UCI p 
Acetoacetate 318 -0.019 -0.065 0.026 0.406 0.013 -0.067 0.094 0.743 317 -0.018 -0.065 0.029 0.459 310 0.008 -0.082 0.098 0.866 
Acetate 315 0.055 -0.037 0.147 0.241 -0.004 -0.051 0.043 0.865 314 -0.014 -0.050 0.023 0.470 310 -0.010 -0.062 0.042 0.704 
Alanine 319 0.006 -0.092 0.105 0.898 -0.114 -0.217 -0.010 0.031 319 -0.114 -0.217 -0.010 0.031 310 -0.080 -0.189 0.028 0.147 
Albumin 319 0.036 -0.052 0.123 0.423 -0.042 -0.148 0.065 0.442 319 -0.042 -0.148 0.065 0.442 310 -0.036 -0.139 0.068 0.502 
Apolipoprotein A1 319 -0.014 -0.059 0.030 0.531 -0.047 -0.097 0.003 0.065 319 -0.047 -0.097 0.003 0.065 310 -0.031 -0.075 0.013 0.170 
Apolipoprotein B 319 -0.005 -0.076 0.065 0.878 -0.053 -0.136 0.030 0.209 319 -0.053 -0.136 0.030 0.209 310 -0.020 -0.095 0.054 0.593 
Beta hydroxybutyrate 319 -0.027 -0.118 0.063 0.555 -0.008 -0.117 0.101 0.881 319 -0.008 -0.117 0.101 0.881 310 -0.014 -0.137 0.109 0.822 
Citrate 319 -0.109 -0.218 0.000 0.050 -0.031 -0.137 0.075 0.565 319 -0.031 -0.137 0.075 0.565 310 -0.048 -0.165 0.069 0.423 
Creatinine 314 0.137 0.008 0.267 0.038 0.049 -0.072 0.170 0.428 314 0.049 -0.072 0.170 0.428 310 0.055 -0.086 0.196 0.444 
Glucose 312 -0.027 -0.144 0.090 0.650 -0.118 -0.249 0.013 0.078 312 -0.118 -0.249 0.013 0.078 310 -0.130 -0.273 0.013 0.075 
Glycoprotein acetyls 319 -0.003 -0.092 0.086 0.947 -0.092 -0.189 0.004 0.061 319 -0.092 -0.189 0.004 0.061 310 -0.088 -0.188 0.012 0.085 
Histidine 319 -0.011 -0.082 0.061 0.768 -0.023 -0.097 0.051 0.548 318 -0.027 -0.100 0.047 0.479 310 -0.008 -0.083 0.067 0.833 
Isoleucine 319 0.034 -0.078 0.147 0.552 -0.076 -0.188 0.037 0.188 319 -0.076 -0.188 0.037 0.188 310 -0.076 -0.198 0.047 0.225 
Lactate 312 -0.031 -0.197 0.135 0.716 -0.121 -0.287 0.045 0.153 311 -0.063 -0.181 0.056 0.298 310 -0.138 -0.331 0.055 0.161 
Leucine 319 -0.022 -0.159 0.114 0.749 -0.148 -0.275 -0.021 0.022 319 -0.148 -0.275 -0.021 0.022 310 -0.136 -0.263 -0.009 0.036 
Phenylalanine 301 -0.032 -0.136 0.072 0.550 -0.077 -0.176 0.021 0.123 300 -0.074 -0.172 0.024 0.141 294 -0.095 -0.206 0.015 0.091 
Total cholesterol 319 -0.019 -0.069 0.031 0.465 -0.050 -0.113 0.012 0.114 319 -0.050 -0.113 0.012 0.114 310 -0.019 -0.071 0.032 0.459 
Triglycerides 319 0.055 -0.034 0.145 0.225 -0.019 -0.121 0.082 0.712 319 -0.019 -0.121 0.082 0.712 310 0.013 -0.085 0.110 0.799 
Sphingomyelins 319 -0.102 -0.212 0.009 0.071 -0.087 -0.193 0.020 0.110 318 -0.052 -0.130 0.027 0.196 310 -0.083 -0.202 0.036 0.170 
Cholines 319 -0.097 -0.194 -0.001 0.047 -0.099 -0.190 -0.007 0.034 318 -0.065 -0.124 -0.006 0.031 310 -0.092 -0.195 0.010 0.078 
Phosphoglycerides 319 -0.035 -0.086 0.017 0.188 -0.078 -0.135 -0.021 0.007 319 -0.078 -0.135 -0.021 0.007 310 -0.059 -0.119 0.000 0.051 
Tyrosine 319 -0.135 -0.248 -0.022 0.019 -0.191 -0.316 -0.066 0.003 319 -0.191 -0.316 -0.066 0.003 310 -0.184 -0.312 -0.056 0.005 





Appendix 23: Full results of the metabolomics analysis with L1-BMD as the exposure. 
  Model 1 Model 3 Excluding outliers Excluding tagged samples 
Outcome N β LCI UCI p β LCI UCI p N β LCI UCI p N β LCI UCI p 
Acetoacetate 317 0.046 -0.039 0.130 0.290 0.065 -0.032 0.162 0.186 316 0.023 -0.027 0.073 0.365 309 0.055 -0.045 0.155 0.281 
Acetate 314 0.003 -0.058 0.064 0.921 0.002 -0.069 0.073 0.963 313 -0.017 -0.077 0.042 0.568 309 -0.003 -0.075 0.069 0.935 
Alanine 318 -0.135 -0.234 -0.036 0.008 -0.171 -0.264 -0.079 <0.001 318 -0.171 -0.264 -0.079 <0.001 309 -0.114 -0.209 -0.019 0.018 
Albumin 318 -0.038 -0.158 0.081 0.529 -0.012 -0.132 0.109 0.850 318 -0.012 -0.132 0.109 0.850 309 0.008 -0.107 0.123 0.893 
Apolipoprotein A1 318 -0.036 -0.087 0.016 0.173 -0.037 -0.088 0.014 0.155 318 -0.037 -0.088 0.014 0.155 309 -0.013 -0.056 0.030 0.558 
Apolipoprotein B 318 -0.032 -0.127 0.063 0.507 -0.055 -0.150 0.041 0.261 318 -0.055 -0.150 0.041 0.261 309 -0.012 -0.100 0.076 0.789 
Beta hydroxybutyrate 318 0.107 0.011 0.202 0.029 0.096 -0.010 0.203 0.076 318 0.096 -0.010 0.203 0.076 309 0.087 -0.023 0.197 0.121 
Citrate 318 0.016 -0.081 0.112 0.749 -0.006 -0.097 0.086 0.902 318 -0.006 -0.097 0.086 0.902 309 -0.010 -0.102 0.083 0.840 
Creatinine 313 0.053 -0.071 0.177 0.404 0.048 -0.054 0.151 0.355 313 0.048 -0.054 0.151 0.355 309 0.059 -0.046 0.163 0.271 
Glucose 311 -0.010 -0.133 0.113 0.869 -0.059 -0.178 0.059 0.328 311 -0.059 -0.178 0.059 0.328 309 -0.059 -0.177 0.060 0.333 
Glycoprotein acetyls 318 0.038 -0.073 0.149 0.499 -0.025 -0.134 0.083 0.649 318 -0.025 -0.134 0.083 0.649 309 -0.006 -0.112 0.101 0.919 
Histidine 318 0.002 -0.079 0.083 0.959 0.004 -0.088 0.095 0.939 317 -0.017 -0.097 0.064 0.685 309 0.028 -0.059 0.114 0.529 
Isoleucine 318 0.012 -0.105 0.129 0.841 -0.019 -0.141 0.104 0.765 318 -0.019 -0.141 0.104 0.765 309 -0.001 -0.122 0.120 0.982 
Lactate 311 -0.099 -0.255 0.058 0.216 -0.123 -0.286 0.041 0.142 310 -0.058 -0.167 0.050 0.292 309 -0.122 -0.286 0.041 0.142 
Leucine 318 -0.056 -0.188 0.076 0.409 -0.088 -0.224 0.049 0.208 318 -0.088 -0.224 0.049 0.208 309 -0.061 -0.193 0.071 0.365 
Phenylalanine 300 0.041 -0.071 0.152 0.477 -0.038 -0.154 0.077 0.517 299 -0.072 -0.168 0.023 0.135 293 -0.040 -0.158 0.077 0.501 
Total cholesterol 318 -0.042 -0.114 0.031 0.265 -0.055 -0.128 0.018 0.140 318 -0.055 -0.128 0.018 0.140 309 -0.018 -0.082 0.047 0.592 
Triglycerides 318 0.013 -0.103 0.129 0.832 -0.011 -0.125 0.103 0.851 318 -0.011 -0.125 0.103 0.851 309 0.033 -0.076 0.141 0.558 
Sphingomyelins 318 -0.148 -0.344 0.048 0.138 -0.150 -0.339 0.038 0.118 317 -0.056 -0.119 0.007 0.081 309 -0.138 -0.336 0.059 0.169 
Cholines 318 -0.138 -0.319 0.044 0.138 -0.148 -0.323 0.027 0.097 317 -0.060 -0.117 -0.003 0.038 309 -0.131 -0.313 0.052 0.160 
Phosphoglycerides 318 -0.039 -0.118 0.041 0.340 -0.064 -0.142 0.013 0.104 318 -0.064 -0.142 0.013 0.104 309 -0.035 -0.113 0.043 0.380 
Tyrosine 318 -0.021 -0.144 0.103 0.743 -0.080 -0.206 0.046 0.213 318 -0.080 -0.206 0.046 0.213 309 -0.051 -0.170 0.068 0.403 





Appendix 24: Full results of the metabolomics analysis with TH-BMD as the exposure. 
  Model 1 Model 3 Excluding outliers Excluding tagged samples 
Outcome N β LCI UCI p β LCI UCI p N Β LCI UCI p N β LCI UCI p 
Acetoacetate 314 -0.001 -0.061 0.060 0.978 0.026 -0.053 0.106 0.514 313 0.003 -0.061 0.067 0.922 306 0.015 -0.065 0.096 0.706 
Acetate 311 0.009 -0.051 0.068 0.779 -0.022 -0.087 0.043 0.505 310 -0.021 -0.082 0.041 0.508 306 -0.034 -0.096 0.029 0.291 
Alanine 315 -0.015 -0.122 0.093 0.786 -0.079 -0.187 0.029 0.153 315 -0.079 -0.187 0.029 0.153 306 -0.023 -0.129 0.082 0.664 
Albumin 315 0.054 -0.053 0.161 0.325 0.023 -0.086 0.132 0.678 315 0.023 -0.086 0.132 0.678 306 0.051 -0.053 0.155 0.339 
Apolipoprotein A1 315 -0.032 -0.075 0.010 0.133 -0.050 -0.095 -0.005 0.029 315 -0.050 -0.095 -0.005 0.029 306 -0.032 -0.073 0.008 0.116 
Apolipoprotein B 315 -0.026 -0.091 0.039 0.433 -0.064 -0.138 0.009 0.086 315 -0.064 -0.138 0.009 0.086 306 -0.028 -0.097 0.042 0.436 
Beta hydroxybutyrate 315 0.010 -0.091 0.110 0.849 0.012 -0.108 0.132 0.847 315 0.012 -0.108 0.132 0.847 306 -0.003 -0.125 0.119 0.961 
Citrate 315 -0.065 -0.170 0.039 0.219 -0.008 -0.113 0.097 0.881 315 -0.008 -0.113 0.097 0.881 306 -0.001 -0.110 0.108 0.981 
Creatinine 310 0.102 -0.020 0.224 0.101 0.097 -0.020 0.215 0.105 310 0.097 -0.020 0.215 0.105 306 0.104 -0.016 0.223 0.088 
Glucose 308 -0.077 -0.208 0.054 0.251 -0.128 -0.262 0.006 0.061 308 -0.128 -0.262 0.006 0.061 306 -0.130 -0.265 0.004 0.058 
Glycoprotein acetyls 315 0.056 -0.049 0.162 0.296 -0.031 -0.130 0.068 0.542 315 -0.031 -0.130 0.068 0.542 306 -0.002 -0.100 0.096 0.974 
Histidine 315 0.040 -0.037 0.116 0.306 0.034 -0.048 0.116 0.418 314 0.022 -0.056 0.100 0.572 306 0.049 -0.030 0.129 0.222 
Isoleucine 315 0.049 -0.059 0.158 0.371 -0.010 -0.116 0.096 0.854 315 -0.010 -0.116 0.096 0.854 306 0.008 -0.096 0.112 0.879 
Lactate 308 0.024 -0.132 0.180 0.763 -0.016 -0.170 0.138 0.839 307 0.009 -0.135 0.153 0.900 306 -0.012 -0.166 0.142 0.879 
Leucine 315 -0.015 -0.145 0.116 0.822 -0.077 -0.195 0.041 0.203 315 -0.077 -0.195 0.041 0.203 306 -0.043 -0.157 0.070 0.452 
Phenylalanine 297 0.025 -0.095 0.144 0.686 -0.038 -0.144 0.069 0.488 296 -0.059 -0.155 0.038 0.234 290 -0.031 -0.141 0.078 0.572 
Total cholesterol 315 -0.031 -0.079 0.017 0.209 -0.056 -0.112 0.000 0.049 315 -0.056 -0.112 0.000 0.049 306 -0.027 -0.079 0.024 0.300 
Triglycerides 315 0.012 -0.078 0.102 0.795 -0.038 -0.132 0.057 0.433 315 -0.038 -0.132 0.057 0.433 306 0.003 -0.088 0.094 0.951 
Sphingomyelins 315 -0.139 -0.319 0.042 0.132 -0.122 -0.286 0.042 0.146 314 -0.044 -0.103 0.014 0.139 306 -0.116 -0.286 0.054 0.180 
Cholines 315 -0.133 -0.300 0.034 0.117 -0.130 -0.283 0.023 0.095 314 -0.056 -0.107 -0.006 0.029 306 -0.120 -0.279 0.038 0.135 
Phosphoglycerides 315 -0.046 -0.102 0.009 0.101 -0.079 -0.141 -0.018 0.012 315 -0.079 -0.141 -0.018 0.012 306 -0.060 -0.122 0.003 0.061 
Tyrosine 315 -0.089 -0.205 0.027 0.134 -0.121 -0.240 -0.002 0.047 315 -0.121 -0.240 -0.002 0.047 306 -0.100 -0.217 0.017 0.093 





Appendix 25: Full results of the metabolomics analysis with hip osteophytes as the outcome. 
  Model 1 Model 3 Excluding outliers Excluding tagged samples 
Outcome N OR LCI UCI p OR LCI UCI p N OR LCI UCI p N OR LCI UCI p 
Acetoacetate 519 0.672 0.486 0.930 0.017 0.670 0.465 0.964 0.031 517 0.685 0.449 1.045 0.079 503 0.665 0.460 0.962 0.031 
Acetate 513 1.108 0.902 1.360 0.328 1.108 0.905 1.357 0.319 509 0.589 0.288 1.205 0.147 503 1.094 0.899 1.332 0.371 
Alanine 521 1.139 0.885 1.466 0.312 1.069 0.831 1.374 0.605 521 1.069 0.831 1.374 0.605 503 1.172 0.907 1.516 0.225 
Albumin 521 0.904 0.720 1.134 0.383 0.985 0.778 1.247 0.900 521 0.985 0.778 1.247 0.900 503 1.014 0.795 1.293 0.912 
Apolipoprotein A1 521 1.089 0.617 1.921 0.769 1.000 0.580 1.725 1.000 521 1.000 0.580 1.725 1.000 503 1.278 0.686 2.380 0.440 
Apolipoprotein B 521 1.247 0.891 1.746 0.198 1.205 0.877 1.655 0.250 521 1.205 0.877 1.655 0.250 503 1.444 0.991 2.104 0.056 
Beta hydroxybutyrate 521 1.011 0.794 1.286 0.932 0.992 0.791 1.243 0.942 521 0.992 0.791 1.243 0.942 503 0.984 0.786 1.234 0.892 
Citrate 521 1.103 0.861 1.413 0.437 0.979 0.752 1.275 0.875 521 0.979 0.752 1.275 0.875 503 0.994 0.757 1.304 0.963 
Creatinine 511 1.182 0.918 1.522 0.195 0.957 0.729 1.258 0.754 511 0.957 0.729 1.258 0.754 503 0.936 0.713 1.228 0.632 
Glucose 507 1.684 1.264 2.245 <0.001 1.492 1.136 1.960 0.004 507 1.492 1.136 1.960 0.004 503 1.473 1.124 1.931 0.005 
Glycoprotein acetyls 521 1.282 1.013 1.624 0.039 1.285 1.009 1.637 0.042 521 1.285 1.009 1.637 0.042 503 1.323 1.025 1.707 0.031 
Histidine 521 0.951 0.827 1.092 0.476 0.979 0.855 1.122 0.762 519 0.998 0.701 1.422 0.993 503 1.011 0.878 1.165 0.875 
Isoleucine 521 1.042 0.833 1.304 0.717 0.990 0.784 1.251 0.935 521 0.990 0.784 1.251 0.935 503 1.022 0.806 1.297 0.856 
Lactate 507 1.063 0.812 1.390 0.657 1.027 0.786 1.342 0.846 505 1.178 0.924 1.500 0.186 503 1.021 0.780 1.338 0.878 
Leucine 521 1.069 0.854 1.338 0.559 1.004 0.796 1.268 0.970 521 1.004 0.796 1.268 0.970 503 1.058 0.828 1.354 0.651 
Phenylalanine 491 1.157 0.912 1.469 0.230 1.120 0.868 1.444 0.383 489 1.085 0.788 1.492 0.618 477 1.116 0.867 1.438 0.395 
Total cholesterol 521 1.158 0.763 1.759 0.490 1.147 0.770 1.709 0.499 521 1.147 0.770 1.709 0.499 503 1.540 0.868 2.733 0.140 
Triglycerides 521 1.271 0.975 1.657 0.077 1.225 0.955 1.571 0.111 521 1.225 0.955 1.571 0.111 503 1.374 1.042 1.811 0.024 
Sphingomyelins 521 1.089 0.900 1.316 0.380 1.093 0.880 1.358 0.422 520 1.041 0.737 1.470 0.819 503 1.127 0.872 1.456 0.360 
Cholines 521 1.226 0.909 1.652 0.182 1.200 0.896 1.607 0.220 520 1.177 0.815 1.698 0.385 503 1.305 0.903 1.885 0.156 
Phosphoglycerides 521 1.456 0.915 2.316 0.113 1.367 0.882 2.119 0.162 521 1.367 0.882 2.119 0.162 503 1.697 0.947 3.042 0.075 
Tyrosine 521 1.178 0.915 1.517 0.203 1.064 0.821 1.380 0.639 521 1.064 0.821 1.380 0.639 503 1.106 0.838 1.459 0.477 
Valine 521 1.097 0.875 1.374 0.424 1.031 0.816 1.303 0.795 519 0.993 0.757 1.304 0.962 503 1.067 0.835 1.362 0.605 
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Appendix 26: Full results of the metabolomics analysis with hip JSN as the outcome. 
  Model 1 Model 3 Excluding outliers Excluding tagged samples 
Outcome N OR LCI UCI p OR LCI UCI p N OR LCI UCI P N OR LCI UCI p 
Acetoacetate 519 1.090 0.799 1.487 0.588 1.110 0.827 1.488 0.488 517 1.307 0.867 1.971 0.201 503 1.131 0.841 1.521 0.417 
Acetate 513 1.110 0.966 1.276 0.141 1.150 0.987 1.340 0.072 509 0.367 0.143 0.945 0.038 503 1.158 0.990 1.355 0.067 
Alanine 521 1.132 0.893 1.433 0.306 1.101 0.865 1.403 0.434 521 1.101 0.865 1.403 0.434 503 1.150 0.863 1.533 0.341 
Albumin 521 0.898 0.697 1.156 0.404 0.985 0.759 1.277 0.908 521 0.985 0.759 1.277 0.908 503 0.972 0.736 1.282 0.838 
Apolipoprotein A1 521 1.021 0.586 1.780 0.941 0.941 0.515 1.717 0.842 521 0.941 0.515 1.717 0.842 503 1.047 0.522 2.100 0.896 
Apolipoprotein B 521 0.981 0.699 1.378 0.913 0.993 0.678 1.455 0.973 521 0.993 0.678 1.455 0.973 503 1.011 0.663 1.544 0.958 
Beta hydroxybutyrate 521 1.049 0.804 1.369 0.724 1.019 0.784 1.324 0.890 521 1.019 0.784 1.324 0.890 503 1.056 0.824 1.355 0.666 
Citrate 521 0.940 0.719 1.228 0.649 0.807 0.607 1.073 0.140 521 0.807 0.607 1.073 0.140 503 0.793 0.589 1.067 0.126 
Creatinine 511 0.950 0.765 1.178 0.639 0.718 0.544 0.947 0.019 511 0.718 0.544 0.947 0.019 503 0.712 0.536 0.945 0.019 
Glucose 507 1.117 0.863 1.446 0.399 1.069 0.794 1.439 0.661 507 1.069 0.794 1.439 0.661 503 1.062 0.785 1.436 0.697 
Glycoprotein acetyls 521 0.959 0.744 1.237 0.749 0.983 0.739 1.308 0.905 521 0.983 0.739 1.308 0.905 503 0.945 0.710 1.257 0.697 
Histidine 521 0.984 0.798 1.213 0.878 1.008 0.820 1.238 0.943 519 1.184 0.810 1.730 0.383 503 1.027 0.833 1.266 0.806 
Isoleucine 521 1.076 0.802 1.444 0.624 1.072 0.780 1.472 0.669 521 1.072 0.780 1.472 0.669 503 1.091 0.792 1.502 0.595 
Lactate 507 0.926 0.724 1.185 0.542 0.901 0.680 1.193 0.466 505 0.937 0.680 1.291 0.690 503 0.906 0.684 1.200 0.492 
Leucine 521 1.144 0.874 1.496 0.328 1.121 0.845 1.486 0.429 521 1.121 0.845 1.486 0.429 503 1.142 0.853 1.530 0.372 
Phenylalanine 491 1.080 0.895 1.303 0.424 1.047 0.859 1.276 0.651 489 1.013 0.678 1.512 0.951 477 1.035 0.846 1.267 0.735 
Total cholesterol 521 0.964 0.606 1.532 0.875 1.005 0.612 1.651 0.985 521 1.005 0.612 1.651 0.985 503 1.070 0.623 1.837 0.806 
Triglycerides 521 0.993 0.753 1.308 0.958 0.986 0.721 1.348 0.929 521 0.986 0.721 1.348 0.929 503 0.978 0.699 1.369 0.899 
Sphingomyelins 521 1.155 0.993 1.342 0.061 1.169 0.988 1.383 0.069 520 1.017 0.704 1.468 0.929 503 1.180 0.998 1.395 0.053 
Cholines 521 1.224 1.038 1.443 0.017 1.234 1.028 1.482 0.024 520 1.113 0.757 1.637 0.587 503 1.253 1.037 1.515 0.020 
Phosphoglycerides 521 1.140 0.811 1.602 0.452 1.129 0.771 1.656 0.533 521 1.129 0.771 1.656 0.533 503 1.193 0.815 1.747 0.364 
Tyrosine 521 1.251 0.986 1.588 0.065 1.182 0.910 1.536 0.211 521 1.182 0.910 1.536 0.211 503 1.209 0.916 1.595 0.180 




Appendix 27: Full results of the metabolomics analysis with knee osteophytes as the outcome. 
  Model 1 Model 3 Excluding outliers Excluding tagged samples 
Outcome N OR LCI UCI p OR LCI UCI p N OR LCI UCI P N OR LCI UCI p 
Acetoacetate 599 1.002 0.738 1.360 0.990 1.070 0.750 1.527 0.710 596 1.094 0.652 1.837 0.733 583 1.024 0.698 1.504 0.902 
Acetate 593 0.864 0.702 1.064 0.168 0.926 0.609 1.410 0.722 588 1.047 0.530 2.067 0.895 583 0.886 0.536 1.464 0.636 
Alanine 601 1.026 0.818 1.286 0.827 0.984 0.741 1.307 0.910 600 0.984 0.741 1.309 0.914 583 0.985 0.723 1.342 0.922 
Albumin 601 0.705 0.532 0.933 0.015 0.956 0.691 1.322 0.784 600 0.954 0.687 1.325 0.778 583 0.939 0.666 1.324 0.720 
Apolipoprotein A1 601 0.968 0.565 1.661 0.907 1.063 0.594 1.902 0.837 600 1.127 0.630 2.017 0.687 583 1.109 0.594 2.070 0.746 
Apolipoprotein B 601 0.976 0.736 1.293 0.863 0.894 0.617 1.296 0.555 600 0.897 0.618 1.301 0.565 583 0.895 0.611 1.312 0.569 
Beta hydroxybutyrate 601 1.121 0.890 1.411 0.333 0.968 0.714 1.313 0.836 598 0.857 0.600 1.223 0.394 583 0.962 0.709 1.306 0.804 
Citrate 601 1.358 1.072 1.719 0.011 0.965 0.738 1.262 0.797 600 0.970 0.742 1.268 0.824 583 0.978 0.746 1.283 0.874 
Creatinine 591 1.171 0.940 1.459 0.160 1.107 0.836 1.465 0.477 590 1.113 0.841 1.471 0.454 583 1.110 0.840 1.468 0.464 
Glucose 588 1.011 0.839 1.218 0.908 0.747 0.550 1.016 0.063 587 0.746 0.552 1.009 0.057 583 0.747 0.551 1.011 0.059 
Glycoprotein acetyls 601 1.101 0.882 1.374 0.395 0.949 0.699 1.289 0.737 600 0.941 0.691 1.282 0.702 583 0.954 0.694 1.311 0.770 
Histidine 601 0.726 0.512 1.029 0.072 0.737 0.512 1.061 0.100 598 0.736 0.496 1.091 0.127 583 0.683 0.465 1.003 0.052 
Isoleucine 601 0.848 0.681 1.055 0.139 0.793 0.613 1.025 0.077 600 0.784 0.604 1.016 0.066 583 0.784 0.604 1.017 0.067 
Lactate 588 0.903 0.724 1.126 0.364 0.868 0.646 1.166 0.347 585 0.783 0.564 1.089 0.146 583 0.893 0.673 1.183 0.430 
Leucine 601 0.925 0.744 1.150 0.483 0.854 0.673 1.084 0.196 600 0.846 0.665 1.077 0.175 583 0.849 0.669 1.077 0.178 
Phenylalanine 565 1.127 0.898 1.413 0.303 0.867 0.663 1.132 0.294 562 0.879 0.626 1.232 0.453 551 0.875 0.671 1.142 0.327 
Total cholesterol 601 0.944 0.651 1.368 0.759 0.857 0.527 1.393 0.533 600 0.880 0.543 1.424 0.602 583 0.868 0.522 1.442 0.584 
Triglycerides 601 0.931 0.742 1.169 0.540 0.882 0.651 1.195 0.419 600 0.873 0.643 1.186 0.386 583 0.883 0.644 1.211 0.441 
Sphingomyelins 601 1.043 0.922 1.180 0.499 1.015 0.809 1.274 0.896 598 0.753 0.456 1.242 0.266 583 1.028 0.839 1.260 0.791 
Cholines 601 1.075 0.957 1.207 0.223 1.021 0.810 1.288 0.858 598 0.718 0.407 1.266 0.252 583 1.035 0.841 1.272 0.748 
Phosphoglycerides 601 1.041 0.755 1.436 0.805 0.784 0.502 1.225 0.285 600 0.793 0.508 1.240 0.310 583 0.805 0.510 1.271 0.352 
Tyrosine 601 1.262 1.014 1.572 0.038 0.934 0.733 1.191 0.583 600 0.929 0.728 1.185 0.553 583 0.944 0.737 1.208 0.644 




Appendix 28: Full results of the metabolomics analysis with knee JSN as the outcome. 
  Model 1 Model 3 Excluding outliers Excluding tagged samples 
Outcome N OR LCI UCI p OR LCI UCI P N OR LCI UCI p N OR LCI UCI p 
Acetoacetate 599 0.933 0.530 1.643 0.811 0.914 0.462 1.808 0.797 596 0.946 0.438 2.043 0.887 583 0.946 0.494 1.811 0.866 
Acetate 593 0.664 0.318 1.388 0.276 0.530 0.190 1.478 0.225 588 0.533 0.188 1.508 0.235 583 0.581 0.180 1.879 0.364 
Alanine 601 1.100 0.852 1.420 0.463 1.068 0.796 1.434 0.660 600 1.060 0.790 1.422 0.699 583 1.104 0.777 1.569 0.582 
Albumin 601 0.776 0.523 1.151 0.208 0.972 0.632 1.496 0.897 600 0.973 0.631 1.502 0.902 583 0.957 0.584 1.566 0.861 
Apolipoprotein A1 601 0.589 0.292 1.188 0.139 0.520 0.242 1.116 0.093 600 0.533 0.249 1.143 0.106 583 0.541 0.238 1.230 0.143 
Apolipoprotein B 601 0.783 0.505 1.214 0.274 0.708 0.401 1.252 0.235 600 0.705 0.398 1.249 0.231 583 0.675 0.351 1.298 0.239 
Beta hydroxybutyrate 601 1.009 0.646 1.577 0.968 0.879 0.530 1.456 0.616 598 0.612 0.355 1.054 0.077 583 0.932 0.598 1.454 0.757 
Citrate 601 1.559 1.186 2.048 0.001 1.242 0.917 1.683 0.161 600 1.238 0.907 1.689 0.179 583 1.262 0.916 1.740 0.155 
Creatinine 591 1.317 1.009 1.719 0.043 1.160 0.842 1.597 0.364 590 1.163 0.844 1.604 0.356 583 1.175 0.846 1.633 0.336 
Glucose 588 1.011 0.783 1.306 0.933 0.829 0.568 1.210 0.331 587 0.821 0.562 1.200 0.309 583 0.808 0.546 1.195 0.285 
Glycoprotein acetyls 601 1.026 0.773 1.362 0.860 0.991 0.687 1.431 0.962 600 0.986 0.682 1.427 0.942 583 0.984 0.654 1.478 0.937 
Histidine 601 0.692 0.411 1.166 0.167 0.701 0.405 1.211 0.203 598 0.696 0.395 1.229 0.212 583 0.654 0.358 1.193 0.166 
Isoleucine 601 0.777 0.519 1.161 0.218 0.744 0.452 1.224 0.244 600 0.747 0.453 1.233 0.254 583 0.757 0.448 1.281 0.300 
Lactate 588 0.632 0.425 0.940 0.023 0.571 0.357 0.914 0.020 585 0.568 0.351 0.920 0.022 583 0.595 0.377 0.941 0.026 
Leucine 601 0.882 0.615 1.265 0.496 0.838 0.552 1.272 0.407 600 0.842 0.553 1.280 0.420 583 0.853 0.542 1.343 0.493 
Phenylalanine 565 1.105 0.879 1.388 0.393 0.957 0.736 1.245 0.746 562 1.026 0.677 1.554 0.905 551 0.946 0.719 1.244 0.690 
Total cholesterol 601 0.682 0.367 1.270 0.228 0.602 0.280 1.297 0.195 600 0.606 0.282 1.304 0.200 583 0.571 0.233 1.396 0.219 
Triglycerides 601 0.826 0.577 1.183 0.297 0.761 0.470 1.235 0.269 600 0.759 0.467 1.231 0.264 583 0.731 0.418 1.279 0.272 
Sphingomyelins 601 1.241 1.039 1.483 0.017 1.268 1.030 1.561 0.025 598 0.755 0.437 1.304 0.313 583 1.276 1.041 1.564 0.019 
Cholines 601 1.290 1.069 1.557 0.008 1.305 1.057 1.611 0.013 598 0.754 0.398 1.430 0.387 583 1.315 1.069 1.617 0.010 
Phosphoglycerides 601 0.943 0.630 1.412 0.775 0.766 0.434 1.352 0.358 600 0.769 0.436 1.357 0.365 583 0.798 0.443 1.437 0.452 
Tyrosine 601 1.068 0.817 1.396 0.631 0.851 0.615 1.179 0.333 600 0.851 0.613 1.182 0.336 583 0.864 0.607 1.230 0.417 




Appendix 29: Full results of the metabolomics analysis with DIP osteophytes as the outcome. 
  Model 1 Model 3 Excluding outliers Excluding tagged samples 
Outcome N OR LCI UCI p OR LCI UCI p N OR LCI UCI p N OR LCI UCI p 
Acetoacetate 318 1.043 0.727 1.497 0.817 1.079 0.760 1.531 0.671 317 1.440 0.853 2.431 0.173 310 1.084 0.760 1.547 0.657 
Acetate 315 0.968 0.795 1.179 0.748 1.114 0.918 1.351 0.276 313 0.578 0.304 1.099 0.094 310 1.138 0.952 1.360 0.156 
Alanine 319 0.914 0.742 1.127 0.400 0.866 0.647 1.158 0.331 319 0.866 0.647 1.158 0.331 310 0.804 0.585 1.104 0.177 
Albumin 319 0.737 0.561 0.969 0.029 1.040 0.769 1.408 0.798 319 1.040 0.769 1.408 0.798 310 0.982 0.733 1.317 0.905 
Apolipoprotein A1 319 0.550 0.320 0.944 0.030 0.511 0.255 1.024 0.058 319 0.511 0.255 1.024 0.058 310 0.470 0.211 1.047 0.064 
Apolipoprotein B 319 0.915 0.657 1.274 0.597 0.884 0.603 1.294 0.526 319 0.884 0.603 1.294 0.526 310 0.835 0.523 1.334 0.451 
Beta hydroxybutyrate 319 1.250 0.968 1.614 0.087 1.210 0.901 1.625 0.204 319 1.210 0.901 1.625 0.204 310 1.234 0.913 1.669 0.172 
Citrate 319 1.360 1.077 1.719 0.010 0.806 0.602 1.077 0.145 319 0.806 0.602 1.077 0.145 310 0.782 0.588 1.041 0.093 
Creatinine 314 1.360 1.041 1.776 0.024 1.056 0.772 1.444 0.734 314 1.056 0.772 1.444 0.734 310 1.056 0.771 1.444 0.736 
Glucose 312 1.045 0.773 1.414 0.775 0.809 0.610 1.073 0.142 312 0.809 0.610 1.073 0.142 310 0.807 0.608 1.071 0.138 
Glycoprotein acetyls 319 1.013 0.797 1.287 0.919 0.993 0.751 1.313 0.959 319 0.993 0.751 1.313 0.959 310 0.957 0.716 1.279 0.766 
Histidine 319 0.975 0.762 1.247 0.840 1.051 0.831 1.328 0.680 318 0.932 0.596 1.455 0.755 310 1.048 0.824 1.333 0.702 
Isoleucine 319 1.021 0.817 1.275 0.855 1.054 0.791 1.404 0.718 319 1.054 0.791 1.404 0.718 310 1.045 0.785 1.392 0.763 
Lactate 312 0.733 0.568 0.947 0.018 0.657 0.487 0.886 0.006 311 0.546 0.388 0.767 <0.001 310 0.660 0.491 0.889 0.006 
Leucine 319 1.036 0.847 1.267 0.732 1.025 0.794 1.322 0.850 319 1.025 0.794 1.322 0.850 310 0.997 0.773 1.287 0.982 
Phenylalanine 301 1.115 0.904 1.377 0.309 0.858 0.668 1.102 0.230 300 0.730 0.514 1.037 0.079 294 0.853 0.661 1.101 0.223 
Total cholesterol 319 0.809 0.537 1.221 0.313 0.798 0.466 1.368 0.413 319 0.798 0.466 1.368 0.413 310 0.739 0.359 1.522 0.411 
Triglycerides 319 1.064 0.801 1.415 0.667 1.100 0.826 1.466 0.514 319 1.100 0.826 1.466 0.514 310 1.093 0.787 1.520 0.595 
Sphingomyelins 319 1.344 0.907 1.991 0.141 1.141 0.876 1.487 0.328 318 1.082 0.746 1.569 0.679 310 1.157 0.872 1.537 0.312 
Cholines 319 1.292 0.875 1.907 0.197 1.076 0.838 1.383 0.565 318 0.958 0.592 1.549 0.862 310 1.096 0.837 1.436 0.504 
Phosphoglycerides 319 0.964 0.642 1.449 0.861 0.807 0.503 1.293 0.372 319 0.807 0.503 1.293 0.372 310 0.810 0.470 1.397 0.449 
Tyrosine 319 1.239 0.982 1.563 0.071 0.865 0.664 1.127 0.283 319 0.865 0.664 1.127 0.283 310 0.855 0.651 1.121 0.257 




Appendix 30: Full results of the metabolomics analysis with CMC osteophytes as the outcome. 
  Model 1 Model 3 Excluding outliers Excluding tagged samples 
Outcome N OR LCI UCI p OR LCI UCI p N OR LCI UCI p N OR LCI UCI p 
Acetoacetate 318 0.775 0.565 1.063 0.114 0.777 0.530 1.138 0.195 317 0.810 0.502 1.306 0.388 310 0.800 0.556 1.153 0.232 
Acetate 315 1.040 0.880 1.228 0.647 1.142 0.976 1.336 0.098 313 1.193 0.662 2.149 0.558 310 1.162 0.980 1.378 0.084 
Alanine 319 1.100 0.845 1.433 0.478 1.087 0.817 1.445 0.567 319 1.087 0.817 1.445 0.567 310 0.983 0.708 1.365 0.919 
Albumin 319 0.847 0.683 1.051 0.131 1.087 0.850 1.391 0.506 319 1.087 0.850 1.391 0.506 310 1.039 0.793 1.361 0.781 
Apolipoprotein A1 319 0.769 0.446 1.326 0.345 0.797 0.418 1.521 0.492 319 0.797 0.418 1.521 0.492 310 0.556 0.270 1.147 0.112 
Apolipoprotein B 319 1.140 0.814 1.598 0.445 1.104 0.766 1.592 0.595 319 1.104 0.766 1.592 0.595 310 0.953 0.611 1.485 0.830 
Beta hydroxybutyrate 319 0.911 0.732 1.135 0.407 0.857 0.659 1.115 0.250 319 0.857 0.659 1.115 0.250 310 0.868 0.663 1.137 0.304 
Citrate 319 1.101 0.857 1.413 0.452 0.773 0.582 1.027 0.076 319 0.773 0.582 1.027 0.076 310 0.764 0.574 1.018 0.066 
Creatinine 314 1.333 0.961 1.850 0.085 1.186 0.795 1.770 0.404 314 1.186 0.795 1.770 0.404 310 1.173 0.785 1.753 0.436 
Glucose 312 1.298 0.903 1.867 0.158 1.095 0.816 1.470 0.546 312 1.095 0.816 1.470 0.546 310 1.100 0.819 1.478 0.526 
Glycoprotein acetyls 319 1.168 0.924 1.478 0.194 1.155 0.901 1.482 0.255 319 1.155 0.901 1.482 0.255 310 1.118 0.859 1.456 0.405 
Histidine 319 0.814 0.624 1.062 0.130 0.864 0.666 1.122 0.274 318 0.957 0.605 1.512 0.849 310 0.826 0.614 1.112 0.208 
Isoleucine 319 1.103 0.883 1.377 0.389 1.112 0.851 1.454 0.436 319 1.112 0.851 1.454 0.436 310 1.079 0.825 1.412 0.578 
Lactate 312 1.023 0.804 1.302 0.852 1.054 0.806 1.377 0.703 311 1.028 0.767 1.377 0.853 310 1.044 0.800 1.363 0.750 
Leucine 319 1.190 0.953 1.487 0.125 1.197 0.908 1.579 0.203 319 1.197 0.908 1.579 0.203 310 1.142 0.859 1.518 0.362 
Phenylalanine 301 1.126 0.791 1.602 0.511 0.930 0.704 1.226 0.605 300 1.097 0.769 1.564 0.611 294 0.930 0.706 1.226 0.607 
Total cholesterol 319 1.125 0.737 1.716 0.586 1.110 0.683 1.805 0.674 319 1.110 0.683 1.805 0.674 310 0.877 0.447 1.721 0.704 
Triglycerides 319 1.206 0.901 1.614 0.208 1.209 0.898 1.629 0.211 319 1.209 0.898 1.629 0.211 310 1.116 0.805 1.546 0.512 
Sphingomyelins 319 1.263 0.858 1.859 0.236 1.117 0.807 1.546 0.505 318 0.999 0.663 1.506 0.997 310 1.076 0.793 1.459 0.638 
Cholines 319 1.417 0.864 2.322 0.167 1.182 0.815 1.715 0.379 318 1.075 0.694 1.665 0.745 310 1.119 0.791 1.583 0.525 
Phosphoglycerides 319 1.398 0.890 2.196 0.146 1.227 0.798 1.887 0.352 319 1.227 0.798 1.887 0.352 310 1.086 0.675 1.747 0.735 
Tyrosine 319 1.385 1.027 1.867 0.033 1.142 0.829 1.573 0.417 319 1.142 0.829 1.573 0.417 310 1.102 0.796 1.526 0.559 




Appendix 31: Full results of the metabolomics analysis with DIP JSN as the outcome. 
  Model 1 Model 3 Excluding outliers Excluding tagged samples 
Outcome N OR LCI UCI p OR LCI UCI P N OR LCI UCI p N OR LCI UCI p 
Acetoacetate 318 1.115 0.790 1.574 0.535 1.184 0.836 1.677 0.341 317 1.474 0.945 2.300 0.087 310 1.219 0.841 1.768 0.296 
Acetate 315 0.783 0.591 1.037 0.088 0.760 0.463 1.247 0.277 313 0.777 0.426 1.416 0.410 310 0.762 0.441 1.317 0.330 
Alanine 319 0.981 0.773 1.244 0.871 0.959 0.734 1.252 0.756 319 0.959 0.734 1.252 0.756 310 0.890 0.660 1.200 0.445 
Albumin 319 0.924 0.729 1.172 0.516 1.273 0.981 1.652 0.069 319 1.273 0.981 1.652 0.069 310 1.255 0.933 1.689 0.134 
Apolipoprotein A1 319 0.604 0.331 1.104 0.101 0.568 0.287 1.122 0.104 319 0.568 0.287 1.122 0.104 310 0.442 0.230 0.851 0.015 
Apolipoprotein B 319 0.746 0.525 1.061 0.103 0.656 0.421 1.020 0.061 319 0.656 0.421 1.020 0.061 310 0.536 0.317 0.906 0.020 
Beta hydroxybutyrate 319 1.158 0.938 1.429 0.172 1.124 0.863 1.463 0.387 319 1.124 0.863 1.463 0.387 310 1.165 0.893 1.521 0.261 
Citrate 319 1.199 0.966 1.490 0.100 0.823 0.631 1.072 0.149 319 0.823 0.631 1.072 0.149 310 0.797 0.609 1.043 0.098 
Creatinine 314 1.198 0.963 1.491 0.105 0.984 0.777 1.247 0.896 314 0.984 0.777 1.247 0.896 310 0.987 0.782 1.246 0.914 
Glucose 312 0.879 0.693 1.115 0.289 0.647 0.464 0.903 0.011 312 0.647 0.464 0.903 0.011 310 0.646 0.461 0.905 0.011 
Glycoprotein acetyls 319 0.942 0.753 1.180 0.604 0.915 0.697 1.200 0.520 319 0.915 0.697 1.200 0.520 310 0.859 0.634 1.164 0.326 
Histidine 319 1.039 0.808 1.336 0.767 1.126 0.898 1.411 0.304 318 0.963 0.631 1.469 0.861 310 1.109 0.880 1.396 0.381 
Isoleucine 319 0.836 0.668 1.047 0.118 0.815 0.643 1.033 0.091 319 0.815 0.643 1.033 0.091 310 0.791 0.620 1.010 0.060 
Lactate 312 0.905 0.713 1.149 0.413 0.888 0.647 1.217 0.459 311 0.975 0.702 1.353 0.879 310 0.898 0.656 1.229 0.503 
Leucine 319 0.883 0.718 1.087 0.241 0.847 0.681 1.052 0.133 319 0.847 0.681 1.052 0.133 310 0.804 0.638 1.014 0.065 
Phenylalanine 301 0.950 0.772 1.170 0.631 0.811 0.634 1.037 0.095 300 0.838 0.615 1.142 0.264 294 0.805 0.622 1.042 0.099 
Total cholesterol 319 0.652 0.404 1.052 0.080 0.562 0.294 1.076 0.082 319 0.562 0.294 1.076 0.082 310 0.386 0.185 0.803 0.011 
Triglycerides 319 0.957 0.723 1.266 0.757 0.945 0.702 1.274 0.712 319 0.945 0.702 1.274 0.712 310 0.888 0.631 1.250 0.497 
Sphingomyelins 319 1.342 0.914 1.970 0.133 1.187 0.934 1.507 0.160 318 1.128 0.797 1.597 0.495 310 1.186 0.937 1.501 0.156 
Cholines 319 1.350 0.886 2.056 0.162 1.162 0.909 1.486 0.230 318 1.066 0.704 1.614 0.763 310 1.135 0.910 1.415 0.262 
Phosphoglycerides 319 0.909 0.617 1.339 0.629 0.737 0.456 1.190 0.212 319 0.737 0.456 1.190 0.212 310 0.644 0.390 1.061 0.084 
Tyrosine 319 0.986 0.798 1.219 0.897 0.742 0.582 0.944 0.015 319 0.742 0.582 0.944 0.015 310 0.680 0.535 0.866 0.002 




Appendix 32: Full results of the metabolomics analysis with CMC JSN as the outcome. 
  Model 1 Model 3 Excluding outliers Excluding tagged samples 
Outcome N OR LCI UCI p OR LCI UCI p N OR LCI UCI p N OR LCI UCI P 
Acetoacetate 318 0.916 0.698 1.202 0.528 0.937 0.672 1.306 0.700 317 1.005 0.637 1.585 0.983 310 0.986 0.717 1.357 0.933 
Acetate 315 0.872 0.677 1.124 0.290 0.924 0.704 1.215 0.573 313 1.445 0.766 2.725 0.256 310 0.960 0.752 1.225 0.741 
Alanine 319 1.168 0.955 1.428 0.131 1.162 0.919 1.469 0.210 319 1.162 0.919 1.469 0.210 310 1.007 0.762 1.331 0.962 
Albumin 319 0.850 0.684 1.055 0.140 1.007 0.801 1.267 0.951 319 1.007 0.801 1.267 0.951 310 0.949 0.732 1.229 0.690 
Apolipoprotein A1 319 1.670 0.982 2.842 0.058 1.858 1.029 3.355 0.040 319 1.858 1.029 3.355 0.040 310 1.364 0.712 2.612 0.349 
Apolipoprotein B 319 1.267 0.966 1.662 0.087 1.284 0.944 1.748 0.111 319 1.284 0.944 1.748 0.111 310 1.044 0.728 1.496 0.816 
Beta hydroxybutyrate 319 1.139 0.912 1.424 0.252 1.111 0.864 1.429 0.410 319 1.111 0.864 1.429 0.410 310 1.166 0.890 1.527 0.265 
Citrate 319 1.160 0.953 1.413 0.139 0.919 0.728 1.160 0.475 319 0.919 0.728 1.160 0.475 310 0.909 0.712 1.161 0.444 
Creatinine 314 1.183 0.923 1.518 0.184 1.040 0.778 1.392 0.790 314 1.040 0.778 1.392 0.790 310 1.040 0.777 1.392 0.792 
Glucose 312 1.008 0.804 1.262 0.947 0.875 0.644 1.190 0.396 312 0.875 0.644 1.190 0.396 310 0.881 0.649 1.196 0.417 
Glycoprotein acetyls 319 1.030 0.837 1.267 0.783 1.006 0.796 1.272 0.960 319 1.006 0.796 1.272 0.960 310 0.947 0.730 1.229 0.682 
Histidine 319 0.849 0.652 1.105 0.224 0.887 0.696 1.130 0.333 318 0.945 0.650 1.372 0.764 310 0.811 0.612 1.074 0.144 
Isoleucine 319 0.996 0.800 1.241 0.975 0.984 0.774 1.252 0.898 319 0.984 0.774 1.252 0.898 310 0.950 0.742 1.218 0.688 
Lactate 312 1.095 0.878 1.366 0.422 1.115 0.850 1.464 0.431 311 1.091 0.786 1.515 0.601 310 1.111 0.848 1.457 0.444 
Leucine 319 1.134 0.943 1.365 0.182 1.118 0.905 1.380 0.301 319 1.118 0.905 1.380 0.301 310 1.049 0.838 1.312 0.679 
Phenylalanine 301 1.242 0.997 1.546 0.053 1.138 0.912 1.420 0.251 300 1.080 0.807 1.445 0.603 294 1.135 0.909 1.419 0.264 
Total cholesterol 319 1.537 1.057 2.237 0.025 1.607 1.076 2.401 0.020 319 1.607 1.076 2.401 0.020 310 1.225 0.787 1.906 0.369 
Triglycerides 319 1.083 0.871 1.347 0.475 1.087 0.849 1.392 0.507 319 1.087 0.849 1.392 0.507 310 0.928 0.695 1.239 0.612 
Sphingomyelins 319 1.204 0.942 1.540 0.139 1.142 0.896 1.454 0.283 318 0.982 0.677 1.425 0.925 310 1.089 0.863 1.375 0.471 
Cholines 319 1.319 0.941 1.849 0.108 1.216 0.914 1.618 0.178 318 1.087 0.722 1.638 0.688 310 1.131 0.883 1.448 0.331 
Phosphoglycerides 319 1.409 1.018 1.951 0.039 1.327 0.950 1.855 0.097 319 1.327 0.950 1.855 0.097 310 1.108 0.765 1.604 0.587 
Tyrosine 319 1.276 1.044 1.559 0.017 1.104 0.891 1.367 0.367 319 1.104 0.891 1.367 0.367 310 1.069 0.865 1.321 0.539 




Appendix 33: Full results of the metabolomics analysis with P1NP as the exposure. 
  Model 1 Model 3 Excluding outliers Excluding tagged samples 
Outcome N β LCI UCI p Β LCI UCI p N β LCI UCI p N β LCI UCI p 
Acetoacetate 319 -0.060 -0.173 0.053 0.296 -0.061 -0.173 0.051 0.288 318 -0.018 -0.087 0.051 0.606 311 -0.045 -0.137 0.047 0.341 
Acetate 316 -0.021 -0.084 0.043 0.522 -0.005 -0.060 0.049 0.851 314 0.012 -0.031 0.055 0.579 311 -0.001 -0.068 0.065 0.974 
Alanine 320 0.132 0.005 0.258 0.042 0.140 0.016 0.263 0.027 320 0.158 0.018 0.298 0.027 311 0.136 0.000 0.273 0.050 
Albumin 320 0.051 -0.043 0.145 0.284 0.077 -0.015 0.169 0.103 320 0.081 -0.016 0.179 0.103 311 0.082 -0.016 0.180 0.103 
Apolipoprotein A1 320 0.007 -0.096 0.111 0.887 0.019 -0.080 0.119 0.703 320 0.009 -0.037 0.054 0.703 311 -0.010 -0.050 0.031 0.640 
Apolipoprotein B 320 -0.040 -0.146 0.066 0.457 -0.037 -0.145 0.071 0.501 320 -0.029 -0.114 0.056 0.501 311 -0.063 -0.132 0.006 0.073 
Beta hydroxybutyrate 320 -0.011 -0.125 0.103 0.850 -0.015 -0.123 0.093 0.783 320 -0.018 -0.147 0.111 0.783 311 -0.016 -0.147 0.114 0.805 
Citrate 320 0.137 0.029 0.245 0.013 0.106 0.004 0.208 0.042 320 0.118 0.004 0.232 0.042 311 0.132 0.014 0.249 0.028 
Creatinine 315 0.137 -0.096 0.370 0.250 0.146 -0.057 0.349 0.160 315 0.170 -0.067 0.406 0.160 311 0.172 -0.069 0.413 0.163 
Glucose 313 0.012 -0.102 0.126 0.835 0.006 -0.097 0.108 0.916 313 0.006 -0.107 0.119 0.916 311 0.007 -0.105 0.120 0.898 
Glycoprotein acetyls 320 -0.040 -0.131 0.051 0.386 -0.034 -0.121 0.053 0.438 320 -0.038 -0.135 0.058 0.438 311 -0.036 -0.133 0.060 0.460 
Histidine 320 0.003 -0.097 0.104 0.951 0.009 -0.093 0.110 0.865 319 0.023 -0.080 0.126 0.661 311 -0.002 -0.109 0.106 0.977 
Isoleucine 320 0.110 -0.079 0.300 0.253 0.121 -0.067 0.309 0.207 320 0.135 -0.074 0.344 0.207 311 0.134 -0.080 0.348 0.219 
Lactate 313 0.018 -0.093 0.129 0.748 0.031 -0.080 0.142 0.585 312 0.031 -0.093 0.156 0.625 311 0.033 -0.095 0.160 0.615 
Leucine 320 0.139 -0.054 0.333 0.159 0.152 -0.037 0.341 0.116 320 0.172 -0.042 0.387 0.116 311 0.172 -0.047 0.391 0.123 
Phenylalanine 302 0.100 -0.028 0.228 0.125 0.088 -0.034 0.211 0.158 301 0.103 -0.045 0.252 0.173 295 0.114 -0.032 0.261 0.126 
Total cholesterol 320 -0.017 -0.123 0.088 0.747 -0.014 -0.124 0.095 0.796 320 -0.008 -0.072 0.055 0.796 311 -0.039 -0.085 0.008 0.102 
Triglycerides 320 -0.039 -0.149 0.071 0.488 -0.029 -0.136 0.078 0.595 320 -0.029 -0.137 0.079 0.595 311 -0.062 -0.162 0.037 0.222 
Sphingomyelins 320 -0.004 -0.089 0.081 0.931 -0.013 -0.102 0.075 0.771 319 -0.005 -0.099 0.088 0.915 311 -0.031 -0.130 0.068 0.538 
Cholines 320 0.003 -0.085 0.090 0.954 -0.007 -0.098 0.084 0.883 319 0.002 -0.086 0.090 0.972 311 -0.024 -0.117 0.070 0.620 
Phosphoglycerides 320 -0.012 -0.136 0.112 0.852 -0.014 -0.138 0.109 0.819 320 -0.010 -0.093 0.073 0.819 311 -0.034 -0.115 0.047 0.406 
Tyrosine 320 0.102 -0.059 0.263 0.215 0.087 -0.064 0.237 0.258 320 0.100 -0.074 0.274 0.258 311 0.097 -0.078 0.272 0.276 
Valine 320 0.159 -0.025 0.343 0.090 0.173 -0.010 0.355 0.063 319 0.111 -0.038 0.259 0.144 311 0.205 -0.009 0.419 0.060 
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Appendix 34: Full results of the metabolomics analysis with osteocalcin as the exposure. 
  Model 1 Model 3 Excluding outliers Excluding tagged samples 
Outcome N β LCI UCI p Β LCI UCI p N β LCI UCI p N β LCI UCI p 
Acetoacetate 319 -0.008 -0.127 0.110 0.891 -0.020 -0.143 0.104 0.755 318 0.011 -0.065 0.087 0.782 311 -0.008 -0.101 0.086 0.873 
Acetate 316 -0.033 -0.086 0.021 0.229 -0.018 -0.067 0.031 0.480 314 0.003 -0.031 0.037 0.859 311 -0.015 -0.068 0.037 0.565 
Alanine 320 0.020 -0.093 0.134 0.725 0.042 -0.067 0.150 0.453 320 0.044 -0.071 0.158 0.453 311 0.013 -0.095 0.121 0.811 
Albumin 320 0.021 -0.077 0.119 0.670 0.036 -0.066 0.138 0.486 320 0.036 -0.064 0.135 0.486 311 0.045 -0.050 0.140 0.355 
Apolipoprotein A1 320 -0.036 -0.158 0.087 0.567 -0.022 -0.141 0.096 0.710 320 -0.010 -0.060 0.041 0.710 311 -0.020 -0.064 0.025 0.385 
Apolipoprotein B 320 -0.094 -0.200 0.012 0.082 -0.079 -0.187 0.030 0.154 320 -0.057 -0.136 0.022 0.154 311 -0.077 -0.134 -0.020 0.008 
Beta hydroxybutyrate 320 0.033 -0.102 0.169 0.628 0.037 -0.095 0.169 0.584 320 0.041 -0.105 0.187 0.584 311 0.041 -0.105 0.188 0.580 
Citrate 320 0.158 0.051 0.265 0.004 0.136 0.034 0.239 0.009 320 0.142 0.035 0.248 0.009 311 0.150 0.042 0.259 0.007 
Creatinine 315 0.170 -0.042 0.381 0.116 0.187 0.003 0.371 0.047 315 0.203 0.003 0.402 0.047 311 0.200 -0.001 0.401 0.051 
Glucose 313 -0.064 -0.167 0.038 0.220 -0.051 -0.135 0.034 0.242 313 -0.052 -0.138 0.035 0.242 311 -0.053 -0.140 0.034 0.232 
Glycoprotein acetyls 320 -0.067 -0.177 0.043 0.234 -0.035 -0.140 0.071 0.518 320 -0.036 -0.145 0.073 0.518 311 -0.019 -0.123 0.086 0.728 
Histidine 320 0.032 -0.073 0.137 0.550 0.038 -0.066 0.142 0.474 319 0.009 -0.079 0.097 0.846 311 0.026 -0.074 0.127 0.607 
Isoleucine 320 -0.047 -0.206 0.113 0.565 -0.023 -0.175 0.130 0.772 320 -0.023 -0.181 0.135 0.772 311 -0.021 -0.183 0.141 0.801 
Lactate 313 -0.123 -0.212 -0.034 0.007 -0.105 -0.193 -0.017 0.020 312 -0.096 -0.184 -0.008 0.033 311 -0.115 -0.210 -0.021 0.017 
Leucine 320 -0.042 -0.180 0.096 0.549 -0.019 -0.148 0.111 0.778 320 -0.020 -0.157 0.117 0.778 311 -0.012 -0.152 0.128 0.868 
Phenylalanine 302 0.012 -0.109 0.132 0.851 0.027 -0.082 0.136 0.630 301 0.046 -0.072 0.163 0.448 295 0.027 -0.095 0.150 0.661 
Total cholesterol 320 -0.053 -0.164 0.058 0.352 -0.041 -0.157 0.075 0.490 320 -0.022 -0.085 0.041 0.490 311 -0.040 -0.081 0.001 0.053 
Triglycerides 320 -0.124 -0.226 -0.021 0.018 -0.102 -0.198 -0.005 0.039 320 -0.096 -0.187 -0.005 0.039 311 -0.112 -0.186 -0.038 0.003 
Sphingomyelins 320 0.020 -0.057 0.097 0.607 0.006 -0.069 0.082 0.871 319 0.007 -0.070 0.085 0.852 311 -0.003 -0.079 0.073 0.938 
Cholines 320 0.006 -0.074 0.086 0.885 -0.003 -0.082 0.076 0.938 319 -0.002 -0.077 0.072 0.948 311 -0.012 -0.084 0.061 0.748 
Phosphoglycerides 320 -0.068 -0.184 0.049 0.256 -0.053 -0.168 0.062 0.369 320 -0.033 -0.106 0.039 0.369 311 -0.046 -0.111 0.018 0.157 
Tyrosine 320 -0.060 -0.173 0.053 0.296 -0.054 -0.159 0.050 0.309 320 -0.058 -0.170 0.054 0.309 311 -0.064 -0.174 0.047 0.258 




Appendix 35: Full results of the metabolomics analysis with β-CTX as the exposure. 
  Model 1 Model 3 Excluding outliers Excluding tagged samples 
Outcome N Β LCI UCI p Β LCI UCI P N β LCI UCI p N β LCI UCI p 
Acetoacetate 319 0.062 -0.074 0.199 0.373 0.057 -0.083 0.197 0.424 318 0.073 -0.026 0.171 0.147 311 0.049 -0.063 0.161 0.388 
Acetate 316 -0.033 -0.070 0.004 0.077 -0.005 -0.047 0.037 0.815 314 -0.016 -0.052 0.021 0.393 311 -0.002 -0.052 0.048 0.945 
Alanine 320 -0.077 -0.166 0.013 0.093 -0.056 -0.147 0.036 0.233 320 -0.062 -0.163 0.040 0.233 311 -0.074 -0.175 0.027 0.152 
Albumin 320 -0.030 -0.128 0.067 0.543 0.018 -0.085 0.121 0.730 320 0.019 -0.088 0.125 0.730 311 0.032 -0.072 0.135 0.548 
Apolipoprotein A1 320 -0.081 -0.177 0.015 0.098 -0.059 -0.152 0.035 0.218 320 -0.026 -0.068 0.015 0.218 311 -0.031 -0.071 0.009 0.128 
Apolipoprotein B 320 -0.126 -0.209 -0.042 0.003 -0.118 -0.207 -0.029 0.009 320 -0.091 -0.159 -0.023 0.009 311 -0.093 -0.159 -0.028 0.005 
Beta hydroxybutyrate 320 0.179 0.010 0.348 0.038 0.174 0.008 0.341 0.040 320 0.203 0.009 0.398 0.040 311 0.212 0.018 0.406 0.032 
Citrate 320 0.235 0.113 0.357 <0.001 0.185 0.071 0.300 0.002 320 0.203 0.078 0.329 0.002 311 0.199 0.072 0.327 0.002 
Creatinine 315 0.053 -0.087 0.194 0.456 0.078 -0.053 0.210 0.241 315 0.090 -0.060 0.239 0.241 311 0.096 -0.053 0.246 0.205 
Glucose 313 -0.095 -0.190 0.001 0.051 -0.097 -0.182 -0.011 0.026 313 -0.104 -0.196 -0.012 0.026 311 -0.102 -0.193 -0.011 0.028 
Glycoprotein acetyls 320 -0.050 -0.143 0.042 0.286 -0.041 -0.133 0.051 0.386 320 -0.044 -0.145 0.056 0.386 311 -0.033 -0.132 0.065 0.508 
Histidine 320 -0.055 -0.136 0.025 0.180 -0.048 -0.133 0.037 0.265 319 -0.033 -0.113 0.048 0.423 311 -0.051 -0.137 0.036 0.254 
Isoleucine 320 -0.076 -0.200 0.047 0.226 -0.051 -0.174 0.072 0.413 320 -0.056 -0.190 0.078 0.413 311 -0.050 -0.187 0.087 0.474 
Lactate 313 -0.086 -0.181 0.010 0.079 -0.065 -0.155 0.025 0.159 312 -0.063 -0.162 0.036 0.214 311 -0.075 -0.178 0.027 0.148 
Leucine 320 -0.071 -0.178 0.036 0.196 -0.046 -0.156 0.063 0.409 320 -0.051 -0.174 0.071 0.409 311 -0.041 -0.165 0.083 0.518 
Phenylalanine 302 -0.008 -0.111 0.095 0.877 -0.028 -0.126 0.070 0.575 301 -0.004 -0.103 0.094 0.930 295 -0.039 -0.152 0.074 0.496 
Total cholesterol 320 -0.076 -0.151 0.000 0.051 -0.068 -0.153 0.016 0.114 320 -0.039 -0.087 0.009 0.114 311 -0.042 -0.088 0.004 0.070 
Triglycerides 320 -0.148 -0.227 -0.070 <0.001 -0.129 -0.209 -0.049 0.002 320 -0.128 -0.208 -0.049 0.002 311 -0.129 -0.205 -0.052 0.001 
Sphingomyelins 320 -0.016 -0.084 0.052 0.651 -0.035 -0.107 0.037 0.341 319 -0.021 -0.096 0.055 0.590 311 -0.037 -0.117 0.043 0.362 
Cholines 320 -0.031 -0.093 0.032 0.336 -0.048 -0.116 0.019 0.158 319 -0.033 -0.096 0.030 0.308 311 -0.048 -0.116 0.019 0.160 
Phosphoglycerides 320 -0.095 -0.174 -0.016 0.018 -0.095 -0.180 -0.010 0.029 320 -0.063 -0.119 -0.006 0.029 311 -0.063 -0.120 -0.007 0.028 
Tyrosine 320 -0.071 -0.173 0.030 0.169 -0.096 -0.196 0.003 0.057 320 -0.109 -0.221 0.003 0.057 311 -0.099 -0.212 0.013 0.083 






























































































































































































































































































































































































































Appendix 37: Summary statistics for the eBMD SNPs used for two-sample MR analyses. 
  Exposure=BMD Outcome= hip OA Outcome= knee OA Outcome=BMI 












rs10015974 A 0 0.24 0.010 0.002 5.50E-09 0.242 -0.008 0.013 5.58E-01 T 0.246 0.010 0.010 3.26E-01 T 0.3083 0.003 0.004 5.25E-01 T 
rs10057211 A 0 0.91 -0.030 0.003 8.40E-18 0.891 0.018 0.018 3.18E-01 T 0.893 0.026 0.015 7.04E-02 T      
rs10145299 T 0 0.51 -0.020 0.002 7.60E-27 0.512 0.010 0.011 3.66E-01 T 0.519 -0.016 0.009 6.85E-02 T 0.5417 0.004 0.004 2.92E-01 T 
rs10147522 A 0 0.66 -0.010 0.002 5.00E-09 0.652 -0.022 0.012 6.11E-02 T 0.657 -0.001 0.009 8.86E-01 T 0.7167 0.007 0.004 7.19E-02 T 
rs10206992 T 0 0.75 0.020 0.002 5.30E-17 0.733 -0.009 0.013 4.61E-01 T 0.729 0.011 0.010 2.86E-01 T 0.7417 0.004 0.004 2.95E-01 T 
rs10239787 C 0 0.67 0.030 0.002 0.00E+00 0.660 -0.019 0.012 1.02E-01 T 0.655 0.001 0.009 8.91E-01 T 0.6083 0.007 0.004 6.35E-02 T 
rs10407062 T 0 0.55 0.010 0.002 2.60E-11 0.537 0.011 0.011 3.09E-01 T 0.537 -0.018 0.009 4.76E-02 T 0.5083 -0.003 0.004 4.15E-01 T 
rs1042704 G 0 0.78 0.030 0.002 5.20E-28 0.800 -0.007 0.014 6.47E-01 T 0.800 -0.013 0.011 2.37E-01 T 0.75 0.006 0.006 2.78E-01 T 
rs1043003 T 0 0.62 0.020 0.002 3.60E-12 0.613 0.011 0.012 3.34E-01 T 0.609 -0.006 0.010 5.21E-01 T 0.6333 0.003 0.004 4.61E-01 T 
rs10462395 A 0 0.8 -0.010 0.002 1.60E-05 0.802 0.009 0.014 5.21E-01 T 0.790 -0.013 0.011 2.54E-01 T 0.8333 -0.009 0.005 7.32E-02 T 
rs10473868 G 0 0.57 0.010 0.002 1.30E-08 0.556 0.011 0.012 3.63E-01 T 0.557 0.020 0.010 3.83E-02 T 0.5417 0.004 0.004 2.56E-01 T 
rs10490046 A 0 0.78 0.030 0.002 7.00E-30 0.761 0.007 0.013 5.67E-01 T 0.759 -0.008 0.010 4.39E-01 T 0.7917 -0.002 0.004 5.85E-01 T 
rs10515269 C 0 0.52 -0.020 0.002 3.60E-15           0.625 -0.006 0.004 8.37E-02 T 
rs10750766 C 0 0.29 -0.030 0.002 3.60E-27 0.284 0.007 0.012 5.70E-01 T 0.291 -0.004 0.010 7.09E-01 T      
rs10756762 T 0 0.59 -0.020 0.002 2.50E-21 0.589 -0.004 0.012 7.02E-01 T 0.592 -0.007 0.010 4.88E-01 T 0.525 0.006 0.004 9.73E-02 T 
rs10764201 C 0 0.48 -0.020 0.002 4.60E-19 0.480 0.006 0.011 5.83E-01 T 0.486 -0.009 0.009 2.93E-01 T 0.45 -0.009 0.004 1.61E-02 T 
rs10765568 C 0 0.63 0.020 0.002 2.70E-15 0.639 0.016 0.012 1.65E-01 T 0.633 -0.006 0.009 5.13E-01 T 0.6083 -0.012 0.004 3.18E-03 T 
rs10779795 A 0 0.66 0.020 0.002 4.40E-22 0.658 0.022 0.012 7.24E-02 T 0.657 0.010 0.009 3.11E-01 T 0.6667 0.010 0.004 1.24E-02 T 
rs10792352 C 0 0.29 -0.010 0.002 3.50E-03 0.296 0.010 0.012 3.97E-01 T 0.306 0.014 0.010 1.58E-01 T      
rs10800531 A 0 0.54 -0.030 0.002 4.50E-35           0.5847 -0.003 0.004 4.45E-01 T 
rs10817896 C 0 0.73 -0.020 0.002 3.70E-10 0.718 -0.008 0.012 5.42E-01 T 0.716 0.000 0.010 9.86E-01 T 0.7083 0.002 0.004 5.52E-01 T 
rs10842704 T 0 0.76 -0.030 0.002 3.40E-28 0.728 0.015 0.013 2.21E-01 T 0.723 0.017 0.010 8.33E-02 T 0.8167 0.009 0.004 6.46E-03 T 
rs10885434 G 0 0.28 0.020 0.002 9.80E-23 0.285 -0.007 0.013 6.01E-01 T 0.297 -0.016 0.011 1.21E-01 T      
rs10893348 C 0 0.56 -0.020 0.002 8.60E-13 0.559 -0.008 0.011 5.02E-01 T 0.564 -0.011 0.009 2.09E-01 T      
rs10917477 A 0 0.52 -0.010 0.002 1.70E-13 0.515 -0.020 0.011 6.96E-02 T 0.522 0.006 0.009 5.33E-01 T 0.5667 0.002 0.004 5.52E-01 T 
rs10920352 T 0 0.58 -0.010 0.002 4.00E-10 0.553 0.012 0.012 3.00E-01 T 0.549 0.011 0.009 2.27E-01 T 0.5678 -0.002 0.004 6.53E-01 T 
rs10931982 T 0 0.23 -0.050 0.002 0.00E+00 0.204 -0.013 0.015 3.98E-01 T 0.205 0.005 0.013 6.62E-01 T 0.3 0.005 0.008 5.10E-01 T 
rs10956974 C 0 0.78 -0.030 0.002 4.00E-27 0.741 -0.005 0.013 6.87E-01 T 0.747 -0.012 0.010 2.46E-01 T 0.7333 0.004 0.004 3.64E-01 T 
rs10980517 A 0 0.53 -0.020 0.002 5.40E-13 0.514 0.003 0.011 7.92E-01 T 0.512 -0.002 0.009 7.93E-01 T      
rs11067228 A 0 0.55 -0.020 0.002 2.10E-16 0.568 -0.009 0.012 4.19E-01 T 0.565 0.001 0.009 9.01E-01 T 0.525 -0.001 0.004 8.12E-01 T 
rs11073930 G 0 0.45 -0.020 0.002 1.10E-27           0.3583 0.003 0.004 4.66E-01 T 
rs11088458 A 0 0.29 0.040 0.002 0.00E+00 0.279 0.002 0.013 8.65E-01 T 0.295 0.001 0.010 9.33E-01 T      
rs11142400 G 0 0.67 -0.010 0.002 2.20E-09 0.644 -0.009 0.012 4.53E-01 T 0.647 -0.004 0.010 7.17E-01 T      
rs11175835 G 0 0.29 0.020 0.002 2.10E-22 0.255 -0.011 0.013 3.96E-01 T 0.264 0.012 0.011 2.89E-01 T 0.325 -0.002 0.004 7.21E-01 T 
rs11196170 G 0 0.79 0.030 0.002 2.90E-31 0.799 -0.002 0.015 8.94E-01 T 0.781 -0.007 0.012 5.87E-01 T      
rs112073168 G 0 0.97 0.040 0.006 9.00E-10 0.972 -0.008 0.036 8.15E-01 T 0.973 -0.043 0.029 1.33E-01 T      
rs11228240 C 1 0.72 0.040 0.002 0.00E+00 0.738 0.001 0.013 9.71E-01 T 0.738 0.027 0.010 7.88E-03 T 0.7667 0.001 0.004 8.89E-01 T 
rs11238526 A 0 0.94 -0.020 0.004 1.20E-06 0.940 0.015 0.026 5.64E-01 T 0.926 0.009 0.019 6.53E-01 T 0.9083 0.000 0.007 9.96E-01 T 
rs11238756 T 0 0.55 -0.010 0.002 5.50E-10 0.539 -0.014 0.011 2.10E-01 T 0.534 -0.006 0.009 4.84E-01 T 0.6333 0.001 0.004 7.05E-01 T 
rs112766772 T 0 0.77 -0.020 0.002 3.30E-10 0.782 -0.020 0.018 2.59E-01 T 0.783 0.012 0.017 4.79E-01 T      
rs1133400 A 0 0.78 -0.030 0.002 4.60E-34 0.788 0.020 0.014 1.68E-01 T 0.789 0.013 0.012 2.57E-01 T NA -0.012 0.008 1.48E-01 T 
rs11576308 G 0 0.39 -0.020 0.002 2.70E-15 0.385 -0.072 0.012 5.87E-09 F 0.384 -0.010 0.010 2.85E-01 T 0.3833 -0.001 0.004 7.72E-01 T 
rs11587434 G 0 0.74 -0.010 0.002 1.00E-06 0.745 -0.010 0.014 4.63E-01 T 0.739 -0.031 0.011 4.79E-03 F NA -0.024 0.004 2.53E-11 F 
 
 554 
rs1159798 A 0 0.22 0.060 0.002 0.00E+00 0.225 -0.011 0.014 4.29E-01 T 0.231 -0.013 0.011 2.25E-01 T 0.2417 0.001 0.006 8.44E-01 T 
rs116228246 G 0 0.98 -0.090 0.006 0.00E+00 0.977 -0.005 0.038 8.92E-01 T 0.979 -0.009 0.032 7.80E-01 T      
rs11643240 A 0 0.73 0.020 0.002 2.10E-12 0.749 0.019 0.013 1.37E-01 T 0.737 -0.023 0.010 2.06E-02 T 0.7083 -0.010 0.004 1.33E-02 T 
rs116504838 G 0 0.97 -0.030 0.006 1.50E-06 0.976 0.040 0.037 2.80E-01 T 0.975 0.025 0.029 3.94E-01 T      
rs11668064 A 0 0.69 0.030 0.002 0.00E+00 0.709 0.005 0.013 7.16E-01 T 0.699 0.014 0.010 1.81E-01 T 0.7583 -0.003 0.004 4.54E-01 T 
rs11670562 T 0 0.74 -0.010 0.002 3.00E-11 0.742 -0.002 0.013 8.56E-01 T 0.740 -0.011 0.010 2.87E-01 T      
rs11675489 A 0 0.54 0.010 0.002 1.30E-09 0.562 0.015 0.011 1.91E-01 T 0.561 -0.018 0.009 4.16E-02 T 0.4833 -0.002 0.004 5.52E-01 T 
rs11679303 C 0 0.78 0.010 0.002 8.40E-09 0.771 0.001 0.013 9.18E-01 T 0.774 -0.004 0.011 6.74E-01 T 0.7417 -0.002 0.004 5.70E-01 T 
rs11688492 T 0 0.54 0.010 0.002 2.30E-11 0.557 0.011 0.012 3.62E-01 T 0.557 0.001 0.010 9.23E-01 T      
rs11696009 A 0 0.66 -0.020 0.002 2.30E-14 0.671 -0.009 0.012 4.76E-01 T 0.675 -0.004 0.009 6.86E-01 T 0.6083 -0.001 0.004 8.61E-01 T 
rs117111740 T 0 0.97 0.110 0.006 0.00E+00 0.965 0.024 0.034 4.90E-01 T 0.969 0.036 0.030 2.28E-01 T      
rs11729023 C 0 0.88 -0.030 0.003 1.30E-14 0.879 -0.013 0.017 4.49E-01 T 0.880 -0.002 0.014 8.64E-01 T 0.8583 -0.008 0.006 1.75E-01 T 
rs11743474 A 0 0.84 0.020 0.003 4.80E-09 0.836 -0.018 0.016 2.42E-01 T 0.840 0.000 0.013 9.75E-01 T 0.8083 0.003 0.005 6.24E-01 T 
rs117481343 C 0 0.97 -0.130 0.006 0.00E+00 0.967 0.064 0.034 6.35E-02 T 0.971 0.037 0.029 1.95E-01 T      
rs118115924 G 0 0.99 0.200 0.009 0.00E+00 0.988 -0.013 0.057 8.26E-01 T 0.989 0.023 0.050 6.46E-01 T      
rs11814082 T 0 0.82 -0.010 0.002 2.30E-05 0.825 -0.019 0.015 2.02E-01 T 0.820 -0.022 0.012 6.05E-02 T 0.8167 0.000 0.005 9.84E-01 T 
rs11880992 G 0 0.59 0.020 0.002 2.20E-15 0.595 0.037 0.012 1.37E-03 T 0.582 -0.017 0.009 6.23E-02 T 0.625 -0.002 0.004 6.36E-01 T 
rs11881367 G 0 0.91 -0.100 0.003 0.00E+00 0.908 0.046 0.020 1.97E-02 T 0.903 0.004 0.015 8.18E-01 T 0.9083 0.000 0.005 9.83E-01 T 
rs11915970 A 0 0.88 -0.040 0.003 0.00E+00 0.868 -0.035 0.017 3.55E-02 T 0.872 0.001 0.013 9.65E-01 T 0.875 -0.009 0.006 1.05E-01 T 
rs11934731 G 1 0.32 0.040 0.002 0.00E+00 0.312 0.003 0.012 7.99E-01 T 0.313 0.000 0.010 9.88E-01 T 0.3417 -0.007 0.004 8.22E-02 T 
rs1206755 C 0 0.53 -0.020 0.002 1.90E-15           0.5 -0.005 0.004 1.44E-01 T 
rs12228756 G 0 0.93 -0.030 0.004 5.10E-13 0.937 0.025 0.023 2.75E-01 T 0.922 0.010 0.018 5.88E-01 T 0.95 -0.008 0.008 3.30E-01 T 
rs12251299 C 0 0.87 0.100 0.003 0.00E+00 0.865 0.002 0.017 8.81E-01 T 0.864 -0.004 0.013 7.68E-01 T 0.8333 0.004 0.006 5.46E-01 T 
rs12452440 T 0 0.42 -0.020 0.002 5.60E-21 0.424 0.005 0.012 6.76E-01 T 0.421 0.005 0.010 5.74E-01 T      
rs12462380 A 0 0.58 -0.010 0.002 1.00E-05 0.561 -0.012 0.012 2.92E-01 T 0.564 -0.002 0.009 8.25E-01 T      
rs12487905 T 0 0.79 -0.010 0.002 4.80E-08 0.803 -0.001 0.014 9.34E-01 T 0.797 -0.010 0.011 3.82E-01 T 0.8 0.005 0.005 2.97E-01 T 
rs12534970 A 0 0.51 -0.010 0.002 6.00E-09 0.500 -0.007 0.012 5.45E-01 T 0.497 0.008 0.010 4.32E-01 T      
rs12545602 C 0 0.87 -0.020 0.003 8.40E-13 0.866 -0.030 0.017 6.81E-02 T 0.869 0.005 0.013 6.77E-01 T 0.875 -0.001 0.006 8.58E-01 T 
rs12616772 A 0 0.35 0.010 0.002 5.50E-09 0.337 -0.014 0.012 2.33E-01 T 0.342 0.002 0.009 8.41E-01 T 0.3417 -0.005 0.003 1.14E-01 T 
rs12673062 G 0 0.78 -0.010 0.002 6.80E-06 0.782 -0.021 0.014 1.35E-01 T 0.785 -0.002 0.011 8.71E-01 T 0.7833 -0.002 0.005 7.44E-01 T 
rs12756373 A 0 0.91 -0.020 0.003 1.80E-10 0.905 -0.014 0.020 4.95E-01 T 0.914 -0.003 0.017 8.82E-01 T 0.8917 -0.004 0.009 6.58E-01 T 
rs12811685 C 0 0.66 0.020 0.002 1.70E-14 0.672 -0.013 0.013 3.33E-01 T 0.671 0.007 0.010 5.21E-01 T 0.725 -0.005 0.004 2.40E-01 T 
rs1286075 C 1 0.83 -0.030 0.002 3.00E-30 0.824 -0.045 0.015 2.47E-03 T 0.813 -0.016 0.011 1.55E-01 T 0.7917 -0.007 0.005 1.23E-01 T 
rs1286662 A 0 0.82 0.020 0.002 8.20E-16 0.820 0.006 0.014 6.82E-01 T 0.816 0.010 0.012 3.86E-01 T 0.8417 0.000 0.005 9.35E-01 T 
rs12942736 C 0 0.76 0.020 0.002 3.80E-23 0.776 0.001 0.016 9.42E-01 T 0.780 0.018 0.015 2.19E-01 T 0.725 -0.005 0.005 2.59E-01 T 
rs12945403 T 0 0.34 0.020 0.002 6.20E-17 0.333 0.006 0.012 6.00E-01 T 0.342 0.009 0.010 3.62E-01 T      
rs13002567 T 0 0.67 -0.020 0.002 5.60E-17 0.663 0.014 0.012 2.54E-01 T 0.670 0.016 0.009 9.03E-02 T 0.6583 -0.002 0.004 6.35E-01 T 
rs13070996 G 0 0.72 0.010 0.002 9.70E-10 0.703 0.007 0.013 5.65E-01 T 0.697 0.003 0.010 7.63E-01 T 0.6917 0.005 0.004 2.62E-01 T 
rs13072536 A 0 0.78 -0.020 0.002 2.20E-09 0.761 -0.036 0.013 6.27E-03 T 0.752 -0.014 0.010 1.76E-01 T 0.8 -0.011 0.004 8.02E-03 T 
rs13088318 A 0 0.66 -0.020 0.002 9.20E-12 0.662 -0.012 0.012 3.32E-01 T 0.664 0.009 0.010 3.84E-01 T 0.6833 0.006 0.004 1.54E-01 T 
rs13179493 T 0 0.71 -0.030 0.002 0.00E+00 0.728 -0.003 0.015 8.42E-01 T 0.726 -0.004 0.014 7.39E-01 T 0.7333 0.001 0.005 8.70E-01 T 
rs13201764 T 0 0.85 -0.030 0.003 4.30E-20 0.857 0.020 0.016 2.08E-01 T 0.854 0.013 0.013 3.06E-01 T 0.8083 -0.003 0.005 5.21E-01 T 
rs13220896 G 0 0.96 0.040 0.005 1.00E-11 0.962 0.022 0.038 5.60E-01 T 0.962 -0.010 0.030 7.42E-01 T      
rs13225158 G 0 0.65 0.010 0.002 2.70E-05 0.655 0.001 0.012 9.30E-01 T 0.659 -0.006 0.009 5.14E-01 T 0.6167 0.000 0.004 9.20E-01 T 
rs13334558 T 0 0.21 -0.020 0.002 1.70E-13 0.200 0.013 0.016 4.18E-01 T 0.197 0.006 0.014 6.83E-01 T 0.2333 0.001 0.005 8.28E-01 T 
rs134613 T 0 0.35 0.040 0.002 0.00E+00 0.359 0.005 0.012 6.61E-01 T 0.353 0.005 0.009 5.73E-01 T 0.2833 -0.001 0.004 8.81E-01 T 
rs1386625 A 0 0.1 0.050 0.003 0.00E+00 0.086 -0.046 0.021 2.86E-02 T 0.081 -0.025 0.017 1.50E-01 T 0.0917 -0.017 0.007 1.17E-02 T 
rs139603701 A 0 0.98 0.110 0.007 0.00E+00 0.984 0.007 0.048 8.88E-01 T 0.985 -0.021 0.041 6.18E-01 T      
rs1414660 C 0 0.81 -0.080 0.002 0.00E+00 0.811 0.008 0.014 5.80E-01 T 0.799 -0.005 0.011 6.24E-01 T 0.8417 0.001 0.006 8.16E-01 T 
 
 555 
rs1428968 C 0 0.82 -0.020 0.002 7.20E-19 0.822 -0.028 0.015 6.16E-02 T 0.825 -0.009 0.012 4.30E-01 T 0.875 -0.009 0.005 6.25E-02 T 
rs142971131 G 0 0.99 0.120 0.010 1.00E-21 0.977 -0.066 0.050 1.85E-01 T 0.980 -0.032 0.046 4.87E-01 T      
rs144412371 C 0 0.96 0.040 0.005 6.60E-13 0.968 -0.060 0.036 1.02E-01 T 0.967 -0.029 0.029 3.26E-01 T      
rs144832051 C 0 0.98 -0.180 0.006 0.00E+00 0.973 0.029 0.037 4.40E-01 T 0.975 -0.045 0.031 1.52E-01 T      
rs1463598 C 0 0.64 -0.020 0.002 2.30E-13 0.609 0.002 0.012 8.57E-01 T 0.600 0.013 0.009 1.72E-01 T 0.5833 0.002 0.004 6.34E-01 T 
rs1475120 G 0 0.45 -0.010 0.002 1.60E-10 0.465 0.017 0.011 1.33E-01 T 0.453 -0.001 0.009 9.04E-01 T 0.5167 -0.004 0.004 2.84E-01 T 
rs1502199 A 0 0.25 0.020 0.002 2.40E-16 0.264 0.015 0.013 2.22E-01 T 0.267 -0.005 0.010 6.29E-01 T 0.3083 -0.006 0.004 1.53E-01 T 
rs150445982 C 0 0.98 -0.100 0.006 2.00E-36 0.978 0.020 0.041 6.28E-01 T 0.979 -0.038 0.034 2.55E-01 T      
rs1548607 A 0 0.67 0.020 0.002 1.10E-14 0.674 0.007 0.013 5.87E-01 T 0.675 0.002 0.010 8.87E-01 T 0.7 -0.001 0.005 8.38E-01 T 
rs1550270 T 0 0.7 -0.020 0.002 7.30E-15 0.687 0.009 0.012 4.60E-01 T 0.682 0.005 0.009 6.17E-01 T 0.6917 -0.003 0.004 4.24E-01 T 
rs1575667 A 0 0.12 0.020 0.003 1.40E-13 0.113 0.002 0.018 9.17E-01 T 0.120 -0.006 0.014 6.47E-01 T 0.175 0.011 0.006 6.05E-02 T 
rs1581630 C 0 0.23 0.020 0.002 2.10E-19 0.242 0.043 0.013 8.74E-04 T 0.257 0.012 0.010 2.52E-01 T 0.2417 -0.002 0.004 6.93E-01 T 
rs167365 C 0 0.38 0.020 0.002 1.90E-15 0.359 0.002 0.012 8.75E-01 T 0.363 -0.013 0.009 1.64E-01 T 0.3559 0.006 0.004 1.40E-01 T 
rs16878921 G 0 0.9 -0.030 0.003 3.80E-26 0.898 -0.034 0.019 6.31E-02 T 0.899 -0.020 0.015 1.78E-01 T 0.875 0.002 0.006 7.59E-01 T 
rs17010957 T 0 0.85 -0.030 0.003 1.10E-28 0.851 -0.023 0.016 1.43E-01 T 0.853 0.006 0.013 6.41E-01 T 0.9167 -0.004 0.004 4.35E-01 T 
rs17035323 G 0 0.84 0.020 0.002 6.20E-14 0.842 0.005 0.015 7.56E-01 T 0.840 -0.001 0.012 9.29E-01 T 0.8583 -0.005 0.005 3.17E-01 T 
rs1706708 G 1 0.67 0.030 0.002 0.00E+00 0.687 0.002 0.012 8.74E-01 T 0.691 0.006 0.010 5.63E-01 T      
rs17173698 G 0 0.97 -0.050 0.006 9.70E-15 0.979 0.031 0.040 4.36E-01 T 0.979 0.009 0.032 7.73E-01 T 0.9569 -0.013 0.017 4.49E-01 T 
rs17265513 T 0 0.8 0.030 0.002 4.70E-36 0.789 0.018 0.014 1.96E-01 T 0.791 0.008 0.011 4.95E-01 T 0.8417 0.001 0.004 7.42E-01 T 
rs1736213 T 0 0.44 0.010 0.002 6.30E-11 0.419 0.008 0.011 4.59E-01 T 0.423 0.015 0.009 8.69E-02 T 0.4417 0.004 0.004 2.69E-01 T 
rs17507577 G 0 0.93 -0.060 0.004 0.00E+00 0.911 0.019 0.020 3.47E-01 T 0.913 0.010 0.016 5.23E-01 T 0.9417 -0.004 0.008 5.99E-01 T 
rs17514738 T 0 0.6 0.020 0.002 7.00E-21 0.579 0.004 0.011 7.26E-01 T 0.584 -0.010 0.009 2.54E-01 T 0.6167 0.002 0.004 5.45E-01 T 
rs1777277 C 0 0.55 0.010 0.002 7.50E-09 0.538 -0.004 0.011 6.88E-01 T 0.545 0.005 0.009 5.83E-01 T 0.3966 -0.003 0.003 4.01E-01 T 
rs1904398 A 0 0.49 -0.020 0.002 1.50E-15 0.517 0.002 0.011 8.48E-01 T 0.508 0.000 0.009 9.73E-01 T 0.5 -0.002 0.003 4.22E-01 T 
rs1907310 G 0 0.17 0.020 0.002 9.40E-15 0.180 -0.017 0.015 2.51E-01 T 0.200 0.021 0.012 8.64E-02 T 0.1333 -0.005 0.005 3.07E-01 T 
rs1991431 G 0 0.56 0.020 0.002 2.40E-16 0.562 -0.008 0.011 4.55E-01 T 0.575 -0.021 0.009 2.29E-02 T 0.5167 -0.007 0.004 7.45E-02 T 
rs2052480 G 0 0.71 -0.030 0.002 3.60E-31 0.719 0.009 0.012 4.65E-01 T 0.717 0.004 0.010 6.96E-01 T 0.7167 0.007 0.004 1.11E-01 T 
rs2069442 G 0 0.75 0.020 0.002 1.60E-16 0.702 -0.002 0.012 8.46E-01 T 0.714 -0.010 0.010 3.19E-01 T 0.775 0.001 0.004 8.91E-01 T 
rs2091624 G 0 0.9 0.030 0.003 1.50E-12 0.900 0.010 0.019 5.83E-01 T 0.881 -0.005 0.014 7.04E-01 T 0.925 0.002 0.006 7.59E-01 T 
rs2095931 A 0 0.16 -0.020 0.003 6.10E-13 0.147 0.004 0.016 8.02E-01 T 0.145 -0.020 0.013 1.33E-01 T 0.125 -0.005 0.006 4.22E-01 T 
rs210374 A 0 0.27 -0.010 0.002 2.30E-09 0.300 0.011 0.013 3.81E-01 T 0.309 0.007 0.011 5.25E-01 T 0.25 -0.001 0.004 9.05E-01 T 
rs212417 G 0 0.33 0.030 0.002 0.00E+00 0.351 0.007 0.012 5.25E-01 T 0.358 -0.003 0.009 7.43E-01 T 0.375 -0.004 0.004 3.17E-01 T 
rs215226 A 0 0.6 -0.020 0.002 4.00E-32 0.597 -0.007 0.011 5.68E-01 T 0.598 -0.024 0.009 7.39E-03 T 0.6333 0.006 0.004 1.10E-01 T 
rs2153672 C 0 0.9 -0.020 0.003 1.60E-10 0.900 -0.001 0.019 9.51E-01 T 0.900 0.006 0.015 7.07E-01 T 0.9167 -0.004 0.006 5.25E-01 T 
rs2174633 A 0 0.26 -0.020 0.002 3.70E-11 0.264 0.000 0.013 9.76E-01 T 0.267 0.008 0.010 4.33E-01 T 0.3417 0.000 0.004 9.43E-01 T 
rs2204015 C 0 0.21 0.010 0.002 2.00E-09 0.202 0.015 0.015 3.10E-01 T 0.219 -0.001 0.012 9.28E-01 T 0.225 -0.005 0.005 2.68E-01 T 
rs2216949 C 0 0.88 -0.030 0.003 1.40E-19 0.844 0.001 0.016 9.30E-01 T 0.835 0.004 0.012 7.28E-01 T 0.8667 0.000 0.005 9.85E-01 T 
rs2227607 C 0 0.89 0.020 0.003 1.60E-09 0.900 0.007 0.019 7.25E-01 T 0.898 -0.009 0.015 5.34E-01 T 0.85 0.009 0.006 1.19E-01 T 
rs2235485 A 0 0.84 0.020 0.002 4.80E-16 0.850 -0.001 0.016 9.61E-01 T 0.850 0.023 0.013 7.54E-02 T 0.8 -0.005 0.005 3.27E-01 T 
rs2271329 G 0 0.81 -0.040 0.002 0.00E+00 0.792 -0.030 0.014 3.00E-02 T 0.802 0.011 0.011 3.33E-01 T 0.8417 -0.006 0.005 1.97E-01 T 
rs2303696 T 0 0.62 -0.020 0.002 2.00E-14 0.619 -0.005 0.012 6.90E-01 T 0.625 0.002 0.010 8.38E-01 T 0.65 -0.003 0.004 4.68E-01 T 
rs2375683 G 0 0.75 0.010 0.002 2.70E-10 0.742 -0.002 0.013 8.70E-01 T 0.738 0.005 0.010 6.09E-01 T 0.7833 0.002 0.005 6.96E-01 T 
rs2423151 G 0 0.35 0.040 0.002 0.00E+00 0.352 0.032 0.012 6.19E-03 T 0.343 0.017 0.009 7.24E-02 T 0.3667 -0.001 0.004 8.61E-01 T 
rs2430689 C 0 0.61 0.020 0.002 3.00E-16 0.622 0.033 0.012 4.67E-03 T 0.623 0.021 0.009 2.12E-02 T 0.6417 0.002 0.004 6.17E-01 T 
rs2442599 G 0 0.28 -0.020 0.002 1.20E-10 0.269 -0.002 0.013 8.98E-01 T 0.273 -0.009 0.010 3.91E-01 T 0.2667 -0.010 0.004 1.73E-02 T 
rs2491105 T 0 0.77 -0.020 0.002 9.40E-21 0.773 -0.016 0.014 2.51E-01 T 0.780 -0.013 0.011 2.36E-01 T      
rs2546984 T 0 0.22 0.010 0.002 3.70E-08 0.221 -0.008 0.014 5.66E-01 T 0.219 0.005 0.011 6.44E-01 T 0.1583 0.000 0.005 1.00E+00 T 
rs2553772 T 0 0.46 -0.030 0.002 0.00E+00 0.459 0.009 0.011 4.11E-01 T 0.451 0.006 0.009 4.88E-01 T 0.3917 -0.002 0.004 5.17E-01 T 
rs2566752 T 1 0.62 -0.040 0.002 0.00E+00 0.616 -0.042 0.012 2.99E-04 T 0.616 -0.006 0.009 5.04E-01 T      
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rs2566774 T 0 0.19 0.040 0.002 0.00E+00 0.184 0.015 0.014 2.81E-01 T 0.185 0.010 0.012 3.62E-01 T 0.1379 -0.002 0.005 7.39E-01 T 
rs2639953 G 0 0.48 0.030 0.002 0.00E+00 0.479 0.001 0.011 9.30E-01 T 0.481 0.010 0.009 2.42E-01 T 0.4667 -0.004 0.004 2.80E-01 T 
rs2647462 T 0 0.17 0.030 0.002 4.60E-38 0.167 0.014 0.015 3.74E-01 T 0.168 0.019 0.012 1.15E-01 T 0.1897 0.002 0.005 7.29E-01 T 
rs2653559 C 0 0.84 0.030 0.002 2.50E-26 0.848 0.009 0.016 5.88E-01 T 0.827 0.010 0.012 4.13E-01 T NA 0.004 0.008 6.30E-01 T 
rs2707518 G 1 0.61 -0.170 0.002 0.00E+00 0.631 0.002 0.012 8.92E-01 T 0.618 -0.002 0.009 7.90E-01 T 0.625 -0.004 0.004 2.95E-01 T 
rs2737252 G 1 0.72 -0.030 0.002 0.00E+00 0.718 -0.007 0.012 5.58E-01 T 0.724 -0.002 0.010 8.27E-01 T 0.725 0.010 0.003 2.63E-03 T 
rs2741856 G 1 0.92 -0.070 0.003 0.00E+00 0.911 -0.055 0.020 5.81E-03 T 0.916 -0.019 0.017 2.69E-01 T 0.9083 -0.002 0.007 8.03E-01 T 
rs2761884 G 0 0.55 0.050 0.002 0.00E+00 0.558 0.022 0.011 5.54E-02 T 0.567 0.027 0.009 3.16E-03 T 0.55 -0.001 0.004 8.95E-01 T 
rs2830913 G 0 0.56 -0.020 0.002 2.30E-30 0.573 0.000 0.011 9.77E-01 T 0.573 0.008 0.009 3.56E-01 T 0.65 -0.001 0.003 8.04E-01 T 
rs28362709 G 0 0.77 0.040 0.002 0.00E+00 0.790 0.033 0.015 2.45E-02 T 0.791 0.010 0.012 3.67E-01 T      
rs28364580 G 0 0.75 0.020 0.002 1.00E-19 0.755 0.008 0.013 5.44E-01 T 0.751 -0.003 0.010 7.44E-01 T      
rs28373428 G 0 0.86 -0.020 0.003 8.80E-15 0.854 -0.013 0.016 4.16E-01 T 0.853 -0.027 0.013 2.99E-02 T      
rs28498618 G 0 0.79 0.020 0.002 9.30E-15 0.783 -0.012 0.014 3.98E-01 T 0.790 -0.001 0.011 9.09E-01 T 0.7 -0.002 0.004 7.16E-01 T 
rs28732148 C 0 0.93 -0.020 0.004 6.40E-08 0.939 0.044 0.029 1.26E-01 T 0.925 0.019 0.022 3.82E-01 T 0.9333 -0.018 0.008 3.62E-02 T 
rs2929308 T 0 0.49 0.040 0.002 0.00E+00           0.475 0.009 0.004 1.55E-02 T 
rs2944590 G 0 0.56 -0.020 0.002 5.40E-24 0.557 0.003 0.011 7.94E-01 T 0.557 0.009 0.009 3.24E-01 T      
rs3118906 G 0 0.72 -0.030 0.002 7.30E-35 0.737 0.013 0.013 3.05E-01 T 0.733 0.026 0.010 9.67E-03 T 0.7583 0.004 0.003 2.65E-01 T 
rs3127084 G 0 0.48 0.010 0.002 3.90E-08 0.487 -0.023 0.012 4.93E-02 T 0.488 -0.003 0.009 7.53E-01 T 0.45 0.004 0.004 2.58E-01 T 
rs34123233 T 0 0.82 -0.020 0.002 3.60E-17 0.837 0.014 0.016 3.86E-01 T 0.831 -0.005 0.013 7.10E-01 T 0.9 0.009 0.004 3.86E-02 T 
rs34324915 A 0 0.64 -0.020 0.002 6.00E-21 0.651 0.016 0.012 1.60E-01 T 0.651 0.011 0.009 2.60E-01 T      
rs34396633 C 0 NA -0.160 0.018 6.60E-13 0.977 -0.127 0.068 5.95E-02 T 0.873 -0.117 0.050 1.78E-02 F 0.975 -0.021 0.011 5.30E-02 T 
rs344078 C 0 0.83 0.040 0.002 0.00E+00 0.824 0.011 0.015 4.70E-01 T 0.822 -0.011 0.012 3.58E-01 T 0.8417 -0.006 0.005 2.11E-01 T 
rs34553872 A 1 0.82 -0.060 0.002 0.00E+00 0.835 -0.013 0.015 3.94E-01 T 0.831 0.016 0.012 1.90E-01 T 0.875 0.004 0.005 4.19E-01 T 
rs34583478 C 0 0.92 0.040 0.003 3.50E-19 0.930 0.001 0.022 9.74E-01 T 0.930 0.021 0.018 2.40E-01 T      
rs35264941 G 0 0.98 0.060 0.007 1.20E-11 0.983 0.020 0.045 6.59E-01 T 0.977 -0.013 0.034 6.93E-01 T 0.9667 -0.006 0.014 6.83E-01 T 
rs35308216 T 0 0.92 0.060 0.003 0.00E+00 0.924 -0.023 0.022 2.84E-01 T 0.916 0.000 0.017 9.83E-01 T      
rs35531047 T 1 0.78 -0.050 0.002 0.00E+00 0.767 -0.011 0.014 4.31E-01 T 0.769 0.002 0.011 8.36E-01 T 0.7417 -0.006 0.005 1.92E-01 T 
rs36010930 T 0 0.72 -0.010 0.002 2.70E-10 0.719 -0.007 0.013 5.51E-01 T 0.705 -0.020 0.010 4.37E-02 T      
rs36016056 G 0 0.75 -0.020 0.002 2.90E-13 0.735 -0.002 0.013 8.61E-01 T 0.742 0.017 0.010 9.31E-02 T 0.7583 0.000 0.004 9.63E-01 T 
rs368510 G 0 0.67 -0.020 0.002 1.30E-29 0.653 -0.003 0.014 8.39E-01 T 0.659 0.019 0.013 1.26E-01 T 0.6917 0.001 0.004 9.05E-01 T 
rs370387 G 1 0.44 -0.050 0.002 0.00E+00 0.459 -0.008 0.011 4.52E-01 T 0.466 -0.015 0.009 8.89E-02 T NA -0.006 0.006 3.66E-01 T 
rs3740861 G 0 0.7 -0.010 0.002 8.40E-07 0.707 0.000 0.012 9.93E-01 T 0.713 0.012 0.010 2.19E-01 T 0.725 -0.003 0.004 4.21E-01 T 
rs3760456 C 0 0.56 0.020 0.002 1.30E-26 0.551 -0.016 0.011 1.61E-01 T 0.559 -0.009 0.009 3.37E-01 T 0.5833 -0.007 0.004 8.24E-02 T 
rs3763745 A 0 0.75 -0.010 0.002 6.30E-09 0.757 -0.009 0.013 4.86E-01 T 0.757 0.014 0.010 1.95E-01 T 0.7167 -0.001 0.004 7.80E-01 T 
rs3765971 C 0 0.35 -0.030 0.002 1.90E-37 0.343 -0.007 0.012 5.45E-01 T 0.330 -0.018 0.009 5.23E-02 T 0.3333 0.005 0.004 2.11E-01 T 
rs3790608 G 0 0.85 -0.040 0.003 0.00E+00 0.864 0.028 0.016 8.89E-02 T 0.860 -0.003 0.013 8.17E-01 T      
rs3801427 C 0 0.24 -0.030 0.002 0.00E+00 0.227 -0.014 0.013 2.81E-01 T 0.233 -0.019 0.011 6.93E-02 T 0.2583 -0.010 0.004 2.56E-02 T 
rs3829849 C 0 0.63 -0.010 0.002 4.60E-14 0.644 0.049 0.012 3.71E-05 F 0.647 -0.025 0.009 7.36E-03 T 0.675 -0.015 0.003 2.17E-06 T 
rs3848474 G 0 0.56 -0.020 0.002 1.80E-11 0.572 0.018 0.012 1.34E-01 T 0.576 0.013 0.009 1.71E-01 T      
rs4081747 G 0 0.38 0.010 0.002 2.80E-10 0.383 0.009 0.012 4.33E-01 T 0.384 0.007 0.009 4.39E-01 T 0.375 0.000 0.004 9.46E-01 T 
rs4233949 C 0 0.39 0.070 0.002 0.00E+00 0.372 0.014 0.012 2.35E-01 T 0.376 0.004 0.009 7.06E-01 T 0.3917 0.003 0.004 4.77E-01 T 
rs42916 C 0 0.26 -0.020 0.002 7.30E-17 0.231 0.019 0.013 1.48E-01 T 0.249 0.039 0.010 1.68E-04 T 0.2083 0.002 0.004 5.70E-01 T 
rs4360494 G 0 0.44 -0.020 0.002 2.50E-23           0.4483 -0.006 0.003 5.64E-02 T 
rs4418639 G 0 0.41 0.020 0.002 1.70E-13 0.391 0.001 0.011 9.24E-01 T 0.390 0.001 0.009 8.85E-01 T 0.45 0.000 0.003 9.13E-01 T 
rs4496284 G 0 0.57 -0.020 0.002 2.50E-19 0.576 0.014 0.011 2.17E-01 T 0.577 0.008 0.009 3.96E-01 T      
rs4505759 C 1 0.69 -0.060 0.002 0.00E+00 0.693 -0.004 0.012 7.32E-01 T 0.695 -0.018 0.010 6.30E-02 T 0.675 -0.007 0.005 1.60E-01 T 
rs45573936 T 0 0.97 0.040 0.006 3.00E-11 0.972 -0.065 0.035 5.86E-02 T 0.973 -0.038 0.029 1.87E-01 T      
rs4635400 G 1 0.64 0.050 0.002 0.00E+00 0.640 -0.013 0.012 2.69E-01 T 0.626 -0.025 0.009 7.61E-03 T 0.6 0.002 0.004 5.45E-01 T 
rs4664604 C 0 0.17 -0.020 0.002 3.30E-11 0.159 0.025 0.015 1.10E-01 T 0.169 -0.013 0.012 2.86E-01 T 0.1833 -0.003 0.005 6.17E-01 T 
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rs4669522 T 0 0.21 -0.020 0.002 1.90E-10 0.191 -0.017 0.014 2.40E-01 T 0.187 -0.001 0.012 9.16E-01 T 0.1583 -0.011 0.005 2.72E-02 T 
rs4683184 G 0 0.36 -0.010 0.002 5.00E-10 0.374 0.009 0.012 4.44E-01 T 0.370 0.003 0.009 7.32E-01 T 0.3583 -0.013 0.004 5.13E-04 T 
rs4739697 A 0 0.34 0.020 0.002 3.70E-18 0.331 -0.009 0.012 4.45E-01 T 0.324 -0.009 0.010 3.27E-01 T 0.325 0.000 0.004 9.20E-01 T 
rs4743930 C 0 0.75 -0.030 0.002 3.80E-35 0.746 -0.009 0.013 4.59E-01 T 0.740 0.026 0.010 1.10E-02 T 0.675 -0.013 0.004 2.31E-03 T 
rs4782351 A 0 0.39 0.010 0.002 4.00E-13 0.382 -0.002 0.012 8.41E-01 T 0.396 -0.002 0.009 8.26E-01 T      
rs4806862 G 0 0.67 -0.020 0.002 2.30E-22 0.657 0.008 0.012 4.89E-01 T 0.652 -0.003 0.010 7.83E-01 T 0.6917 0.005 0.004 2.52E-01 T 
rs4821797 T 0 0.67 0.020 0.002 6.80E-24 0.662 0.023 0.012 5.92E-02 T 0.654 -0.007 0.009 4.65E-01 T 0.6667 0.001 0.004 7.64E-01 T 
rs482339 C 0 0.69 0.070 0.002 0.00E+00 0.689 -0.003 0.012 8.11E-01 T 0.677 -0.003 0.010 7.20E-01 T 0.6583 -0.002 0.004 6.43E-01 T 
rs4849701 T 0 0.48 0.020 0.002 3.90E-17 0.468 0.007 0.011 5.40E-01 T 0.481 0.000 0.009 9.64E-01 T 0.45 -0.004 0.004 2.58E-01 T 
rs4876858 G 0 0.21 0.020 0.002 4.40E-19 0.205 0.011 0.015 4.38E-01 T 0.219 -0.007 0.012 5.64E-01 T 0.125 -0.005 0.005 2.59E-01 T 
rs4878008 C 0 0.61 0.010 0.002 8.80E-10 0.608 0.008 0.012 4.72E-01 T 0.622 -0.002 0.009 8.59E-01 T 0.6083 0.000 0.004 9.79E-01 T 
rs4912085 G 0 0.43 0.020 0.002 1.10E-21           0.4661 -0.001 0.004 7.32E-01 T 
rs4964511 T 0 0.49 0.010 0.002 4.50E-10 0.504 -0.018 0.011 1.21E-01 T 0.486 -0.004 0.009 6.40E-01 T NA 0.019 0.007 6.52E-03 F 
rs4979905 C 0 0.82 0.030 0.002 5.60E-24 0.819 -0.035 0.015 1.68E-02 T 0.798 -0.027 0.012 1.66E-02 T 0.7917 -0.008 0.005 1.04E-01 T 
rs55787537 T 0 0.83 0.030 0.002 1.00E-19 0.833 -0.015 0.016 3.46E-01 T 0.832 0.018 0.013 1.89E-01 T      
rs56225285 A 0 0.7 -0.020 0.002 1.70E-17 0.681 0.002 0.014 8.76E-01 T 0.688 0.014 0.013 2.67E-01 T      
rs56240884 C 0 0.71 -0.020 0.002 5.50E-23 0.716 -0.027 0.014 4.73E-02 T 0.711 -0.006 0.011 5.55E-01 T 0.6333 -0.014 0.004 8.33E-04 T 
rs56320441 T 0 0.91 -0.020 0.003 5.20E-12 0.914 -0.042 0.020 3.78E-02 T 0.913 0.012 0.016 4.72E-01 T      
rs56682471 A 1 0.79 -0.030 0.002 7.20E-30 0.781 -0.020 0.013 1.38E-01 T 0.781 -0.018 0.011 9.70E-02 T 0.8417 0.007 0.005 1.28E-01 T 
rs56940811 C 0 0.93 -0.030 0.004 1.10E-08 0.932 -0.015 0.025 5.34E-01 T 0.902 -0.005 0.018 8.00E-01 T      
rs57043009 C 0 0.85 -0.050 0.003 0.00E+00 0.844 -0.003 0.015 8.40E-01 T 0.843 -0.001 0.012 9.49E-01 T 0.8583 0.001 0.005 8.75E-01 T 
rs571356 G 0 0.68 0.020 0.002 1.40E-12 0.691 -0.036 0.012 3.12E-03 T 0.688 -0.024 0.010 1.33E-02 T 0.6667 0.001 0.004 9.03E-01 T 
rs5735 T 0 0.69 0.020 0.002 8.10E-16 0.679 -0.006 0.012 6.05E-01 T 0.681 -0.006 0.010 5.49E-01 T 0.7167 0.001 0.004 8.84E-01 T 
rs5754387 G 0 0.8 0.020 0.002 1.20E-09 0.788 -0.004 0.014 7.82E-01 T 0.781 -0.009 0.011 3.89E-01 T 0.8583 -0.015 0.005 9.52E-04 T 
rs5770908 G 0 0.67 0.020 0.002 7.10E-19 0.664 0.016 0.012 1.85E-01 T 0.662 -0.002 0.010 8.23E-01 T 0.6833 0.004 0.004 3.53E-01 T 
rs603424 G 0 0.83 0.030 0.002 4.80E-27 0.842 -0.005 0.016 7.38E-01 T 0.826 0.002 0.013 9.07E-01 T 0.8 0.002 0.004 7.33E-01 T 
rs6086143 A 0 0.56 0.000 0.002 3.50E-01 0.578 0.014 0.011 1.97E-01 F 0.567 -0.006 0.009 4.91E-01 F 0.6167 -0.002 0.004 4.99E-01 T 
rs60891864 C 0 0.6 -0.030 0.002 0.00E+00 0.584 0.031 0.012 7.22E-03 T 0.587 0.004 0.009 6.64E-01 T 0.5667 -0.005 0.004 1.63E-01 T 
rs6117294 T 0 0.6 0.020 0.002 2.60E-13 0.596 -0.025 0.012 2.67E-02 T 0.595 -0.011 0.009 2.25E-01 T 0.6083 0.002 0.004 5.63E-01 T 
rs6120804 C 0 0.82 -0.030 0.002 1.30E-22 0.814 -0.012 0.014 4.09E-01 T 0.811 0.003 0.011 7.95E-01 T 0.8 -0.006 0.005 2.09E-01 T 
rs6129493 A 0 0.72 0.010 0.002 5.30E-09 0.731 -0.013 0.013 3.26E-01 T 0.735 0.012 0.010 2.38E-01 T 0.75 0.004 0.004 2.84E-01 T 
rs61733768 G 0 0.97 0.080 0.006 7.70E-36 0.963 0.027 0.030 3.77E-01 T 0.965 -0.004 0.025 8.76E-01 T 0.975 -0.002 0.008 8.20E-01 T 
rs61780429 T 0 0.78 0.020 0.002 2.40E-13 0.788 -0.021 0.014 1.35E-01 T 0.790 -0.032 0.011 4.46E-03 T 0.7963 -0.004 0.005 3.84E-01 T 
rs6185 C 0 0.75 0.020 0.002 5.50E-16 0.728 -0.027 0.013 4.49E-02 T 0.725 0.012 0.011 2.68E-01 T 0.775 0.000 0.004 9.64E-01 T 
rs61998565 G 0 0.85 0.020 0.003 1.40E-07 0.849 -0.008 0.018 6.50E-01 T 0.847 0.005 0.017 7.60E-01 T 0.8583 0.001 0.006 9.31E-01 T 
rs62007684 T 0 0.66 0.040 0.002 0.00E+00 0.645 0.029 0.012 1.40E-02 T 0.643 0.018 0.009 5.48E-02 T 0.625 0.014 0.004 3.18E-04 T 
rs62182131 G 0 0.92 0.030 0.003 6.40E-13 0.914 -0.036 0.021 8.13E-02 T 0.918 -0.002 0.017 8.99E-01 T 0.8917 0.010 0.007 1.57E-01 T 
rs62271373 T 0 0.94 -0.030 0.004 1.50E-12 0.955 -0.019 0.028 4.98E-01 T 0.955 0.023 0.022 3.10E-01 T      
rs62302300 C 0 0.84 0.020 0.003 1.50E-14 0.850 0.008 0.016 6.15E-01 T 0.846 0.020 0.013 1.01E-01 T 0.8083 -0.008 0.005 1.36E-01 T 
rs62321667 G 0 0.88 0.020 0.003 3.80E-13 0.896 -0.007 0.018 7.09E-01 T 0.891 0.001 0.014 9.47E-01 T      
rs62453057 A 0 0.82 -0.020 0.002 1.20E-16 0.808 0.005 0.015 7.50E-01 T 0.819 0.012 0.012 3.06E-01 T 0.7833 0.000 0.005 9.35E-01 T 
rs630539 C 0 0.05 -0.030 0.004 3.30E-09 0.057 -0.002 0.025 9.41E-01 T 0.055 -0.006 0.020 7.51E-01 T 0.0333 -0.001 0.009 9.26E-01 T 
rs6471752 C 0 0.85 0.020 0.003 5.20E-14 0.837 -0.018 0.015 2.40E-01 T 0.833 0.024 0.012 4.09E-02 T 0.7833 -0.004 0.005 4.80E-01 T 
rs6485702 T 1 0.34 0.030 0.002 0.00E+00 0.343 -0.001 0.012 9.49E-01 T 0.344 0.002 0.009 8.22E-01 T 0.225 -0.002 0.003 4.72E-01 T 
rs6542920 A 0 0.35 -0.010 0.002 6.60E-10 0.353 -0.027 0.012 2.33E-02 T 0.356 -0.015 0.009 1.06E-01 T 0.3 -0.003 0.004 5.00E-01 T 
rs6546334 C 0 0.66 0.020 0.002 1.40E-16 0.638 -0.019 0.012 1.07E-01 T 0.640 -0.024 0.009 8.56E-03 T 0.6833 0.001 0.004 8.61E-01 T 
rs6564890 C 0 0.46 0.020 0.002 6.80E-28 0.471 0.010 0.011 3.56E-01 T 0.478 0.010 0.009 2.46E-01 T 0.4417 -0.002 0.003 5.53E-01 T 
rs6583866 T 0 0.46 0.010 0.002 2.10E-11           0.4917 -0.002 0.004 6.08E-01 T 
rs660240 T 0 0.22 0.010 0.002 4.10E-09 0.216 0.039 0.013 3.82E-03 T 0.213 0.008 0.011 4.80E-01 T 0.2845 0.006 0.004 9.16E-02 T 
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rs6664489 G 0 0.22 -0.010 0.002 1.30E-08 0.237 0.015 0.013 2.51E-01 T 0.233 0.010 0.011 3.41E-01 T 0.2167 0.003 0.004 4.53E-01 T 
rs6716216 A 0 0.88 -0.030 0.003 1.20E-25 0.874 -0.017 0.017 3.21E-01 T 0.875 -0.029 0.014 3.62E-02 T      
rs6722557 G 0 0.75 -0.020 0.002 4.60E-14 0.732 -0.031 0.013 1.29E-02 T 0.735 -0.005 0.010 6.13E-01 T 0.7083 0.003 0.004 5.45E-01 T 
rs6761320 C 0 0.57 -0.010 0.002 1.20E-06 0.583 -0.009 0.012 4.55E-01 T 0.573 -0.032 0.009 5.85E-04 F 0.5167 -0.003 0.004 4.00E-01 T 
rs6769511 T 0 0.69 -0.010 0.002 3.30E-08 0.694 -0.018 0.012 1.43E-01 T 0.692 -0.004 0.010 6.98E-01 T 0.7083 0.010 0.003 2.61E-03 T 
rs6782178 C 0 0.58 -0.010 0.002 1.00E-14 0.606 0.002 0.012 8.49E-01 T 0.605 0.004 0.009 6.73E-01 T      
rs6794670 C 0 0.8 0.010 0.002 8.40E-11 0.781 0.002 0.014 8.68E-01 T 0.771 -0.020 0.011 8.59E-02 T 0.7917 0.004 0.005 4.31E-01 T 
rs6839437 T 0 0.16 -0.030 0.002 9.00E-36 0.169 -0.019 0.015 2.11E-01 T 0.177 0.000 0.012 9.93E-01 T      
rs6861681 G 0 0.7 -0.010 0.002 3.70E-08 0.681 -0.008 0.012 5.15E-01 T 0.690 0.007 0.010 4.56E-01 T 0.7083 0.011 0.003 9.49E-04 T 
rs6864688 C 0 0.47 0.010 0.002 2.70E-13 0.484 0.014 0.011 2.16E-01 T 0.478 0.012 0.009 1.72E-01 T 0.475 0.004 0.004 2.24E-01 T 
rs687914 G 0 0.75 0.020 0.002 7.50E-20 0.769 0.014 0.015 3.61E-01 T 0.773 0.046 0.013 5.30E-04 T      
rs6882422 G 0 0.88 0.030 0.003 1.90E-19 0.895 0.016 0.018 3.69E-01 T 0.897 0.014 0.015 3.45E-01 T 0.9167 0.012 0.006 5.49E-02 T 
rs6885822 G 0 0.84 0.020 0.003 2.90E-20 0.864 -0.012 0.017 4.62E-01 T 0.862 -0.007 0.013 5.72E-01 T 0.8 0.005 0.005 3.26E-01 T 
rs6901631 T 0 0.87 -0.010 0.003 3.70E-08 0.872 -0.024 0.017 1.62E-01 T 0.869 0.003 0.013 8.39E-01 T 0.8583 -0.001 0.006 9.18E-01 T 
rs6903443 A 0 0.46 0.050 0.002 0.00E+00 0.430 0.025 0.011 2.71E-02 T 0.437 0.012 0.009 1.91E-01 T 0.45 -0.001 0.004 7.92E-01 T 
rs6930181 A 0 0.54 0.010 0.002 1.10E-07           0.5333 -0.002 0.004 6.27E-01 T 
rs6931664 A 0 0.4 -0.070 0.002 0.00E+00 0.390 -0.004 0.011 6.94E-01 T 0.404 -0.014 0.009 1.34E-01 T 0.4333 0.006 0.004 9.21E-02 T 
rs6938070 T 0 0.3 0.020 0.002 1.70E-24 0.295 0.024 0.012 4.57E-02 T 0.291 -0.001 0.010 9.61E-01 T 0.2417 -0.001 0.004 8.30E-01 T 
rs6965122 A 0 0.67 0.050 0.002 0.00E+00 0.676 0.027 0.012 2.58E-02 T 0.673 -0.011 0.009 2.59E-01 T 0.725 0.007 0.004 9.72E-02 T 
rs6985616 A 0 0.56 -0.010 0.002 8.70E-08 0.552 0.005 0.011 6.45E-01 T 0.548 -0.010 0.009 2.84E-01 T 0.6 -0.002 0.004 5.99E-01 T 
rs7000279 C 0 0.73 -0.010 0.002 7.70E-09 0.731 -0.007 0.013 5.70E-01 T 0.734 -0.011 0.010 2.94E-01 T      
rs7014448 T 0 0.32 0.030 0.002 7.00E-28 0.319 0.000 0.012 9.80E-01 T 0.320 0.013 0.010 1.89E-01 T 0.325 -0.002 0.004 5.92E-01 T 
rs7017252 C 0 0.62 -0.020 0.002 6.40E-16 0.627 -0.012 0.012 3.00E-01 T 0.620 -0.007 0.009 4.83E-01 T 0.625 0.000 0.004 9.37E-01 T 
rs7040344 C 0 0.65 0.030 0.002 0.00E+00 0.658 0.029 0.012 1.50E-02 T 0.652 0.004 0.009 6.61E-01 T 0.6667 0.000 0.003 9.08E-01 T 
rs7102 T 0 0.63 0.020 0.002 3.50E-20 0.625 -0.001 0.012 9.64E-01 T 0.625 0.000 0.009 9.78E-01 T 0.6917 0.001 0.003 8.03E-01 T 
rs7121378 T 0 0.12 -0.020 0.003 7.50E-11 0.114 -0.024 0.018 1.70E-01 T 0.119 -0.011 0.014 4.51E-01 T 0.1833 0.003 0.006 6.42E-01 T 
rs7121746 A 0 0.41 0.060 0.002 0.00E+00 0.381 -0.002 0.012 8.25E-01 T 0.394 0.003 0.009 7.22E-01 T 0.3833 0.005 0.004 2.06E-01 T 
rs7135535 G 0 0.55 0.010 0.002 1.20E-10 0.546 -0.003 0.011 7.74E-01 T 0.557 0.004 0.009 6.32E-01 T      
rs71390846 G 1 0.81 0.040 0.002 0.00E+00 0.813 -0.014 0.014 3.19E-01 T 0.813 0.000 0.012 9.89E-01 T      
rs71420186 G 0 0.93 0.030 0.004 3.40E-10 0.923 -0.007 0.022 7.51E-01 T 0.925 -0.009 0.018 5.92E-01 T      
rs7167692 T 0 0.95 0.050 0.004 3.40E-25 0.950 -0.022 0.026 3.86E-01 T 0.949 0.003 0.021 8.99E-01 T 0.9417 -0.004 0.009 6.58E-01 T 
rs7170637 G 0 0.84 0.020 0.003 2.80E-10 0.841 -0.028 0.017 9.43E-02 T 0.839 0.012 0.014 3.82E-01 T 0.85 0.010 0.007 2.00E-01 T 
rs7175531 T 1 0.35 -0.030 0.002 0.00E+00 0.338 0.009 0.012 4.34E-01 T 0.342 0.033 0.009 4.13E-04 T 0.2833 0.001 0.004 9.05E-01 T 
rs7198843 T 0 0.43 -0.020 0.002 6.10E-11 0.427 -0.018 0.012 1.22E-01 T 0.433 -0.015 0.009 9.98E-02 T 0.3917 -0.003 0.004 4.07E-01 T 
rs7209460 C 1 0.3 -0.050 0.002 0.00E+00 0.305 -0.032 0.012 8.63E-03 T 0.314 -0.037 0.010 1.15E-04 T 0.3833 -0.007 0.004 7.91E-02 T 
rs722526 A 0 0.49 -0.010 0.002 4.10E-05 0.472 -0.018 0.011 1.04E-01 T 0.482 0.011 0.009 2.18E-01 T 0.4333 0.000 0.004 9.57E-01 T 
rs7236090 T 0 0.44 -0.010 0.002 1.60E-07 0.479 0.004 0.012 7.58E-01 T 0.475 0.002 0.010 8.35E-01 T 0.55 0.002 0.004 6.01E-01 T 
rs7237942 A 0 0.21 0.020 0.002 3.20E-12 0.210 -0.043 0.014 1.94E-03 T 0.207 -0.031 0.011 5.06E-03 T 0.2583 0.007 0.004 7.18E-02 T 
rs72656010 T 0 0.87 -0.020 0.003 6.30E-10 0.869 0.019 0.017 2.51E-01 T 0.864 0.032 0.013 1.39E-02 T      
rs72692842 C 0 0.91 0.030 0.003 4.90E-13 0.908 -0.043 0.020 3.06E-02 T 0.910 -0.026 0.017 1.15E-01 T 0.8833 -0.011 0.007 9.36E-02 T 
rs7274697 G 0 0.92 -0.020 0.003 8.20E-08 0.913 -0.024 0.020 2.28E-01 T 0.915 -0.016 0.016 3.10E-01 T 0.8917 0.003 0.007 6.37E-01 T 
rs72805220 C 0 0.93 0.060 0.004 0.00E+00 0.940 -0.011 0.024 6.55E-01 T 0.939 -0.001 0.019 9.50E-01 T      
rs72813180 C 0 0.85 0.020 0.003 8.20E-09 0.861 0.006 0.016 7.24E-01 T 0.844 0.008 0.013 5.33E-01 T      
rs72868839 A 0 0.93 -0.050 0.004 8.10E-37 0.919 0.059 0.023 8.73E-03 T 0.925 -0.008 0.019 6.59E-01 T 0.8833 0.004 0.007 6.08E-01 T 
rs72945685 C 0 0.89 -0.020 0.003 2.00E-12 0.894 -0.010 0.018 5.71E-01 T 0.892 0.003 0.014 8.55E-01 T 0.8917 -0.005 0.006 4.48E-01 T 
rs7301013 A 0 0.85 -0.020 0.003 1.30E-18 0.840 -0.001 0.015 9.46E-01 T 0.839 -0.013 0.012 3.01E-01 T 0.8917 -0.004 0.005 4.06E-01 T 
rs73029263 A 0 0.87 0.030 0.003 1.80E-26 0.864 -0.051 0.016 1.98E-03 T 0.867 -0.024 0.013 7.20E-02 T      
rs73066226 T 0 0.84 -0.010 0.003 5.30E-08 0.832 0.029 0.015 5.65E-02 T 0.834 -0.001 0.012 9.34E-01 T      
rs73156468 G 0 0.86 0.020 0.003 1.70E-08 0.851 -0.036 0.016 2.01E-02 T 0.855 -0.009 0.013 4.90E-01 T 0.8833 0.004 0.005 4.37E-01 T 
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rs73238169 G 0 0.87 0.020 0.003 2.10E-10 0.869 0.005 0.016 7.52E-01 T 0.868 0.016 0.013 2.20E-01 T 0.9083 -0.009 0.006 1.00E-01 T 
rs73479996 G 0 0.93 0.020 0.004 9.70E-10 0.924 0.005 0.022 8.36E-01 T 0.923 0.037 0.018 3.34E-02 T      
rs737534 A 0 0.81 0.020 0.002 2.40E-07 0.817 0.022 0.015 1.38E-01 T 0.814 0.017 0.012 1.42E-01 T 0.7667 0.000 0.005 9.84E-01 T 
rs74119759 C 0 0.84 0.030 0.003 1.70E-26 0.833 0.013 0.015 4.03E-01 T 0.835 0.016 0.012 1.90E-01 T 0.875 0.002 0.005 6.57E-01 T 
rs747091 T 0 0.44 -0.010 0.002 7.30E-11 0.450 0.001 0.011 9.41E-01 T 0.441 -0.016 0.009 7.92E-02 T 0.4167 -0.012 0.004 1.30E-03 T 
rs7484147 T 0 0.36 0.050 0.002 0.00E+00 0.397 0.017 0.012 1.29E-01 T 0.390 0.011 0.009 2.41E-01 T 0.3667 -0.009 0.004 2.36E-02 T 
rs7488974 G 0 0.6 -0.050 0.002 0.00E+00 0.593 -0.023 0.011 3.92E-02 T 0.593 -0.004 0.009 6.96E-01 T 0.6083 0.006 0.003 6.57E-02 T 
rs74910854 A 0 0.93 0.020 0.004 2.10E-11 0.937 0.033 0.027 2.22E-01 T 0.937 0.009 0.024 7.12E-01 T      
rs7504492 T 0 0.62 -0.010 0.002 4.60E-10 0.616 -0.017 0.012 1.47E-01 T 0.623 0.016 0.009 9.34E-02 T 0.6083 -0.001 0.004 7.64E-01 T 
rs7516171 C 0 0.82 -0.030 0.002 1.10E-21 0.807 -0.013 0.014 3.56E-01 T 0.808 0.007 0.011 5.65E-01 T      
rs751979 C 0 0.65 -0.020 0.002 8.10E-25 0.648 -0.004 0.012 7.17E-01 T 0.641 -0.015 0.009 1.04E-01 T 0.6417 -0.001 0.004 8.68E-01 T 
rs75230517 G 0 0.95 0.100 0.004 0.00E+00 0.946 0.035 0.025 1.62E-01 T 0.945 0.000 0.020 9.83E-01 T 0.9417 -0.007 0.008 3.66E-01 T 
rs7527300 C 0 0.59 0.030 0.002 3.40E-30 0.577 -0.016 0.011 1.48E-01 T 0.589 0.000 0.009 9.99E-01 T 0.625 -0.001 0.004 8.74E-01 T 
rs7546500 T 0 0.67 -0.020 0.002 2.50E-12 0.677 0.023 0.013 8.37E-02 T 0.680 0.003 0.010 7.79E-01 T 0.681 -0.003 0.005 5.37E-01 T 
rs75660521 C 0 0.94 0.020 0.004 4.40E-06 0.931 -0.027 0.023 2.47E-01 T 0.926 0.006 0.018 7.59E-01 T 0.925 0.004 0.008 6.51E-01 T 
rs7679094 C 0 0.59 0.010 0.002 4.00E-09 0.609 0.004 0.012 7.63E-01 T 0.600 -0.002 0.010 8.80E-01 T 0.6417 0.000 0.004 9.37E-01 T 
rs76833657 G 0 0.92 0.040 0.003 1.70E-24 0.929 0.000 0.022 9.93E-01 T 0.905 0.004 0.017 8.08E-01 T 0.9083 -0.019 0.007 1.36E-02 T 
rs7694707 A 0 0.38 0.010 0.002 3.00E-08 0.365 0.007 0.012 5.71E-01 T 0.362 -0.013 0.009 1.74E-01 T      
rs76983463 T 0 0.96 -0.040 0.005 3.70E-15 0.970 -0.036 0.034 2.91E-01 T 0.969 -0.002 0.027 9.26E-01 T      
rs7703751 A 0 0.74 0.020 0.002 2.00E-26 0.760 -0.013 0.013 3.25E-01 T 0.758 -0.027 0.010 9.52E-03 T 0.7083 -0.005 0.004 2.55E-01 T 
rs77392239 T 0 0.92 -0.040 0.003 1.80E-21 0.928 -0.029 0.024 2.25E-01 T 0.919 0.016 0.020 4.03E-01 T 0.9083 0.009 0.006 1.44E-01 T 
rs77431781 A 0 0.92 0.030 0.004 2.00E-12 0.935 0.017 0.023 4.68E-01 T 0.935 0.007 0.019 6.94E-01 T      
rs77718124 A 1 0.94 -0.050 0.004 1.40E-26 0.949 -0.013 0.030 6.58E-01 T 0.951 -0.012 0.026 6.51E-01 T      
rs78015143 G 0 0.9 -0.030 0.003 1.40E-16 0.910 0.008 0.020 7.00E-01 T 0.910 -0.019 0.016 2.50E-01 T      
rs7814941 A 0 0.8 -0.020 0.002 1.30E-13 0.805 0.071 0.014 5.90E-07 F 0.787 0.019 0.011 9.23E-02 T 0.8 -0.006 0.005 1.85E-01 T 
rs78150433 G 0 0.97 -0.040 0.006 4.60E-12 0.974 -0.056 0.044 2.05E-01 T 0.977 0.014 0.039 7.27E-01 T      
rs7820881 G 0 0.62 -0.010 0.002 1.50E-07 0.631 -0.039 0.012 7.61E-04 F 0.637 -0.024 0.009 1.02E-02 T 0.55 0.002 0.004 6.17E-01 T 
rs78432519 C 0 0.89 0.040 0.003 2.30E-31 0.884 0.030 0.018 9.00E-02 T 0.882 0.017 0.014 2.29E-01 T      
rs785836 C 0 0.65 -0.010 0.002 2.70E-10 0.649 0.024 0.013 5.46E-02 T 0.648 0.010 0.010 3.21E-01 T 0.7 -0.003 0.004 4.38E-01 T 
rs7866211 T 1 0.7 0.020 0.002 3.60E-28 0.686 0.002 0.012 8.46E-01 T 0.684 0.013 0.010 1.84E-01 T 0.725 -0.004 0.004 3.67E-01 T 
rs78817479 C 0 0.91 -0.030 0.003 2.40E-11 0.913 -0.004 0.020 8.23E-01 T 0.917 0.028 0.016 8.94E-02 T      
rs79016257 G 0 0.96 -0.040 0.005 2.10E-14 0.952 0.006 0.027 8.13E-01 T 0.953 -0.023 0.022 2.93E-01 T      
rs7937689 C 0 0.78 0.020 0.002 1.50E-22 0.786 0.014 0.014 3.10E-01 T 0.787 0.010 0.011 3.55E-01 T 0.8167 -0.005 0.005 3.17E-01 T 
rs7953929 C 0 0.8 0.020 0.002 2.10E-12 0.791 0.034 0.014 1.39E-02 T 0.793 0.033 0.011 3.19E-03 T 0.8167 -0.002 0.005 6.17E-01 T 
rs7959604 C 0 0.93 0.060 0.004 0.00E+00 0.924 -0.006 0.023 8.02E-01 T 0.915 -0.010 0.018 5.79E-01 T      
rs79719017 T 0 0.7 -0.020 0.002 8.00E-20 0.721 -0.021 0.013 9.84E-02 T 0.726 -0.005 0.010 5.84E-01 T 0.6833 0.008 0.004 6.67E-02 T 
rs79730878 T 0 0.77 0.020 0.002 3.90E-22 0.796 -0.008 0.014 5.68E-01 T 0.790 0.014 0.011 2.05E-01 T 0.8 -0.004 0.005 4.19E-01 T 
rs798545 C 0 0.7 -0.010 0.002 7.20E-07 0.713 -0.007 0.012 5.54E-01 T 0.712 0.028 0.010 3.72E-03 T 0.7167 0.001 0.004 7.70E-01 T 
rs8002850 G 0 0.66 0.030 0.002 1.00E-38 0.683 0.020 0.013 1.17E-01 T 0.677 -0.007 0.010 5.15E-01 T      
rs80222069 C 0 0.89 0.020 0.003 2.30E-10 0.895 -0.062 0.018 7.97E-04 F 0.897 -0.039 0.015 7.92E-03 T 0.9167 0.007 0.006 2.45E-01 T 
rs8070737 G 0 0.82 -0.010 0.002 4.40E-09 0.829 -0.001 0.015 9.48E-01 T 0.825 -0.006 0.012 6.32E-01 T 0.8917 -0.001 0.005 9.22E-01 T 
rs8095921 G 0 0.78 -0.020 0.002 1.10E-09 0.780 -0.003 0.014 8.46E-01 T 0.784 0.005 0.011 6.21E-01 T 0.7833 -0.001 0.005 8.62E-01 T 
rs8121146 C 0 0.46 0.010 0.002 3.80E-08 0.489 0.000 0.011 9.89E-01 T 0.485 0.005 0.009 6.06E-01 T      
rs825453 A 0 0.39 0.020 0.002 1.60E-14 0.385 -0.002 0.011 8.25E-01 T 0.397 0.021 0.009 1.78E-02 T 0.45 0.012 0.004 1.90E-03 T 
rs833823 A 0 0.03 0.040 0.006 8.20E-08 0.024 -0.004 0.039 9.20E-01 T 0.026 0.018 0.029 5.38E-01 T 0.0333 -0.007 0.013 5.63E-01 T 
rs868127 C 0 0.71 0.020 0.002 9.10E-13 0.721 -0.008 0.015 5.77E-01 T 0.721 -0.006 0.014 6.86E-01 T 0.6917 0.010 0.006 9.21E-02 T 
rs884205 A 1 0.25 -0.030 0.002 3.00E-26 0.264 0.008 0.013 5.20E-01 T 0.259 0.006 0.010 5.68E-01 T 0.3 -0.003 0.004 4.29E-01 T 
rs890074 G 0 0.52 -0.010 0.002 7.90E-09 0.492 -0.037 0.011 1.07E-03 F 0.486 -0.004 0.009 6.92E-01 T 0.5417 -0.009 0.004 1.74E-02 T 
rs899631 G 0 0.61 -0.020 0.002 2.70E-19 0.598 -0.007 0.012 5.95E-01 T 0.597 0.009 0.010 3.85E-01 T 0.6 0.001 0.004 7.13E-01 T 
 
 560 
rs901865 T 0 0.17 0.030 0.002 8.40E-22 0.165 0.015 0.015 3.31E-01 T 0.164 -0.026 0.012 3.06E-02 T 0.175 0.000 0.005 9.84E-01 T 
rs9290351 G 0 0.88 -0.020 0.003 5.90E-15 0.861 -0.017 0.016 3.04E-01 T 0.850 -0.006 0.013 6.56E-01 T 0.85 0.000 0.006 1.00E+00 T 
rs9296151 G 0 0.97 0.040 0.005 4.40E-13 0.965 0.013 0.032 6.83E-01 T 0.962 -0.024 0.024 3.19E-01 T      
rs9364386 T 0 0.82 0.030 0.002 2.30E-26 0.836 0.002 0.015 8.70E-01 T 0.831 0.011 0.012 3.59E-01 T 0.7167 0.009 0.005 6.53E-02 T 
rs9378485 T 0 0.62 0.010 0.002 1.50E-11 0.612 -0.004 0.011 7.03E-01 T 0.604 -0.015 0.009 1.06E-01 T 0.6167 -0.003 0.004 4.77E-01 T 
rs939666 C 1 0.8 -0.070 0.002 0.00E+00 0.803 -0.014 0.014 3.29E-01 T 0.801 -0.020 0.011 7.33E-02 T 0.7417 0.002 0.005 6.17E-01 T 
rs9447004 A 0 0.48 0.020 0.002 1.00E-30 0.503 -0.015 0.011 1.81E-01 T 0.500 -0.004 0.009 6.18E-01 T 0.3917 0.001 0.004 7.46E-01 T 
rs945508 T 0 0.47 -0.010 0.002 1.80E-08 0.480 -0.016 0.011 1.40E-01 T 0.469 -0.015 0.009 9.84E-02 T 0.5 -0.001 0.004 8.33E-01 T 
rs9466056 A 1 0.38 -0.010 0.002 2.80E-11 0.363 -0.014 0.012 2.40E-01 T 0.370 -0.011 0.009 2.35E-01 T 0.45 0.003 0.004 3.71E-01 T 
rs947091 G 0 0.52 -0.040 0.002 0.00E+00 0.549 0.004 0.011 7.30E-01 T 0.546 0.012 0.009 1.85E-01 T 0.55 0.003 0.004 3.71E-01 T 
rs9482770 T 0 0.55 -0.070 0.002 0.00E+00 0.548 0.014 0.011 2.00E-01 T 0.552 0.002 0.009 7.99E-01 T 0.525 -0.005 0.004 1.97E-01 T 
rs9513510 G 0 0.3 0.040 0.002 0.00E+00 0.324 0.005 0.012 6.75E-01 T 0.321 -0.010 0.009 2.81E-01 T 0.25 -0.001 0.004 8.61E-01 T 
rs9521510 T 0 0.68 0.020 0.002 8.50E-22 0.657 -0.009 0.012 4.60E-01 T 0.657 0.005 0.009 5.74E-01 T 0.7083 0.002 0.004 7.08E-01 T 
rs9530279 T 0 0.74 0.020 0.002 1.70E-15 0.747 0.005 0.013 7.18E-01 T 0.743 0.018 0.011 9.83E-02 T 0.775 -0.004 0.004 3.17E-01 T 
rs9532858 G 0 0.32 0.010 0.002 1.10E-13 0.323 0.010 0.012 4.03E-01 T 0.317 -0.013 0.009 1.60E-01 T 0.325 -0.001 0.004 7.51E-01 T 
rs9594738 C 1 0.51 0.050 0.002 0.00E+00 0.483 0.029 0.011 8.65E-03 T 0.502 0.036 0.009 5.20E-05 T 0.5667 0.001 0.004 8.29E-01 T 
rs960192 C 0 0.4 -0.020 0.002 9.00E-19 0.396 0.018 0.012 1.21E-01 T 0.402 0.008 0.009 3.69E-01 T 0.4083 -0.004 0.004 3.17E-01 T 
rs9606138 G 0 0.89 0.120 0.003 0.00E+00 0.889 0.047 0.019 1.32E-02 T 0.892 0.037 0.016 2.22E-02 T 0.95 0.002 0.008 7.72E-01 T 
rs9873544 T 0 0.38 -0.010 0.002 7.10E-13 0.378 -0.001 0.012 9.30E-01 T 0.374 0.009 0.009 3.05E-01 T 0.3167 -0.003 0.004 4.00E-01 T 
rs9896306 C 0 0.73 0.030 0.002 4.80E-27 0.723 -0.011 0.013 3.97E-01 T 0.712 -0.007 0.010 4.97E-01 T 0.65 -0.001 0.004 8.86E-01 T 
rs9921222 C 1 0.53 0.030 0.002 2.80E-33 0.505 0.019 0.011 9.11E-02 T 0.528 0.011 0.009 2.39E-01 T 0.525 0.003 0.004 4.45E-01 T 
rs9927137 A 0 0.52 0.010 0.002 5.50E-11 0.524 -0.011 0.012 3.34E-01 T 0.528 0.014 0.009 1.17E-01 T      
rs9952412 A 0 0.48 -0.020 0.002 6.50E-16 0.489 -0.012 0.012 3.07E-01 T 0.479 -0.005 0.010 5.76E-01 T      
rs9974172 A 0 0.15 -0.020 0.003 3.40E-08 0.134 0.013 0.017 4.58E-01 T 0.133 -0.012 0.014 3.69E-01 T 0.15 -0.003 0.006 6.42E-01 T 





Appendix 38: BMI SNPs used as instruments in two-sample MR analyses. 
 Exposure= BMI Outcome=eBMD Outcome=hip OA Outcome=knee OA 












rs1000940 G 0.320 0.019 0.003 1.28E-08 0.301 0.007 0.002 1.50E-03 F 0.302 0.009 0.013 4.80E-01 T 0.301 0.007 0.010 4.74E-01 T 
rs10132280 C 0.682 0.023 0.003 1.14E-11 0.700 0.000 0.002 5.50E-01 T 0.699 0.018 0.013 1.66E-01 T 0.700 0.027 0.010 7.54E-03 T 
rs1016287 T 0.287 0.023 0.003 2.25E-11 0.299 -0.003 0.002 1.80E-01 T 0.298 -0.010 0.013 4.36E-01 T 0.298 0.019 0.010 6.54E-02 T 
rs10182181 G 0.462 0.031 0.003 8.78E-24 0.488 0.004 0.002 7.60E-02 T 0.488 0.016 0.012 1.62E-01 T 0.487 -0.022 0.009 1.73E-02 T 
rs10938397 G 0.434 0.040 0.003 3.21E-38 0.434 0.008 0.002 5.10E-05 T 0.473 0.015 0.012 1.93E-01 T 0.473 -0.006 0.009 5.24E-01 T 
rs10968576 G 0.320 0.025 0.003 6.61E-14 0.324 0.000 0.002 9.60E-01 T 0.436 0.006 0.012 5.95E-01 T 0.435 0.014 0.009 1.44E-01 T 
rs11030104 A 0.792 0.041 0.004 5.56E-28 0.797 -0.010 0.002 7.20E-04 T 0.323 0.020 0.012 1.11E-01 T 0.323 0.010 0.010 3.33E-01 T 
rs11057405 G 0.901 0.031 0.006 2.02E-08 0.894 -0.001 0.003 8.50E-01 T 0.797 -0.003 0.015 8.21E-01 T 0.797 0.008 0.012 4.92E-01 T 
rs11165643 T 0.583 0.022 0.003 2.07E-12 0.592 0.000 0.002 9.70E-01 T 0.894 0.064 0.019 8.29E-04 F 0.894 0.023 0.015 1.30E-01 T 
rs1167827 G 0.553 0.020 0.003 6.33E-10 0.565 0.003 0.002 8.20E-02 T 0.592 0.005 0.012 7.03E-01 T 0.592 0.008 0.009 4.29E-01 T 
rs11727676 T 0.910 0.036 0.006 2.55E-08 0.904 -0.018 0.003 1.40E-07 F 0.565 -0.004 0.012 7.06E-01 T 0.566 0.022 0.009 1.68E-02 T 
rs12286929 G 0.523 0.022 0.003 1.31E-12 0.526 -0.029 0.002 1.00E-49 F 0.905 -0.088 0.020 9.69E-06 F 0.905 -0.027 0.016 8.93E-02 T 
rs12401738 A 0.352 0.021 0.003 1.15E-10 0.383 -0.003 0.002 1.20E-01 T 0.526 0.005 0.012 6.44E-01 T 0.526 0.007 0.009 4.40E-01 T 
rs12429545 A 0.133 0.033 0.005 1.09E-12 0.129 0.008 0.003 1.60E-03 F 0.381 -0.018 0.012 1.41E-01 T 0.382 0.036 0.010 1.39E-04 T 
rs12940622 G 0.575 0.018 0.003 2.49E-09 0.559 0.003 0.002 1.80E-01 T 0.129 0.004 0.018 8.25E-01 T 0.129 0.022 0.014 1.21E-01 T 
rs13021737 G 0.828 0.060 0.004 1.11E-50 0.829 0.015 0.002 3.60E-08 T 0.559 0.025 0.012 3.37E-02 T 0.559 0.015 0.009 1.21E-01 T 
rs13078960 G 0.196 0.030 0.004 1.74E-14 0.201 0.004 0.002 3.10E-01 T 0.829 0.028 0.016 6.61E-02 T 0.829 0.023 0.012 6.29E-02 T 
rs13107325 T 0.072 0.048 0.007 1.83E-12 0.075 -0.016 0.004 2.50E-05 F 0.202 0.022 0.015 1.30E-01 T 0.201 0.021 0.012 6.51E-02 T 
rs13191362 A 0.879 0.028 0.005 7.34E-09 0.875 0.001 0.003 4.80E-01 T 0.075 0.098 0.022 9.53E-06 F 0.075 0.074 0.018 2.69E-05 T 
rs1516725 C 0.872 0.045 0.005 1.89E-22 0.863 -0.003 0.003 3.80E-01 T 0.875 -0.006 0.018 7.41E-01 T 0.875 0.040 0.014 4.24E-03 T 
rs1528435 T 0.631 0.018 0.003 1.20E-08 0.621 0.004 0.002 5.20E-02 T 0.862 0.036 0.017 3.49E-02 T 0.863 0.048 0.014 4.35E-04 T 
rs1558902 A 0.415 0.082 0.003 ######## 0.402 0.019 0.002 1.20E-19 T 0.621 -0.003 0.012 8.28E-01 T 0.621 0.022 0.010 2.29E-02 T 
rs16851483 T 0.066 0.048 0.008 3.55E-10 0.066 0.010 0.004 4.00E-03 F 0.404 0.057 0.012 1.92E-06 T 0.403 0.043 0.010 6.12E-06 T 
rs16951275 T 0.784 0.031 0.004 1.91E-17 0.775 0.000 0.002 9.80E-01 T 0.066 0.060 0.024 1.04E-02 T 0.066 0.039 0.019 3.71E-02 T 
rs17001654 G 0.153 0.031 0.005 7.76E-09 0.148 -0.001 0.003 8.60E-01 T 0.775 0.009 0.014 5.00E-01 T 0.775 0.021 0.011 6.00E-02 T 
rs17024393 C 0.040 0.066 0.009 7.03E-14 0.026 0.004 0.006 7.30E-01 T 0.148 -0.023 0.017 1.74E-01 T 0.148 0.000 0.013 9.92E-01 T 
rs17094222 C 0.211 0.025 0.004 5.94E-11 0.213 0.002 0.002 9.50E-01 T 0.027 -0.011 0.037 7.55E-01 T 0.026 0.008 0.029 7.77E-01 T 
rs17405819 T 0.700 0.022 0.003 2.07E-11 0.702 0.003 0.002 2.90E-01 T 0.213 0.010 0.014 4.72E-01 T 0.213 0.012 0.011 2.90E-01 T 
rs17724992 A 0.746 0.019 0.004 3.42E-08 0.733 0.000 0.002 6.70E-01 T 0.702 -0.019 0.013 1.38E-01 T 0.702 0.002 0.010 8.86E-01 T 
rs1808579 C 0.534 0.017 0.003 4.17E-08 0.515 -0.006 0.002 1.00E-02 F 0.733 -0.009 0.013 5.05E-01 T 0.733 0.018 0.011 9.01E-02 T 
rs1928295 T 0.548 0.019 0.003 7.91E-10 0.570 0.001 0.002 3.00E-01 T 0.516 0.026 0.012 2.44E-02 T 0.515 0.020 0.009 3.44E-02 T 
rs2033529 G 0.293 0.019 0.003 1.39E-08 0.288 0.005 0.002 6.00E-03 F 0.569 0.002 0.012 8.80E-01 T 0.570 0.030 0.009 1.15E-03 T 
rs2033732 C 0.747 0.019 0.004 4.89E-08 0.744 0.001 0.002 4.10E-01 T 0.746 0.008 0.013 5.52E-01 T 0.745 0.002 0.011 8.90E-01 T 
rs205262 G 0.273 0.022 0.004 1.75E-10 0.267 0.001 0.002 7.90E-01 T 0.268 0.018 0.013 1.71E-01 T 0.268 0.054 0.011 2.88E-07 F 
rs2112347 T 0.629 0.026 0.003 6.19E-17 0.640 0.007 0.002 7.40E-04 T 0.640 -0.009 0.012 4.38E-01 T 0.641 0.017 0.010 8.76E-02 T 
rs2121279 T 0.152 0.025 0.004 2.31E-08 0.126 -0.002 0.003 4.30E-01 T 0.126 0.021 0.018 2.24E-01 T 0.126 -0.002 0.014 8.62E-01 T 
rs2176598 T 0.251 0.020 0.004 2.97E-08 0.246 -0.003 0.002 2.10E-01 T 0.246 -0.010 0.014 4.75E-01 T 0.246 0.015 0.011 1.61E-01 T 
rs2207139 G 0.177 0.045 0.004 4.13E-29 0.170 0.000 0.002 4.90E-01 T 0.169 0.017 0.016 2.82E-01 T 0.169 0.019 0.012 1.18E-01 T 
rs2245368 C 0.180 0.032 0.006 3.19E-08 0.167 0.008 0.002 1.80E-03 F 0.168 0.036 0.016 1.97E-02 T 0.168 0.040 0.012 1.37E-03 T 
rs2287019 C 0.804 0.036 0.004 4.59E-18 0.818 0.006 0.002 3.90E-03 T 0.818 0.026 0.015 8.34E-02 T 0.818 0.003 0.012 8.27E-01 T 
rs2365389 C 0.582 0.020 0.003 1.63E-10 0.592 0.007 0.002 1.30E-02 T 0.592 0.034 0.012 3.88E-03 T 0.592 0.012 0.010 2.10E-01 T 
rs2820292 C 0.555 0.020 0.003 1.83E-10 0.568 0.006 0.002 2.70E-02 T 0.567 0.017 0.012 1.51E-01 T 0.567 0.019 0.009 3.84E-02 T 
rs29941 G 0.669 0.018 0.003 2.41E-08 0.673 0.002 0.002 7.60E-01 T 0.673 0.006 0.012 6.10E-01 T 0.673 0.009 0.010 3.71E-01 T 
 
 562 
rs3101336 C 0.613 0.033 0.003 2.66E-26 0.600 0.010 0.002 7.10E-05 T 0.601 0.021 0.012 8.29E-02 T 0.601 0.014 0.010 1.37E-01 T 
rs3736485 A 0.454 0.018 0.003 7.41E-09 0.461 0.003 0.002 2.00E-01 T 0.461 0.021 0.012 7.03E-02 T 0.461 0.036 0.009 1.14E-04 T 
rs3817334 T 0.407 0.026 0.003 5.15E-17 0.408 -0.001 0.002 9.90E-01 T 0.408 -0.033 0.012 4.90E-03 T 0.408 -0.016 0.009 8.23E-02 T 
rs3849570 A 0.359 0.019 0.003 2.60E-08 0.348 -0.002 0.002 3.20E-01 T 0.347 0.002 0.012 8.44E-01 T 0.347 0.010 0.010 3.25E-01 T 
rs3888190 A 0.403 0.031 0.003 3.14E-23 0.402 -0.003 0.002 1.90E-01 T 0.400 -0.010 0.012 4.24E-01 T 0.400 0.010 0.010 3.10E-01 T 
rs4256980 G 0.646 0.021 0.003 2.90E-11 0.655 0.005 0.002 2.70E-02 T 0.655 0.003 0.012 7.82E-01 T 0.654 -0.007 0.010 4.51E-01 T 
rs4740619 T 0.542 0.018 0.003 4.56E-09 0.552 0.004 0.002 5.50E-02 T 0.551 0.013 0.012 2.80E-01 T 0.551 0.010 0.009 2.65E-01 T 
rs543874 G 0.193 0.048 0.004 2.62E-35 0.207 0.012 0.002 3.60E-06 T 0.207 0.036 0.014 1.36E-02 T 0.207 0.032 0.012 4.96E-03 T 
rs6477694 C 0.365 0.017 0.003 2.67E-08 0.353 0.003 0.002 1.50E-01 T 0.353 0.041 0.012 8.53E-04 F 0.353 0.021 0.010 3.34E-02 T 
rs6567160 C 0.236 0.056 0.004 3.93E-53 0.233 0.015 0.002 2.90E-07 T 0.234 0.049 0.014 3.36E-04 T 0.233 0.031 0.011 4.38E-03 T 
rs657452 A 0.394 0.023 0.003 5.48E-13 0.391 -0.002 0.002 1.00E+00 T 0.391 -0.010 0.012 4.23E-01 T 0.391 -0.003 0.010 0.7419 T 
rs6804842 G 0.575 0.019 0.003 2.48E-09 0.573 0.003 0.002 3.10E-01 T 0.574 -0.003 0.012 7.77E-01 T 0.574 0.019 0.009 0.04028 T 
rs7138803 A 0.384 0.032 0.003 8.15E-24 0.368 0.012 0.002 9.20E-07 F 0.369 0.051 0.012 2.85E-05 T 0.368 0.011 0.010 0.2501 T 
rs7141420 T 0.527 0.024 0.003 1.23E-14 0.516 0.006 0.002 9.10E-03 T 0.516 0.019 0.012 1.14E-01 T 0.516 0.014 0.009 0.1412 T 
rs758747 T 0.265 0.023 0.004 7.47E-10 0.277 0.004 0.002 7.10E-02 T 0.278 -0.012 0.013 3.66E-01 T 0.278 -0.017 0.010 0.113 T 
rs7599312 G 0.724 0.022 0.003 1.17E-10 0.732 0.005 0.002 1.50E-01 T 0.732 0.005 0.013 6.85E-01 T 0.732 0.015 0.011 0.1623 T 
rs7899106 G 0.052 0.040 0.007 2.96E-08 0.050 0.005 0.004 2.50E-01 T 0.050 -0.007 0.027 7.90E-01 T 0.050 -0.011 0.021 0.6035 T 
rs7903146 C 0.713 0.023 0.003 1.11E-11 0.710 -0.011 0.002 8.10E-09 F 0.710 -0.012 0.013 3.42E-01 T 0.710 0.033 0.010 0.001212 T 





Appendix 39: Hip OA SNPs used in two-sample MR analysis with BMD as the outcome. 
  Exposure=Hip OA Outcome=eBMD   
SNP EA EAF  Beta SE p EAF Beta SE P 
Passed Steiger 
filtering 
rs10843013 A 0.781 -0.105 0.014 8.40E-15 0.794 0 0.002 8.50E-01 T 
rs11164653 T 0.418 -0.076 0.011 2.46E-11 0.409 -0.004 0.002 2.40E-02 T 
rs12209223 A 0.116 0.125 0.018 8.76E-13 0.102 0.003 0.003 5.10E-01 T 
rs13057823 A 0.31 0.073 0.012 1.63E-09 0.304 0.013 0.002 3.60E-06 T 
rs1321917 C 0.404 0.067 0.011 2.71E-09 0.408 -0.001 0.002 9.20E-01 T 
rs1913707 A 0.599 0.069 0.011 2.09E-09 0.612 -0.001 0.002 9.20E-01 T 
rs2078396 T 0.366 -0.074 0.012 2.70E-10 0.383 0.001 0.002 2.30E-01 T 
rs2268023 A 0.419 0.066 0.011 7.12E-09 0.395 0.006 0.002 2.30E-02 T 
rs111844273 A 0.02 0.26 0.041 3.34E-10 0.021 0.005 0.006 5.70E-01 T 
 
 
Appendix 40: Summary statistics for the knee OA instruments used in two-sample MR with BMD as the outcome. 
    Exposure= knee OA Outcome=eBMD   




rs143384 A 0.586 0.06 0.009 5.40E-11 0.598 0.003 0.002 3.30E-01 T 
rs4548913 A 0.623 -0.053 0.009 6.62E-09 0.639 -0.025 0.002 4.50E-32 F 
rs66906321 T 0.172 -0.074 0.012 5.69E-10 0.181 -0.015 0.002 1.10E-08 T 





Appendix 41: Hip OA SNPs used in two-sample MR analysis with BMI as the outcome. 
  Exposure= hip OA Outcome= BMI 
SNP EA EAF Beta SE P EAF Beta SE P Passed Steiger Filtering 
rs10492367 T 0.19 0.1518 0.0148 1.25E-24 0.175 -0.0017 0.0047 0.7176 T 
rs11059094 T 0.4777 0.0759 0.0117 7.38E-11 0.4224 0.0077 0.0043 0.07334 T 
rs11583641 T 0.2764 -0.0811 0.0131 5.58E-10 0.25 0.0025 0.0044 0.5699 T 
rs12040949 T 0.3843 -0.0665 0.012 2.84E-08 0.3793 0.0046 0.004 0.2501 T 
rs12209223 A 0.1032 0.1558 0.0191 3.88E-16 0.1333 -0.0176 0.0062 0.00453 T 
rs1913707 A 0.6123 0.0795 0.012 2.96E-11 0.55 -0.0033 0.004 0.4094 T 
rs2785988 A 0.2988 0.0828 0.0127 7.30E-11 0.2797 0.0086 0.0034 0.01098 T 
rs2836618 A 0.2613 0.0876 0.0132 3.20E-11 0.325 0.0038 0.0042 0.3656 T 
rs3774355 A 0.3601 0.0907 0.0121 8.20E-14 0.2917 0.0103 0.0031 0.000986 T 
rs4338381 A 0.6319 0.095 0.0121 4.37E-15 0.6121 0.0043 0.0038 0.2578 T 
rs62063281 A 0.7771 -0.0964 0.014 5.30E-12 0.8 -0.004 0.0047 0.3947 T 
rs7222178 A 0.1991 0.0965 0.0146 3.78E-11 0.1833 0.0082 0.0056 0.1431 T 
rs74767794 A 0.6829 0.0751 0.0126 2.56E-09 0.6583 0.0067 0.0033 0.0429 T 
rs7571789 T 0.4761 0.0886 0.0117 3.26E-14 0.4583 0.003 0.0037 0.4175 T 
rs79056043 A 0.9497 -0.1625 0.0268 1.33E-09 0.9667 0.007 0.0083 0.399 T 
rs798748 T 0.3817 -0.0715 0.012 2.50E-09 0.3083 -0.0021 0.0038 0.5805 T 





Appendix 42: Knee OA SNPs used in two-sample MR analysis with BMI as the outcome. 
  Exposure= Knee OA Outcome= BMI 
SNP EA EAF Beta SE P EAF Beta SE P Passed Steiger Filtering 
rs1078301 A 0.7315 -0.0679 0.0106 1.27E-10 0.7417 -0.0035 0.0044 0.4263 T 
rs143384 A 0.5966 0.0935 0.0095 4.77E-23 0.6 -7E-04 0.0033 0.8247 T 
rs17567417 C 0.4698 -0.0655 0.0093 1.96E-12 0.4167 -0.0082 0.0038 0.03094 T 
rs28817269 C 0.3557 0.0599 0.0097 6.46E-10 0.425 0.0029 0.0044 0.5098 T 
rs4775006 A 0.4114 0.0578 0.0094 8.40E-10 0.4224 -0.0052 0.0046 0.2583 T 
rs6499244 A 0.5596 0.0622 0.0094 3.88E-11 0.5333 0.0127 0.0037 0.000598 T 
rs8067763 A 0.5936 -0.0566 0.0095 2.39E-09 0.6 0.0043 0.0038 0.2578 T 
rs8067895 A 0.2858 0.0616 0.0103 1.89E-09 0.2917 0.0045 0.0041 0.2724 T 






Appendix 43: Forest plots of leave-one-out analyses in the bidirectional MR analyses. 
 





































Appendix 44: Miami plots comparing GWAS results without and with adjustment for 















Appendix 46: IGF-1-associated SNPs used in 2SMR analyses and their associations with IGF-1 in the GIANT consortium, with hip and knee 
OA in the GWAS meta-analysis of UK Biobank and arcOGEN and with hand OA in UK Biobank. 
SNP Closest gene EA NEA 
IGF-1 Hip OA Knee OA Hand OA 
EAF Beta SE p Beta SE p Beta SE p Beta SE P 
rs1065656* NUBP2 C G 0.306 -0.054 0.009 1.17x10-8 0.006 0.013 0.265 -0.006 0.010 0.568 1x10-4 2x10-4 0.480 
rs2153960 FOXO3 A G 0.687 0.055 0.009 5.16x10-9 0.027 0.013 0.033 0.023 0.010 0.028 -7x10-5 2x10-4 0.750 
rs509035 GHSR A G 0.308 0.051 0.009 2.09x10-8 4x10-4 0.013 0.976 0.024 0.010 0.017 1x10-4 2x10-4 0.550 
rs646776* CELSR2 T C 0.785 -0.028 0.010 6.87x10-9 a -0.040 0.014 0.004 -0.003 0.011 0.794 7x10-5 2x10-4 0.760 
rs700753* TNS3 C G 0.347 -0.092 0.009 1.60x10-23 0.004 0.012 0.753 0.010 0.010 0.292 3x10-5 2x10-4 0.860 
rs780093 GCKR T C 0.409 -0.065 0.009 2.19x10-13 -0.031 0.012 0.010 -0.023 0.010 0.014 3x10-4 2x10-4 0.930 
rs934073 ASXL2 C G 0.711 -0.053 0.009 6.48x10-9 -0.014 0.013 0.265 0.006 0.010 0.563 -5x10-5 2x10-4 0.820 
rs978458 IGF1 T C 0.265 0.057 0.010 1.56x10-10 0.038 0.013 0.005 0.013 0.011 0.209 1x10-4 2x10-4 0.520 




Appendix 47: Associations between BMI instruments and BMI in UK Biobank. 
SNP EA Beta SE P 
rs1000940 G 0.068 0.013 5x10-8 
rs10132280 A -0.107 0.013 2x10-17 
rs1016287 C -0.100 0.013 3x10-15 
rs10182181 G 0.159 0.012 <1x10-300 
rs10733682 G -0.061 0.012 2x10-7 
rs10938397 G 0.152 0.012 <1x10-300 
rs10968576 G 0.115 0.012 7x10-21 
rs11030104 G -0.181 0.014 8x10-37 
rs11057405 A -0.127 0.019 1x10-11 
rs11165643 T 0.086 0.012 2x10-13 
rs1167827 G 0.099 0.012 2x10-17 
rs11727676 C -0.036 0.019 0.061 
rs12286929 G 0.085 0.012 2x10-13 
rs12401738 A 0.082 0.012 4x10-12 
rs12429545 A 0.122 0.017 2x10-12 
rs12940622 A -0.089 0.012 1x10-14 
rs13021737 G 0.257 0.015 <1x10-300 
rs13078960 G 0.087 0.014 1x10-9 
rs13107325 T 0.231 0.022 6x10-26 
rs13191362 G -0.093 0.017 9x10-8 
rs1516725 C 0.159 0.017 2x10-21 
rs1528435 T 0.077 0.012 1x10-10 
rs1558902 A 0.354 0.012 <1x10-300 
rs16851483 T 0.173 0.023 9x10-14 
rs16951275 C -0.134 0.014 2x10-22 
rs17001654 G 0.063 0.016 1x10-4 
rs17024393 C 0.347 0.036 1x10-21 
rs17094222 C 0.070 0.014 5x10-7 
rs17405819 C -0.094 0.013 6x10-14 
rs17724992 G -0.070 0.013 9x10-8 
rs1808579 T -0.104 0.012 2x10-19 
rs1928295 C -0.058 0.012 6x10-7 
rs2033529 G 0.094 0.013 2x10-13 
rs2033732 C 0.050 0.013 2x10-4 
rs205262 G 0.143 0.013 2x10-28 
rs2112347 G -0.141 0.012 8x10-32 
rs2121279 T 0.054 0.017 0.002 
rs2176598 C -0.083 0.013 4x10-10 
rs2207139 G 0.199 0.015 2x10-38 
rs2245368 T -0.115 0.015 7x10-14 
rs2287019 T -0.154 0.015 7x10-25 
rs2365389 T -0.063 0.012 9x10-8 
rs2820292 C 0.090 0.012 9x10-15 
rs29941 G 0.072 0.012 4x10-9 
rs3101336 C 0.107 0.012 1x10-19 
rs3736485 G -0.076 0.012 6x10-11 
rs3817334 T 0.114 0.012 2x10-22 
rs3849570 A 0.053 0.012 1x10-5 
rs3888190 A 0.124 0.012 3x10-26 
rs4256980 G 0.080 0.012 3x10-11 
rs4740619 C -0.087 0.012 7x10-14 
rs543874 G 0.224 0.014 <1x10-300 
rs6477694 T -0.052 0.012 2x10-5 
rs6567160 C 0.259 0.014 <1x10-300 
rs657452 G -0.069 0.012 4x10-9 
rs6804842 G 0.059 0.012 5x10-7 
rs7138803 A 0.127 0.012 2x10-26 
rs7141420 T 0.096 0.012 8x10-17 
rs758747 T 0.052 0.013 6x10-5 
rs7599312 A -0.078 0.013 3x10-9 
rs7899106 G 0.122 0.026 4x10-6 
rs7903146 T -0.084 0.013 3x10-11 




Appendix 48: Associations between height instruments and height in UK Biobank. 
SNP Beta SE p value EA 
rs425277 0.127 0.018 8.98E-13 T 
rs2284746 0.283 0.016 <1.00E-300 G 
rs2806561 -0.125 0.016 4.33E-15 G 
rs2219320 -0.192 0.018 3.22E-26 C 
rs7544462 -0.226 0.029 3.31E-15 C 
rs6600365 -0.229 0.016 <1.00E-300 T 
rs564914 0.135 0.016 5.67E-17 T 
rs6691924 0.188 0.025 3.96E-14 T 
rs2815379 0.127 0.018 4.68E-13 G 
rs17391694 0.231 0.023 1.03E-23 T 
rs7551732 0.165 0.016 1.19E-24 A 
rs2811594 0.157 0.016 9.5E-22 G 
rs7517682 -0.168 0.016 7.55E-26 A 
rs1321666 0.081 0.016 3.41E-07 C 
rs9428104 0.283 0.018 <1.00E-300 G 
rs6658763 -0.135 0.030 6.51E-06 T 
rs7534365 0.255 0.023 1.83E-28 C 
rs2298265 -0.206 0.025 2.19E-16 T 
rs6694089 0.267 0.017 <1.00E-300 A 
rs17369123 0.196 0.020 4.5E-22 T 
rs4652773 -0.100 0.016 2.93E-10 G 
rs3814333 0.320 0.017 <1.00E-300 T 
rs10863936 -0.124 0.016 4.02E-15 A 
rs1244981 0.067 0.022 0.001996 A 
rs991967 0.258 0.017 <1.00E-300 C 
rs1544196 -0.145 0.019 6.73E-14 A 
rs11799609 0.070 0.022 0.001254 T 
rs17038954 0.162 0.033 6.76E-07 T 
rs3885668 -0.173 0.016 3.42E-27 T 
rs13006748 0.083 0.017 1.84E-06 C 
rs2289195 0.265 0.016 <1.00E-300 A 
rs711245 -0.160 0.017 2.22E-21 A 
rs17511102 0.311 0.028 3.08E-29 T 
rs897080 -0.136 0.019 5.32E-13 T 
rs354196 0.075 0.016 2.9E-06 G 
rs3791679 -0.471 0.019 <1.00E-300 G 
rs7568069 -0.238 0.016 <1.00E-300 A 
rs11684404 0.197 0.017 3.16E-32 C 
rs13388725 0.056 0.016 0.000486 G 
rs2166898 -0.196 0.021 1.77E-20 A 
rs7567288 0.082 0.020 5.06E-05 C 
rs4953951 -0.183 0.030 1.65E-09 T 
rs12987566 0.159 0.018 7.94E-19 T 
rs6746356 -0.141 0.018 1.69E-14 C 
rs12693589 0.098 0.018 5.61E-08 C 
rs6435143 -0.053 0.016 0.000891 C 
rs994533 -0.209 0.017 9.7E-35 C 
rs12470505 -0.275 0.027 3.77E-25 G 
rs16859517 0.397 0.042 4.23E-21 T 
rs3116168 0.273 0.018 <1.00E-300 C 
rs4344931 0.102 0.017 5.09E-09 C 
rs2633761 0.068 0.016 2.26E-05 A 
rs13078528 0.233 0.037 2.16E-10 A 
rs2597513 -0.272 0.026 7.96E-26 T 
rs9816693 0.165 0.020 8.68E-16 C 
rs2581830 -0.225 0.016 <1.00E-300 C 
rs9835332 -0.169 0.016 1.52E-26 C 
rs17806888 -0.177 0.025 5.28E-13 C 
rs12330322 -0.214 0.019 4.39E-29 T 
rs9825951 -0.154 0.017 1.19E-20 A 
rs1797625 0.134 0.017 1.15E-15 T 
rs1546391 0.163 0.030 4.62E-08 G 
rs6439168 0.237 0.019 7.93E-36 G 
rs724016 0.547 0.016 <1.00E-300 G 
rs4325879 -0.119 0.018 5.16E-11 T 
rs6441170 0.121 0.016 2.04E-13 C 
rs7652177 0.261 0.016 <1.00E-300 G 
 
 578 
rs720390 0.205 0.016 3.23E-36 A 
rs4686904 -0.161 0.017 2.11E-22 T 
rs3958122 0.166 0.017 4.36E-23 T 
rs11722554 -0.287 0.041 3.75E-12 A 
rs2302580 -0.173 0.016 5.28E-27 T 
rs7692995 -0.548 0.022 <1.00E-300 C 
rs16994718 -0.134 0.024 1.34E-08 T 
rs1996422 0.088 0.017 5E-07 G 
rs17081935 0.233 0.020 2.08E-30 T 
rs9993613 -0.214 0.016 <1.00E-300 G 
rs17556750 0.286 0.017 <1.00E-300 A 
rs6813055 -0.129 0.016 3.05E-16 T 
rs12639764 -0.232 0.016 <1.00E-300 C 
rs1562975 0.130 0.017 4.78E-14 A 
rs6838153 0.128 0.017 4.13E-14 G 
rs12513181 -0.108 0.018 2.39E-09 A 
rs1812175 0.589 0.021 <1.00E-300 G 
rs13150868 0.079 0.016 7.94E-07 T 
rs955748 0.155 0.018 3.84E-17 G 
rs9292468 -0.238 0.016 <1.00E-300 C 
rs3812040 -0.170 0.018 4.32E-22 C 
rs7716219 -0.232 0.017 <1.00E-300 C 
rs2662027 -0.134 0.026 2.25E-07 T 
rs9291926 -0.120 0.016 3.78E-14 G 
rs34651 -0.275 0.029 3.72E-21 T 
rs6894139 -0.198 0.016 7.03E-36 G 
rs13177718 -0.236 0.030 2.31E-15 T 
rs6887276 0.098 0.016 5.83E-10 G 
rs7701414 0.262 0.016 <1.00E-300 G 
rs165189 0.129 0.023 1.46E-08 G 
rs4624820 0.074 0.016 2.83E-06 A 
rs4620037 -0.223 0.019 1.02E-30 C 
rs12153391 -0.172 0.018 6E-21 A 
rs4868126 0.247 0.017 <1.00E-300 G 
rs422421 0.292 0.019 <1.00E-300 C 
rs4246079 0.239 0.024 4.59E-23 G 
rs9392918 0.294 0.016 <1.00E-300 C 
rs1047014 0.232 0.018 2.1E-36 C 
rs806794 -0.370 0.018 <1.00E-300 G 
rs2857693 -0.264 0.016 <1.00E-300 T 
rs12214804 -0.601 0.028 <1.00E-300 T 
rs16895130 0.155 0.018 2.84E-18 G 
rs10948222 0.139 0.016 7.11E-18 C 
rs12190423 -0.080 0.016 1.02E-06 C 
rs648831 0.191 0.016 4.17E-33 T 
rs310421 0.194 0.016 2.31E-34 T 
rs314263 -0.332 0.017 <1.00E-300 T 
rs6920372 -0.168 0.016 1.8E-25 A 
rs389663 -0.104 0.017 7.27E-10 C 
rs1155939 0.318 0.016 <1.00E-300 A 
rs1415701 -0.294 0.018 <1.00E-300 A 
rs4896582 -0.368 0.017 <1.00E-300 A 
rs6902771 0.230 0.016 <1.00E-300 T 
rs1832871 -0.142 0.017 2.39E-17 G 
rs991946 -0.121 0.016 1.81E-14 T 
rs2763273 -0.199 0.019 4.71E-26 T 
rs798497 -0.408 0.017 <1.00E-300 G 
rs4725061 0.152 0.016 1.51E-21 G 
rs3807931 0.167 0.016 5.26E-26 A 
rs12538407 -0.217 0.016 <1.00E-300 G 
rs552707 -0.355 0.017 <1.00E-300 C 
rs6974574 0.170 0.017 9.99E-25 T 
rs1113765 -0.112 0.021 6.05E-08 A 
rs17807185 0.094 0.016 6.23E-09 G 
rs42039 0.427 0.018 <1.00E-300 T 
rs2188177 0.090 0.016 1.67E-08 T 
rs6952113 -0.121 0.016 8.4E-14 A 
rs6962887 -0.130 0.017 4.1E-14 G 
rs273945 0.112 0.016 3.08E-12 C 
rs6955948 0.151 0.018 1.27E-17 T 
 
 579 
rs4875421 -0.069 0.016 1.59E-05 A 
rs429433 -0.197 0.037 8.47E-08 G 
rs7823327 0.078 0.016 8.05E-07 T 
rs4273857 -0.206 0.019 2.61E-28 G 
rs2013265 -0.180 0.018 5.62E-23 T 
rs9650315 -0.395 0.023 <1.00E-300 T 
rs16939034 0.127 0.029 1.24E-05 T 
rs4735677 0.283 0.018 <1.00E-300 T 
rs7007200 -0.022 0.017 0.203406 C 
rs1599473 -0.201 0.018 1.15E-27 T 
rs10283100 0.279 0.035 6.68E-16 G 
rs4733724 -0.349 0.020 <1.00E-300 G 
rs1036821 -0.227 0.017 <1.00E-300 A 
rs7033940 -0.106 0.025 2.56E-05 C 
rs2149163 0.106 0.016 6.59E-11 C 
rs1576900 -0.062 0.018 0.000448 A 
rs3763631 -0.114 0.017 2.32E-11 G 
rs11144688 -0.357 0.024 <1.00E-300 A 
rs958225 0.184 0.034 7.68E-08 A 
rs7043114 -0.143 0.016 2.42E-19 T 
rs817300 -0.528 0.030 <1.00E-300 A 
rs7870753 0.301 0.019 <1.00E-300 G 
rs989393 -0.135 0.017 8.57E-15 C 
rs3739707 -0.147 0.018 8.71E-16 A 
rs10119624 0.114 0.017 1.09E-11 A 
rs7033487 -0.282 0.020 <1.00E-300 C 
rs1742829 -0.206 0.028 8.86E-14 A 
rs7466269 -0.212 0.017 1.35E-37 G 
rs7849585 0.172 0.017 1.01E-24 T 
rs12779328 -0.201 0.018 1.82E-30 T 
rs7069985 0.129 0.019 1.92E-11 G 
rs10995319 -0.152 0.019 3.53E-16 C 
rs1171615 -0.185 0.019 6.16E-23 T 
rs10997979 0.162 0.016 1.61E-24 G 
rs1815314 -0.180 0.016 2.46E-29 A 
rs1923367 -0.209 0.016 <1.00E-300 C 
rs2631676 0.215 0.020 1.92E-26 G 
rs7899004 -0.208 0.016 8.67E-39 C 
rs6584575 0.159 0.027 2.38E-09 A 
rs291979 0.195 0.019 2.85E-25 A 
rs1614303 0.113 0.020 3.03E-08 T 
rs7097701 0.151 0.016 1.14E-21 C 
rs10794175 0.136 0.016 2.25E-17 T 
rs4320932 -0.216 0.020 3.33E-26 C 
rs2237886 0.323 0.026 9.04E-36 T 
rs2099745 -0.026 0.035 0.460234 A 
rs757081 0.117 0.017 2.62E-12 G 
rs10767838 -0.103 0.018 9.72E-09 G 
rs3802758 0.141 0.029 1.26E-06 A 
rs1681630 -0.173 0.017 2.7E-25 C 
rs2510396 0.218 0.022 5.19E-23 C 
rs2509133 0.108 0.016 8.47E-12 C 
rs11236294 0.114 0.018 6.44E-11 T 
rs606452 -0.348 0.023 <1.00E-300 C 
rs632124 0.145 0.016 2E-19 A 
rs11221442 -0.099 0.018 6.44E-08 C 
rs11612228 0.176 0.017 6.19E-26 T 
rs2856321 -0.194 0.016 3.22E-32 A 
rs12228415 0.122 0.016 1.72E-14 G 
rs10770705 -0.168 0.017 8.82E-24 C 
rs11049611 -0.268 0.017 <1.00E-300 T 
rs10843390 0.151 0.018 1.18E-17 T 
rs10880969 0.131 0.017 2.68E-14 C 
rs2164968 0.132 0.016 6.85E-16 C 
rs11175992 -0.226 0.019 1.16E-31 A 
rs17783015 -0.069 0.022 0.00182 T 
rs3825199 0.381 0.019 <1.00E-300 G 
rs7971536 -0.175 0.016 1.89E-28 A 
rs2888893 -0.107 0.016 1.4E-11 T 
rs4767473 0.165 0.024 2.98E-12 A 
 
 580 
rs7980687 0.255 0.020 9.79E-39 A 
rs11057552 0.126 0.021 1.56E-09 A 
rs1199734 0.141 0.021 1.74E-11 G 
rs12323101 0.110 0.016 2.19E-11 A 
rs3118905 -0.368 0.018 <1.00E-300 A 
rs4883972 -0.034 0.016 0.032816 G 
rs3818416 0.116 0.019 4.74E-10 C 
rs7319045 -0.187 0.016 2.09E-30 G 
rs7985356 -0.142 0.019 3.66E-14 A 
rs8017130 0.141 0.017 2.08E-16 G 
rs1950500 -0.184 0.017 4.18E-26 C 
rs12435366 -0.084 0.019 7.24E-06 T 
rs10131337 0.130 0.018 2.28E-12 T 
rs8006657 0.106 0.016 9.67E-11 G 
rs11624136 0.079 0.016 6.35E-07 A 
rs2093210 -0.285 0.016 <1.00E-300 T 
rs2058092 -0.060 0.016 0.000176 C 
rs862034 0.188 0.016 3.23E-30 G 
rs7154721 -0.211 0.016 <1.00E-300 C 
rs1190545 0.156 0.018 3.41E-18 C 
rs12882130 -0.182 0.016 2E-28 G 
rs10152739 0.087 0.018 2.48E-06 T 
rs316618 -0.125 0.019 9.56E-11 A 
rs16964211 -0.357 0.037 1.78E-21 A 
rs7177711 -0.144 0.016 1.41E-19 G 
rs7162825 0.040 0.016 0.012057 T 
rs731874 0.131 0.017 2.77E-14 A 
rs5742915 0.215 0.016 <1.00E-300 C 
rs7162542 0.343 0.016 <1.00E-300 G 
rs2238300 -0.071 0.016 1.18E-05 A 
rs2871865 -0.414 0.025 <1.00E-300 G 
rs4246302 0.128 0.017 8.69E-14 G 
rs11648796 0.257 0.020 <1.00E-300 G 
rs26868 0.166 0.016 1.24E-25 A 
rs960006 0.091 0.016 9.93E-09 C 
rs1659127 0.163 0.017 3.62E-22 A 
rs11642612 0.150 0.016 1.35E-20 C 
rs9929889 -0.082 0.016 3.16E-07 T 
rs8058684 0.190 0.017 1.34E-28 A 
rs3790086 -0.155 0.016 1.71E-22 G 
rs217181 0.104 0.020 1.98E-07 T 
rs2326458 -0.138 0.018 2.94E-14 A 
rs8052560 0.168 0.019 2.24E-19 A 
rs9217 0.226 0.016 <1.00E-300 C 
rs8067165 0.145 0.016 4.44E-19 G 
rs3760318 -0.317 0.016 <1.00E-300 A 
rs2028067 0.139 0.022 1.22E-10 C 
rs584828 -0.165 0.016 1.49E-24 T 
rs4986172 -0.198 0.017 1.05E-32 T 
rs227724 0.147 0.017 1.25E-18 T 
rs1401795 -0.187 0.016 8.2E-32 G 
rs2079795 -0.303 0.017 <1.00E-300 C 
rs2070776 0.315 0.017 <1.00E-300 G 
rs2072268 -0.101 0.016 1.98E-10 A 
rs1552173 -0.110 0.016 4.77E-12 T 
rs4239020 -0.088 0.017 1.79E-07 T 
rs888403 0.092 0.017 2.8E-08 G 
rs14062 0.025 0.017 0.130853 G 
rs4369779 0.476 0.019 <1.00E-300 C 
rs2337143 -0.108 0.017 1.26E-10 G 
rs9967417 -0.237 0.016 <1.00E-300 C 
rs11152213 0.203 0.019 1.22E-27 C 
rs8097893 -0.149 0.039 0.000155 G 
rs11659752 -0.138 0.017 5.53E-16 G 
rs11880992 0.244 0.016 <1.00E-300 A 
rs1346490 -0.079 0.016 1.59E-06 C 
rs4072910 -0.200 0.016 1.92E-36 C 
rs8103992 -0.162 0.020 2.53E-16 C 
rs7253628 0.154 0.021 2.78E-13 G 
rs4803468 -0.175 0.016 2.67E-27 G 
 
 581 
rs11880124 -0.167 0.028 4.01E-09 G 
rs7273787 0.195 0.017 8.08E-32 G 
rs1884897 -0.319 0.016 <1.00E-300 G 
rs6085662 0.110 0.016 3.06E-11 C 
rs7261425 -0.107 0.018 1.25E-09 G 
rs1074683 -0.294 0.018 <1.00E-300 G 
rs143384 0.590 0.016 <1.00E-300 G 
rs17450430 0.248 0.019 <1.00E-300 T 
rs6020202 -0.134 0.019 1.5E-12 A 
rs2057291 -0.110 0.017 3.03E-11 G 
rs6061231 -0.087 0.017 6.64E-07 A 
rs2834442 0.145 0.016 1.36E-18 A 
rs9977276 0.130 0.019 5.81E-12 G 
rs5757318 0.145 0.022 4.08E-11 T 
rs738288 -0.046 0.016 0.004089 A 
 
 
